<SEC-DOCUMENT>0001730463-21-000008.txt : 20210506
<SEC-HEADER>0001730463-21-000008.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506160501
ACCESSION NUMBER:		0001730463-21-000008
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Autolus Therapeutics plc
		CENTRAL INDEX KEY:			0001730463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38547
		FILM NUMBER:		21897654

	BUSINESS ADDRESS:	
		STREET 1:		FOREST HOUSE, 58 WOOD LANE
		STREET 2:		WHITE CITY
		CITY:			LONDON
		STATE:			X0
		ZIP:			W12 7RZ
		BUSINESS PHONE:		44 20 3829 6230

	MAIL ADDRESS:	
		STREET 1:		FOREST HOUSE, 58 WOOD LANE
		STREET 2:		WHITE CITY
		CITY:			LONDON
		STATE:			X0
		ZIP:			W12 7RZ

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Autolus Therapeutics Ltd
		DATE OF NAME CHANGE:	20180205
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>autl-20210331_d2.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae,d:1e9715fc465e4ff580cbc490f6509618--><html xmlns:autl="http://www.autolus.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>autl-20210331_d2</title></head><body><div id="i1e9715fc465e4ff580cbc490f6509618_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:245.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:221.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 6-K</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:221.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-16 OR 15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Month of May 2021</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: 001-38547</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:221.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">Autolus Therapeutics plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:221.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forest House</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">58 Wood Lane</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">White City</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">London W12 7RZ</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United Kingdom</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:221.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x&#160;&#160;Form 20-F&#160;&#160;&#160;&#160;&#9744;&#160;&#160;Form 40-F</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160;&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160;&#9744;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1e9715fc465e4ff580cbc490f6509618_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2021, included as Exhibit 99.1 of this Report on Form 6-K (the &#8220;Report&#8221;) and the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 202, included as Exhibit 99.2 of this Report shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-226457) and Form F-3 (File No. 333-232690) of Autolus Therapeutics plc (the "Company") and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently furnished.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1e9715fc465e4ff580cbc490f6509618_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company&#8217;s expectations and assumptions as of the date of this Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements. For a discussion of risk factors that may cause the Company&#8217;s actual results to differ from those expressed or implied in the forward-looking statements in this Report, you should refer to the Company&#8217;s filings with the U.S. Securities and Exchange Commission, including the &#8220;Risk Factors&#8221; sections contained therein. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company&#8217;s views as of any date subsequent to the date of this Report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1e9715fc465e4ff580cbc490f6509618_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="autl-20210331.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992-operatingresult.htm">99.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from this Report on Form&#160;6-K&#160;are formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2020 and 2019 (Unaudited), (ii) Condensed Consolidated Balance Sheets as at September 30, 2020 and December&#160;31, 2019 (Unaudited), (iii) Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity for the Three and Nine Months ended September 30, 2020 and 2019 (Unaudited), (iv) Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2020 and 2019 (Unaudited), and (v)&#160;Notes to Condensed Consolidated Financial Statements (Unaudited).</span></div><div><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i1e9715fc465e4ff580cbc490f6509618_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Autolus Therapeutics plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christian Itin</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Itin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>autl-20210331.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae,d:8ceb2bb5972147538045c26086b1df4d--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:autl="http://www.autolus.com/20210331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>autl-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i444cc5149ffb4ff3aebc41d214a9558c_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09">P5Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yOC9mcmFnOmNlMjNiNzFkMWY2NDQ2ZGU5YTRmZTEwYjY4MjYxMTE3L3RhYmxlOjdiZDMzOWZjOWM3NzRiMzg4ZDkzYjU4Zjg2ODczNzgyL3RhYmxlcmFuZ2U6N2JkMzM5ZmM5Yzc3NGIzODhkOTNiNThmODY4NzM3ODJfMi0xLTEtMS0w_2ff72b78-18eb-4332-bcc3-445d98df0b41">1</ix:nonFraction><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18wLTEtMS0xLTEyMg_72695144-99f4-4bb3-a007-ced49a3a8d64">Autolus Therapeutics plc</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18xLTEtMS0xLTEyMg_112f6498-621c-4523-8a07-3be80ab3bb5f">0001730463</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18yLTEtMS0xLTEyMg_0bd63f36-1afb-4b16-8627-a729df4cb26a">6-K</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18zLTEtMS0xLTEyMg_1defc65d-0f91-4135-8126-8e4b9edbb3a6">3/31/2021</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y180LTEtMS0xLTEyMg_d3849bfe-1b7e-4136-b39d-249538ba339e">false</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y181LTEtMS0xLTEyMg_6f92aa2f-1b39-4e2e-90c7-17a99d553b8f">2021</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y182LTEtMS0xLTEyMg_a41256ce-e0d0-45ce-8201-ec4e373bd528">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y183LTEtMS0xLTEyNQ_e70f33e0-a833-4f7b-a96f-b975c015d30b">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="autl-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id858f1b0dc6f47c58cb69a3594277923_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cf6d3934504912b31c2783e517e671_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40a6c0216e3a4a178d18533172f5eead_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56612f0340b24dd9ae96b45ea23779ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cfb1d3e9b454ea1902388d923852617_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f164bd4080b4036848be45a434b1183_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib659d9739ed84217a438b97c75c6edb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e043145ac6040a696157aeace3f9b4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be88049689e47d9a6b45c2c0165bca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6c95b827c147d9834cea80ba9c76ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a397d0ab374ebf9ecf4ba734ae5899_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i973d0bab1a8546f9883c52cfb0e637fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee15fdaf6af94a6fabfb9578aff371ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5635c7ca4780434ab4798595f173a5b3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc130c21a1045bb8cb7f0a7e50d23cc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43bf285d959642828ad34fca6a197946_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8124081013b040f48152051d2fef650f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c21a05bfb74f80973b93799c2a14b9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022edc107d0143858a241d8c91b0faa5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0691ee4c8ba40abae69ca13311d4688_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8412d6479b1f4abeb4d9efb97ec4a49c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fd77def720648068ce0e83aceb985cb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d535d1cff574284bf3469db856638c1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210da8084e084840a2b797ed219d3290_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4a40b22a3e4903aa2404f3046690ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4384483d59d8411298573965d8975dfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49989be8f3a74255a4d08b2dfaf2f5a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id192f441ae29485b91f10751a6a033c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b837afacb0f45118327f9635557485f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9abac6332284e97991a2832e326a6ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435a50a0218748dd91c2cfcdbc133e2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b508b0d25c4c9f8965def0a415d097_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2969b50377465b89f51740cb4e64f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62cebd19059d4be08369d4361a770ec4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23fe26c1f0bd4aba944f09803669b655_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica69ca24ff9c48549c99f04588c27692_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5ee0501a8f469a8d6aff5456d7a531_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b543afe63da4f298f4f355d5b1fa4ec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4daa51bf814b1b806ec67107d32d58_D20180622-20180622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a82058bfcb64fce894d3dd5382848b0_I20180622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-15</xbrli:startDate><xbrli:endDate>2019-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85577d0805ae43f28ac6d00d72e6ffc9_I20190415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idece61323c9d42bdbbd6d64fe516d660_D20190415-20190415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-15</xbrli:startDate><xbrli:endDate>2019-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9549cc85aa24734a469de8134065606_D20200127-20200127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-27</xbrli:startDate><xbrli:endDate>2020-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e0070edc0a4b0c87c8b6d88f9244d0_I20200127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc3cbb83148416dbc07992923a63cad_D20200127-20200127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-27</xbrli:startDate><xbrli:endDate>2020-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932c7033a2c64d83b9e11b73ab217086_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c4c15ff52c42d49a43d574cf188723_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d639c705934456ab14641f84359651_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524bbe2dd39341faac717c3d8d151567_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25159a1662d546f8b7c7111c26504274_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">autl:LetterofCreditCollateralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4a12fcb03747dfaa82aec40ecf9ab6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">autl:SecurityDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32728553356471ba7bc0e4c651239d0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444cc5149ffb4ff3aebc41d214a9558c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6476ec587b401aaa02d1e7fc32b2d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe7330eedb514187a0f2f7858509b56d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="region"><xbrli:measure>autl:region</xbrli:measure></xbrli:unit><xbrli:context id="ia59d20ea5e8a4d7cbfe95212fb978221_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4f427ba0764b8d8cd7204223dfb93f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fb8cf98b7c46c1b399e564aa4b4ec1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca9e1c4a7374941a2c5d250cd93db6f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>autl:segment</xbrli:measure></xbrli:unit><xbrli:context id="i1fac6fac3aa7454b9e09eae49685ed05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54aa60e569634a13a1858ea934dcb0bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6617f38eb9f4460a622b2d3e9279f54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53347ee136fa448db35974e8e31a9d0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2f75a31f494e2aa9a5db9ab782201c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847ce03d632a4b45add274b3cfcf12b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61a689210f94943a3d41c76d40e1ebd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2651a7e1481c490393262e2898c2333d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33f618510fd4997a9c685478ea3f3ba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493cf0d67e02413cabd32aafc94e263f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a9ff78fd994500b70e17771c035eaf_I20180626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-26</xbrli:startDate><xbrli:endDate>2018-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ef2b2dd83148a89ab674028ea86908_I20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2070486d12ea46aa83b02cb4d9488798_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied33dc884b13464f896f1ce66590f479_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152c0f30695a40f9a86760ec0cbcc834_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">autl:PerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">autl:PerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916d4ef54fa54d7793e6e79e3ce53f4b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049951a6daee47029d1139d31d05bfa3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a573508e9c143009ce350d6d6b25350_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01ce88311fc413e92a876264e4e7673_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a527a130d6d456fb3e905c90988f2cb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6abb4fb36a41389bd1c9e0a53cb994_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91d5db238bf4cbf8f5dd387c179eec8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c78c180c11e46c6bbf16e7e78cf9f89_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c774dce7d34ff78fe33ab4eb91cbee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5403abf0cda041f49722bec6a5bd107b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">autl:CapitalizedFixedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5ac4db8415442786609952726649c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">autl:CapitalizedFixedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bb2de6245d44fd989ae0fadd180dcf_D20140901-20140930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-01</xbrli:startDate><xbrli:endDate>2014-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dae7352e4564813bd4e58c8bfac3d0c_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i194d9cd7426f43bdb92c35c4b53da10d_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc189fb946a4e56907d007ff790d9d3_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740603bdf79a4a19ab28501a2828b0da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f3546488134bd188df42bb75467850_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:RegulatoryApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5ef338879d45cfa5e65e5c7f749b73_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836d7bd86d1742f8b994ba61b0ebc03a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:NetSalesLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba521a09dfc43cc965da6b20f859156_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i340f4450111245dd99b493da501889f5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba75fdc622554754b612b6ca2d81e8dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib312439b752b4257b958d24ddae1acc2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8fc906e9cef419a9335fea6d40a569f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">autl:AdditionalSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9b766ba80440d696ca8311b8127c2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ManufacturingSpaceInEnfieldUnitedKingdomMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>autl:unit</xbrli:measure></xbrli:unit><xbrli:context id="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ManufacturingSpaceInEnfieldUnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa970f510b84d03bcdab0bf779d4aaa_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeSpaceInRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1eb5a9f0484994b0f3d8ee7aa1718f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeSpaceInRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd6038d37304152829044a7577d308f_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb8d879d3684656b339162dcd9fbfcb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda9c1c6f5574294ad1bf162a75b78b0_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001730463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8ceb2bb5972147538045c26086b1df4d_4"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7"> and December 31, 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7">020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_7">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10"> Months</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10"> Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">Condensed Consolidated Statements of Shareholders&#8217; Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">Condensed Consolidated Statements of Cash Flows for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16"> Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_19">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8ceb2bb5972147538045c26086b1df4d_19">6</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Condensed Consolidated Balance Sheets (Unaudited)</span></div><div style="margin-bottom:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV80LTEtMS0xLTA_99f7ae98-aa40-47e5-8411-8692218dc0c5">239,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV80LTMtMS0xLTA_1697cf66-bcec-4770-bbfb-f945c30a89d1">153,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV81LTEtMS0xLTA_e9b6abcb-0e4e-447d-b5a3-89c04d010cda">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV81LTMtMS0xLTA_f1b7e974-6777-4c7a-9ca6-acfc9d2a1c86">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV82LTEtMS0xLTA_5f9a0295-4954-40c5-90df-f02c2d7cc0c8">48,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV82LTMtMS0xLTA_4a881862-1c0d-43d8-99a7-61e887bce381">42,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV83LTEtMS0xLTA_6e50a027-2f4b-41af-94c2-1f691edf9160">288,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV83LTMtMS0xLTA_ff0d5079-a6d4-4856-bdb5-c79e983ac820">196,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV85LTEtMS0xLTA_12d64a1d-5420-4b9c-8756-15029e634dce">33,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV85LTMtMS0xLTA_66f3814c-4b9c-46d7-97b1-220cdda8e26b">38,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMC0xLTEtMS0w_0e9d04fd-4381-4fe0-aacf-28011d43761a">21,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMC0zLTEtMS0w_ace863ea-a557-4d5e-a8ca-85378187806e">51,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deposits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMS0xLTEtMS0w_75c4e83d-671e-40c3-aa5e-af66ad4222b9">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMS0zLTEtMS0w_dadc0148-9e82-4745-8ae1-d8ca0fdb60bf">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMi0xLTEtMS0w_95b5be6d-7397-4509-bc04-ad4c19b89e6e">2,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMi0zLTEtMS0w_e65044a1-d0b5-4669-944c-9ab9fca63332">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMy0xLTEtMS0w_15ac3488-c9f4-43e0-a2ac-173c7a58722e">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMy0zLTEtMS0w_657507e9-e4d2-47ac-b37b-f10bda04a777">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNC0xLTEtMS0w_e56d05cb-dabd-42b1-93a3-362ec6ffebaa">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNC0zLTEtMS0w_13552b83-3541-484a-9226-be3ebdd0d0a0">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNS0xLTEtMS0w_dad76068-d64a-4e63-ac4a-aeea5cc5d29d">349,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNS0zLTEtMS0w_704782fa-c3cc-434d-9ab5-13d175baad9a">294,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders' equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOC0xLTEtMS0w_813961aa-9c54-4371-8b33-73c78def7294">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOC0zLTEtMS0w_9684184f-7eb5-4ded-b9fe-4a24222c782b">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOS0xLTEtMS0w_284b3b98-70cb-442b-91ed-b51a7b887faf">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOS0zLTEtMS0w_e72ad1d3-8971-49ff-92b6-82c7dc4d9b74">27,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMC0xLTEtMS0w_46ec1feb-68a5-40ae-999e-cd6724603bfa">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMC0zLTEtMS0w_fca41aa0-b23a-4175-a59f-625d86921201">3,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMS0xLTEtMS0w_09efac10-b2c7-4d51-b42c-8f46a8a08f48">30,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMS0zLTEtMS0w_da720d41-e0f9-4311-b5c0-8d23d5bd4cbf">33,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMy0xLTEtMS0w_c0fd2bce-09fb-407e-a871-c78abbb9b776">19,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMy0zLTEtMS0w_45df437c-a9eb-443a-b678-68e98a4a443c">50,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNC0xLTEtMS0w_1b502878-33b3-4623-90ad-40cfbd66c6ae">50,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNC0zLTEtMS0w_1e2c327c-0112-4a99-b734-a048e6e30414">84,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMjI_9876af70-0c55-4433-ab9a-78ad8ba2f89d"><ix:nonFraction unitRef="usdPerShare" contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMjI_c109a7c5-6ad3-4f47-8c79-72b067c2bbac">0.000042</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMzY_d9dc114e-9d06-4488-a104-be8a01719be1"><ix:nonFraction unitRef="shares" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMzY_e73be7dd-8b65-4fd1-bac2-7bde5535f602">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfODk_2ef92cbb-f7a4-4f10-9ef4-66225eb217aa"><ix:nonFraction unitRef="shares" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfODk_4db1cefe-cddf-4b51-9282-76842e5eb743">70,515,354</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfOTY_1a387c04-5bdb-4734-b067-1073a90d930b"><ix:nonFraction unitRef="shares" contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfOTY_d1f88395-7cfd-44dd-8154-40392415c0fd">52,346,231</ix:nonFraction></ix:nonFraction>, shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0xLTEtMS0w_2918f491-7f8a-4831-9196-f39c367fbd36">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0zLTEtMS0w_a63e4520-c7f1-4a39-946f-82a94c1dcca3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMjI_5f490979-b6ad-4113-96c8-bf54a9bb8c66"><ix:nonFraction unitRef="gbpPerShare" contextRef="i25cf6d3934504912b31c2783e517e671_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMjI_e20cdac2-e1b1-4b21-939c-526f2658a046">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i25cf6d3934504912b31c2783e517e671_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_95102ad8-586d-409f-a770-52d75bbef36e"><ix:nonFraction unitRef="shares" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_9f4c0fcf-0f9f-4047-bb80-8051faca737c"><ix:nonFraction unitRef="shares" contextRef="i25cf6d3934504912b31c2783e517e671_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_a6720add-1ae1-4b7c-8528-18cb4dde39ef"><ix:nonFraction unitRef="shares" contextRef="i25cf6d3934504912b31c2783e517e671_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_b806e9da-a9e9-4617-ab2d-760cf2034224"><ix:nonFraction unitRef="shares" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_ce730b8f-ed2d-4022-a490-3b99de83a713"><ix:nonFraction unitRef="shares" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_e8886ebc-e612-4a74-8c90-b1731d589c41">34,425</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0xLTEtMS0w_323c3c0e-a3c3-41aa-a151-68e89b761c4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25cf6d3934504912b31c2783e517e671_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0zLTEtMS0w_86ea5c5d-9a04-4bdf-98c7-06933e851acc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred B shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMjQ_0e8ab42d-e691-4be6-8828-94f51dc6a1d1"><ix:nonFraction unitRef="gbpPerShare" contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMjQ_a89d1dc3-11b5-4295-ae1f-40ab6056db7c">0.00099</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_55636322-dde9-4c00-b3f8-f041b1284d41"><ix:nonFraction unitRef="shares" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_73c72b96-876e-4340-bb60-f07b0001e220"><ix:nonFraction unitRef="shares" contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_c6a603f1-240a-4e4e-acd8-7ac743d67a36"><ix:nonFraction unitRef="shares" contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_d036ec7e-c51f-4a3e-975e-d736fec3d9dc"><ix:nonFraction unitRef="shares" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_eab78b24-4cff-4937-adcf-21da1dde8a7d"><ix:nonFraction unitRef="shares" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_f431558f-2e99-4158-8e7d-a002402beab0">88,893,548</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0xLTEtMS0w_3d26b86f-1c15-48a0-aff7-abc83a6a71c2">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0zLTEtMS0w_74e838fd-717f-48cb-998c-c91007735939">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred C shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMjQ_3564a666-5259-4faa-9feb-bbcd3dd9c4d5"><ix:nonFraction unitRef="gbpPerShare" contextRef="i6f164bd4080b4036848be45a434b1183_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMjQ_3f4b3f0e-bc67-474b-aabf-c62d8404723d">0.000008</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_7cd96333-b462-4f64-accd-b7990879d3c7"><ix:nonFraction unitRef="shares" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_9eadb403-5084-45f9-9eb0-f10b42c7fb79"><ix:nonFraction unitRef="shares" contextRef="i6f164bd4080b4036848be45a434b1183_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_a1ecb67e-9a89-4b31-be61-afdcebeac4a6"><ix:nonFraction unitRef="shares" contextRef="i6f164bd4080b4036848be45a434b1183_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_c47c4053-16b2-4d82-9c07-3ac8bff5a079"><ix:nonFraction unitRef="shares" contextRef="i6f164bd4080b4036848be45a434b1183_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_e519cb49-262d-47a4-9b9e-6dd94ce886c0"><ix:nonFraction unitRef="shares" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_e908cbe7-b3f6-4ee9-8f7f-41c0d571c98b">1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> share authorized, issued and outstanding at March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0xLTEtMS0w_94ebfcc1-a112-457a-8d2a-1479a1bca033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f164bd4080b4036848be45a434b1183_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0zLTEtMS0w_adcda38a-cf4d-4b3f-b707-e550eae92ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMS0xLTEtMS0w_8ce395a2-3d76-40bb-ade0-a4d9b19b7461">716,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMS0zLTEtMS0w_bd556359-787a-4dab-80f0-f686a99206b3">595,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMi0xLTEtMS0w_c91d0f28-d603-4a0e-93db-c8653df103da">4,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMi0zLTEtMS0w_ee4fb888-2bad-48c5-ba94-ff4cb1b0deca">5,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMy0xLTEtMS0w_d1fdf613-edee-49d3-a4e4-cdfdc4c24fec">412,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMy0zLTEtMS0w_24e1ef05-08ed-4aef-bfa0-294b44749040">379,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNC0xLTEtMS0w_8b741c12-0e7f-498a-b926-62885d7025da">299,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNC0zLTEtMS0w_e5093cae-e809-49c5-bcc6-5a0f3877da07">210,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNS0xLTEtMS0w_946ae501-8c54-485f-9319-d3a42672ec00">349,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNS0zLTEtMS0w_1232941f-2111-49eb-a571-27e02d541837">294,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.805%"><tr><td style="width:1.0%"></td><td style="width:55.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.838%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMi0xLTEtMS0w_0e6d4746-577a-41bf-9c66-9a963a75a2ae">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMi0zLTEtMS0w_1953e57a-1895-4923-a60d-b10b5b6392f8">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNS0xLTEtMS0w_c65e5467-6cff-4fb8-b024-c215d79ce9dc">30,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNS0zLTEtMS0w_c154992a-8070-4321-b5ae-403fd222d949">31,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNi0xLTEtMS0w_ae43df72-1d67-4334-afce-55dbab1e0010">8,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNi0zLTEtMS0w_9633c970-9410-4439-a846-9b26ff64ef86">7,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="autl:GainLossOnDispositionOfLeaseholdImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0xLTEtMS01MTM_4d41eb0a-7da4-4a35-b4a3-fb1f761f2d84">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="autl:GainLossOnDispositionOfLeaseholdImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0zLTEtMS01MTM_fedbdd3d-6ea9-4e0b-ac88-e1c3763b7732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0xLTEtMS0w_3c591f49-13fb-4239-860f-20014cbe7f0d">39,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0zLTEtMS0w_8b608ae4-7237-4d31-9480-2113874f93b7">38,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfOS0xLTEtMS0w_5533ff2e-007f-4df9-abfa-094d33115fc6">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfOS0zLTEtMS0w_9eb7147c-dd24-4f5a-88f8-8d30a66b85fe">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTAtMS0xLTEtMA_9f2fc6a5-9830-46c7-8bbf-f7d8a52014e0">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTAtMy0xLTEtMA_15774857-33d5-4ac1-830a-85965d64db19">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTEtMS0xLTEtMA_57188941-a48d-478a-a54f-5ac7a40aaf67">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTEtMy0xLTEtMA_3246538c-9899-4169-8fb8-b9f37c5a00b6">4,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTItMS0xLTEtMA_a073e640-eca8-4297-86f8-9a5793b77f51">38,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTItMy0xLTEtMA_14214454-21ae-44fb-aa75-a9ee8b256f96">33,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTMtMS0xLTEtMA_2dc9ceb5-9312-4830-8642-3917dc5b4f49">5,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTMtMy0xLTEtMA_c4d3df85-6774-431b-b80c-b37542af028e">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to ordinary shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTQtMS0xLTEtMA_1cb67fb1-089b-4c42-8a93-a03f22a31e1e">33,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTQtMy0xLTEtMA_221d2b01-88dd-4e87-8e81-8460e8cb8c2e">29,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTYtMS0xLTEtMA_6a1b9cdd-0590-4bd1-888f-74237fb93a71">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTYtMy0xLTEtMA_bcf30158-8aaf-4e8e-867b-49e11f906ac9">17,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTctMS0xLTEtMA_18f1d1d0-b039-4b99-a9cd-d61f089ea5c3">31,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTctMy0xLTEtMA_36400336-796e-43c7-9d4b-a04f4e71bcd1">47,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per ordinary share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTktMS0xLTEtMA_6693b4db-5796-4d73-aa8a-51e4c84a0699">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTktMy0xLTEtMA_60d6d5d6-85f0-403a-9a09-48cb1cdc1cae">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMjAtMS0xLTEtMA_5433869e-29ef-4b7a-b0f9-b75d336deb0a">62,447,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMjAtMy0xLTEtMA_0d4de522-d004-4114-8589-4bacaf915465">49,859,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Condensed Consolidated Statements of Shareholders&#8217; Equity (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(In thousands, except share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.839%"><tr><td style="width:1.0%"></td><td style="width:16.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred B Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred C Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib659d9739ed84217a438b97c75c6edb2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xLTEtMS0xNTcx_6c3e7402-c71c-4705-b20b-bf7f9ab4fc27">44,983,006</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib659d9739ed84217a438b97c75c6edb2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0zLTEtMS0xNTcx_71c10fa3-e03d-4af6-a1f3-6f7925bf7032">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy01LTEtMS0xNTcx_367ce8a2-5ed5-4529-a628-07f67f5c1d1c">34,425</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy03LTEtMS0xNTcx_3452f5fa-a512-4b95-91df-51e90f2a9cfc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e043145ac6040a696157aeace3f9b4b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy05LTEtMS0xNTcx_d9d67685-f647-44aa-942b-cd7ab24e1053">88,893,548</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e043145ac6040a696157aeace3f9b4b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMS0xLTEtMTU3MQ_5034f3ba-9995-4eeb-94a7-cd8f0533961c">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1be88049689e47d9a6b45c2c0165bca2_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMy0xLTEtMTU3MQ_3a8b6170-fc0d-4aff-8e17-cd3cb35572c1">1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be88049689e47d9a6b45c2c0165bca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNS0xLTEtMTU3MQ_c1eb495a-cd30-49e2-9d89-7e738b3bda9f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6c95b827c147d9834cea80ba9c76ef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNy0xLTEtMTU3MQ_8f72ef9f-b8b9-492e-84e0-42245fbda3f1">500,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a397d0ab374ebf9ecf4ba734ae5899_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xOS0xLTEtMTU3MQ_e0df04ff-8750-4ccd-b9ab-8e7ed64090af">8,691</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973d0bab1a8546f9883c52cfb0e637fc_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMS0xLTEtMTU3MQ_c09c7830-69b9-4d75-b500-feecddb8d1e3">237,150</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee15fdaf6af94a6fabfb9578aff371ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMy0xLTEtMTU3MQ_9e1c2bf2-d59c-4a06-b12f-b0c10030d431">254,839</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xLTEtMS0xNTcx_b7eace6b-2676-4f2c-9c62-a53e2ba9994e">7,250,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0zLTEtMS0xNTcx_891bfd4a-dfa5-4844-9230-d3a2e959a9a3">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xNy0xLTEtMTU3MQ_745023ed-c110-4ed1-bf8f-b0edc95ad92c">73,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0yMy0xLTEtMTU3MQ_aaa9be15-1f46-4ed2-a5ac-f27a80ac3efe">73,953</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNS0xNy0xLTEtMTU3MQ_5a47eafa-e2cc-4849-b403-dfe215d718a2">6,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNS0yMy0xLTEtMTU3MQ_90e9c36d-aa60-4311-af46-e8c68828520e">6,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted shares - forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0xLTEtMS0xNTcx_a7dd7066-80d4-48b0-9a62-6da8f8b1b6f8">50</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS0xNTcx_36d6df8f-6f5e-4829-bb00-656350397231">14,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xNy0xLTEtMTU3MQ_793088e7-520c-493f-a2e3-28bb5a2fc981">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0yMy0xLTEtMTU3MQ_846fe5bc-b9b1-4680-b5fb-1f76a5fe739e">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5635c7ca4780434ab4798595f173a5b3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0xOS0xLTEtMTU3MQ_e41eb002-60fe-4887-82bb-15010cb5da4c">17,701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0yMy0xLTEtMTU3MQ_4baf2f4c-e68e-41ed-bd16-9834539546c1">17,701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc130c21a1045bb8cb7f0a7e50d23cc_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMS0xLTEtMTU3MQ_63ed0be7-6a37-4efd-8a49-152f9d54b62c">29,873</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMy0xLTEtMTU3MQ_d8e28100-44bd-4e58-8974-ac561de43e4e">29,873</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43bf285d959642828ad34fca6a197946_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMS0xLTEtMTU3MQ_2490bc8d-4931-4488-bfc0-9a5af3c0cb29">52,247,932</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43bf285d959642828ad34fca6a197946_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMy0xLTEtMTU3MQ_6ba470cb-9ee8-448c-9f1e-7d2694b54965">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8124081013b040f48152051d2fef650f_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNS0xLTEtMTU3MQ_801bd5ac-a422-41a8-8187-a492923dc239">34,425</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8124081013b040f48152051d2fef650f_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNy0xLTEtMTU3MQ_c0869079-11b5-431f-aace-41a23205496f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0c21a05bfb74f80973b93799c2a14b9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtOS0xLTEtMTU3MQ_4670c6bb-7d86-48e0-89e6-8453b106a36a">88,893,548</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c21a05bfb74f80973b93799c2a14b9_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTEtMS0xLTE1NzE_c0230d0b-6a6e-4013-bb52-887708d8b1dd">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i022edc107d0143858a241d8c91b0faa5_I20200331" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTMtMS0xLTE1NzE_a2402e89-be44-4747-845d-f635abfd38ed">1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022edc107d0143858a241d8c91b0faa5_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTUtMS0xLTE1NzE_6d0e2a3a-198b-473e-8ebb-40c7a88f4a00">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0691ee4c8ba40abae69ca13311d4688_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTctMS0xLTE1NzE_c736f58d-be94-41af-9165-33992dfc08c3">580,772</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8412d6479b1f4abeb4d9efb97ec4a49c_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTktMS0xLTE1NzE_ca597388-8c60-4a86-bee4-6814c795053a">26,392</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fd77def720648068ce0e83aceb985cb_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjEtMS0xLTE1NzE_9e808179-8a70-4ac9-bdac-e149bd66b788">267,023</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d535d1cff574284bf3469db856638c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjMtMS0xLTE1NzE_d3c51e11-2821-4143-9417-59c6ae8e1ee4">287,478</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="72" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred B Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred C Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xLTEtMS0w_32e30bdb-df71-468c-972f-67716e1a1fe9">52,346,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0zLTEtMS0w_9fd7759e-9750-433c-a68d-e93e089a91c2">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i210da8084e084840a2b797ed219d3290_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy01LTEtMS0w_9d0b5b8f-74dd-424f-99ec-aa2cf65acd9b">34,425</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210da8084e084840a2b797ed219d3290_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy03LTEtMS0w_19417d6b-f74c-4017-b6d0-309b520cc085">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy05LTEtMS0w_ce82a33a-ae04-4076-9d02-2de4c2658d24">88,893,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMS0xLTEtMA_cff94f94-6013-457d-bfe8-100dafb416dc">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d4a40b22a3e4903aa2404f3046690ee_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMy0xLTEtMA_98ea6a5c-df4c-4e5f-a1da-1b930720c5f2">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4a40b22a3e4903aa2404f3046690ee_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNS0xLTEtMA_cd7b35ba-07a7-4166-9c6a-bbaae04406a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4384483d59d8411298573965d8975dfb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNy0xLTEtMA_7dd17076-1e15-439a-8afb-db107705acdb">595,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49989be8f3a74255a4d08b2dfaf2f5a2_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xOS0xLTEtMA_72779ec3-8798-43c7-b216-53ba35d0e804">5,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id192f441ae29485b91f10751a6a033c4_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMS0xLTEtMA_b0606912-9927-4f73-acf4-3003bab1550b">379,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMy0xLTEtMA_8d72f6fd-a8f9-4275-a554-6c5b8c0d5f3c">210,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xLTEtMS0w_9c727132-4241-45d3-8c4f-03f78d4a69ee">18,147,078</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xNy0xLTEtMA_065857bd-ad5a-4f90-a627-b9b803f9fd7f">122,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0yMy0xLTEtMA_7d0aad2b-f479-4f85-b1ee-c421305a962b">122,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331" decimals="-3" name="autl:APICShareBasedPaymentArrangementReversalOfCostRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0xNy0xLTEtNTI3_1586bd38-0552-4d8a-b034-7e6d782629bc">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="autl:APICShareBasedPaymentArrangementReversalOfCostRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0yMy0xLTEtNTI3_7cb121d3-d607-4d0b-b2b1-a459c0687928">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b837afacb0f45118327f9635557485f_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS01Mjc_a7ee6f7a-ad15-4659-9646-6454f526d0dd">21,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS0w_f895d897-b826-4933-b36e-48540502cd11">545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9abac6332284e97991a2832e326a6ee_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0xOS0xLTEtMA_aeb9e025-19f2-42db-a9a3-388dcd23101c">1,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0yMy0xLTEtMA_13e229f2-41ed-4e16-8162-1ac93b60cef6">1,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i435a50a0218748dd91c2cfcdbc133e2d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMS0xLTEtMA_be0102ed-085a-4571-9813-25acef2fbe69">33,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMy0xLTEtMA_50952211-0d1d-422e-b68d-6df61887ef20">33,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50b508b0d25c4c9f8965def0a415d097_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMS0xLTEtNTc_67c48f7c-2be4-4adb-924b-1a79026f7a11">70,515,354</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b508b0d25c4c9f8965def0a415d097_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMy0xLTEtNTc_7ef7b8d7-822b-4a9b-9d1a-76b119c95bfb">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb2969b50377465b89f51740cb4e64f0_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNS0xLTEtNTc_2716b536-ada1-4378-94ad-1f4ec7196092">34,425</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2969b50377465b89f51740cb4e64f0_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNy0xLTEtNTc_def6975d-901e-4edb-97c0-08c9182b0e23">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62cebd19059d4be08369d4361a770ec4_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtOS0xLTEtNTc_fd80fe46-7838-4d9f-a8e6-01cff60e7326">88,893,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62cebd19059d4be08369d4361a770ec4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTEtMS0xLTU3_e50c1bbb-8043-42ab-9299-a096b828e178">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23fe26c1f0bd4aba944f09803669b655_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTMtMS0xLTU3_af820320-a6b2-41e2-89d6-2e306db857bb">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23fe26c1f0bd4aba944f09803669b655_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTUtMS0xLTU3_8bbf0307-a38e-481d-b617-96864e8b4e06">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica69ca24ff9c48549c99f04588c27692_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTctMS0xLTU3_0f7df668-e8f2-4f15-a774-73a1ce387d3d">716,544</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e5ee0501a8f469a8d6aff5456d7a531_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTktMS0xLTU3_622f201c-a501-41d6-a8a1-208833478a1e">4,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b543afe63da4f298f4f355d5b1fa4ec_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjEtMS0xLTU3_15d0f98d-723a-430e-98f7-acce28560a0b">412,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjMtMS0xLTU3_c7aa8043-6b16-4185-aa22-6dec3f285e25">299,567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.916%"><tr><td style="width:1.0%"></td><td style="width:69.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended  March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMy0xLTEtMS0w_a1e892df-c645-49bc-b768-d86a34783534">33,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMy0zLTEtMS0w_19bbd8a0-edee-4793-b090-9ca818d71198">29,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNS0xLTEtMS0w_e2f5ca49-d51a-4d34-8959-a2d4e895c1ed">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNS0zLTEtMS0w_39d54603-2ff3-4a79-a281-ffa4fd09ce67">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Share-based compensation (net of amount capitalized)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNi0xLTEtMS0w_227d206b-86d2-4e01-9c53-0b2c3b316779">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNi0zLTEtMS0w_e1457d2c-3f8b-46e8-8ad3-df268e66f10a">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss (gain) on termination of operating lease</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOC0xLTEtMS0w_93ef03e9-cbb5-421e-befc-153868f62494">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOC0zLTEtMS0w_c90f4485-45ff-4d0b-9817-1b347347c97b">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOS0xLTEtMS0w_72a418ab-7080-49f2-82d3-9a1b2332fb89">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOS0zLTEtMS0w_1d8f0ef7-c40e-4471-b439-13e8ca9f7bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTAtMS0xLTEtMTQ2MA_01b38746-edd3-4a90-b465-2322b5e9352f">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTAtMy0xLTEtMTQ2MA_a4dee05f-2274-44f3-9b21-03090442a57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Changes in operating assets and liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTEtMS0xLTEtMA_49a7e743-f6da-481e-be9e-1c88472416cd">5,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTEtMy0xLTEtMA_e670d3d2-88ec-4162-a0e5-3b9efe3c40ae">1,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTItMS0xLTEtMA_7599b8dc-c06a-4379-9b5b-cff4b3162e83">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTItMy0xLTEtMA_1475570d-dd3e-4bb0-a092-dc8f8687ee5d">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term deposits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTMtMS0xLTEtMA_27cc51b3-9324-4362-96a5-77001ada1cf1">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTMtMy0xLTEtMA_b78f8f3b-584c-4374-bcb0-e529cf3f1e73">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right of use assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTQtMS0xLTEtMA_3cfc44b7-8c23-4256-b29a-4aead84d2c41">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" name="autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTQtMy0xLTEtMA_8733cb42-18c9-4255-bf40-3a7622cf322a">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTUtMS0xLTEtMA_b36f5ccb-2d75-4504-9e69-514b2aa8ba5a">902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTUtMy0xLTEtMA_050f2a16-f264-4dab-856a-e18f1b0b93f9">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTYtMS0xLTEtMA_6ff28310-abf3-4d0d-8d88-bc3968d563c2">1,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" name="autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTYtMy0xLTEtMA_b11df567-29f9-4131-bf47-40e5a04e8e4a">361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="autl:NetIncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTctMS0xLTEtMA_1cd6e936-dfcf-4230-8ceb-bb5066b1e718">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" name="autl:NetIncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTctMy0xLTEtMA_0ed0dc12-f368-431b-9fbd-69d8f7b414b3">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTgtMS0xLTEtMA_de372599-7047-49fb-b9c4-721c1b28de1e">37,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTgtMy0xLTEtMA_53726674-a8b8-468f-ad20-2e2cde5f53ec">24,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjAtMS0xLTEtMA_1554d247-fa86-4748-bac9-f83f80f55c3d">1,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjAtMy0xLTEtMA_def8e665-59c8-4081-86a3-dd476eb461a5">2,637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjEtMS0xLTEtMA_f84d95c0-fab9-4514-b930-31679266638e">1,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjEtMy0xLTEtMA_5fcceccb-ae39-448a-b042-082825d8f56a">2,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds of issuance of ordinary shares, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjMtMS0xLTEtMA_5ca34c13-44ec-4f6f-9922-38c28e878b08">123,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjMtMy0xLTEtMA_0f24aaac-cfa4-488b-acc2-eeb6f3a3642e">74,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjQtMS0xLTEtMA_ea1366aa-9796-4fc4-abf8-9921bb1ed587">123,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjQtMy0xLTEtMA_c1f965a6-8e8e-4c62-82da-ef08c40bd294">74,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Effect of exchange rate changes on cash and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjUtMS0xLTEtMA_e357667e-9591-4011-9043-ebe3ae3c9509">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjUtMy0xLTEtMA_2c520fc6-f437-44a6-b75c-cdcbadfddcdd">14,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net increase in cash and restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjYtMS0xLTEtMA_da84137a-c374-41cf-820c-1532d51cac9a">85,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjYtMy0xLTEtMA_91b1e487-618a-413d-aaae-977861d56415">32,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash and restricted cash, beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjctMS0xLTEtMA_f612fcb6-d97b-4672-bf69-d4974ebe2521">154,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee15fdaf6af94a6fabfb9578aff371ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjctMy0xLTEtMA_643273c0-93ff-4eab-ba55-c6bb5f97badd">211,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash and restricted cash, end of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.25pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjgtMS0xLTEtMA_3c0758b4-89a1-4382-8167-d0866a362c8e">239,798</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d535d1cff574284bf3469db856638c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjgtMy0xLTEtMA_c5a11027-345e-4e3f-bb59-fa948d9b6e47">244,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Supplemental non-cash flow information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment purchases included in accounts payable and accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzEtMS0xLTEtMA_87f0316e-8d06-497d-aed0-cccfc5c3720f">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzEtMy0xLTEtMA_598ea9be-84f1-487b-9f04-3c1dac440e50">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right of use assets terminated and obtained in exchange for operating lease liabilities, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzItMS0xLTEtMA_4e1465a1-1f42-4433-bce4-9b8875387860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzItMy0xLTEtMA_d95cef0a-23a4-4582-ad06-7c49142f3a91">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized implementation costs included in accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" name="autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzMtMS0xLTEtMA_acefd3c4-c5be-46e4-8cc8-17ea2609af13">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzMtMy0xLTEtMA_d0183572-e7ab-4529-b5bc-1ec30df29bb3">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Issuance costs included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMS0xLTEtNTM5_f74b3a43-c978-4305-9d05-96ae04f5b239">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMy0xLTEtNTM5_43cbec74-73a4-4ba3-8f85-a1b785718490">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;Capitalized share-based compensation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="autl:CapitalizedSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMS0xLTEtMA_79e6d8fc-bc74-49a5-8c68-6be6e7467e5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" name="autl:CapitalizedSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMy0xLTEtMA_75091513-fc63-4701-82a7-ce5668fe604e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease assets terminated</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:LeaseAssetsTerminated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMS0xLTEtMjAyMA_e8d1b123-f6ed-478b-aea4-29472928c45e">28,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="autl:LeaseAssetsTerminated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMy0xLTEtMjA1OQ_f1773a77-8139-4f13-8503-d1af0583fdb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMS0xLTEtMA_af7ce17c-3126-484a-b9cb-e4e87993d9a1">239,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d535d1cff574284bf3469db856638c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMy0xLTEtMA_67eac220-2a0a-4f8c-ad06-01c6d7c9f210">243,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzgtMS0xLTEtMA_4a40803e-d959-4f0a-b70f-993417dd6aa9">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d535d1cff574284bf3469db856638c1_I20200331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzgtMy0xLTEtMA_fb25f723-5d7b-4445-b87b-cafb5439211b">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash and restricted cash</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzktMS0xLTEtMA_40128a9f-bd55-4781-9c7c-4c19a7e5a7a5">239,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d535d1cff574284bf3469db856638c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzktMy0xLTEtMA_214c0a7e-0063-4094-9b9d-5bde5e480f15">244,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div></div><div style="margin-top:18pt"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfNjQ4MA_76a69095-fb0c-48df-9c5d-0f6513156755" continuedAt="i0d774ac8fd534d25be8e53b8d1f7efcb" escape="true">Nature of the Business</ix:nonNumeric></span></div><ix:continuation id="i0d774ac8fd534d25be8e53b8d1f7efcb" continuedAt="i1a58040aa7eb4d5baee4822cb60d53fb"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc (the &#8220;Company&#8221;) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a public limited company incorporated in England and Wales. On June 22, 2018, the Company completed its initial public offering ("IPO") of American Depositary Shares (&#8220;ADSs&#8221;). In the IPO, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfOTUw_171bcb98-ce05-4d99-94fa-1d51487495a5">10,147,059</ix:nonFraction> ADSs representing the same number of ordinary shares, including <ix:nonFraction unitRef="shares" contextRef="i3c4daa51bf814b1b806ec67107d32d58_D20180622-20180622" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTAxNw_fa73b5ad-75ce-4980-8b2e-63fdf9154a50">1,323,529</ix:nonFraction> ADSs pursuant to the underwriters&#8217; option to purchase additional ADSs, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a82058bfcb64fce894d3dd5382848b0_I20180622" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTEyMQ_8e5bd9a3-2993-4009-97f0-f436d287b568">17.00</ix:nonFraction> per ADS. Net proceeds were $<ix:nonFraction unitRef="usd" contextRef="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTE1MQ_d247d0fa-0066-47a5-a1ca-916567deace2">156.5</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2019, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTMyOQ_21b64f0e-9025-4dee-9eb2-a16cc2f0ca1e">4,830,000</ix:nonFraction> ADSs representing <ix:nonFraction unitRef="shares" contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTM1MA_21b64f0e-9025-4dee-9eb2-a16cc2f0ca1e">4,830,000</ix:nonFraction> ordinary shares, at a public offering price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i85577d0805ae43f28ac6d00d72e6ffc9_I20190415" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTQwMA_8fdea881-6120-49c9-87b2-b2375efe1ff2">24.00</ix:nonFraction>&#160;per ADS, which includes an additional <ix:nonFraction unitRef="shares" contextRef="idece61323c9d42bdbbd6d64fe516d660_D20190415-20190415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTQ0MQ_5d23f8be-d73d-4112-b576-738a273caaf0">630,000</ix:nonFraction> ADSs issued upon the exercise in full of the underwriters&#8217; option to purchase additional ADSs.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$<ix:nonFraction unitRef="usd" contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTYzNg_5836282a-ca75-4299-896e-1ef1aa0c8e32">108.8</ix:nonFraction> million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2020, the Company completed an underwritten public offering of&#160;<ix:nonFraction unitRef="shares" contextRef="ia9549cc85aa24734a469de8134065606_D20200127-20200127" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTcxOQ_4bc9841e-e65a-45e0-8880-2f5e9db3b3e0">7,250,000</ix:nonFraction>&#160;ADSs representing&#160;<ix:nonFraction unitRef="shares" contextRef="ia9549cc85aa24734a469de8134065606_D20200127-20200127" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTc0MA_c4e72a27-38d1-4da5-b884-4fbb1fafbfbe">7,250,000</ix:nonFraction>&#160;ordinary shares, at a public offering price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i64e0070edc0a4b0c87c8b6d88f9244d0_I20200127" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTc5MA_2868b956-a580-4802-a904-65c51c3a7451">11.00</ix:nonFraction>&#160;per ADS.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$<ix:nonFraction unitRef="usd" contextRef="i0dc3cbb83148416dbc07992923a63cad_D20200127-20200127" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjE5OTAyMzI3MDgzOA_c9ef9d63-5dc5-4317-a03d-d3cdd1936df1">75.0</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0Mjg0Mg_aafa6d7f-8483-460f-bf9f-1f9280598056">1,718,506</ix:nonFraction> ADSs under its Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC as sales agent. Aggregate net proceeds to the Company, after commission fees and offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0MzA1Ng_e47b2913-8a7b-4e75-8085-1ee24f5a950c">15.3</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i932c7033a2c64d83b9e11b73ab217086_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDQ5OQ_7858eae3-e9b1-4fa0-b98f-46b5e8064a8d">14,285,715</ix:nonFraction> ADSs, which includes the full exercise by the underwriters to purchase an additional <ix:nonFraction unitRef="shares" contextRef="id8c4c15ff52c42d49a43d574cf188723_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDU4OA_29b4dff6-7b7f-464f-a766-0782d483053d">2,142,857</ix:nonFraction> ADSs, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i41d639c705934456ab14641f84359651_I20210212" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDYyOA_4d9e1186-1414-42b3-8a64-1bf0390a29e7">7.00</ix:nonFraction> per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i524bbe2dd39341faac717c3d8d151567_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0MzAzNQ_9441f5d5-8504-49ad-8ea4-6dc4efa12b87">106.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjk3Ng_b8edda7a-1096-40f7-88df-1f5fc9275a60">33.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjk4Mw_0e38074d-2500-4203-a16e-dc340851eaed">29.9</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively.  In addition, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzEyOQ_8c188b27-5ef0-41d0-aac5-3771e9d9a0b4">412.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzEzNg_65b8fb2f-cdf8-4f78-87b1-b675b84684f2">379.2</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i1a58040aa7eb4d5baee4822cb60d53fb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or that additional funding will be available on terms acceptable to the Company, or at all. The Company believes the cash on hand at March 31, 2021 of $<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzc3Nw_094a2f47-e336-4abb-a5d0-1d7470020c21">239.0</ix:nonFraction> million will be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance of these financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Impact of COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the ongoing coronavirus 2019, or COVID-19, pandemic, the Company established a cross-functional task force and have implemented business continuity plans designed to address and mitigate its impact on the Company's employees and business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Company has not experienced any significant financial impact to date, the overall disruption caused by the COVID-19 pandemic on global healthcare systems, and the other risks and uncertainties associated with the pandemic, could cause its business, financial condition, results of operations and growth prospects to be materially adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, our global workforce transitioned to working remotely with the exception of research and clinical trial related activities that required laboratory-based activity or manufacturing. We implemented protocols and procedures to ensure the safety of our employees working on site, including requirement to wear personal protective equipment, temperature checks at entry and offered COVID-19 testing for any employee with symptoms or at suspected risk of exposure to virus. In June 2020, we began the implementation of our workplace re-entry plan, based on a phased approach that is principles-based and local in design, with a focus on continuity of patient treatment and working to bring its workforce back on-site safely. We have also implemented policies to control and limit office and lab access in line with social distancing guidelines and for contact tracing if needed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to track COVID-19 developments in Europe and the United States closely for their potential impact on our clinical trial sites, logistics and supply chain to ensure we can continue to maintain clinical trial conduct and data integrity. As the patients in our clinical trials are severely immune suppressed as a consequence of their underlying disease and the treatment they receive in the trials, we are also monitoring other transmissible infectious diseases, including influenza.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not aware of any specific event or circumstance that has impacted on its operations in a manner which would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities during the three months ended March 31, 2021. However, these estimates may change, as new events occur and additional information is obtained, relating to the COVID-19 pandemic or otherwise. Changes in estimates would be recognized in the consolidated financial statements as soon as they become known.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1Nzc_fbec7e60-e83a-4dae-8aec-45e9a2d69a00" continuedAt="i051b0e05ff7a4ec387c294392f742a60" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i051b0e05ff7a4ec387c294392f742a60" continuedAt="ic31c478315154fee93538108c25ad1c9"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1NzI_e49c51d9-48f8-47a9-adca-9d4ed1e5496e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include those of the Company, its wholly-owned subsidiary, Autolus Limited, and its U.S. subsidiary, Autolus Inc., and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). All intercompany accounts and transactions have been eliminated upon consolidation.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTQ_5818996d-45ad-46df-b366-57f13505447d" continuedAt="i454a227cc7ed42f384955cbea7e5d41f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="ic31c478315154fee93538108c25ad1c9" continuedAt="i0605ca13144041919676cbbd4742ad1b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i454a227cc7ed42f384955cbea7e5d41f">they become known. Actual results could differ materially from those estimates.</ix:continuation></span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1NzM_ca461ba1-a803-4ebc-8ed7-fc75e7509ddc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash and cash equivalents in the condensed consolidated financial statements to include cash at banks with a maturity of less than three months, which is subject to an insignificant risk of changes in value.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a lease that requires a letter of credit supported by $<ix:nonFraction unitRef="usd" contextRef="i25159a1662d546f8b7c7111c26504274_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTcwNQ_8f196ecd-e8a2-49dc-94e4-3843784c3487">0.6</ix:nonFraction> million&#160;deposit held by the Company's bank for the duration of the lease and a credit card arrangement that requires a security deposit of $<ix:nonFraction unitRef="usd" contextRef="idb4a12fcb03747dfaa82aec40ecf9ab6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTgzOQ_cfe92b2c-7353-4b6b-a995-54760a966d4e">0.2</ix:nonFraction> million. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTc_65bc0eb5-3877-4ca5-8a9b-0b41f9e36a1a" escape="true">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the Company's condensed consolidated statements of cash flows.</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTg_1a0fe020-31a8-4c77-a832-0f6c72c53ff8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1Nzk_46619496-59c0-4f13-b49a-7fc9b76f99b9" continuedAt="ie0ed229cf206408183611b20097b418c" escape="true">Concentration of Credit Risk</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0ed229cf206408183611b20097b418c">Financial instruments that subject the Company to credit risk consist primarily of cash and restricted cash. The Company places cash and restricted cash in established financial institutions. The Company has no significant&#160;off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTM_25478c91-3a51-4d4a-b2ed-0065bbfd0722" continuedAt="i2c8af15eae874422a7040b50d5dbe3fa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of March 31, 2021 and December&#160;31, 2020, the Company&#8217;s property and equipment consisted of office equipment, lab equipment, furniture and fixtures, and leasehold improvements. The office equipment has an estimated useful life of <ix:nonNumeric contextRef="if32728553356471ba7bc0e4c651239d0_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzE1OA_607a8340-f852-4fcd-bd1d-88f3ade147a6">three years</ix:nonNumeric>, lab equipment has an estimated useful life of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09">five</span>&#160;or&#160;<ix:nonNumeric contextRef="idb6476ec587b401aaa02d1e7fc32b2d9_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIxNA_e60e6f6f-c5a3-43d2-8663-7fc9b14e4573">ten years</ix:nonNumeric>, and furniture and fixtures have an estimated useful life of&#160;<ix:nonNumeric contextRef="ibe7330eedb514187a0f2f7858509b56d_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzI3OA_d085c8a0-2f90-4edc-91f5-49a53c3ad334">five years</ix:nonNumeric>. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Assets under construction primarily consist of costs incurred with leasehold improvements, and, once placed into service, will be depreciated over the shorter of the lease term or the estimated useful life of the asset.  Upon retirement or sale, the cost of assets are disposed of, and the related accumulated depreciation, is removed from the accounts and any resulting gain or loss is included in the statement of operations and other comprehensive loss. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a disposal loss of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" name="autl:GainLossOnDispositionOfLeaseholdImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTgxMg_5113d2fd-7cdc-4149-a3fc-b6c4f3694a1c">0.7</ix:nonFraction> million in the three months ended March 31, 2021 in leasehold improvements which are no longer being utilized in the facility in White City,  and did <ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjE5OTAyMzI4OTYwMw_f1b3d8ff-614d-497c-a08b-cbd76d99268b">no</ix:nonFraction>t recognize a disposal loss in the three months ended March 31, 2020.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2c8af15eae874422a7040b50d5dbe3fa">The Company evaluates an asset for potential impairment when events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Recoverability is measured by comparing the book value of the asset to the expected future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the asset exceeds the fair value.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMyNg_9c5851e1-ff8c-4e16-8ca5-b661a18665cd"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMyNg_c5e91b69-9d9d-40d0-b2ae-c2bc230c90cb">no</ix:nonFraction></ix:nonFraction>t recognize an impairment in the three months ended March 31, 2021 and 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><ix:continuation id="i0605ca13144041919676cbbd4742ad1b" continuedAt="i9901a2419c5c49e6922b0c666d5ec064"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODA_59061fc7-e0da-43eb-9ead-d9bd402c0407" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received, initial direct costs, or prepayments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company accounts for the lease and non-lease components of leases for classes of all underlying assets and allocates all of the contract consideration to the lease component.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODE_c65958eb-cd3f-4cb3-b573-3b5359dbd35b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets Subject to Amortization</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets are related to acquired software licenses with finite lives and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators of impairment are present, the Company tests for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company evaluates the useful lives for these intangible assets each reporting period to determine whether events and circumstances warrant a revision in their remaining useful lives.&#160;The Company did <ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMzNw_9c5851e1-ff8c-4e16-8ca5-b661a18665cd"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMzNw_c5e91b69-9d9d-40d0-b2ae-c2bc230c90cb">no</ix:nonFraction></ix:nonFraction>t recognize an impairment loss in the three months ended March 31, 2021 and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDE_ad3f25f3-66e0-4401-9a62-e958a0653566" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and its chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is the business of developing and commercializing gene therapies; however, the Company operates in <ix:nonFraction unitRef="region" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfNzk3OQ_0836ef41-b0ef-41fc-a4e8-007231988538">two</ix:nonFraction> geographic regions: the United Kingdom and the United States. Substantially all of the Company&#8217;s assets are held in the United Kingdom.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDg_40cb3316-63aa-4b0c-97bf-68b92505a7a6" continuedAt="ic9f4ed26ba0e4eada42cd026279fcf78" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9f4ed26ba0e4eada42cd026279fcf78" continuedAt="i183b9655bef04e75a3ac4cafa704c990">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, depreciation expense, third-party license fees, external costs of outside vendors engaged to conduct clinical development activities, clinical trials, costs to manufacture clinical trial materials and certain tax credits associated with research and development activities.</ix:continuation> The Company recorded the U.K. research and development expenditure credit (&#8220;RDEC&#8221;) in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:ResearchAndDevelopmentTaxCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfODc1MA_f2d72510-093e-468b-aaaa-95c736f6b2b3">30,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="autl:ResearchAndDevelopmentTaxCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfODc1Nw_ebb6c020-e4c5-455f-8047-e029852e646f">28,000</ix:nonFraction> for the three months ended March 31, 2021 and 2020, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i9901a2419c5c49e6922b0c666d5ec064" continuedAt="i7b3657f634784b958a763e80f723678b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, as reductions of research and development expenses within the Company&#8217;s statement of operations and comprehensive loss.</span></div><ix:continuation id="i183b9655bef04e75a3ac4cafa704c990"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing its condensed consolidated financial statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company&#8217;s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes judgments and estimates in determining the accrued balance in any accounting period.</span></div></ix:continuation><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTE_17bc1cb3-397f-4955-b60c-d4e04bf4c3c1" continuedAt="ic7dd91843d4b49d6be7f4a074325fcba" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for equity awards based on the grant date fair value of the award. The Company recognizes share-based compensation expense for awards granted to employees that have a graded vesting schedule based on a service condition only on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards (the &#8220;graded-vesting attribution method&#8221;), based on the estimated grant date fair value for each separately vesting tranche. For equity awards with a graded vesting schedule and a combination of service and performance conditions, the Company recognizes share-based compensation expense using a graded-vesting attribution method over the requisite service period when the achievement of a performance-based milestone is probable, based on the relative satisfaction of the performance condition as of the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For share-based awards granted to consultants and&#160;non-employees,&#160;compensation expense is recognized using the graded-vesting attribution method over the period during which services are rendered by such consultants and&#160;non-employees&#160;until completed. The measurement date for employee awards is the date of grant, and share-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 7 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lacks company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, it uses a combination of the historical volatility of the ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as the Company has adequate historical data regarding the volatility of its own traded security price.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i7b3657f634784b958a763e80f723678b" continuedAt="i8a55b663d0ce461dbb44ebad83bd39ce"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><ix:continuation id="ic7dd91843d4b49d6be7f4a074325fcba"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of the Company&#8217;s ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select Market on the date the grant is approved by the Board.</span></ix:continuation></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDM_b223a483-0a70-43c5-885c-e01279f76461" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement and Translation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is the pound sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates.&#160;Non-monetary&#160;assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. The Company recorded a  foreign exchange loss of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTM0OA_38fb8a72-37bb-4dff-92a8-5ec08411d23e">1.2</ix:nonFraction> million and foreign exchange gain of  $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTM3MDg_1efcb543-7e34-4cd3-8e04-22342086f0d9">4.3</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively. Foreign exchange gains are included in other income in the statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, the condensed consolidated financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#8217; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining the Company's net loss but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders&#8217; equity.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="autl:PatentCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTI_4e7aea17-6a15-4ede-a936-310825a5aa27" continuedAt="i65c2f0aa03e0498a96c471515881fb48" escape="true">Patent Costs</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i65c2f0aa03e0498a96c471515881fb48">The Company expenses patent prosecution and related legal costs as they are incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</ix:continuation> The Company recorded patent expenses of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTQ4NjA_e3657fef-7eef-4a3d-a65a-27c84639775a">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MjQ4Mw_17670df9-5f28-427f-b334-81064ead0cb2">0.6</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTA_88e5758d-93e3-47ee-9d05-1240ab78b648" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received research grants under which it is reimbursed for specific research and development activities. Payments received are recognized as income in the statements of operations and comprehensive loss over the period in which the Company recognizes the related costs. At the time the Company recognizes grant income, it has complied with the conditions attached to it and the receipt of the reimbursement is reasonably assured. The Company has received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance. For grants with refund provisions, the Company reviews the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. The Company has determined that the likelihood of any repayment events included in its current grants is remote.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTU_85511d77-2baa-4323-97ca-ebd63e6b3948" continuedAt="i365fb24bdbe24b12892d57e8d940d8c5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:232%">License Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASC Topic 606&#8221;).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i8a55b663d0ce461dbb44ebad83bd39ce" continuedAt="i242c7a6150044f41a895860575ec6a9c"><ix:continuation id="i365fb24bdbe24b12892d57e8d940d8c5"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company  fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contingent Research Milestone Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company&#8217;s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. The Company considers all relevant factors.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For three months ended March 31, 2021, the Company has not recognized any variable consideration with regards to the development milestones which are included in the license agreement that was executed in the period. This is due to the fact that those development milestones have not yet been met and the recognition of the related revenue is not yet probable.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i242c7a6150044f41a895860575ec6a9c" continuedAt="i92c0fb04bd8b4c99b33f9e177d065b2d"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTE_a823b08f-ef35-4b95-ac35-f03786f5b19d" continuedAt="i856f6f10f41b484889c285e51e67b5cd" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision (benefit) for income taxes represents income taxes paid or payable (or a reduction of such amounts) for the current year plus deferred taxes. Deferred taxes result from differences between the condensed consolidated financial statements and tax bases of the Company&#8217;s assets and liabilities, and are adjusted for changes in tax rates and tax law when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of United Kingdom and United States tax law and requires judgment and estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the realizability of its deferred tax assets at each reporting date, and establishes a valuation allowance when it is more likely than not that all or a portion of its deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. The Company considers all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that the Company&#8217;s deferred tax assets are not more likely than not realizable, the Company establishes a valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a&#160;two-step&#160;approach for recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that the Company believes is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in the Company&#8217;s income tax returns and the amount of tax benefits recognized in the its condensed consolidated financial statements represent the Company&#8217;s unrecognized income tax benefits, which it either records as a liability or reduction of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Credit</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i856f6f10f41b484889c285e51e67b5cd">The Company benefits from the U.K. research and development tax credit regime under both the small and medium sized enterprise, or SME, scheme and by claiming an RDEC in respect of grant funded projects. Under the SME regime, a portion of the Company&#8217;s losses can be surrendered for a cash rebate of up to 33.35% of eligible expenditures. SME credits are accounted for within the tax provision in the year in which the expenditures were incurred. RDEC credits are accounted for within other income in the condensed consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTI_9846371f-0406-4f2e-8fc8-040098a009f1" continuedAt="i16443a2259644145a86031c077751653" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:continuation id="i16443a2259644145a86031c077751653" continuedAt="ie1fd01585ab14b97a02e19b8ab19f721"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 220,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1fd01585ab14b97a02e19b8ab19f721">, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive loss is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners.</ix:continuation> The Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjUzOTg_db7fc2ff-7504-4469-b776-edce411d2c26">1.3</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjU0MjM_1eda1123-633d-4503-a6ca-282c4365e5bd">17.7</ix:nonFraction> million related to foreign currency translation adjustments during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODQ_bad07445-f48e-471f-9c7d-b038e388f9d7" continuedAt="iea7a1673577946c0a9e616aa52ad4e61" escape="true">Net Loss Per Share</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i92c0fb04bd8b4c99b33f9e177d065b2d"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea7a1673577946c0a9e616aa52ad4e61">Basic and diluted net loss per ordinary share is determined by dividing net loss by the weighted average number of ordinary shares outstanding during the period. For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented.</ix:continuation></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTc_b21750f4-f0f5-4617-9f59-70d968fa010d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"></td><td style="width:61.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted incentive shares and units</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia59d20ea5e8a4d7cbfe95212fb978221_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMi0xLTEtMS0w_874ba1b6-eb02-45d1-8410-3592d0d2abf4">1,360,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b4f427ba0764b8d8cd7204223dfb93f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMi0zLTEtMS0w_63f1dfda-38a7-47db-adae-a0090eea19be">722,028</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fb8cf98b7c46c1b399e564aa4b4ec1_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMy0xLTEtMS0w_4ce7eeda-0486-4a92-b0c1-ec96f49c9d90">6,881,620</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ca9e1c4a7374941a2c5d250cd93db6f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMy0zLTEtMS0w_769253d1-fbb5-4d7c-80a3-ffc97c4a88aa">5,914,949</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfNC0xLTEtMS0w_97da7562-0a30-461d-8d6a-61f09e1a30ac">8,241,779</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfNC0zLTEtMS0w_9e991973-a358-4d67-bf59-682f4e955ac5">6,636,977</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act and Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exemptions provided by the JOBS Act will apply until December 31, 2023 or such earlier time that the Company no longer meets the requirements of being an emerging growth company. The Company would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, has more than $700 million in market value of its securities held by non-affiliates as of the last day of its second fiscal quarter, or it issues more than $1 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also currently relies on other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging growth company, the Company is not required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on the Company&#8217;s system of internal controls over financial reporting pursuant to Section&#160;404(b), (ii)&#160;provide all of the compensation disclosure that may be required of&#160;non-emerging&#160;growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv)&#160;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. These exemptions will also apply until the Company is no longer an emerging growth company.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDY_d9c671a9-bdb9-47ec-9405-7a04dd2c35b0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company's financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTQ2_fbc1df91-cfe9-40e9-9837-5e1feac30803" continuedAt="i249fffc6d4a84250b2c1f3addf532923" escape="true">Prepaid Expenses and Other Assets, Current</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i249fffc6d4a84250b2c1f3addf532923" continuedAt="i2e2a6e652a5b4a23b9fee6a06dd2a5e8"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTQ4_523b3b51-d28e-4eaa-a904-db0c8855f230" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets, current consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:64.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development claims receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:ResearchAndDevelopmentClaimsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMS0xLTEtMS0w_486842c2-8748-46cc-b74c-2240b7af3d15">30,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="autl:ResearchAndDevelopmentClaimsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMS0zLTEtMS0w_89a0e00a-c59d-4f3a-96de-45d008a5861f">24,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMi0xLTEtMS0w_2b43a35e-4079-4795-8e92-8da29c5b4f85">7,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMi0zLTEtMS0w_aa226961-3375-447b-a3e1-b8e6ef8ddc52">10,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMy0xLTEtMS0w_2f5ed664-f444-4b36-838b-d25eb5c51eb9">3,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMy0zLTEtMS0w_e642ef92-0683-4f34-9a67-2a0143ff821e">3,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivables from terminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseIncentiveReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNC0xLTEtMS0w_572881fa-dad9-443f-8dc9-794913c38cb5">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseIncentiveReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNC0zLTEtMS0w_e32985eb-1c9e-4ba2-b685-7c2a3a9692e7">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:GrantsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNi0xLTEtMS0w_a64da9fd-433c-491f-8f6c-df63c8c98489">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="us-gaap:GrantsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNi0zLTEtMS0w_11c1107b-85a2-4d9e-94fc-2814c1d1a239">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNy0xLTEtMS0w_56a181cc-b400-4bf0-a4a6-16fb845b2301">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNy0zLTEtMS0w_e5784a11-7a65-49e8-b6d1-375f58d6be6b">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0xLTEtMS0yNDc_5c0836a9-da1b-4d48-a091-4930586e7b01">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0zLTEtMS0yNDM_e2c04a7a-2443-4c6d-a135-96dcf53f5d9f">3,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0xLTEtMS0w_20cdce4f-f1c9-49cf-a002-1734c31cfc44">48,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0zLTEtMS0w_b467ddff-cdcb-4173-88bc-816f5f7a7044">42,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in prepayments of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" name="autl:IncreaseDecreaseToPrepaidFacilityAndManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTA5OTUxMTYyODc5Nw_933c804d-0ece-4427-9cbc-81982371b7ab">2.7</ix:nonFraction> million as at March 31, 2021 when compared to December 31, 2020 is primarily related to decreases in prepayments for clinical trials and lower payments of directors' and officers liability insurance due to the timing of payments in the period when compared to the same period in the prior year. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e2a6e652a5b4a23b9fee6a06dd2a5e8">The increase in research and development claims receivable is due to an increase in the effective tax rate when compared to the same period last year. More information on the movement in the tax position between periods can be found in Note 9.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMjU2_cd110598-7fa8-4a81-a07a-3d4fe21d25ea" continuedAt="ib2e61bb79955408c96c1a608c07d10e6" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib2e61bb79955408c96c1a608c07d10e6" continuedAt="ia82dc2a29d5f4490883e750a67e6318d"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMjU0_42178805-a4a1-4aef-acff-12fb522e90c8" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.512%"><tr><td style="width:1.0%"></td><td style="width:64.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fac6fac3aa7454b9e09eae49685ed05_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMS0xLTEtMS0w_cea6c002-c9ca-4019-886f-b7884f3556a8">23,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54aa60e569634a13a1858ea934dcb0bb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMS0zLTEtMS0w_4c8a64fd-55fa-4b95-945f-7169e95b4c83">23,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6617f38eb9f4460a622b2d3e9279f54_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMi0xLTEtMS0w_5e049d8b-1535-4d7e-a1a8-f18be8aa8c75">3,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53347ee136fa448db35974e8e31a9d0b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMi0zLTEtMS0w_00d1e3c0-5a5b-476f-b0ad-bcd74e1d4f42">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2f75a31f494e2aa9a5db9ab782201c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMy0xLTEtMS0w_3e85e099-2faa-46dd-934f-0dc50c378436">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847ce03d632a4b45add274b3cfcf12b6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMy0zLTEtMS0w_a42a2ed3-9a33-48b1-8433-a7f891918187">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61a689210f94943a3d41c76d40e1ebd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNC0xLTEtMS0w_cf9a79a2-27e6-4b7b-ae97-aba31ebd433b">10,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2651a7e1481c490393262e2898c2333d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNC0zLTEtMS0w_5ad9d366-386a-484c-8d70-a6575939ba9d">10,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33f618510fd4997a9c685478ea3f3ba_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNS0xLTEtMS0w_3d598a10-6154-4c3f-935d-553a3e4d811a">11,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493cf0d67e02413cabd32aafc94e263f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNS0zLTEtMS0w_a50616fb-0918-48f7-8843-34f9ed823680">14,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNi0xLTEtMS0w_2a52648a-16f3-42e2-a058-73dc7acb12ae">16,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNi0zLTEtMS0w_b13282ce-f112-41e0-840e-d93d2cb4cebf">14,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNy0xLTEtMS0w_49612f5a-aed6-45ac-b46d-1d9e4ee784e0">33,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNy0zLTEtMS0w_9aebdf85-1b37-496e-bf24-0b2eecf3e5bc">38,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia82dc2a29d5f4490883e750a67e6318d">Depreciation expense for the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMTYy_a84cdeec-acc4-4679-9bea-6e60c7e36618">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMTY5_c7f6b6cc-e1e9-41c8-a1dc-a97e8cb099d9">1.3</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i8ceb2bb5972147538045c26086b1df4d_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RleHRyZWdpb246N2QxY2IyM2YxMTY4NDE0Y2FlZTgzMzIzNDE5MmFmODFfMTM3_40f16188-a3f9-4ef3-bd19-7be047be5833" continuedAt="i1110eeb0d5c84ba6be91a2cbde120a5e" escape="true">Accrued Expenses and Other Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1110eeb0d5c84ba6be91a2cbde120a5e"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RleHRyZWdpb246N2QxY2IyM2YxMTY4NDE0Y2FlZTgzMzIzNDE5MmFmODFfMTM4_6e89fd5e-25c2-48b8-9c43-32f38b0903f5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:66.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMS0xLTEtMS0w_c574d2ea-987e-46bf-b3ec-8e0bf39837c6">8,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMS0zLTEtMS0w_0149144b-da3d-44ad-8236-b9cecceca360">8,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="autl:AccruedResearchAndDevelopmentCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMi0xLTEtMS0w_dc49e6d8-844a-4660-8b44-e11328a9a7ae">11,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="autl:AccruedResearchAndDevelopmentCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMi0zLTEtMS0w_0f6300cc-34f3-4edf-8315-bd409e99c286">15,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCLB milestone and option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="autl:AccruedLicenseFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMy0xLTEtMS0w_c18026b1-21c7-4a9b-883b-bc15e62f8866">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="autl:AccruedLicenseFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMy0zLTEtMS0w_52088972-8176-45d6-bab9-67e6a47c1b57">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNC0xLTEtMS0w_07eadf4b-357b-4106-9d0f-8cfb0b204fea">3,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNC0zLTEtMS0w_1759521a-4632-4eff-ab41-f6f723f6a6b6">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate income and local taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNS0xLTEtMS0w_b5257cad-2c7a-459c-b795-2592d171ec65">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNS0zLTEtMS0w_aafd7016-cd57-45b5-a45e-08f07b6bf561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNi0xLTEtMS0w_cb9d8410-af37-4830-8ba2-bf0302f09707">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNi0zLTEtMS0w_db4c79eb-feed-476c-ad2e-af509d51d6c5">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNy0xLTEtMS0w_49ec0813-bf70-4a64-8af4-83a7aeb8738c">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNy0zLTEtMS0w_2ad85656-3c2a-4e27-962f-a03c838d78b3">27,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:2.25pt"><span><br/></span></div><div style="padding-left:2.25pt"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_40"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5Mw_37010284-75a6-4e98-aafe-181f0311f8c1" continuedAt="i2941f23e450849089d94315e3e2f8925" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2941f23e450849089d94315e3e2f8925" continuedAt="i75c6168cf2df4355b6851b0f11ddfc38"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ordinary Shares</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of March 31, 2021, the Company has not declared any dividends.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective from June 26, 2018, the board of directors has the authority to allot new ordinary shares or to grant rights to subscribe for or to convert any security into ordinary shares in the Company up to a maximum aggregate nominal amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i52a9ff78fd994500b70e17771c035eaf_I20180626" decimals="INF" format="ixt:numdotdecimal" name="autl:MaximumNominalAmountOfSharesAuthorizedForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfNTU1_2a5a5359-e35b-4ae2-a51f-939f9ead5d6d">8,400</ix:nonFraction>. This authority runs for <ix:nonNumeric contextRef="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626" format="ixt-sec:durwordsen" name="autl:AuthorizedGrantLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfNTgz_8afbea30-f495-4576-91c2-b8617a38db97">five years</ix:nonNumeric> and will expire on June 26, 2023. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective from June 26, 2018, the board also has the authority to allot ordinary shares for cash or to grant rights to subscribe for or to convert any security into ordinary shares in the Company without first offering them to existing shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i52a9ff78fd994500b70e17771c035eaf_I20180626" decimals="INF" format="ixt:numdotdecimal" name="autl:MaximumNominalAmountOfSharesAuthorizedForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfOTU1_e9812bfd-d4e8-4706-8bd2-5189a019e4fe">8,400</ix:nonFraction>. This authority runs for <ix:nonNumeric contextRef="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626" format="ixt-sec:durwordsen" name="autl:AuthorizedGrantLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfOTgz_1d686b76-bcdf-4497-9301-753d598fb365">five years</ix:nonNumeric> and will expire on June 26, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i75c6168cf2df4355b6851b0f11ddfc38" continuedAt="ia5d2577c055c43f9aa074b45128e0f49"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 the Company&#8217;s issued capital share consisted of&#160;<ix:nonFraction unitRef="shares" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTA4MA_1b2fa88b-acbf-4ddb-8985-6ed58c720f4b">70,515,354</ix:nonFraction>&#160;ordinary shares, with a nominal value of&#160; $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTEyNQ_0aeabc4e-b86e-4eec-9c2b-93c41f319864">0.000042</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share, (ii)&#160;<ix:nonFraction unitRef="shares" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTE0NA_400c0f13-0618-4a4f-bb2e-e360d598e209">34,425</ix:nonFraction>&#160;deferred shares, with a nominal value of&#160;&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTE4OA_c1b9d2e0-2bae-4b93-9804-1ed11a5975c0">0.00001</ix:nonFraction>&#160;per share, (iii)&#160;<ix:nonFraction unitRef="shares" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTIwOA_14e35812-2c98-4ee7-8ea3-4e73969a1b7c">88,893,548</ix:nonFraction>&#160;B deferred shares, with a nominal value of&#160;&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTI1NA_51746136-3c0b-45d1-9057-1b5e7d2f44cf">0.00099</ix:nonFraction>&#160;per share and (iv)&#160;<ix:nonFraction unitRef="shares" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTI3Ng_5bd37fe3-bd81-458a-ba92-f2d8460e6ce6">1</ix:nonFraction>&#160;C deferred share, with a nominal value of&#160;&#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTMyMQ_bbb52178-55fb-49fd-9b76-39082a427470">0.000008</ix:nonFraction>. Each issued share has been fully paid.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Open Market Sale Agreement</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><ix:continuation id="ia5d2577c055c43f9aa074b45128e0f49" continuedAt="i0dcab97bafc848a186f4c9e2a47bc599"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 18, 2020, the Company entered into an Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC, under which the Company may, at its option, offer and sell ADSs having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i89ef2b2dd83148a89ab674028ea86908_I20200918" decimals="-6" format="ixt:numdotdecimal" name="autl:SaleOfStockAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTYxOA_a07ea4e4-f5cf-461d-8b6f-6996a1fba112">100</ix:nonFraction>&#160;million from time to time through Jefferies, acting as sales agent. Any such sales made through our sales agent can be made by any method that is deemed an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act, or in other transactions pursuant to an effective shelf registration statement on Form F-3.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company agreed to pay Jefferies a commission of <ix:nonFraction unitRef="number" contextRef="i89ef2b2dd83148a89ab674028ea86908_I20200918" decimals="INF" name="autl:CommissionPercentageOfGrossSalesPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTk5OQ_8b191cda-c6e7-4452-9058-6471a3c139d0">3.0</ix:nonFraction>% of the gross proceeds of any sales of ADSs sold pursuant to the Sales Agreement. During </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three months ended March 31, 2021,</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2070486d12ea46aa83b02cb4d9488798_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5OTAyMzI1ODAzNA_31f0e2b9-2452-46a5-876f-8b138bc3f80d">1.7</ix:nonFraction>&#160;million ADSs under the Sales Agreement for net proceeds, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after underwriting discounts and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5OTAyMzI1ODAxOQ_2a2f1bcf-1db2-4156-a007-bb3609bf4c9a">15.3</ix:nonFraction>&#160;million</span></ix:continuation><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i0dcab97bafc848a186f4c9e2a47bc599">.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMQ_f65eda25-7c55-40c3-a8be-7960d38cb312" continuedAt="i0b43a4eedc3f4439a4044bdb432a6893" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i0b43a4eedc3f4439a4044bdb432a6893" continuedAt="ie309c7d16e2b4d1f8ea7e4340fbb7e11"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Company's 2018 Equity Incentive Plan (the "2018 Plan") and 2017 Stock Option Plan (the "2017 Plan"), as well as restricted shares granted as employee incentives, typically vest over a <ix:nonNumeric contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5Ng_fcd68f2d-0dc8-4c87-a648-2c9610aca19e">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjc2_55bf2c50-403d-46c3-a6b8-a1a69bdb6998">25</ix:nonFraction>% of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining <ix:nonNumeric contextRef="ied33dc884b13464f896f1ce66590f479_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfNDAx_b0a7ce5b-0025-42af-b06e-90dacd9e667f">three years</ix:nonNumeric>, unless the award contains specific performance vesting provisions. For equity awards issued that have both a performance vesting condition and a services condition, once the performance criteria is achieved, the awards are then subject to a <ix:nonNumeric contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5OQ_a055a95a-1fbc-4d4a-9577-8cd6e42c77e8">four-year</ix:nonNumeric> service vesting with <ix:nonFraction unitRef="number" contextRef="i152c0f30695a40f9a86760ec0cbcc834_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfNjc1_c9de6f00-5a2d-4ec7-8d57-6abf58024b40">25</ix:nonFraction>% of the award vesting on the first anniversary of the performance condition being achieved and the balance vesting monthly over the remaining <ix:nonNumeric contextRef="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfODE5_8a200fb5-f51f-42d7-b33b-1d94e1c00f72">three years</ix:nonNumeric>. Options granted in January 2021 contained performance conditions related to specified clinical milestones. Options granted under the 2018 Plan and 2017 Plan generally expire <ix:nonNumeric contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfODkw_e211c186-abe7-4773-bea2-be1915cd0dda">10</ix:nonNumeric> years from the date of grant. For certain senior members of management and directors, the board of directors has approved an alternative vesting schedule. Restricted stock units awarded in December 2019 vest over a&#160;<ix:nonNumeric contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTEwMg_f5a8d774-0877-4242-8ec9-4adac1da8eaa">3</ix:nonNumeric>-year service period with&#160;<ix:nonFraction unitRef="number" contextRef="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTEzMA_7f0f769b-aad7-4745-85af-780479bd96f0">50</ix:nonFraction>%&#160;of the award vesting one and a half years, or <ix:nonNumeric contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTE3OQ_aca0399e-7d42-463a-8ab3-782e57e06ac9"><ix:nonNumeric contextRef="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTE3OQ_d285f589-b8b4-4084-a3b0-42910c622893">18</ix:nonNumeric></ix:nonNumeric> months, from commencement date and the remaining&#160;<ix:nonFraction unitRef="number" contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTIzMQ_d430edd9-660b-4c50-bef4-8dcbf6e7f6a6">50</ix:nonFraction>%&#160;of the award vesting at the end of the third year.  Restricted stock units awarded in January 2021 contained a performance condition related to specified clinical milestone.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5Mw_39a7eadb-7703-414d-9b3c-dfab2ecb332d" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted by the Company during the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.032%"><tr><td style="width:1.0%"></td><td style="width:66.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="i916d4ef54fa54d7793e6e79e3ce53f4b_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMi0xLTEtMS0wL3RleHRyZWdpb246YWI1ZjVkNjJjNWFhNDcxYzgyNWM3ZGVlYWU5ODg3MmZfMTA_7c11fee7-6bd0-4aea-b67f-0d33005c6eba">6.08</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMy0xLTEtMS0wL3RleHRyZWdpb246Y2RjMmNjZjRjMTZmNDY0ZDlkMDc2Y2RmZDM4ZmI0YTBfNA_788ab23a-c852-41ea-a08b-7a8591df2729">0.62</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMy0xLTEtMS0wL3RleHRyZWdpb246Y2RjMmNjZjRjMTZmNDY0ZDlkMDc2Y2RmZDM4ZmI0YTBfMTA_131a9961-29c1-4cea-b825-4cb61ae0c780">0.99</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNC0xLTEtMS0wL3RleHRyZWdpb246ODMwNzJiYjkwZTIyNDc5NThlYWM2Y2RmZmNhYjVmMjRfNA_0858b9b7-b6c7-4bb3-82cd-0880e629fbf6">81.33</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNC0xLTEtMS0wL3RleHRyZWdpb246ODMwNzJiYjkwZTIyNDc5NThlYWM2Y2RmZmNhYjVmMjRfMTA_b2e2ae9a-7070-40e9-92a1-b42dfaf9ed65">81.34</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNS0xLTEtMS0w_348e9b34-aa33-47e9-ba84-b5f003f60bd6">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="ie309c7d16e2b4d1f8ea7e4340fbb7e11" continuedAt="i8e0342956e6a41cebaeba93a65ba0859"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Options</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMg_2dd8a1b2-6710-4230-9b24-506143a40266" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS0xLTEtMS0w_f672e071-272d-468b-aa3b-a2a9a2c0a946">5,611,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS0zLTEtMS0w_f3d80b98-3702-4789-b781-9722ee0d9cab">17.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i049951a6daee47029d1139d31d05bfa3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS01LTEtMS0w_aaa4530a-3f37-4d98-ac11-23cba5cfa74a">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS03LTEtMS0w_011688a6-82ca-4904-a959-ea486412d4bf">4,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMi0xLTEtMS0w_d54c9ad1-137d-4ac3-92cc-11ad02701cc2">1,828,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMi0zLTEtMS0w_a8df24f7-9ef6-4b21-8f66-10cf190d1a90">8.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMy0xLTEtMS0w_4167ea30-46c6-41ef-bafd-f02ce66f0047">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMy0zLTEtMS0w_b4d8d750-08b2-4772-90c6-e6ffbf812bee">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNC0xLTEtMS0w_929bd46f-5e4c-4ece-a0ae-c18933b2373d">557,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNC0zLTEtMS0w_3b091fb9-6323-45ea-acc6-971d47c1e60e">16.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS0xLTEtMS0w_c4211b0c-359b-4cf9-9490-b746b2f97677">6,881,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS0zLTEtMS0w_f22daeea-d114-403f-b96e-77bac4183be4">14.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS01LTEtMS0w_b2e7b57f-2d8d-4568-bb6a-049d5db5de74">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS03LTEtMS0w_3fe64876-9684-4763-b8b1-44a81f6cb12e">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi0xLTEtMS0w_e9a61e66-af22-4fbd-ab28-50587c75a8a6">2,954,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi0zLTEtMS0w_64f9de6b-cf76-4ade-8458-13727874cbd1">17.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi01LTEtMS0w_a496427e-26d5-4485-901f-25141ab81dd3">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi03LTEtMS0w_6baf1374-3cfc-49b3-a312-2d1509d03fbd">2,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy0xLTEtMS0w_d2002b70-504e-4033-8933-1dce18d2df3b">6,881,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy0zLTEtMS0w_08be0740-cdf3-45b5-bb55-efeff4f86490">14.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy01LTEtMS0w_d6ae29e2-114c-4c16-bb46-031e23e46e63">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy03LTEtMS0w_6414f2de-5474-448c-afcf-f4e6fb8582cb">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ADSs for those share options that had exercise prices lower than the fair value of the Company&#8217;s ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTg4NQ_c962f604-5659-4224-b37c-8649711c9dc4">5.96</ix:nonFraction> per share for the three months ended March 31, 2021, of which none were vested at the date of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the total unrecognized compensation expense related to unvested options was $<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjAyNQ_c43256c1-c0b1-4f89-ab8b-e1a7fea83080">9.4</ix:nonFraction> million, which the Company expects to recognize over a weighted average vesting period of <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjExMA_d45c0366-ff09-428d-ae68-dbd54cca8e54">2.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzEyMQ_286b4021-3b34-4a79-8ef8-5b270f4abd1c">1,602,500</ix:nonFraction> options with performance conditions related to specified clinical milestones.  As of March 31, 2021, the performance conditions were not determined to be probable and no expense was recorded for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Ordinary Shares</span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMA_b8811f18-9b82-40d1-95ce-1b400b702bd7" continuedAt="i0fb9fa23b3d146b29ad8f30a9b00f2cd" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s restricted ordinary shares during the three months ended March 31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:64.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a573508e9c143009ce350d6d6b25350_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMS0xLTEtMS0w_d51741ca-1a63-48bf-8ed6-6ae488698120">90,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a573508e9c143009ce350d6d6b25350_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMS0zLTEtMS0w_8e31f0ad-0846-4e16-b63f-2c0ab87ffa5f">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMi0xLTEtMS0w_b4f9ff76-6696-4ce6-a200-8f3f96796955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMi0zLTEtMS0w_9f563f78-8662-499b-9f39-808c9178e829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMy0xLTEtMS0w_df2bdf0e-81c5-48d5-8ffa-af7fd9ef519f">40,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMy0zLTEtMS0w_559d831e-265d-4081-9cec-bae0228313f4">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNC0xLTEtMS0w_54688498-7e50-4bad-835d-da6e2b805ea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNC0zLTEtMS0w_74252d81-a5d4-46fe-a909-ba7693d3f05a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNS0xLTEtMS0w_3b5349a6-7151-434c-89a0-e94c2773b55f">50,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNS0zLTEtMS0w_c69dc343-d944-4858-aa6b-3c6008eaaeb0">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMTk2Ng_e38dfe8f-3ea6-4666-bb1a-f3ee3677ccf1">no</ix:nonFraction> unrecognized compensation expense.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i8e0342956e6a41cebaeba93a65ba0859" continuedAt="i4b8c942a22384988b42f005d4d5ecf12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one of the Company&#8217;s ADSs upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#8217;s ADSs on the date of grant. The Company historically granted RSUs with service conditions that vest over&#160;<ix:nonNumeric contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjY5MA_77049c7a-1339-46e7-b80d-337f3c0f2a12">3</ix:nonNumeric>-year service period with&#160;<ix:nonFraction unitRef="number" contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjcxOA_d75bbdcf-d29a-4f82-88c6-6bdaa67c9b97">50</ix:nonFraction>%&#160;of the award vesting one-and-half years from grant date and the remaining&#160;<ix:nonFraction unitRef="number" contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjc5NQ_4c9c071e-6e41-45a2-bbf5-da14995a23c8">50</ix:nonFraction>%&#160;of the award vesting at the end of the third year. In January 2021, the Company awarded restricted stock units that contained a performance condition based on a condition related to a specified clinical milestone. In March 2021, the Company awarded restricted stock units with service conditions that vest over a <ix:nonNumeric contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjE5OTAyMzI2MjIwMw_64571aae-f970-4c1b-9389-04bc793f1e96">four year</ix:nonNumeric> period with <ix:nonFraction unitRef="number" contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjE5OTAyMzI2MjIwNQ_591e9d0c-4c3a-4883-9fe7-e5aa167e8677">25</ix:nonFraction>%  on the first anniversary of the grant date, and the balance vesting quarterly over the remaining <ix:nonNumeric contextRef="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzNDM3Mg_8a200fb5-f51f-42d7-b33b-1d94e1c00f72">three years</ix:nonNumeric>.&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0fb9fa23b3d146b29ad8f30a9b00f2cd"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2018 Plan for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:66.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic01ce88311fc413e92a876264e4e7673_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMS0xLTEtMS0w_d6ed4ab1-acbe-478f-8426-ab283c8f3535">415,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic01ce88311fc413e92a876264e4e7673_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMS0zLTEtMS0w_d8c53a7a-4853-4c05-991f-7a476fa2bba1">12.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMi0xLTEtMS0w_e4489b08-6188-4ac3-9fa2-1d03a2b428d3">1,035,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMi0zLTEtMS0w_529cca18-ec29-4afc-b4c7-41b8443ae6ea">8.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMy0xLTEtMS0w_184fea5c-565f-46c9-a063-5c278f58b331">21,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMy0zLTEtMS0w_f3156d51-6ef3-4c3f-a8ea-96cc6013ea90">8.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNC0xLTEtMS0w_693119eb-edd7-4de1-9a78-b2d99d0c928f">119,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNC0zLTEtMS0w_d4f4262d-8518-4fcc-b22e-b3ca6e2f3cd1">11.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNS0xLTEtMS0w_e091492d-314d-4d11-885f-9f544d41f926">1,309,900</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNS0zLTEtMS0w_690e4743-a7d7-4225-9637-71e5de1ed97e">9.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was&#160;$<ix:nonFraction unitRef="usd" contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzAyMA_15abd93a-9549-4f42-b23a-8f15f4141850">2.0</ix:nonFraction> million&#160;of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average vesting period of&#160;<ix:nonNumeric contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzE2NA_556b4d8b-eb44-4327-b024-b93b744daee0">2.5</ix:nonNumeric> years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzMyOA_0cad9a8e-072c-47ac-b623-86563e95131e">920,000</ix:nonFraction> RSUs with a performance condition related to a specified clinical milestone.  As of March 31, 2021, the performance condition was not determined to be probable and accordingly, no expense was recorded for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMw_fb1de7fe-6568-4ec7-a842-a92edaa8ee8c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development expenses, general and administrative expenses, and capitalized to property and equipment is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.474%"><tr><td style="width:1.0%"></td><td style="width:64.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6abb4fb36a41389bd1c9e0a53cb994_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMi0xLTEtMS0w_72b44415-840b-487f-89e6-82c6d43edbb6">1,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91d5db238bf4cbf8f5dd387c179eec8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMi0zLTEtMS0w_d1da2dd3-f4e6-49ee-8c3d-5011213e30d9">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78c180c11e46c6bbf16e7e78cf9f89_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMy0xLTEtMS0w_fd4df79a-c707-4fbc-99e4-51b6ffbe50ef">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c774dce7d34ff78fe33ab4eb91cbee_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMy0zLTEtMS0w_2baa69b1-c713-422b-b5b3-0f764ce94e9b">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized to property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5403abf0cda041f49722bec6a5bd107b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNC0xLTEtMS0w_48b778b7-6f1e-4eed-9786-081ef5526f17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5ac4db8415442786609952726649c3_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNC0zLTEtMS0w_6832183c-9946-43b5-b6b5-13a819fd7129">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation expense</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNS0xLTEtMS0w_eacc96c0-fda4-4281-ab7f-0aa1815ed333">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNS0zLTEtMS0w_a549dffd-2012-4ccd-aa8a-6cf818ce9c7c">6,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b8c942a22384988b42f005d4d5ecf12">The decrease in share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" name="autl:ShareBasedPaymentArrangementExpenseIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzY1MA_7e549b55-6ab0-4b3d-a9ea-83aaa01d7912">6.9</ix:nonFraction> million in the three months ended March 31, 2021 relates to forfeitures of share-based payment awards as a result of the reduction in workforce that began to take place during the period.</ix:continuation> </span></div><div id="i8ceb2bb5972147538045c26086b1df4d_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="autl:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfNDYzNA_95e39a84-a1ec-49ae-9606-11dfbda79de2" continuedAt="i5a0a023a2bec45d484c3469a19c8f01c" escape="true">License Agreements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i5a0a023a2bec45d484c3469a19c8f01c" continuedAt="i6a52659e981746498224ae242b41c517">UCL Business plc License</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i6a52659e981746498224ae242b41c517" continuedAt="id3514cc401784f24a7998e49994628f9"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, the Company entered into an exclusive license agreement (the &#8220;License&#8221;) with UCL Business Ltd. (&#8220;UCLB&#8221;), the technology transfer company of University College London (&#8220;UCL&#8221;), to obtain licenses to certain technology rights in the field of cancer therapy and diagnosis. In March 2016, the License was amended to include additional rights.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the License in September 2014, the Company issued <ix:nonFraction unitRef="shares" contextRef="i65bb2de6245d44fd989ae0fadd180dcf_D20140901-20140930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjYzNA_fb63075c-76f4-4673-a3a3-622ec9cdb55e">1,497,643</ix:nonFraction>&#160;ordinary shares to UCLB. The Company paid upfront fees of $<ix:nonFraction unitRef="usd" contextRef="i2dae7352e4564813bd4e58c8bfac3d0c_D20160301-20160331" decimals="-5" format="ixt:numdotdecimal" name="autl:PaymentOfUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjY5Ng_985d751a-f851-409f-aa89-508846859b4b">0.3</ix:nonFraction> million and issued an additional <ix:nonFraction unitRef="shares" contextRef="i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjcyNQ_24a39264-09ab-4ed6-8663-f14c6bcb66b2">313,971</ix:nonFraction> ordinary shares to UCLB when the License was amended in March 2016.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the License was further amended and restated to include a license to the Company's product candidate, AUTO1, for which UCL is conducting Phase&#160;1 clinical trials of AUTO1 in pediatric and adult ALL patients. The Company paid an upfront fee of &#163;<ix:nonFraction unitRef="gbp" contextRef="i194d9cd7426f43bdb92c35c4b53da10d_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="autl:PaymentOfUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzA1NQ_c9dd087e-351b-40d7-94a1-39800b54a210">1.5</ix:nonFraction> million for consideration for the amended and restated License and paid the additional &#163;<ix:nonFraction unitRef="gbp" contextRef="i8cc189fb946a4e56907d007ff790d9d3_I20180331" decimals="-4" format="ixt:numdotdecimal" name="autl:AccruedLicenseFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzEzOA_708297de-7e9e-4bc2-bbfb-0824538b51fb">0.35</ix:nonFraction>&#160;million in connection with UCLB's transfer of clinical data to the Company in December 2020. No equity was issued as part of the upfront fee consideration.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may be obligated to make payments to UCLB under the amended and restated License upon the initiation of certain clinical activities in an aggregate amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="i740603bdf79a4a19ab28501a2828b0da_I20210331" decimals="-4" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzQ3NQ_45c047d9-8144-420a-8683-d9286e8a1d35">0.18</ix:nonFraction>&#160;million, the receipt of specified regulatory approvals in an aggregate amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="ia6f3546488134bd188df42bb75467850_I20210331" decimals="-5" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzU1Mg_2a9b2505-5b83-4e59-8a9e-aa29a06365a0">37.5</ix:nonFraction>&#160;million, the start of commercialization in an aggregate amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="i6d5ef338879d45cfa5e65e5c7f749b73_I20210331" decimals="-6" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzYxNA_9a7f8417-bece-4d79-9925-291c44b664e0">18</ix:nonFraction> million, and the achievement of net sales levels in an aggregate amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="i836d7bd86d1742f8b994ba61b0ebc03a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzY4NQ_43e05189-d229-4d41-9f1f-ea75c2a65516">51</ix:nonFraction> million, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technologies. On a per-product basis, these milestone payments range from &#163;<ix:nonFraction unitRef="gbp" contextRef="i6ba521a09dfc43cc965da6b20f859156_I20210331" decimals="-6" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzg3MA_0b5b87b8-3449-4716-8def-51c150f528e7">1</ix:nonFraction> million to &#163;<ix:nonFraction unitRef="gbp" contextRef="i340f4450111245dd99b493da501889f5_I20210331" decimals="-5" format="ixt:numdotdecimal" name="autl:ConditionalPaymentBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzg3Nw_d9527168-95d0-41cb-a5ab-a94285d24378">18.5</ix:nonFraction> million, depending on which T cell programming modules are used in the product achieving the milestone.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of any of the Company&#8217;s products that use the&#160;in-licensed&#160;patent rights, the Company will be obligated to pay UCLB a flat royalty for each licensed product ranging from the&#160;low-&#160;to&#160;mid-single&#160;digits, depending on which technologies are deployed in the licensed product, based on worldwide annual net sales of each licensed product, subject to certain reductions, including for the market entry of competing products and for loss of patent coverage of licensed products. The Company may deduct from the royalties payable to UCLB one-half of any payments made to a third party to obtain a license to such third party&#8217;s intellectual property that is necessary to exploit any licensed products. Once net sales of a licensed product have reached a certain specified threshold, the Company may exercise an option to buy out UCLB&#8217;s rights to the remaining milestone payments, royalty payments, and sublicensing revenue payments for such licensed product, on terms to be negotiated at the time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License expires on a product-by-product and country-by-country basis upon the expiration of the royalty term with respect to each product in each country. The Company may unilaterally terminate the license agreement for any reason upon advance notice to UCLB. Either party may terminate the License for the uncured material breach by the other party or for the insolvency of the other party. If UCLB terminates the License following the Company&#8217;s insolvency or the Company&#8217;s material breach of the License, or if the Company terminates the License unilaterally, all rights and licenses granted to the Company will terminate, and all patent rights and&#160;know-how&#160;transferred to the Company pursuant to the License will revert back to UCLB, unless and to the extent the Company has exercised its option to acquire ownership of the licensed patent rights. In addition, UCLB has the right to negotiate with the Company for the grant of an exclusive license to the Company&#8217;s improvements to the T cell programming modules the Company has licensed on terms to be agreed upon at the time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noile-Immune Biotech Inc.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. ("Noile") under which the Company will have the right to develop CAR T cell therapies incorporating Noile&#8217;s PRIME (proliferation-inducing and migration-enhancing) technology. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient&#8217;s own T cells.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3514cc401784f24a7998e49994628f9">The Company paid an upfront fee and may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology.</ix:continuation></span></div><div><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_49"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTQ5NA_3d7f14c0-9a15-4b52-83ae-426d43d1a040" continuedAt="if6d93e620d884cbca5bb851f7e97c300" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><ix:continuation id="if6d93e620d884cbca5bb851f7e97c300"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is based upon the estimated annual effective tax rates for the year applied to the current period loss before tax plus the tax effect of any significant unusual items, discrete events or changes in tax law. Fluctuations in the distribution of pre-tax income among the Company&#8217;s operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the three months ended March 31, 2021 and 2020, the actual effective tax rates were <ix:nonFraction unitRef="number" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTA5OTUxMTYyOTUyOA_321e3847-5bb1-42b3-b5be-4b6b2d47d91e">14.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfNTI0_62625404-883a-4bac-a320-1046dffefdd4">11.0</ix:nonFraction>%, respectively. The increase in the effective tax rate for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020 was due an increase in the forecast proportion of qualifying research and development expenditure for the year.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual effective tax rates are lower than the <ix:nonFraction unitRef="number" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfODUw_b13c53f3-877a-4ee9-a461-c1e2364c0ce5">19</ix:nonFraction>% statutory rate of U.K. tax primarily due to the manner in which the UK research and development credit operates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit for the three months ended March 31, 2021 increased to $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTAwNw_c1dd690f-032a-4a4f-a153-6d82515e1d57">5.7</ix:nonFraction> million from $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTAxNQ_1fb8a4fd-5a69-45d6-ad3c-bc6ec2d631bb">3.7</ix:nonFraction> million for three months ended March 31, 2020 due to an increase in pre-tax losses and the increased effective tax rate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries a&#160;$<ix:nonFraction unitRef="usd" contextRef="iba75fdc622554754b612b6ca2d81e8dc_I20210331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTI3NA_418ffbf6-6f20-45e1-8f03-835ee087d2dd">2.0</ix:nonFraction> million&#160;deferred tax asset balance related to its U.S. subsidiary.  The Company has recorded a valuation allowance against the net deferred tax asset where the recoverability due to future taxable profits is unknown.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i8ceb2bb5972147538045c26086b1df4d_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUwMg_cdf2ebf5-af30-499e-992d-2cd76f93369b" continuedAt="i4ada7b03d4f3403c9ba473a8928342b6" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4ada7b03d4f3403c9ba473a8928342b6" continuedAt="i651424e3785140118b77bf826af06152"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an exclusive license agreement with UCLB which has subsequently been amended and restated (see Note 8). In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments upon the achievement of specified milestones. The Company has estimated the probability of the Company achieving each potential milestone in accordance with ASC 450,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that, as of March 31, 2021, there were no milestones for which the likelihood of achievement was probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><ix:continuation id="i651424e3785140118b77bf826af06152"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters are located in London, United Kingdom. The Company leases space at this location from Imperial (Forest House) Limited under a <ix:nonNumeric contextRef="ib312439b752b4257b958d24ddae1acc2_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUxMA_c548ad81-852e-48a6-b9ae-795939a545af">ten-year</ix:nonNumeric> lease, the term of which commenced in September 2015. The lease included an option for the Company to lease additional space within a <ix:nonNumeric contextRef="ie8fc906e9cef419a9335fea6d40a569f_I20210331" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMTkxMg_4be6190c-4763-48e6-821e-b2460b54cfef">15</ix:nonNumeric>-month period, which the Company exercised in October 2016. The exercise of the option resulted in a separate new lease agreement with a concurrent term through September 2025. The landlord exercised its option to give notice in September 2020 to terminate the Forest House lease and pay the Company a break-lease payment fee in September 2021. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i6d9b766ba80440d696ca8311b8127c2b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjI4Mg_d03a93b3-31c5-4445-a8e4-f41a91741ceb">1.3</ix:nonFraction>&#160;million gain upon the notice of lease termination in the third quarter of 2020 and has a lease incentive receivable of $<ix:nonFraction unitRef="usd" contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseIncentiveReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjM2MQ_c9466824-5f01-4e80-b771-5a4d7d37ac45">1.5</ix:nonFraction>&#160;million as of March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company signed a binding letter of intent to enter into a lease for manufacturing space in Enfield, United Kingdom. The letter of intent required the Company to enter into a <ix:nonNumeric contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDM4NA_e5c41bbb-4d65-4ddd-bd29-fa5cd2b4f937">15</ix:nonNumeric>-year lease provided that the landlord completed the required leasehold improvements described in the agreement. The Company executed lease agreements for <ix:nonFraction unitRef="unit" contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfUnitsInRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDU0MQ_7d9e2194-3568-420b-9036-3a1be9769322">three</ix:nonFraction> manufacturing space units, each for <ix:nonNumeric contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDU4MA_e5c41bbb-4d65-4ddd-bd29-fa5cd2b4f937">15</ix:nonNumeric>-year lease terms. The leases commenced in February 2019 with option to terminate the lease in February 2029.  In March 2021, the Company surrendered one of the units. Upon the surrender, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2ODM4MQ_170a004d-53f7-42f3-9d47-9501f94e95e4">0.1</ix:nonFraction>&#160;million gain in other income after a after recognizing a termination fee of $<ix:nonFraction unitRef="usd" contextRef="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="autl:LeaseTerminationFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2OTA2Ng_a7eb66d8-41e9-4a36-af11-2886d14acb6b">0.2</ix:nonFraction>&#160;million. The Company has no further obligations for the surrendered unit and the right of use asset and lease liability which were recorded for this unit have been written off in the period. The Company is actively seeking to sub-lease or assign the remaining lease arrangements to a third party. The Company completed an asset impairment analysis of the right of use asset concluding the undiscounted cash flows exceeded the carrying value as of March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company executed an agreement to sublease office space in Rockville, Maryland for a term through October 2021.  The Company then terminated the sublease in February 2020 and immediately entered into a <ix:nonNumeric contextRef="i9aa970f510b84d03bcdab0bf779d4aaa_D20181001-20181031" format="ixt-sec:durwordsen" name="autl:OperatingLeaseRentFreePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUxMQ_2a2cf439-7707-4d89-af63-6c816f8bc260">five-year</ix:nonNumeric> lease for the same space with the landlord. As a result of the sublease termination, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i1a1eb5a9f0484994b0f3d8ee7aa1718f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNTkyNg_8b689a1b-d4b7-4c4b-bc26-60d4fa251525">0.2</ix:nonFraction> million gain in other income (expense) in the three months ending March 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he lease related to this facility is classified as an operating lease. The Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. These costs are considered to be variable lease payments and are not included in the determination of the lease&#8217;s right-of-use asset or lease liability.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2019, the Company executed a lease agreement to lease additional office and manufacturing space in Rockville, Maryland. The lease agreement required the Company to enter into a lease provided that the landlord completes the required leasehold improvements described in the agreement. The lease commenced in August 2020 for a term through June 2036. In March 2021, the Company announced plans to move the site of its global launch of manufacturing capacity to the United Kingdom from the United States. As a part of this strategy, the Company entered into a termination agreement with the landlord of its Rockville, Maryland property to terminate the lease for office and manufacturing space. As a result, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i1cd6038d37304152829044a7577d308f_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTk1NA_d391d0a6-da6c-4301-b1a0-a752bfa93beb">2.0</ix:nonFraction>&#160;million termination fee gain from the landlord, a $<ix:nonFraction unitRef="usd" contextRef="i1cd6038d37304152829044a7577d308f_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTkyNg_16afddf1-7b49-4866-8aab-d8e61c4c9a10">2.3</ix:nonFraction>&#160;million gain from the removal of the leased right of use asset and corresponding lease liability, and expensed $<ix:nonFraction unitRef="usd" contextRef="i7eb8d879d3684656b339162dcd9fbfcb_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLeasehold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTk0MA_f95aa388-1743-4997-8024-d90318d5b242">2.4</ix:nonFraction>&#160;million of leasehold improvements for the three months ended March 31, 2021. The $<ix:nonFraction unitRef="usd" contextRef="idda9c1c6f5574294ad1bf162a75b78b0_D20210401-20210430" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2ODM5Nw_f7f8a268-6c3c-4efa-a78e-5328c02c0089">2.0</ix:nonFraction> million termination fee receivable from the landlord in included in Prepaid and other current assets in the Balance Sheet at March 31, 2021. The payment form the landlord  was received in April 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_55"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfOTc0_f239404e-8394-485a-a40f-4fa9ce56009e" continuedAt="i3ef535b4ce424e8db672b4fdeb5cd646" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i3ef535b4ce424e8db672b4fdeb5cd646" continuedAt="ic8632c7b012d46f4b269c11b373ea22c"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United Kingdom, the Company makes contributions to private defined benefit pension schemes on behalf of its employees. The Company expensed $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfMTg1_2faf1350-6410-4ee8-a5ef-4ba929d66103">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfMTky_86c44fb5-af1d-4d2a-bcb7-0843e4f099e0">0.3</ix:nonFraction> million in contributions for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code in October 2018. The plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches employee contributions up to <ix:nonFraction unitRef="number" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzI0_63826f09-fd9f-4cb1-b293-67562dce63d5">four</ix:nonFraction> percent of the employee&#8217;s annual salary. The </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AUTOLUS THERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8632c7b012d46f4b269c11b373ea22c">Company expensed $<ix:nonFraction unitRef="usd" contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzg5_62105e13-2cd3-4298-a3a7-67e0b8720940">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzk2_dc977670-bab7-4032-928d-ab75a3e28227">0.1</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively. The Company pays all administrative fees related to the 401(k) plan.</ix:continuation></span></div><div><span><br/></span></div><div id="i8ceb2bb5972147538045c26086b1df4d_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81OC9mcmFnOmE0YWQ4NjdhYmRmMDQzMDk5ZTY4NTQ1ZDljNzI5N2M5L3RleHRyZWdpb246YTRhZDg2N2FiZGYwNDMwOTllNjg1NDVkOWM3Mjk3YzlfNTU0_0c1db052-79ef-4691-b086-8f6ac9f3364c" continuedAt="i88cf6a70f8a74deaa76237e491ba78c2" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i88cf6a70f8a74deaa76237e491ba78c2">The Company evaluated subsequent events through May 6, 2021, the date on which these financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure.</ix:continuation></span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-operatingresult.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibad8af47b13141db98a3eeb2bbf59bf5_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on May 6, 2021. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the SEC on March 4, 2021.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We maintain our books and records in pounds sterling, our results are subsequently converted to U.S. dollars and we prepare our consolidated financial statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. All references in this Report on Form 6-K to &#8220;$&#8221; are to U.S. dollars and all references to &#8220;&#163;&#8221; are to pounds sterling. Our consolidated statements of operations and cash flows for the three months ended March 31, 2021 and 2020 have been translated from pounds sterling into U.S. dollars at the rate of &#163;1.00 to $1.3787 and &#163;1.00 to $1.2805 respectively.  Our consolidated balance sheets as of March 31, 2021 and December 31, 2020 have been translated from pounds sterling into U.S. dollars at the rate of &#163;1.00 to $1.3766 and &#163;1.00 to $1.3663, respectively. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as of that or any other date.</font></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated or the context otherwise requires, all references to &#8220;Autolus,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Autolus Therapeutics plc and its consolidated subsidiaries.</font></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The statements in this discussion regarding our expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the &#8220;Risk Factors&#8221; section of our Annual Report and any subsequent reports that we file with the SEC.</font></div><div><font><br></font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_4"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. We believe our programmed T cell therapies have the potential to be&#160;best-in-class&#160;and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In recent years, we have devoted substantially all of our resources to conducting preclinical studies and clinical trials, raising capital and establishing our intellectual property portfolio. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from government grants and sales of our equity securities, including the net proceeds from our initial public offering of American Depository Shares, or ADSs, in June 2018 as well as from follow-on public offerings. From our inception in 2014 through March 31, 2021, we have received aggregate net proceeds of $638.3 million from sales of our equity securities. We do not expect to generate significant revenue unless and until we obtain marketing approval for and commercialize one of our product candidates.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. For the three months ended March 31, 2021 and 2020, we incurred a net loss of $33.3 million and $29.9 million, respectively, and had an accumulated deficit of $412.5 million as of March 31, 2021.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses for the foreseeable future as we advance our product candidates through preclinical and clinical development, seek regulatory approval and pursue commercialization of any approved product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution. In addition, we may incur expenses in connection with the&#160;in-license&#160;or acquisition of additional product candidates. Furthermore, we have incurred and expect to continue to incur, additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our drug candidates or delay our pursuit of potential&#160;in-licenses&#160;or acquisitions.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had cash on hand of $239.0 million. Based on our current clinical development plans, we believe our existing cash and cash equivalents will be able to fund our current and planned operating expenses and capital expenditure requirements through at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we expect.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ATM Facility</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 18, 2020, we entered into an Open Market Sale Agreement or the Sales Agreement with Jefferies LLC, or Jeffries, under which we may, at our option, offer and sell ADSs having an aggregate offering price of up to $100&#160;million from time to time through Jefferies, acting as sales agent. Any such sales made through our sales agent can be made by any method that is deemed an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act, or in other transactions pursuant to an effective shelf registration statement on Form F-3.</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have agreed to pay Jefferies a commission of 3.0% of the gross proceeds of any sales of ADSs sold pursuant to the Sales Agreement. During the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three months ended March 31, 2021,</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we issued and aggregate of 1.7&#160;million ADSs under the Sales Agreement for net proceeds, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after underwriting discounts and offering expenses of $15.3&#160;million</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"> COVID-19 Response</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing coronavirus 2019, or COVID-19, pandemic, we established a cross-functional task force and have implemented business continuity plans designed to address and mitigate its impact on our employees and business.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any significant financial impact to date, the overall disruption caused by the COVID-19 pandemic on global healthcare systems, and the other risks and uncertainties associated with the pandemic, could cause our business, financial condition, results of operations and growth prospects to be materially adversely affected. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, our global workforce transitioned to working remotely with the exception of research and clinical trial related activities that required laboratory-based activity or manufacturing. We implemented protocols and procedures to ensure the safety of our employees working on site, including requirement to wear personal protective equipment, temperature checks at entry and offered COVID-19 testing for any employee with symptoms or at suspected risk of exposure to virus. In June 2020, we began the implementation of our workplace re-entry plan, based on a phased approach that is principles-based and local in design, with a focus on continuity of patient treatment and working to bring its workforce back on-site safely. We have also implemented policies to control and limit office and lab access in line with social distancing guidelines and for contact tracing if needed. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to track COVID-19 developments in Europe and the United States closely for their potential impact on our clinical trial sites, logistics and supply chain to ensure we can continue to maintain clinical trial conduct and data integrity. As the patients in our clinical trials are severely immune suppressed as a consequence of their underlying disease and the treatment they receive in the trials, we are also monitoring other transmissible infectious diseases, including influenza.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Realignment of Program Prioritization and Corporate Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we announced the restructuring of our R&#38;D strategy and namely, the prioritization of the AUTO1 program. We also intend to seek a partner for the AUTO3 program before progressing AUTO3 into its next phase of development. We also announced an adjustment of our workforce and infrastructure footprint during the first quarter of 2021, which involved an overall reduction in headcount of approximately 20%.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Manufacturing Adjustments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, we announced our plans to establish global commercial launch capacity in the United Kingdom as opposed to the United States, enabling us to leverage the expertise and skill base of our U.K.-based employees. Our proposed manufacturing growth in the United Kingdom will be supported by a combination of the extension of our existing clinical trial manufacturing facility at The Cell and Gene Therapy Catapult (CGTC) facility as well as a new Autolus facility. This revised strategy aims to deliver a less capital-intensive commercial manufacturing infrastructure at a lower cost base. In conjunction with this new strategy, we terminated our lease for the manufacturing and office facility in Rockville, Maryland. The mutual termination triggered a cash payment to us and ended all of our prior payment obligations under the lease. We disposed of leasehold improvements in connection with the termination of the lease and expensed $2.4 million in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2021.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_7"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Income</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income consists of proceeds from government research grants used to perform specific research and development activities. We recognize grant income over the period in which we recognize the related costs covered under the terms and conditions of the grant. We have received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance with the terms of the grant. For grants with refund provisions, we review the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. We have concluded that the likelihood of any repayment events included in our current grants is remote.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for our revenue pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASC Topic 606&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products approved for commercial sale and have not generated any revenue from commercial product sales to date. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps&#58; (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License Fees and Multiple Element Arrangements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, we consider the nature of service that we promise to transfer to the customer. When we decide on a method of measurement, we will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contingent Research Milestone Payments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements&#58; the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the consideration in a contract includes a variable amount, we will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if our entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. We consider contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We assess whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. We consider all relevant factors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred in connection with the research and development of our product candidates, which are partially offset by U.K. research and development expenditure tax credits provided by Her Majesty&#8217;s Revenue&#160;&#38; Customs, or HMRC. We expense research and development costs as incurred. These expenses include&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing&#160;scale-up&#160;expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and development functions&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred for outsourced professional scientific development services&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for laboratory materials and supplies used to support our research activities&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated facilities costs, depreciation and other expenses, which include rent and utilities&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upfront, milestone and management fees for maintaining licenses under our third-party licensing agreements.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct research and development expenses are tracked on a&#160;program-by-program&#160;basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants and CROs in connection with our preclinical development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under license agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee research and development as well as for managing our preclinical development, process development, manufacturing and clinical development activities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail on our research and development expenses&#58;</font></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.147%"><tr><td style="width:1.0%"></td><td style="width:56.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct research and development expenses</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt"><font><br></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:15.75pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B cell malignancies (AUTO1 &#38; AUTO3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:right"><font><br></font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:right"><font><br></font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:15.75pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other projects (AUTO 4, 5, 6, 7, &#38; 8)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total direct research and development expense</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,648</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,095</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,553</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and discovery expense and unallocated costs&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt;text-align:right"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt;text-align:right"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:2.25pt;text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:15.75pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel related (including share-based compensation)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,263&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,715)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:15.75pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,535&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,731</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:right"><font><br></font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;text-align:right"><font><br></font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(556)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 2.12pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 2.12pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next few years as we increase personnel costs, initiate and conduct additional clinical trials and prepare regulatory filings related to our product candidates. We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements to acquire the rights related to our product candidates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from sales of any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with development and commercialization activities, including the uncertainty of&#58;</font></div><div style="text-indent:31.5pt"><font><br></font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our clinical trials and other research and development activities, including establishing an appropriate safety profile with&#160;IND enabling studies&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful patient enrollment in, and the initiation and completion of, clinical trials&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial manufacturing&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of the product candidates following approval&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition and rapidly changing technologies within the biopharmaceutical industry.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if a regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. Commercialization of our product candidates will take several years and millions of dollars in development costs.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel in executive, finance, legal and administrative functions. General and administrative expenses also include allocated facility-related costs, patent filing and prosecution costs and professional fees for marketing, insurance, legal, consulting, accounting and audit services.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the planned development of our product candidates. We anticipate continued increased costs associated with being a public company listed in the United States, including accounting, audit, legal, regulatory and compliance expenses associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer insurance premiums, and higher investor and public relations costs.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we believe a regulatory approval of one of our product candidates appears likely, we would anticipate an increase in payroll and third party expense as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Other income (expense) consists primarily of interest income earned on our cash balances held at commercial banks and foreign currency transaction gains (losses). In the three months ended March 31, 2021 and 2020, other income also included gains recognized on termination of a leases, subleases, and a lease incentive.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate taxation in the United Kingdom and in the United States. Due to the nature of our business, we have generated losses since inception. Our income tax benefit recognized represents the sum of the research and development tax credits recoverable in the United Kingdom and income tax payable in the United States.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a company that carries out extensive research and development activities, we benefit from the U.K. research and development tax credit regime under the scheme for small or medium-sized enterprises, or SMEs, and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also claim a Research and Development Expenditure Credit, or RDEC, to the extent that our projects are grant funded. Under the SME regime, we are able to surrender some of our trading losses that arise from our qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditure. The net tax benefit of the RDEC reflected in our financial statements for the three months ended March 31, 2021 was 10.5%. We meet the conditions of the SME regime, but also can make claims under the RDEC regime to the extent that our projects are grant funded. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced CRO costs and utilities costs incurred as part of research projects, and do not equate directly to our reported research and development expenses. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.67%. A large portion of costs relating to our research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to continue to claim research and development tax credits under the SME regime in the future because we may no longer qualify. However, we should continue to be able to make claims under the RDEC regime.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Un-surrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.&#160;After accounting for tax credits receivable, we had accumulated tax losses for carry forward in the United Kingdom of $241.4 million as of March 31, 2021. The Company carries a&#160;$2.0 million&#160;deferred tax asset balance related to the U.S. entity.  We have recorded a valuation allowance against the net deferred tax asset where the recoverability due to future taxable profits is unknown.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we generate revenues in the future, we may benefit from the U.K. &#8220;patent box&#8221; regime that allows profits attributable to revenues from patents or patented products to be taxed at an effective rate of 10%.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value Added Tax, or VAT, is broadly charged on all taxable supplies of goods and services by VAT-registered businesses. Under current rates, an amount of 20% of the value, as determined for VAT purposes, of the goods or services supplied is added to all sales invoices and is payable to HMRC. Similarly, VAT paid on purchase invoices is generally reclaimable from HMRC.</font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_10"></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended March 31, 2021 and 2020 </font></div><div><font><br></font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020 (in thousands)&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,731)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,287)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,738)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,614)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of leasehold improvements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses, net</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,872)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,563)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,309)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest  income</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(466)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,484&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,646)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,112)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,990)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,569)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,421)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to ordinary shareholders</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,266)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,873)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,393)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Income</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income remained mostly flat at $0.3 million for the three months ended March 31, 2021.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to $30.7 million for the three months ended March 31, 2021 from $31.3 million for the three months ended March 31, 2020. Cash costs, which exclude depreciation and amortization as well as share-based compensation, increased to $30.7 million from $25.6 million. The increase in research and development cash costs of $5.1&#160;million consisted primarily of (i) an increase in compensation and employment related costs, net of lower travel costs as a result of restricted travel due to the ongoing COVID-19 pandemic, of $3.5&#160;million due to a combination of an increase in employee headcount to support the advancement of our product candidates in clinical development and severance payments related to the reduction in workforce that began to take place during the quarter, (ii) an increase of $2.2 million in facilities costs related to the continued scaling of manufacturing operations, and (iii)  an increase of $0.4 million related to cell logistics, which is offset by decreases in purchased materials in the amount of $0.6 million and project expenses of $0.4 million. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash costs decreased to $36,000 for the three months ended March 31, 2021 from $5.7 million for the three months ended March 31, 2020. The decrease is primarily related to share-based compensation expense included in research and development expenses, which decreased by $6.2 million as a result of forfeitures of incentive share options related to employees affected by the reduction in workforce. This was offset by an increase in depreciation of $0.5 million. </font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased to $8.7 million for the three months ended March 31, 2021 from $7.6 million for the three months ended March 31, 2020. Cash costs, which exclude depreciation expense as well as share-based expense compensation increased to $7.6 million from $5.9 million. The increase in general and administrative cash costs of $1.7 million related to an increase of (i) $0.4 million in facilities cost, (ii) an increase of $0.6 million in legal fees and audit fees,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (iii) an increase of $0.3 million of expenses related to preparations for becoming a commercial stage company, an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d (iv) an increase of  $0.4 million in compensation and employment related costs due to an increase in headcount, and severance payments related to the reduction in workforce that began to take place during the quarter.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash costs decreased to $1.1 million for the three months ended March 31, 2021 from $1.7 million for the three months ended March 31, 2020. The decrease is attributed to share-based compensation expense as a result of the lower fair value of stock options recognized during the period. </font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Disposal of Leasehold Improvements</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of leasehold improvements of $0.7 million related to the leasehold improvements no longer being utilized in the facility in White City, London.</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $0.5 million for three months ended March 31, 2021 due to lower interest rates for cash held on deposit.</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-align:justify;text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income decreased by $3.7 million for the three months ended March 31, 2021 from other income of $4.5 million for the three months ended March 31, 2020 to $0.8 million. There was a decrease of $5.7 million primarily due to the weakening of the U.S. dollar exchange rate relative to the pound sterling during the three months ended March 31, 2021 as compared to the three months ended March 31, 2020, offset by gains on lease terminations of $2.0 million, net of the related expenses.</font></div><div style="text-align:justify;text-indent:29.25pt"><font><br></font></div><div style="text-indent:31.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</font></div><div style="text-indent:31.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit increased to $5.7 million for the three months ended March 31, 2021 from $3.7 million for the three months ended March 31, 2020 due to increased research and development credits. As research and development credits grew at a faster rate than our net loss before income tax, this led to a higher effective tax rate. Research and development credits are obtained at a maximum rate of 33.35% of our qualifying research and development expenses, and the increase in the net credit was primarily attributable to an increase in our eligible research and development expenses.</font></div><div style="margin-top:12pt;text-indent:31.5pt"><font><br></font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_13"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have not generated any product revenue and have incurred operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through preclinical and clinical development, and seek regulatory approval and pursue commercialization of any approved product candidates. We expect that our research and development and general and administrative costs will increase in connection with our planned research, clinical development and potential commercialization activities. As a result, we will need additional capital to fund our operations until such time as we can generate significant revenue from product sales.</font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not currently have any approved products and have never generated any revenue from product sales or otherwise. We have funded our operations to date primarily with proceeds from government grants and sales of our equity securities. From our inception in 2014 through March 31, 2021, we have received aggregate net cash proceeds of $638.3 million from sales of our equity securities. As of March 31, 2021, we had cash of $239.0 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</font></div><div><font><br></font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods presented&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:61.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,343)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,033)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,637)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,324&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and restricted cash</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,972)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and restricted cash</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,713&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,668&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, operating activities used $37.3 million of cash, resulting from our net loss of $33.3 million, and net cash used resulting from changes in our operating assets and liabilities of $5.5 million, partially offset by&#160;non-cash&#160;charges of $1.4 million. Net cash used resulting from changes in our operating assets and liabilities for the three months ended March 31, 2021 consisted primarily of a $4.9 million increase in prepaid expenses and other current and non-current assets, $2.0 million of which related to the termination fee receivable from landlord for the property at Medical Center Drive, a decrease in in accrued expenses and other liabilities of $1.6 million, and a decrease in accounts payable of $0.9 million. This cash used was offset by a decrease in long term deposits of $0.8 million, and a $1.1 million decrease in right of use assets from amortization and lease liabilities, net. </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, operating activities used $24.0 million of cash, resulting from our net loss of $29.9 million, and net cash used resulting from changes in our operating assets and liabilities of $1.5 million, partially offset by&#160;non-cash&#160;charges of $7.3 million. Net cash used resulting from changes in our operating assets and liabilities for the three months ended March 31, 2020 consisted primarily of a $1.4&#160;million increase in prepaid expenses and other current and non-current assets, and a decrease in accrued expenses of $0.4 million, offset by $0.5 million decrease in right of use assets from amortization and lease liabilities, net.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Investing Activities</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we used $1.9 million and $2.6 million, respectively, of cash in investing activities, all of which consisted of purchases of property and equipment.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, net cash provided by financing activities was $123.3 million, consisting primarily of the proceeds from sales pursuant to our ATM Facility and our February 2021 follow-on offering, net of issuance costs. </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 net cash provided by financing activities was $74.3 million, consisting of $74.0 million net cash proceeds from our January 2020 follow-on offering and $0.3 million in unpaid issuance costs. There was minimal cash provided by employee stock option exercises.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. Our expenses will increase as we&#58;</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">seek regulatory approvals for any product candidates that successfully complete preclinical and clinical trials&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">establish a sales, marketing and distribution infrastructure in anticipation of commercializing of any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">hire additional clinical, medical and development personnel&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expand our infrastructure and facilities to accommodate our growing employee base&#59; and</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">maintain, expand and protect our intellectual property portfolio.</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research and development services, laboratory and related supplies, legal and other regulatory expenses, and administrative and overhead costs. Our future funding requirements will be heavily determined by the resources needed to support development of our product candidates. We currently have no ongoing material financing commitments, such as lines of credit or guarantees, which are expected to affect our liquidity over the next five years, other than our lease obligations and supplier purchase commitments.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current clinical development plans, we believe our existing cash of $239.0 million at March 31, 2021 will be sufficient to fund our current and planned operating expenses and capital expenditure requirements for at least the next 12 months. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we receive regulatory approval for our other product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We may also require additional capital to pursue&#160;in-licenses&#160;or acquisitions of other product candidates.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including&#58;</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope, progress, outcome and costs of our clinical trials and other research and development activities&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs and timing of hiring new employees to support our continued growth&#59;</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59; and</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the extent to which we&#160;in-license&#160;or acquire additional product candidates or technologies.</font></div><div style="padding-left:13.5pt;text-align:justify;text-indent:9pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings. To the extent that we raise additional capital through the sale of equity, the ownership interest of existing shareholders will be diluted. If we raise additional funds through other third-party funding, collaborations agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_16"></div><div style="margin-top:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;2 to our condensed consolidated financial statements appearing in Exhibit 99.1 of this Report on Form 6-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our condensed consolidated financial statements.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue ordinary shares as well as options and other securities exercisable for or convertible into ordinary shares or ADSs as incentives to our employees and directors. To the extent such incentives are in the form of share options, the options are granted pursuant to the terms of our 2017 Share Option Plan, or the 2017 Plan, or pursuant to the terms of our 2018 Equity Incentive Plan, or the 2018 Plan. Options granted under the 2017 Plan and 2018 Plan, as well as shares granted as employee incentives, typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining three years, unless the awards contain specific performance vesting provisions. For equity awards issued that have both a performance vesting condition and a services condition, or performance awards, once the performance criteria is achieved, the performance awards are then subject to a four-year service vesting with 25% of the performance award vesting on the first anniversary of the performance condition being achieved, with the balance vesting monthly over the remaining three years. For certain members of senior management and directors, the board has approved an alternative vesting schedule for the equity awards. The options granted under the 2017 Plan and 2018 Plan generally expire ten&#160;years from the date of grant.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for equity awards based on the grant date fair value of the award. For equity awards that vest based on a service condition, the share-based compensation expense is recognized on a straight-line basis over the requisite service period. For equity awards that contain both performance and service </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions, we recognize share-based compensation expense ratably over the requisite service period when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance condition as of the reporting date.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is recognized as an expense in the condensed consolidated financial statements based on the grant date fair value over the requisite service period. For awards granted to our employees and directors that vest based on service conditions, we use the accelerated method to allocate compensation expense to reporting periods. We do not adjust share-based compensation for estimated forfeitures and account for forfeitures when they occur.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We use the fair value of our ordinary shares, determined by reference to the closing price of our ADSs on the Nasdaq Global Select Market on the date of grant, to determine the fair value of restricted share awards.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of share options. This option-pricing model requires the input of various subjective assumptions, including the option&#8217;s expected life and the price volatility of the security.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model and applying assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following&#58;</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lack company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, we use a combination of the historical volatility of our ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded security price.</font></div><div style="padding-left:31.5pt;text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The expected term of options granted represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The expected term of our share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield of zero is based on the fact that we have never paid cash dividends on ordinary shares and do not expect to pay any cash dividends in the foreseeable future.</font></div><div style="padding-left:31.5pt;text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Fair value of ordinary shares.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The fair market value of our ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select market on the date the grant is approved by the Board.</font></div><div style="padding-left:31.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus deferred taxes. Deferred taxes result from differences between the financial statements and tax bases of our assets and liabilities, and are adjusted for changes in tax rates and tax laws when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate income taxes in the United Kingdom and the United States. The calculation of our tax provision involves the application of U.K. tax law and requires judgment and estimates.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the realizability of our deferred tax assets at each reporting date, and we establish a valuation allowance when it is more likely than not that all or a portion of our deferred tax assets will not be realized.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. We consider all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that our deferred tax assets are not more likely than not realizable, we establish a valuation allowance.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a&#160;two-step&#160;approach to recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that we believe is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in our income tax returns and the amount of tax benefits recognized in our financial statements represent our unrecognized income tax benefits, which we either record as a liability or as a reduction of deferred tax assets.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax and Current Tax Credits</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognized in the statement of operations, except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years. Tax credits are accrued for the year based on calculations that conform to the U.K. research and development tax credit regime, under both the SME and large company regimes. We meet the conditions of the SME regime, but also can make claims under the RDEC regime to the extent that our projects are grant funded.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to continue to claim research and development tax credits under the SME regime in the future because we may no longer qualify as a small or medium-sized company. However, we should continue to be able to make claims under the RDEC regime.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. No deferred tax assets are recognized on our losses carried forward and other attributes because there is currently no indication that we will make sufficient profits to utilize these attributes.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our condensed consolidated financial statements, we are required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on our behalf and determining the value of these services. In addition, we make estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. We make judgments and estimates in determining the accrued balance in any accounting period.</font></div><div id="ibad8af47b13141db98a3eeb2bbf59bf5_19"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The Jumpstart Our Business Startups Act, or the JOBS Act, provides that, among other things, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. As an emerging growth company, we have irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for implementation of new or revised accounting standards and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth public companies.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We also currently rely on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, we are not required to, among other things, (i) provide an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b), (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">These exemptions will apply until December 31, 2023 or, if earlier, until we no longer satisfy the conditions for being an emerging growth company.</font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2, &#8220;Summary of Significant Accounting Policies,&#8221; to our condensed consolidated financial statements included in Exhibit 99.1 of this Report on Form 6-K.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>autl-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:autl="http://www.autolus.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.autolus.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="autl-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="autl-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="autl-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="autl-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.autolus.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParentheticals" roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityUnaudited" roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Shareholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusiness" roleURI="http://www.autolus.com/role/NatureoftheBusiness">
        <link:definition>2101101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessDetails" roleURI="http://www.autolus.com/role/NatureoftheBusinessDetails">
        <link:definition>2402401 - Disclosure - Nature of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPatentCostsDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Patent Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails">
        <link:definition>2413409 - Disclosure - Summary of Significant Accounting Policies - Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails">
        <link:definition>2414410 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsCurrent" roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent">
        <link:definition>2115103 - Disclosure - Prepaid Expenses and Other Assets, Current</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsCurrentTables" roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables">
        <link:definition>2316302 - Disclosure - Prepaid Expenses and Other Assets, Current (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsCurrentDetails" roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails">
        <link:definition>2417411 - Disclosure - Prepaid Expenses and Other Assets, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails">
        <link:definition>2418412 - Disclosure - Prepaid Expenses and Other Assets, Current - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.autolus.com/role/PropertyandEquipmentNet">
        <link:definition>2119104 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.autolus.com/role/PropertyandEquipmentNetTables">
        <link:definition>2320303 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.autolus.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2421413 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativesDetails" roleURI="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails">
        <link:definition>2422414 - Disclosure - Property and Equipment, Net - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilities" roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities">
        <link:definition>2123105 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesTables" roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables">
        <link:definition>2324304 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherLiabilitiesDetails" roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>2425415 - Disclosure - Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.autolus.com/role/ShareholdersEquity">
        <link:definition>2126106 - Disclosure - Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityOrdinarySharesDetails" roleURI="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails">
        <link:definition>2427416 - Disclosure - Shareholders&#8217; Equity - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityOpenMarketSalesAgreementDetails" roleURI="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails">
        <link:definition>2428417 - Disclosure - Shareholders&#8217; Equity - Open Market Sales Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.autolus.com/role/ShareBasedCompensation">
        <link:definition>2129107 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.autolus.com/role/ShareBasedCompensationTables">
        <link:definition>2330305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2018Planand2017PlanDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails">
        <link:definition>2431418 - Disclosure - Share-Based Compensation - 2018 Plan and 2017 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationOptionsValuationAssumptionsDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails">
        <link:definition>2432419 - Disclosure - Share-Based Compensation - Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareOptionsRollforwardDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails">
        <link:definition>2433420 - Disclosure - Share-Based Compensation - Share Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareOptionsNarrativesDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails">
        <link:definition>2434421 - Disclosure - Share-Based Compensation - Share Options Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails">
        <link:definition>2435422 - Disclosure - Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails">
        <link:definition>2436423 - Disclosure - Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails">
        <link:definition>2437424 - Disclosure - Share-Based Compensation - Restricted Stock Units Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>2438425 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationAllocationDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails">
        <link:definition>2439426 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails">
        <link:definition>2440427 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.autolus.com/role/LicenseAgreements">
        <link:definition>2141108 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.autolus.com/role/LicenseAgreementsDetails">
        <link:definition>2442428 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.autolus.com/role/IncomeTaxes">
        <link:definition>2143109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.autolus.com/role/IncomeTaxesDetails">
        <link:definition>2444429 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.autolus.com/role/CommitmentsandContingencies">
        <link:definition>2145110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativesDetails" roleURI="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails">
        <link:definition>2446430 - Disclosure - Commitments and Contingencies - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.autolus.com/role/EmployeeBenefitPlans">
        <link:definition>2147111 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.autolus.com/role/EmployeeBenefitPlansDetails">
        <link:definition>2448431 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.autolus.com/role/SubsequentEvent">
        <link:definition>2149112 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="autl_PerformanceBasedMember" abstract="true" name="PerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_UCLBusinessplcMember" abstract="true" name="UCLBusinessplcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_OfficeSpaceInRockvilleMarylandMember" abstract="true" name="OfficeSpaceInRockvilleMarylandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_PaymentOfUpfrontFees" abstract="false" name="PaymentOfUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_CommissionPercentageOfGrossSalesPrice" abstract="false" name="CommissionPercentageOfGrossSalesPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" abstract="true" name="ManufacturingSpaceInEnfieldUnitedKingdomMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_DeferredClassCSharesMember" abstract="true" name="DeferredClassCSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_AdditionalSpaceMember" abstract="true" name="AdditionalSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" abstract="false" name="IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_SecurityDepositMember" abstract="true" name="SecurityDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="autl_ScheduleOfLicenseAgreementsLineItems" abstract="true" name="ScheduleOfLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" abstract="true" name="OfficeAndManufacturingSpaceinRockvilleMarylandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_LicenseAgreementsAbstract" abstract="true" name="LicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="autl_PatentCostsPolicyTextBlock" abstract="false" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="autl_AuthorizedGrantLife" abstract="false" name="AuthorizedGrantLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="autl_ConditionalPaymentsDomain" abstract="true" name="ConditionalPaymentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_GainLossOnDispositionOfLeaseholdImprovements" abstract="false" name="GainLossOnDispositionOfLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" abstract="false" name="ShareBasedPaymentArrangementExpenseIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_LeaseAssetsTerminated" abstract="false" name="LeaseAssetsTerminated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_LeaseTerminationFeeExpense" abstract="false" name="LeaseTerminationFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_LetterofCreditCollateralMember" abstract="true" name="LetterofCreditCollateralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_ScheduleOfLicenseAgreementsTable" abstract="true" name="ScheduleOfLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" abstract="false" name="HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ImperialForestHouseLimitedMember" abstract="true" name="ImperialForestHouseLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_MaximumNominalAmountOfSharesAuthorizedForGrant" abstract="false" name="MaximumNominalAmountOfSharesAuthorizedForGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_DeferredClassASharesMember" abstract="true" name="DeferredClassASharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_OrdinarySharesMember" abstract="true" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_DeferredClassBSharesMember" abstract="true" name="DeferredClassBSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_ProductSalesMember" abstract="true" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_CapitalizedSharebasedCompensation" abstract="false" name="CapitalizedSharebasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ResearchAndDevelopmentClaimsReceivableCurrent" abstract="false" name="ResearchAndDevelopmentClaimsReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_NetSalesLevelsMember" abstract="true" name="NetSalesLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_RegulatoryApprovalMember" abstract="true" name="RegulatoryApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" abstract="false" name="IncreaseDecreaseToPrepaidFacilityAndManufacturing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ResearchAndDevelopmentTaxCredits" abstract="false" name="ResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_OperatingLeaseRentFreePeriod" abstract="false" name="OperatingLeaseRentFreePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="autl_AccruedResearchAndDevelopmentCostCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_AccruedLicenseFeesCurrent" abstract="false" name="AccruedLicenseFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" abstract="false" name="RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_ClinicalActivitiesMember" abstract="true" name="ClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" abstract="false" name="IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="NetIncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_CapitalizedFixedAssetsMember" abstract="true" name="CapitalizedFixedAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="autl_ConditionalPaymentsAxis" abstract="true" name="ConditionalPaymentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="autl_ConditionalPaymentBasis" abstract="false" name="ConditionalPaymentBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" abstract="false" name="APICShareBasedPaymentArrangementReversalOfCostRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>autl-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.autolus.com/role/Cover" xlink:type="simple" xlink:href="autl-20210331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_531e9ca5-5664-47f8-9017-0fcb566024e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_AssetsCurrent_531e9ca5-5664-47f8-9017-0fcb566024e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b7f87e3-f76f-45a1-bdc8-d39e4172413f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b7f87e3-f76f-45a1-bdc8-d39e4172413f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_640a194a-65ce-47f7-b828-65459b71b084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_640a194a-65ce-47f7-b828-65459b71b084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_3ba4fe2f-163a-44f7-9791-dd958e084044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_3ba4fe2f-163a-44f7-9791-dd958e084044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_c5f5f13c-4722-46b7-958a-df5d714cd33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_c5f5f13c-4722-46b7-958a-df5d714cd33d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2751d7a8-7d04-4683-bdf0-3ca0b34c0f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2751d7a8-7d04-4683-bdf0-3ca0b34c0f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fda2d587-d348-4f9a-a57b-b3ba61898b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1fbd8197-91ac-4c68-a46a-47d215110481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fda2d587-d348-4f9a-a57b-b3ba61898b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b9ece6fa-c925-4493-9aeb-e8ef2634c212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5ba5fe7e-c04f-4e77-b8cd-1dbb3446d512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b9ece6fa-c925-4493-9aeb-e8ef2634c212" xlink:to="loc_us-gaap_LiabilitiesCurrent_5ba5fe7e-c04f-4e77-b8cd-1dbb3446d512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b6ec8d9-f075-43e0-a984-0812ec83f0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b9ece6fa-c925-4493-9aeb-e8ef2634c212" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b6ec8d9-f075-43e0-a984-0812ec83f0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f464bc4f-1518-4f93-817c-3f39e290d608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_36d008dc-1b18-4457-a1aa-f977359bce7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f464bc4f-1518-4f93-817c-3f39e290d608" xlink:to="loc_us-gaap_Cash_36d008dc-1b18-4457-a1aa-f977359bce7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_14148038-b74c-4935-8adf-a3c8391001f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f464bc4f-1518-4f93-817c-3f39e290d608" xlink:to="loc_us-gaap_RestrictedCashCurrent_14148038-b74c-4935-8adf-a3c8391001f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26520401-6be0-42ea-8d55-1cda27a74628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f464bc4f-1518-4f93-817c-3f39e290d608" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26520401-6be0-42ea-8d55-1cda27a74628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f797a19a-142f-481b-aeea-02cbc6b1f67a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b762592d-ba86-4090-9658-980169cc6b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f797a19a-142f-481b-aeea-02cbc6b1f67a" xlink:to="loc_us-gaap_Liabilities_b762592d-ba86-4090-9658-980169cc6b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d28e7c9f-85be-4019-8679-1860e8e16592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f797a19a-142f-481b-aeea-02cbc6b1f67a" xlink:to="loc_us-gaap_StockholdersEquity_d28e7c9f-85be-4019-8679-1860e8e16592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_43dc1dcc-f466-4d66-87e3-c876d13c4c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a9c3f465-0719-48be-8ef9-ecf1b74508cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43dc1dcc-f466-4d66-87e3-c876d13c4c53" xlink:to="loc_us-gaap_AccountsPayableCurrent_a9c3f465-0719-48be-8ef9-ecf1b74508cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b3b07a60-75d3-4abd-bc4c-b77648e8237e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43dc1dcc-f466-4d66-87e3-c876d13c4c53" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b3b07a60-75d3-4abd-bc4c-b77648e8237e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_385d25e0-a228-4ebd-b0eb-868f35a98f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43dc1dcc-f466-4d66-87e3-c876d13c4c53" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_385d25e0-a228-4ebd-b0eb-868f35a98f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73f2e0c2-a32e-442f-a726-ca32b7562841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1153bb61-f45b-4602-b410-fbfbcb3f1556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_73f2e0c2-a32e-442f-a726-ca32b7562841" xlink:to="loc_us-gaap_CommonStockValue_1153bb61-f45b-4602-b410-fbfbcb3f1556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_af25ce0e-0843-44d7-9e3c-79b2658dc2ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_73f2e0c2-a32e-442f-a726-ca32b7562841" xlink:to="loc_us-gaap_AdditionalPaidInCapital_af25ce0e-0843-44d7-9e3c-79b2658dc2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a29506ea-24a4-41e3-9e2a-bcc7114ef655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_73f2e0c2-a32e-442f-a726-ca32b7562841" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a29506ea-24a4-41e3-9e2a-bcc7114ef655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f429c44-9296-48c2-ba70-19ad528983dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_73f2e0c2-a32e-442f-a726-ca32b7562841" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f429c44-9296-48c2-ba70-19ad528983dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParentheticals"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eeec5233-c9f5-461d-a67f-bcfa81971766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_72e46b63-d545-4b9b-9d65-24867d0083c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eeec5233-c9f5-461d-a67f-bcfa81971766" xlink:to="loc_us-gaap_Revenues_72e46b63-d545-4b9b-9d65-24867d0083c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e7096c34-d21d-4bee-954e-4195548df9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eeec5233-c9f5-461d-a67f-bcfa81971766" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e7096c34-d21d-4bee-954e-4195548df9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ebfd9288-2c64-4f2a-8968-d6ca2f5cf975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eeec5233-c9f5-461d-a67f-bcfa81971766" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ebfd9288-2c64-4f2a-8968-d6ca2f5cf975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_4bd0d81c-f799-426f-b2b0-3c80890d4983" xlink:href="autl-20210331.xsd#autl_GainLossOnDispositionOfLeaseholdImprovements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eeec5233-c9f5-461d-a67f-bcfa81971766" xlink:to="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_4bd0d81c-f799-426f-b2b0-3c80890d4983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c211ad5a-15f3-4f98-b969-e746865151ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1936916a-df2f-4a44-8d55-86659ce91250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c211ad5a-15f3-4f98-b969-e746865151ac" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_1936916a-df2f-4a44-8d55-86659ce91250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f682f3ae-7867-4d14-95b5-df8ceb140455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c211ad5a-15f3-4f98-b969-e746865151ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f682f3ae-7867-4d14-95b5-df8ceb140455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7496c942-7f93-467f-816d-7d3bf0377cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ad04bf9-c3f6-4ad0-b3fa-78f5e18139c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7496c942-7f93-467f-816d-7d3bf0377cc3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ad04bf9-c3f6-4ad0-b3fa-78f5e18139c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b02a7b2-abf5-4ae7-964f-99f6b70b4bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7496c942-7f93-467f-816d-7d3bf0377cc3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b02a7b2-abf5-4ae7-964f-99f6b70b4bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b0eeea6-fd83-4343-b8e1-55a736b09870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dbded5c6-8606-4a8c-b00f-402fc73a14dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b0eeea6-fd83-4343-b8e1-55a736b09870" xlink:to="loc_us-gaap_OperatingIncomeLoss_dbded5c6-8606-4a8c-b00f-402fc73a14dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f16ef51-b4a8-4c76-b90e-957cb6620221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b0eeea6-fd83-4343-b8e1-55a736b09870" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8f16ef51-b4a8-4c76-b90e-957cb6620221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a6b73f4-21c1-48ed-b7f5-1681fcb2bc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a203ef04-c4af-442a-96e3-4e34e77ba504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a6b73f4-21c1-48ed-b7f5-1681fcb2bc29" xlink:to="loc_us-gaap_NetIncomeLoss_a203ef04-c4af-442a-96e3-4e34e77ba504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_57166722-0a60-4dfd-b0da-aa9d6a422deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a6b73f4-21c1-48ed-b7f5-1681fcb2bc29" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_57166722-0a60-4dfd-b0da-aa9d6a422deb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68902f95-82e7-4a84-8caa-085e009c0824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2e62d42-b447-4b60-8f3b-8f42d08ec99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68902f95-82e7-4a84-8caa-085e009c0824" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2e62d42-b447-4b60-8f3b-8f42d08ec99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0530e3b2-5556-45a2-8a9d-716bf14697f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68902f95-82e7-4a84-8caa-085e009c0824" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0530e3b2-5556-45a2-8a9d-716bf14697f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_592e436a-2efa-4a56-9b74-334562e96ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68902f95-82e7-4a84-8caa-085e009c0824" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_592e436a-2efa-4a56-9b74-334562e96ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f42167ab-c124-41a5-ba93-79c992c9c1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68902f95-82e7-4a84-8caa-085e009c0824" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f42167ab-c124-41a5-ba93-79c992c9c1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a876f0e-b2c2-49c4-9000-46671329d45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40ab81bb-9a31-4d93-81bc-331deb79718f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7a876f0e-b2c2-49c4-9000-46671329d45c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40ab81bb-9a31-4d93-81bc-331deb79718f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_194a3632-bef2-4125-9a38-b95ca2491ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_NetIncomeLoss_194a3632-bef2-4125-9a38-b95ca2491ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fff74035-1787-48d7-ad85-2d3470d94dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fff74035-1787-48d7-ad85-2d3470d94dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_2a2c67ef-9a4c-480a-aa9c-600a3abf0e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_2a2c67ef-9a4c-480a-aa9c-600a3abf0e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1eae1c85-782b-4c64-b4ce-e8cddf51e1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1eae1c85-782b-4c64-b4ce-e8cddf51e1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e070ec1c-0ec0-4ebc-83d7-05f7eb8918b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e070ec1c-0ec0-4ebc-83d7-05f7eb8918b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_269deef3-f507-4a31-b59a-a4282052b116" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_269deef3-f507-4a31-b59a-a4282052b116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1cb8ff68-9e8f-4d28-905b-b2decce7c80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1cb8ff68-9e8f-4d28-905b-b2decce7c80c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_efe3465d-c611-43d8-85fe-f85579416658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_efe3465d-c611-43d8-85fe-f85579416658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_e2cfea09-1cd4-4602-bc25-ff748d0761e0" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_e2cfea09-1cd4-4602-bc25-ff748d0761e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_879099e3-1713-495f-a613-66742080159d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_879099e3-1713-495f-a613-66742080159d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_e819ff85-9fc6-4f89-965c-e3494a8e7043" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_e819ff85-9fc6-4f89-965c-e3494a8e7043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_da1939cd-2272-4194-84b2-28ec60bd3436" xlink:href="autl-20210331.xsd#autl_NetIncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_da1939cd-2272-4194-84b2-28ec60bd3436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a8f5a3ed-1908-4e0f-8a22-173d11412e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cef7d78e-1df8-4fb8-b134-8f7d09e868a6" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a8f5a3ed-1908-4e0f-8a22-173d11412e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fbd1401-45dc-4133-9568-193a471ac0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_35a7ca99-d388-4192-bde9-db20045a99cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2fbd1401-45dc-4133-9568-193a471ac0f5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_35a7ca99-d388-4192-bde9-db20045a99cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9c0aa0e-f642-464f-bd5f-89690ebf7b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_775360a1-dbd4-42ab-a327-c769dc69604a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9c0aa0e-f642-464f-bd5f-89690ebf7b9c" xlink:to="loc_us-gaap_Cash_775360a1-dbd4-42ab-a327-c769dc69604a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2ba82b0b-f540-461f-b19c-b80862fa2b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9c0aa0e-f642-464f-bd5f-89690ebf7b9c" xlink:to="loc_us-gaap_RestrictedCashCurrent_2ba82b0b-f540-461f-b19c-b80862fa2b43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusiness"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPatentCostsDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrent"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentTables"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent_d3335ea9-163f-4d9e-9640-e2a0215fe763" xlink:href="autl-20210331.xsd#autl_ResearchAndDevelopmentClaimsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent_d3335ea9-163f-4d9e-9640-e2a0215fe763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_7a6c986a-7e6e-44ce-94b4-33b85a644c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_7a6c986a-7e6e-44ce-94b4-33b85a644c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_02d41866-e949-4af9-a3d0-d8215816bd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_02d41866-e949-4af9-a3d0-d8215816bd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivableCurrent_16db23e5-9689-4a37-ba41-7a7f7f854655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_LeaseIncentiveReceivableCurrent_16db23e5-9689-4a37-ba41-7a7f7f854655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_b13ac7e0-5988-4b31-97b2-41bb97ce7052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_GrantsReceivableCurrent_b13ac7e0-5988-4b31-97b2-41bb97ce7052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ce294883-4631-408d-8ff1-788931db6bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ce294883-4631-408d-8ff1-788931db6bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_ea6e4ab7-cb9e-4076-9275-86cab92db3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9b6e6817-755b-4466-9623-741e00de458e" xlink:to="loc_us-gaap_DeferredCostsCurrent_ea6e4ab7-cb9e-4076-9275-86cab92db3f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNet"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d40b440-2a79-4a07-b755-bd3a83f82f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_db412766-261f-4dd1-bb6c-f66f6034eab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7d40b440-2a79-4a07-b755-bd3a83f82f93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_db412766-261f-4dd1-bb6c-f66f6034eab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_802cb702-47f1-49d2-a07b-c233f9b20799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7d40b440-2a79-4a07-b755-bd3a83f82f93" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_802cb702-47f1-49d2-a07b-c233f9b20799" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilities"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3e8baae-2a78-471a-b6f7-de401f2362d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3e8baae-2a78-471a-b6f7-de401f2362d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedResearchAndDevelopmentCostCurrent_6c1984d7-07dc-4756-90f5-d7e7ba0d1499" xlink:href="autl-20210331.xsd#autl_AccruedResearchAndDevelopmentCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_autl_AccruedResearchAndDevelopmentCostCurrent_6c1984d7-07dc-4756-90f5-d7e7ba0d1499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedLicenseFeesCurrent_68448d79-315a-4c89-9cde-23337ccde3e7" xlink:href="autl-20210331.xsd#autl_AccruedLicenseFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_autl_AccruedLicenseFeesCurrent_68448d79-315a-4c89-9cde-23337ccde3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d343d750-12a6-4e8a-bad8-60fa81dc6154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d343d750-12a6-4e8a-bad8-60fa81dc6154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_65fa60d5-c0d2-42d7-b619-e007fa85306a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_us-gaap_TaxesPayableCurrent_65fa60d5-c0d2-42d7-b619-e007fa85306a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f90c0964-b65c-4853-9cee-037cac5ae3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9838d099-d61c-4b8f-b946-70507f7e3d42" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f90c0964-b65c-4853-9cee-037cac5ae3f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOrdinarySharesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOpenMarketSalesAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation2018Planand2017PlanDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationOptionsValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsRollforwardDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreements" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxes" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingenciesNarrativesDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SubsequentEvent" xlink:type="simple" xlink:href="autl-20210331.xsd#SubsequentEvent"/>
  <link:calculationLink xlink:role="http://www.autolus.com/role/SubsequentEvent" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>autl-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.autolus.com/role/Cover" xlink:type="simple" xlink:href="autl-20210331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/Cover" xlink:type="extended" id="iec5fec2212b54325bc725a3d96113e24_Cover"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="icdc6c4460b0342c7bc6b9a1768842866_CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:to="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_5fd52653-cc1c-4300-971c-31b211ee2a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_Cash_5fd52653-cc1c-4300-971c-31b211ee2a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5c80e8fc-37fe-4f8a-b2d9-f3f92231e0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_RestrictedCashCurrent_5c80e8fc-37fe-4f8a-b2d9-f3f92231e0cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3dcc59d3-9d01-4918-a9d7-348ab7e0bb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3dcc59d3-9d01-4918-a9d7-348ab7e0bb77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0351cbf-4bc5-4099-a148-c15c53d72eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_AssetsCurrent_d0351cbf-4bc5-4099-a148-c15c53d72eeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7a99a5bc-3ec6-4720-a5fd-66bb75a1b35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7a99a5bc-3ec6-4720-a5fd-66bb75a1b35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5a37905-34f0-4727-8275-a244d04cf3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5a37905-34f0-4727-8275-a244d04cf3eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_c2555db7-36e1-477b-ac9d-a593a613398f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_c2555db7-36e1-477b-ac9d-a593a613398f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_6faa0fd0-a0f2-48c5-8660-dfff7c81b271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_6faa0fd0-a0f2-48c5-8660-dfff7c81b271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f0c54a4e-d555-4090-bd61-0ed83bd3840c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f0c54a4e-d555-4090-bd61-0ed83bd3840c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d269cd10-0b04-4af8-b501-0141f224c282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d269cd10-0b04-4af8-b501-0141f224c282" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_784f3342-1542-4dc1-ab3a-df8bc919f401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_Assets_784f3342-1542-4dc1-ab3a-df8bc919f401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3a5eb9d4-22ce-498b-93f9-26710942ea82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_AccountsPayableCurrent_3a5eb9d4-22ce-498b-93f9-26710942ea82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7148539f-4371-4433-8980-9a8ed226a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7148539f-4371-4433-8980-9a8ed226a8b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cced0879-e9a2-450b-8fb5-bc43de148804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cced0879-e9a2-450b-8fb5-bc43de148804" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_61f97950-4444-4838-bbb1-b02ee4fb9082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_LiabilitiesCurrent_61f97950-4444-4838-bbb1-b02ee4fb9082" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47301d03-8faa-42fc-b13c-53455634f199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47301d03-8faa-42fc-b13c-53455634f199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a1ba8d2-3f8f-46c2-a29d-fd0d6e717a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_Liabilities_7a1ba8d2-3f8f-46c2-a29d-fd0d6e717a1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_625df893-c84a-4b47-9f85-12a7a4ca18a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_CommonStockValue_625df893-c84a-4b47-9f85-12a7a4ca18a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ab04194d-5be5-46a4-b7f5-fb03be670ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ab04194d-5be5-46a4-b7f5-fb03be670ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c251a69-18c0-4028-ac24-06aa2166084b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c251a69-18c0-4028-ac24-06aa2166084b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82d16718-fd72-404e-b44c-c4f7abd06744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82d16718-fd72-404e-b44c-c4f7abd06744" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b388df47-93f5-408b-9379-340edc5f9fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_StockholdersEquity_b388df47-93f5-408b-9379-340edc5f9fa9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e7f08dd-14a0-4ad9-9a08-d05348dc0ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e7f08dd-14a0-4ad9-9a08-d05348dc0ddc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:to="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aeea5ebe-2030-460c-9a63-dbef19e4c010_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:to="loc_us-gaap_ClassOfStockDomain_aeea5ebe-2030-460c-9a63-dbef19e4c010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:to="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_c06071f4-ec7f-4296-a4ef-a0739b1a4095" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_OrdinarySharesMember_c06071f4-ec7f-4296-a4ef-a0739b1a4095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_c5a9602e-ff10-4968-a8a9-5e7ef6d0d0e0" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassASharesMember_c5a9602e-ff10-4968-a8a9-5e7ef6d0d0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_b07ade74-63ac-4170-ad75-9a43abe25c3a" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassBSharesMember_b07ade74-63ac-4170-ad75-9a43abe25c3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_ac686163-fb96-455c-b4b4-91635b73eb42" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassCSharesMember_ac686163-fb96-455c-b4b4-91635b73eb42" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParentheticals"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="extended" id="ib0d1cb0f52b94aceae5602f68a9fbadd_CondensedConsolidatedBalanceSheetsUnauditedParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3a1f9e-7a66-4b42-9845-fc72c6059fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3a1f9e-7a66-4b42-9845-fc72c6059fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a653e8d2-d428-4cc8-b4b3-45298cb3874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a653e8d2-d428-4cc8-b4b3-45298cb3874e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c60d8663-c6f4-430c-b201-fe703c061a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesIssued_c60d8663-c6f4-430c-b201-fe703c061a91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b121dea-bbd1-4ed9-b6b1-3531afff0fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b121dea-bbd1-4ed9-b6b1-3531afff0fd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:to="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_23aead98-3565-4fd1-a8f0-84a24d4d68ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:to="loc_us-gaap_ClassOfStockDomain_23aead98-3565-4fd1-a8f0-84a24d4d68ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:to="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_f7b3f526-49ba-4766-9f81-bd94d1a12817" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_OrdinarySharesMember_f7b3f526-49ba-4766-9f81-bd94d1a12817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_a96663b1-4982-4e36-80b6-52fc1b1bf291" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassASharesMember_a96663b1-4982-4e36-80b6-52fc1b1bf291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_82870303-dcaa-449f-bea4-92529f72f0e1" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassBSharesMember_82870303-dcaa-449f-bea4-92529f72f0e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_4fe691ea-3d51-4e90-a8f3-d0bb1f3bb045" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassCSharesMember_4fe691ea-3d51-4e90-a8f3-d0bb1f3bb045" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="i1781be82d8c24523a622d681c35762cf_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended" id="i74cc6f2f69de4047a6eaf935f6ea2d8b_CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_218f84dd-28b1-4aa7-bf6d-460736e39642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockholdersEquity_218f84dd-28b1-4aa7-bf6d-460736e39642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c8a9ad7-6caf-4f51-9118-d55fad4589e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_SharesOutstanding_1c8a9ad7-6caf-4f51-9118-d55fad4589e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7169844f-4a12-49d2-aa01-e21915ac3c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7169844f-4a12-49d2-aa01-e21915ac3c8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99a73fdf-3560-4714-827c-d20458a1e45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99a73fdf-3560-4714-827c-d20458a1e45a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d52a2ff-a19e-4e6e-92e1-ece99cd4e576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d52a2ff-a19e-4e6e-92e1-ece99cd4e576" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_2a15e936-2177-4c07-92ab-a11f5dfca191" xlink:href="autl-20210331.xsd#autl_APICShareBasedPaymentArrangementReversalOfCostRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_2a15e936-2177-4c07-92ab-a11f5dfca191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_998e52f0-bd20-4b1a-b539-2a725e17614f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_998e52f0-bd20-4b1a-b539-2a725e17614f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_99248a26-76df-41d1-90ac-66afcfc84d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_99248a26-76df-41d1-90ac-66afcfc84d41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9b234083-cd29-46dd-995d-156b60cfdaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9b234083-cd29-46dd-995d-156b60cfdaaa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0c81aad-bac5-4c5d-ba45-7e4a21a2adb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0c81aad-bac5-4c5d-ba45-7e4a21a2adb1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20ec7ade-13b9-4a55-b580-b44e2fea829d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20ec7ade-13b9-4a55-b580-b44e2fea829d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9794ed3c-d520-4745-a260-45fbca7992bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_NetIncomeLoss_9794ed3c-d520-4745-a260-45fbca7992bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e97d450-900a-497f-9127-439a3b0fecdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a39fef5c-9c57-4795-bd47-3e9988f255ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:to="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1262c60-c839-4eaf-9533-cbb38e51cdbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:to="loc_us-gaap_EquityComponentDomain_a1262c60-c839-4eaf-9533-cbb38e51cdbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:to="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f967d2ef-bd51-4c2d-9fe6-c88f9e885c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_CommonStockMember_f967d2ef-bd51-4c2d-9fe6-c88f9e885c54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fbe6d6e2-8a7c-43f2-8175-4556ac2b12ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fbe6d6e2-8a7c-43f2-8175-4556ac2b12ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_deb8f97f-d8f2-460b-876b-530905310d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_deb8f97f-d8f2-460b-876b-530905310d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ab9092d-810b-40f7-b10a-f1157386b67d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_RetainedEarningsMember_1ab9092d-810b-40f7-b10a-f1157386b67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_349afc34-488f-493f-8e01-03f02cf398b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:to="loc_us-gaap_ClassOfStockDomain_349afc34-488f-493f-8e01-03f02cf398b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:to="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_a4b50016-7a86-4143-bafb-cfb16043b3bb" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_OrdinarySharesMember_a4b50016-7a86-4143-bafb-cfb16043b3bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_ce12854e-d482-4c3b-91c8-d13f974330d6" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassASharesMember_ce12854e-d482-4c3b-91c8-d13f974330d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_6c39ecc0-14c2-47ec-8dbd-cfb7134740e7" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassBSharesMember_6c39ecc0-14c2-47ec-8dbd-cfb7134740e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_541463c0-a4df-41f2-9797-682de1ff64e7" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassCSharesMember_541463c0-a4df-41f2-9797-682de1ff64e7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ia7706b9e47ac492cb35057fe173f1a37_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusiness"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="extended" id="i8bfbb2a068f24ef5b28b1782e0e12d0d_NatureoftheBusiness"/>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="extended" id="i86580e698558456ebbf1d8b4520b13bc_NatureoftheBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7bff6ef6-ea49-4a73-b259-80edf3220302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7bff6ef6-ea49-4a73-b259-80edf3220302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7e42bec4-29a7-4b88-a77a-26b6b4948502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7e42bec4-29a7-4b88-a77a-26b6b4948502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1d7c78f0-b6fd-4bf8-bace-5aa5241c5408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1d7c78f0-b6fd-4bf8-bace-5aa5241c5408" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_419de4ae-8a08-4cc5-b0b8-192cdae43156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_NetIncomeLoss_419de4ae-8a08-4cc5-b0b8-192cdae43156" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5d1f9179-354d-405b-94de-8ad8391d4f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5d1f9179-354d-405b-94de-8ad8391d4f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_978dd8d4-4d15-482b-b492-3fe9b4b94416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_Cash_978dd8d4-4d15-482b-b492-3fe9b4b94416" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b5e34fbe-9beb-49b7-9151-75cdcb21e39d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:to="loc_us-gaap_ClassOfStockDomain_b5e34fbe-9beb-49b7-9151-75cdcb21e39d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:to="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_0efe7cfb-0638-4947-866f-495437c63cc0" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:to="loc_autl_OrdinarySharesMember_0efe7cfb-0638-4947-866f-495437c63cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59954ee1-90d1-4d06-a9e9-67d8ea181918_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59954ee1-90d1-4d06-a9e9-67d8ea181918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2fbae489-66ce-486e-881e-9c02faa3b553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_us-gaap_IPOMember_2fbae489-66ce-486e-881e-9c02faa3b553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_99d08d0d-6125-43c3-8929-90d1f2b91d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_99d08d0d-6125-43c3-8929-90d1f2b91d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PublicStockOfferingMember_0ca0f53c-8d03-4c50-af57-ef440e8b54d6" xlink:href="autl-20210331.xsd#autl_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_autl_PublicStockOfferingMember_0ca0f53c-8d03-4c50-af57-ef440e8b54d6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="iec12d29ed4334f45a45763fd476a1b61_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i9a4c1cf36379451fa0450240930df16c_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ie0d054d08d964700ba206465feb8a619_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" id="idd0ac4be3d4c497583b74c6415fa85db_SummaryofSignificantAccountingPoliciesRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2092ccbf-0291-4e9c-a9f9-6a5710a3b5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:to="loc_us-gaap_RestrictedCashCurrent_2092ccbf-0291-4e9c-a9f9-6a5710a3b5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b23c50-ad35-4756-8447-84ab372aa767_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b23c50-ad35-4756-8447-84ab372aa767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LetterofCreditCollateralMember_c8a1e739-9c92-4c3f-955a-20a93161c198" xlink:href="autl-20210331.xsd#autl_LetterofCreditCollateralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:to="loc_autl_LetterofCreditCollateralMember_c8a1e739-9c92-4c3f-955a-20a93161c198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SecurityDepositMember_c30cad89-c194-4fff-b531-ed5df43ad3fa" xlink:href="autl-20210331.xsd#autl_SecurityDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:to="loc_autl_SecurityDepositMember_c30cad89-c194-4fff-b531-ed5df43ad3fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended" id="ie75d323cb1054940aa74e77b8d36ed82_SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b090342c-6b13-4571-92fb-b43477d7df48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b090342c-6b13-4571-92fb-b43477d7df48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_cd6996c2-0d2c-42e3-903a-0416557e91e1" xlink:href="autl-20210331.xsd#autl_GainLossOnDispositionOfLeaseholdImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_cd6996c2-0d2c-42e3-903a-0416557e91e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1fcbd65a-efa2-4583-8cb7-0bf722207fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1fcbd65a-efa2-4583-8cb7-0bf722207fa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52f7e02e-4cba-4dc6-964d-5c92960a1fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52f7e02e-4cba-4dc6-964d-5c92960a1fa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d55c6cf3-bd94-4baa-830f-e38da1fb94fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d55c6cf3-bd94-4baa-830f-e38da1fb94fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_806c4bd1-a761-4500-9829-bc136dbe1031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_OfficeEquipmentMember_806c4bd1-a761-4500-9829-bc136dbe1031" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2deeec75-dd46-4fa5-b8c9-c75c2dd0924a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_EquipmentMember_2deeec75-dd46-4fa5-b8c9-c75c2dd0924a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7bc5ec22-630a-4e0e-bf60-c182ca192492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7bc5ec22-630a-4e0e-bf60-c182ca192492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:to="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cdba4101-753e-4c5f-84ea-ca4707c64ba7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:to="loc_srt_RangeMember_cdba4101-753e-4c5f-84ea-ca4707c64ba7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:to="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a394d3fa-2997-40e2-aa56-1970b9a3488b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:to="loc_srt_MinimumMember_a394d3fa-2997-40e2-aa56-1970b9a3488b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfec9ad5-9356-44a6-a817-173c75d1b5a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:to="loc_srt_MaximumMember_dfec9ad5-9356-44a6-a817-173c75d1b5a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="extended" id="i19b27270967446188e2cc6350d966edc_SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" id="i176bc7198a0f42cbb937e23434ed0ab3_SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="extended" id="i65085344621946b592b7ba3c5c4b45da_SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="extended" id="ifbfc717d8b564b83addc9f0360937355_SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPatentCostsDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="extended" id="ie43eb560900b4f078061dc31ec57f245_SummaryofSignificantAccountingPoliciesPatentCostsDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="extended" id="i11ad643a8afe48449d73ebda637aa5bc_SummaryofSignificantAccountingPoliciesComprehensiveLossDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="extended" id="i0c6e37cd682e4cfea475b9cbc511a223_SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283a04a0-8430-41d1-82df-84c37ff3faf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283a04a0-8430-41d1-82df-84c37ff3faf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9804518a-df4f-4cfb-8c27-3d48dc410672_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9804518a-df4f-4cfb-8c27-3d48dc410672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0447e92e-125b-41e6-a7e8-aff0ccb3c978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0447e92e-125b-41e6-a7e8-aff0ccb3c978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a8ea7aa-7b16-446f-b76a-a1f0cf305c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a8ea7aa-7b16-446f-b76a-a1f0cf305c87" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrent"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="extended" id="ib506849027c04aa99e60fe7083f81570_PrepaidExpensesandOtherAssetsCurrent"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentTables"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="extended" id="ie4dfb5dec5884ef1834c8dfe11cfb284_PrepaidExpensesandOtherAssetsCurrentTables"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="extended" id="i4e05211777644340bf5d801bf453d304_PrepaidExpensesandOtherAssetsCurrentDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="extended" id="i6564477696bb4bffa8c402997018cf55_PrepaidExpensesandOtherAssetsCurrentNarrativeDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNet"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="extended" id="i79820e550e3647b5a3c9e4003487c2ae_PropertyandEquipmentNet"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="extended" id="if83443f04aa641d7a744719b25ab880d_PropertyandEquipmentNetTables"/>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i2be4213dc08945978d5b3fea95163abc_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8d0496ae-37bf-4c6b-b7f4-829211818b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8d0496ae-37bf-4c6b-b7f4-829211818b41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70d6dfd4-02cd-4e0d-bd37-8c2f2182d8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70d6dfd4-02cd-4e0d-bd37-8c2f2182d8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ed69a869-28fb-4950-8527-a9da28614780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ed69a869-28fb-4950-8527-a9da28614780" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1111df7c-12f0-4cc8-bb92-f61d4334fa95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1111df7c-12f0-4cc8-bb92-f61d4334fa95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_861f2e9e-7c07-4470-8c15-016ccea1a96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_EquipmentMember_861f2e9e-7c07-4470-8c15-016ccea1a96e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_88a48ba4-0bd8-49f0-98ff-34329bf105fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_OfficeEquipmentMember_88a48ba4-0bd8-49f0-98ff-34329bf105fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_05968d3f-4ddb-430c-8bd8-11da20b42aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_05968d3f-4ddb-430c-8bd8-11da20b42aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbe11102-62be-41c4-a2bd-a058eb4862fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbe11102-62be-41c4-a2bd-a058eb4862fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_74802b5e-8356-4b13-889b-9c1ce1170604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_AssetUnderConstructionMember_74802b5e-8356-4b13-889b-9c1ce1170604" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="extended" id="i51a1275d9195469a905cfaa794e20a88_PropertyandEquipmentNetNarrativesDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilities"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="extended" id="i34f952606da349408ee6cd52ee5bb427_AccruedExpensesandOtherLiabilities"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="extended" id="if68c94374ee341c0862adae88a47563f_AccruedExpensesandOtherLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended" id="iaba825fb80fd4df889e2626b73839917_AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareholdersEquity" xlink:type="extended" id="i8d42e1d4f47441dda4c091293a7ac0cf_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOrdinarySharesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="extended" id="i4d9fe36c705a498bb4338a78924a186a_ShareholdersEquityOrdinarySharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_fe41d74e-8070-48da-9115-26c6c20de130" xlink:href="autl-20210331.xsd#autl_MaximumNominalAmountOfSharesAuthorizedForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_fe41d74e-8070-48da-9115-26c6c20de130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AuthorizedGrantLife_a518d580-14ac-4a0d-8e12-524cb684bcf6" xlink:href="autl-20210331.xsd#autl_AuthorizedGrantLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_autl_AuthorizedGrantLife_a518d580-14ac-4a0d-8e12-524cb684bcf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_33fdbfa9-281f-46a0-9ef4-555a3b0d9947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_us-gaap_CommonStockSharesIssued_33fdbfa9-281f-46a0-9ef4-555a3b0d9947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1f3aeea6-5f83-4a53-9e57-305cc5987154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1f3aeea6-5f83-4a53-9e57-305cc5987154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eb961ec6-258e-49b6-9ce8-67126c8fdc6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:to="loc_us-gaap_ClassOfStockDomain_eb961ec6-258e-49b6-9ce8-67126c8fdc6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:to="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_28e96b9f-880e-485b-96a7-46893c4a9765" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:to="loc_autl_OrdinarySharesMember_28e96b9f-880e-485b-96a7-46893c4a9765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:to="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_d7071dec-204d-4ac0-ac53-034983a5af5c" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:to="loc_autl_DeferredClassBSharesMember_d7071dec-204d-4ac0-ac53-034983a5af5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_b810808b-0785-4555-aa3a-f33897991b5c" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:to="loc_autl_DeferredClassCSharesMember_b810808b-0785-4555-aa3a-f33897991b5c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOpenMarketSalesAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="extended" id="id7099fea91414253aa137ae7aa76bf98_ShareholdersEquityOpenMarketSalesAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SaleOfStockAuthorizedAmount_87df3484-daed-4758-945a-d73cfa164cbd" xlink:href="autl-20210331.xsd#autl_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_autl_SaleOfStockAuthorizedAmount_87df3484-daed-4758-945a-d73cfa164cbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CommissionPercentageOfGrossSalesPrice_4a5210d8-ef77-4ef8-a950-bc2451ef8c42" xlink:href="autl-20210331.xsd#autl_CommissionPercentageOfGrossSalesPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_autl_CommissionPercentageOfGrossSalesPrice_4a5210d8-ef77-4ef8-a950-bc2451ef8c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e201bc66-ba13-47af-b8a4-effbdff540dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e201bc66-ba13-47af-b8a4-effbdff540dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4da56f7-fa2e-4387-9206-365acd248536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4da56f7-fa2e-4387-9206-365acd248536" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PublicStockOfferingMember_4d43a855-3398-49a8-8716-0062d95f8ab1" xlink:href="autl-20210331.xsd#autl_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:to="loc_autl_PublicStockOfferingMember_4d43a855-3398-49a8-8716-0062d95f8ab1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="extended" id="i6ced721e777d4c81b014a122fb3ac2ea_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i5f19229f8cc94a679a7c2c4ca3156fe6_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation2018Planand2017PlanDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="extended" id="ie6a6681412b44fb79edb58e8db89a51a_ShareBasedCompensation2018Planand2017PlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ecd966e6-7149-4b18-8bae-52bd6fa4ede8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ecd966e6-7149-4b18-8bae-52bd6fa4ede8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a2662376-dd72-4cc9-8840-b1ccb3755956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a2662376-dd72-4cc9-8840-b1ccb3755956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ccb0ab40-b124-44c8-aaa6-e8c234e32172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ccb0ab40-b124-44c8-aaa6-e8c234e32172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:to="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49753946-8281-492c-916d-6544a762524f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49753946-8281-492c-916d-6544a762524f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PerformanceBasedMember_77888f31-9760-42d6-ac36-e2f4ea2aa4a5" xlink:href="autl-20210331.xsd#autl_PerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_autl_PerformanceBasedMember_77888f31-9760-42d6-ac36-e2f4ea2aa4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_198f5400-3fbb-4afc-a7ce-bb414e8f11b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_198f5400-3fbb-4afc-a7ce-bb414e8f11b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d8bb18-79cd-48ce-8d0c-f7067a2fdbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d8bb18-79cd-48ce-8d0c-f7067a2fdbd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:to="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4df166d4-c45f-4b76-9d5e-6d2d3839850e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:to="loc_us-gaap_VestingDomain_4df166d4-c45f-4b76-9d5e-6d2d3839850e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:to="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_90160653-248e-4c21-ac6e-55c9e7dd6f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_90160653-248e-4c21-ac6e-55c9e7dd6f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16f3c476-06cb-41ac-9fd0-ab3125579fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16f3c476-06cb-41ac-9fd0-ab3125579fb9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="extended" id="iaaed3268888f4f5da8cf047c32d727c4_ShareBasedCompensationOptionsValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ffec7386-f784-4856-adc0-51aad966398b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ffec7386-f784-4856-adc0-51aad966398b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_132051ed-a3c0-4090-9f8b-76189d353ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_132051ed-a3c0-4090-9f8b-76189d353ef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4c54cf4-9dfd-4d72-8645-e67f285dc697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4c54cf4-9dfd-4d72-8645-e67f285dc697" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6247066d-209a-472c-81bc-32c7c64dae83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6247066d-209a-472c-81bc-32c7c64dae83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7a8984c1-6466-446a-b963-1bcbbad8d8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7a8984c1-6466-446a-b963-1bcbbad8d8b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac9fe82e-29a4-426a-a20c-a30bddbf3969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac9fe82e-29a4-426a-a20c-a30bddbf3969" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:to="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a14d5d7-0ddc-4c66-813e-9005e73999a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a14d5d7-0ddc-4c66-813e-9005e73999a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4e64aa1-efea-4290-935d-9dcae1a3c7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4e64aa1-efea-4290-935d-9dcae1a3c7af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:to="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_871fb28b-58ee-44c2-9133-b75b0ac329f5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:to="loc_srt_RangeMember_871fb28b-58ee-44c2-9133-b75b0ac329f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:to="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d84c574-c110-4a30-86f5-f61035ae64bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:to="loc_srt_MaximumMember_1d84c574-c110-4a30-86f5-f61035ae64bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="extended" id="i754788df4d0345ac8cbdbf2af26fa342_ShareBasedCompensationShareOptionsRollforwardDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="extended" id="i175c7e44f998429194cb61b83f24ad9e_ShareBasedCompensationShareOptionsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_061ede0a-aab0-4e05-afeb-457047a37a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_061ede0a-aab0-4e05-afeb-457047a37a99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4353cbd6-7c9b-4c81-8af5-75d48610e3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4353cbd6-7c9b-4c81-8af5-75d48610e3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72f17eeb-aa7e-4d4f-907c-63e075ea5798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72f17eeb-aa7e-4d4f-907c-63e075ea5798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_177100da-cd56-4da5-9bd7-fe36588bc0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_177100da-cd56-4da5-9bd7-fe36588bc0d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:to="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c3057db-a520-4f2e-8f4f-7b0c39029036_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c3057db-a520-4f2e-8f4f-7b0c39029036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10144bac-894b-46c0-83ae-8aa4481d8b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10144bac-894b-46c0-83ae-8aa4481d8b7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="extended" id="i7053c4a1125a496d95217aa91fc62b23_ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf6bb572-2092-47d1-ac19-7c6f29fa6e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf6bb572-2092-47d1-ac19-7c6f29fa6e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3b6653d7-0588-4dc3-9427-c4e16686baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3b6653d7-0588-4dc3-9427-c4e16686baf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1035620d-c229-45ab-b5c0-133ba27ba3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1035620d-c229-45ab-b5c0-133ba27ba3a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9dcb91fd-d291-46bd-abf5-d9c481c8902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9dcb91fd-d291-46bd-abf5-d9c481c8902c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21727a03-75aa-4994-84bc-fe5ee90edc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34daa6fe-37bd-4cb7-b4a7-735ca5057376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34daa6fe-37bd-4cb7-b4a7-735ca5057376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc911153-03db-44f5-a5f9-175b860fae30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc911153-03db-44f5-a5f9-175b860fae30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_17e8f243-4339-4f4e-bf56-2cd99ce81246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_17e8f243-4339-4f4e-bf56-2cd99ce81246" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b1c282f5-f0b6-407a-bae0-084e3565da90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b1c282f5-f0b6-407a-bae0-084e3565da90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b2cee2b-c253-46cf-9d46-64c06ed0ae44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:to="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b7ffa0d-a39b-4a31-aed3-61e4bf565837_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b7ffa0d-a39b-4a31-aed3-61e4bf565837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_092e2f0f-9c65-4aa8-b168-de27798b01b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:to="loc_us-gaap_RestrictedStockMember_092e2f0f-9c65-4aa8-b168-de27798b01b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="extended" id="ic43d89596c714da983a24c6f70795b3a_ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1a48dde9-ffe1-42c3-b807-0abbcd77225a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1a48dde9-ffe1-42c3-b807-0abbcd77225a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2e011d7-3d39-4f96-bc28-a030f44fc12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2e011d7-3d39-4f96-bc28-a030f44fc12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:to="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_836bf5bc-ac80-4985-bf67-a54f731d0d94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_836bf5bc-ac80-4985-bf67-a54f731d0d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b9811438-482d-44c3-8735-6238d74867bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:to="loc_us-gaap_RestrictedStockMember_b9811438-482d-44c3-8735-6238d74867bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="extended" id="i83189c39f8434f2799d42ec52ffa1a3e_ShareBasedCompensationRestrictedStockUnitsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d555774-4d56-40bc-be72-279546b2680c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d555774-4d56-40bc-be72-279546b2680c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5887e454-0658-4f25-8210-65c99d7472dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5887e454-0658-4f25-8210-65c99d7472dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2377c8da-5167-47e0-a39f-ecfa552b939e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2377c8da-5167-47e0-a39f-ecfa552b939e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa405e3c-59e5-439a-bdcf-2e00b50fe7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa405e3c-59e5-439a-bdcf-2e00b50fe7bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0636879b-ca01-4ebb-a6ab-49f7692b7301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0636879b-ca01-4ebb-a6ab-49f7692b7301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:to="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_986a2617-5718-4859-941d-17af9e47e3aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_986a2617-5718-4859-941d-17af9e47e3aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a7140ba7-05a1-4a3a-9143-d1794e3230f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a7140ba7-05a1-4a3a-9143-d1794e3230f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:to="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_76f74bb6-6d62-4c50-ba52-92473ced59cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:to="loc_us-gaap_VestingDomain_76f74bb6-6d62-4c50-ba52-92473ced59cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:to="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940fc5cf-4e60-4c6e-a445-e90f427dcfd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940fc5cf-4e60-4c6e-a445-e90f427dcfd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c69d51a5-d041-491b-b024-0c900bdcacd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c69d51a5-d041-491b-b024-0c900bdcacd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i168cc1d248c64238804060dac63a1a9c_ShareBasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6c640d6-304c-4506-95c1-c466d05c5b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6c640d6-304c-4506-95c1-c466d05c5b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7dedf9b3-7266-4eaf-abed-61a9478b814f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7dedf9b3-7266-4eaf-abed-61a9478b814f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_561356a9-57a9-44ea-94fb-55bd36d8fb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_561356a9-57a9-44ea-94fb-55bd36d8fb72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc631932-239f-4ca0-a3c0-b2c4abdaffb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc631932-239f-4ca0-a3c0-b2c4abdaffb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7afcba45-1126-4fb1-9e6a-6d334f035c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1948a696-b958-417d-950b-4c8f31f9b2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1948a696-b958-417d-950b-4c8f31f9b2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5506f568-60d0-4024-ad57-0697e618c954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5506f568-60d0-4024-ad57-0697e618c954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7f374adf-7c65-4a0b-8522-0abc2159a9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7f374adf-7c65-4a0b-8522-0abc2159a9f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b79c3bbf-dbf3-44ca-a7d4-e6ac0d1bdcf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b79c3bbf-dbf3-44ca-a7d4-e6ac0d1bdcf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19b5b5c0-0163-495f-bf21-dcaa26a125a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:to="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303b6ea9-70b5-4e53-bca9-31aa1a20fc53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303b6ea9-70b5-4e53-bca9-31aa1a20fc53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3fc2187a-bae1-443f-8326-95c47bc94cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3fc2187a-bae1-443f-8326-95c47bc94cde" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="extended" id="i0234f810177b476da21ec9c3cc56a966_ShareBasedCompensationShareBasedCompensationAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72c6bbd8-4e83-484c-9000-11a6e2694ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72c6bbd8-4e83-484c-9000-11a6e2694ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_371c71ab-d0f4-4f0d-97f6-2851a990bfea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_371c71ab-d0f4-4f0d-97f6-2851a990bfea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9046137-e755-480e-b0aa-981b2637d2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9046137-e755-480e-b0aa-981b2637d2f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_071f59fa-45bc-4a06-a109-822b8e862208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_071f59fa-45bc-4a06-a109-822b8e862208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CapitalizedFixedAssetsMember_d2538723-1f99-4d72-9946-50d87d1bbfcc" xlink:href="autl-20210331.xsd#autl_CapitalizedFixedAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_autl_CapitalizedFixedAssetsMember_d2538723-1f99-4d72-9946-50d87d1bbfcc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="extended" id="i9c0d566d722845a9aa23748ace36906e_ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreements" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/LicenseAgreements" xlink:type="extended" id="ifd8b1032510a4031be4f709daa4020f8_LicenseAgreements"/>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="extended" id="iee57c403e48046cfb8c8f2b68c5adeb9_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_510a3bce-3e78-4824-a5de-1299bef4aa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_510a3bce-3e78-4824-a5de-1299bef4aa0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PaymentOfUpfrontFees_fb4fafc1-8792-44fe-b45a-951ce30a8c4a" xlink:href="autl-20210331.xsd#autl_PaymentOfUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_PaymentOfUpfrontFees_fb4fafc1-8792-44fe-b45a-951ce30a8c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedLicenseFeesCurrent_0553066b-9f33-4a9b-b7c1-dee74f9f9b15" xlink:href="autl-20210331.xsd#autl_AccruedLicenseFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_AccruedLicenseFeesCurrent_0553066b-9f33-4a9b-b7c1-dee74f9f9b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentBasis_de629d8a-bcce-4b76-8553-600a35278c55" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_ConditionalPaymentBasis_de629d8a-bcce-4b76-8553-600a35278c55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4eb595c0-b36a-4c2e-886c-2cff79923f7b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4eb595c0-b36a-4c2e-886c-2cff79923f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_UCLBusinessplcMember_400da149-a276-45a6-be64-8156a9ecb760" xlink:href="autl-20210331.xsd#autl_UCLBusinessplcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:to="loc_autl_UCLBusinessplcMember_400da149-a276-45a6-be64-8156a9ecb760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsDomain_523f24ef-d6dc-415f-ab91-47e07f2fb10f_default" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:to="loc_autl_ConditionalPaymentsDomain_523f24ef-d6dc-415f-ab91-47e07f2fb10f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:to="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ClinicalActivitiesMember_007f3810-b9d7-469e-876d-3ec2df3a94cb" xlink:href="autl-20210331.xsd#autl_ClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_ClinicalActivitiesMember_007f3810-b9d7-469e-876d-3ec2df3a94cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_RegulatoryApprovalMember_58d0a4c3-5aba-4a83-9267-72d289babf6b" xlink:href="autl-20210331.xsd#autl_RegulatoryApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_RegulatoryApprovalMember_58d0a4c3-5aba-4a83-9267-72d289babf6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ProductSalesMember_3cb592e0-2550-44d9-b760-bdd2386d15ce" xlink:href="autl-20210331.xsd#autl_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_ProductSalesMember_3cb592e0-2550-44d9-b760-bdd2386d15ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetSalesLevelsMember_5c027fb9-fc5f-4684-9a84-b82e3ea30d4e" xlink:href="autl-20210331.xsd#autl_NetSalesLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_NetSalesLevelsMember_5c027fb9-fc5f-4684-9a84-b82e3ea30d4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:to="loc_srt_RangeMember_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:to="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5a75396-2b25-4b6c-acb5-84b376f12835" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:to="loc_srt_MinimumMember_e5a75396-2b25-4b6c-acb5-84b376f12835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56c76db1-663d-4302-af6a-58184e09671c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:to="loc_srt_MaximumMember_56c76db1-663d-4302-af6a-58184e09671c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxes" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/IncomeTaxes" xlink:type="extended" id="i4c25ce278fa04d1ba1202d030b5f65fc_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="extended" id="i8c83c675ab18486d9295976dcade0003_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bcf1b0c1-506d-4bfa-8fb1-586b3cd2591c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bcf1b0c1-506d-4bfa-8fb1-586b3cd2591c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4372610-43fd-4202-819a-96d62720c65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4372610-43fd-4202-819a-96d62720c65d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18e2a2e0-5f9b-478c-8176-a2cd879442bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18e2a2e0-5f9b-478c-8176-a2cd879442bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2c1dbc9-2b49-4be2-a7c2-f339cd502093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2c1dbc9-2b49-4be2-a7c2-f339cd502093" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5b11fdef-1b90-469d-a4d5-01455f596868_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5b11fdef-1b90-469d-a4d5-01455f596868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_2d608aa5-73a9-4d1a-82b9-6419b7377852" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:to="loc_srt_SubsidiariesMember_2d608aa5-73a9-4d1a-82b9-6419b7377852" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="extended" id="ib928898f869746dc996c896fcca62def_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingenciesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="extended" id="ic4f477865f6943ffbcfb5996d7459919_CommitmentsandContingenciesNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5537b067-b140-4705-95e7-5f5532620343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5537b067-b140-4705-95e7-5f5532620343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_a9b2642f-50f7-406c-8592-f7944e1f7c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_a9b2642f-50f7-406c-8592-f7944e1f7c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivable_4aef07ac-e842-41a0-91f6-70d5eea306da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_LeaseIncentiveReceivable_4aef07ac-e842-41a0-91f6-70d5eea306da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfUnitsInRealEstateProperty_db7880fe-9d58-4c4d-824e-b981e4b4a753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfUnitsInRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_NumberOfUnitsInRealEstateProperty_db7880fe-9d58-4c4d-824e-b981e4b4a753" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LeaseTerminationFeeExpense_271abda7-109f-4f2b-a640-3bc37db84229" xlink:href="autl-20210331.xsd#autl_LeaseTerminationFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_autl_LeaseTerminationFeeExpense_271abda7-109f-4f2b-a640-3bc37db84229" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OperatingLeaseRentFreePeriod_eddf472c-daac-416e-853b-047dbdf6865e" xlink:href="autl-20210331.xsd#autl_OperatingLeaseRentFreePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_autl_OperatingLeaseRentFreePeriod_eddf472c-daac-416e-853b-047dbdf6865e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_678ea56d-d7e1-49fb-b9dc-b120067194f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_678ea56d-d7e1-49fb-b9dc-b120067194f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_58f650a8-e9cc-4aed-8c95-252f34df4470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_58f650a8-e9cc-4aed-8c95-252f34df4470" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02f7f63b-3e00-414d-abdc-1c60e9537635_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02f7f63b-3e00-414d-abdc-1c60e9537635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9094a191-1014-4816-b78b-ee17bc1943d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:to="loc_us-gaap_BuildingMember_9094a191-1014-4816-b78b-ee17bc1943d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AdditionalSpaceMember_84325674-89f7-4629-816d-b2db4eff2292" xlink:href="autl-20210331.xsd#autl_AdditionalSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:to="loc_autl_AdditionalSpaceMember_84325674-89f7-4629-816d-b2db4eff2292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9441c14d-23a2-4cfa-8897-28e9c8fd0a27_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9441c14d-23a2-4cfa-8897-28e9c8fd0a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ImperialForestHouseLimitedMember_659e77ea-0f8a-4840-929f-9ee6a988cea8" xlink:href="autl-20210331.xsd#autl_ImperialForestHouseLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_ImperialForestHouseLimitedMember_659e77ea-0f8a-4840-929f-9ee6a988cea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_c2f0bf67-4b1f-46e9-a37b-98b808b084ee" xlink:href="autl-20210331.xsd#autl_ManufacturingSpaceInEnfieldUnitedKingdomMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_c2f0bf67-4b1f-46e9-a37b-98b808b084ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeSpaceInRockvilleMarylandMember_794c93cb-71f3-4ea9-81a1-a240dfc571e6" xlink:href="autl-20210331.xsd#autl_OfficeSpaceInRockvilleMarylandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_OfficeSpaceInRockvilleMarylandMember_794c93cb-71f3-4ea9-81a1-a240dfc571e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_18f32e83-6dc1-4209-83b6-f99dda21fbfe" xlink:href="autl-20210331.xsd#autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_18f32e83-6dc1-4209-83b6-f99dda21fbfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_89122ff0-b162-4f21-82a2-644d501c1daa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_89122ff0-b162-4f21-82a2-644d501c1daa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_22955f70-a6b0-4bde-bbe2-94634b54469f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:to="loc_us-gaap_SubsequentEventMember_22955f70-a6b0-4bde-bbe2-94634b54469f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i27696bd4863d4c65971c8204d9b030fe_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="ib12cdc9b18dc41a58c824655ad364525_EmployeeBenefitPlansDetails"/>
  <link:roleRef roleURI="http://www.autolus.com/role/SubsequentEvent" xlink:type="simple" xlink:href="autl-20210331.xsd#SubsequentEvent"/>
  <link:definitionLink xlink:role="http://www.autolus.com/role/SubsequentEvent" xlink:type="extended" id="ib2b82fd27eb646c2baab43c4a9e37331_SubsequentEvent"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>autl-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ebcbb999-0585-4255-b31c-81efb5275391_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4afb6a09-4086-4e66-9d1f-4673de32a77f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d8027729-7dbf-445c-a70c-0cf935519030_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (aggregate intrinsic value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_53bc4b90-e7cc-462e-a4e0-c2b4ddfca4c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_268951f1-1f3e-4445-bbed-4013c20c239c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_31378390-c5d8-456f-8737-81c7a6e46279_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cbfd3926-1b1e-4196-8ff6-f065522ca6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_7b5de7e3-5f99-44c0-969c-f7eb2705630d_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseIncentiveReceivable_ef15dd91-ef73-4c79-ac35-5fd309bf984a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive receivable</link:label>
    <link:label id="lab_us-gaap_LeaseIncentiveReceivable_label_en-US" xlink:label="lab_us-gaap_LeaseIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentiveReceivable" xlink:to="lab_us-gaap_LeaseIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2fd6e7a3-f526-4069-9280-264a1402250c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d4f8422b-5043-497b-97f3-da5ac57a7907_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_PatentCostsPolicyTextBlock_61730367-a1d1-442e-85c0-7cc97ce7d939_terseLabel_en-US" xlink:label="lab_autl_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_autl_PatentCostsPolicyTextBlock_label_en-US" xlink:label="lab_autl_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:label id="lab_autl_PatentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_autl_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PatentCostsPolicyTextBlock" xlink:href="autl-20210331.xsd#autl_PatentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_PatentCostsPolicyTextBlock" xlink:to="lab_autl_PatentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_553569e2-4ec3-4bb3-b12c-ade6ae430feb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_383d6628-d000-4e59-9209-ada40c3f0ba7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25989543-fd25-46ae-b743-d792d91575b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_878a2a16-2a6e-4ede-8a08-fa700129fe3d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_5073a4d4-df59-4482-a0dc-84e802243abe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b4016bff-489d-4864-9fe2-51912079bc2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_4a212015-ae06-410d-9a0e-f0c799b97051_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cd5d72ad-545b-4231-9faa-32696e988f6f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_54b89f71-9f86-487f-8718-ceeb4a520de3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation not yet recognized for unvested shares other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_AccruedLicenseFeesCurrent_eb6f14ab-515f-4ed2-9fcf-fed0f0ef9e9c_terseLabel_en-US" xlink:label="lab_autl_AccruedLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCLB milestone and option</link:label>
    <link:label id="lab_autl_AccruedLicenseFeesCurrent_e65fd429-7f31-444a-98ff-187a8aae3157_verboseLabel_en-US" xlink:label="lab_autl_AccruedLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued license fees payable</link:label>
    <link:label id="lab_autl_AccruedLicenseFeesCurrent_label_en-US" xlink:label="lab_autl_AccruedLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued License Fees, Current</link:label>
    <link:label id="lab_autl_AccruedLicenseFeesCurrent_documentation_en-US" xlink:label="lab_autl_AccruedLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued License Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedLicenseFeesCurrent" xlink:href="autl-20210331.xsd#autl_AccruedLicenseFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_AccruedLicenseFeesCurrent" xlink:to="lab_autl_AccruedLicenseFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7a56003f-7c6e-4cca-a60a-c7eb3b2c537d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69e4ac56-f8c1-4458-859e-c6ab7a2719f8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06d46315-5fde-48d2-bb63-688248712c74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d3da2299-9ab0-4881-935f-bfaed848d043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_67114afe-b3e0-4d32-bd28-2517717b5e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_18ec97e8-0b03-4e74-9550-6bd937ee711a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6583d7f5-0769-4670-9517-1fadfd967ed8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_df2962fc-8ea7-4a74-be63-fbef9e0c32fd_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_117d6b1a-eed9-4f88-8edb-e288cd45f3a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_309aa1dd-4f32-4a19-9e68-25be9c8c1216_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7bfc897e-d9c4-4148-8eb5-d451ee0900f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6f556512-2d2a-499d-b27b-803385896802_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses, net</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8a941fbb-d628-4f26-a100-6a0ef4246a44_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_AdditionalSpaceMember_22f15d5f-12e3-4a2b-ac64-ba6b83dd9177_terseLabel_en-US" xlink:label="lab_autl_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space</link:label>
    <link:label id="lab_autl_AdditionalSpaceMember_label_en-US" xlink:label="lab_autl_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space [Member]</link:label>
    <link:label id="lab_autl_AdditionalSpaceMember_documentation_en-US" xlink:label="lab_autl_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AdditionalSpaceMember" xlink:href="autl-20210331.xsd#autl_AdditionalSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_AdditionalSpaceMember" xlink:to="lab_autl_AdditionalSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6273b3c7-2fad-4e0f-aae2-eefa8a38aea8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3afdd75e-2bae-4c09-b679-6946192fee21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5032bbd4-8186-4e12-9a95-44e0fa1a1699_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7dbdbcaf-a26a-44d3-9f93-dd94d81dc7da_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_329c3b1d-443e-4805-9171-b3d7970c9adf_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48d10dfb-0409-4679-974a-42206241f87b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding beginning balance weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ec5b395d-337c-4a5b-af57-37ea62319cfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding ending balance weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_14640a99-40a0-41aa-9d29-8e48b22e4814_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_da841b94-86e2-4d17-94e2-82730ea364e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a182a60-4d02-40fb-b4b3-44e60072ba8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_559af831-b8f7-47af-9af7-4014aaacb1ee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a27da609-bec7-46bf-b3ca-05ec4e060c7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93bc651f-6a0c-4c7e-8076-ffd5146f6dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ResearchAndDevelopmentTaxCredits_5c0c218f-eb85-4457-b039-377f2044863f_terseLabel_en-US" xlink:label="lab_autl_ResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_autl_ResearchAndDevelopmentTaxCredits_label_en-US" xlink:label="lab_autl_ResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credits</link:label>
    <link:label id="lab_autl_ResearchAndDevelopmentTaxCredits_documentation_en-US" xlink:label="lab_autl_ResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ResearchAndDevelopmentTaxCredits" xlink:href="autl-20210331.xsd#autl_ResearchAndDevelopmentTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ResearchAndDevelopmentTaxCredits" xlink:to="lab_autl_ResearchAndDevelopmentTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ffc6354d-900a-47de-acdc-43a6a86512fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_NetSalesLevelsMember_6177b8ce-9a23-4057-ac27-7cd1c51afe41_terseLabel_en-US" xlink:label="lab_autl_NetSalesLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Levels</link:label>
    <link:label id="lab_autl_NetSalesLevelsMember_label_en-US" xlink:label="lab_autl_NetSalesLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Levels [Member]</link:label>
    <link:label id="lab_autl_NetSalesLevelsMember_documentation_en-US" xlink:label="lab_autl_NetSalesLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Levels [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetSalesLevelsMember" xlink:href="autl-20210331.xsd#autl_NetSalesLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_NetSalesLevelsMember" xlink:to="lab_autl_NetSalesLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4459bf24-86af-4abc-850d-71ac59ad3c5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_0733edb3-6eff-4282-a2f0-136c3caf0a5e_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_03931de1-bda7-43e9-821d-bad9e5c1b691_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_daaa82ec-173c-4937-870c-eebd9109a78b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. corporate income and local taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8098ed2a-70d5-4024-ab03-c79b9f5f7f8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ProductSalesMember_f13598f8-c0fb-489c-bff3-93dc79dfe1b0_terseLabel_en-US" xlink:label="lab_autl_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_autl_ProductSalesMember_label_en-US" xlink:label="lab_autl_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:label id="lab_autl_ProductSalesMember_documentation_en-US" xlink:label="lab_autl_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ProductSalesMember" xlink:href="autl-20210331.xsd#autl_ProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ProductSalesMember" xlink:to="lab_autl_ProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90dc4471-d5dd-4264-ac90-64d018ccb6ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_00310b7e-6917-4051-b0f8-a2c0876991ae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_98ed44e1-9144-4292-882e-54f2494b10b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fed2a832-9705-424d-ab58-51a17d78614d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5d63e0d7-db8b-47d0-84e5-b0b7d53c702b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7bafba28-912d-4f87-8513-ab7630299254_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_102e8b1e-1aa7-468f-875b-c5f5fee122da_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c6a08469-55d8-4803-9819-6ba156bfb2b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_CapitalizedFixedAssetsMember_f364532d-e989-4053-b56a-33cdb80bb3e0_terseLabel_en-US" xlink:label="lab_autl_CapitalizedFixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized to property and equipment</link:label>
    <link:label id="lab_autl_CapitalizedFixedAssetsMember_label_en-US" xlink:label="lab_autl_CapitalizedFixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Fixed Assets [Member]</link:label>
    <link:label id="lab_autl_CapitalizedFixedAssetsMember_documentation_en-US" xlink:label="lab_autl_CapitalizedFixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Fixed Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CapitalizedFixedAssetsMember" xlink:href="autl-20210331.xsd#autl_CapitalizedFixedAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_CapitalizedFixedAssetsMember" xlink:to="lab_autl_CapitalizedFixedAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ConditionalPaymentsDomain_37bf1b4c-6f20-4afe-8105-b9894fc111e4_terseLabel_en-US" xlink:label="lab_autl_ConditionalPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payments [Domain]</link:label>
    <link:label id="lab_autl_ConditionalPaymentsDomain_label_en-US" xlink:label="lab_autl_ConditionalPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payments [Domain]</link:label>
    <link:label id="lab_autl_ConditionalPaymentsDomain_documentation_en-US" xlink:label="lab_autl_ConditionalPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Conditional Payments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsDomain" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ConditionalPaymentsDomain" xlink:to="lab_autl_ConditionalPaymentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_27efc5ce-3c1d-4997-bf2d-ca58e27f2d01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7393156-7b2d-4b07-b8db-bbdd47befc7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_922eb330-ec1f-47e2-abcd-5f8a1d492d97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4a8f9b0d-aa5c-4eeb-9815-7dee7b603321_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement and Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4e1c198d-5e9f-4612-901f-d6084d1a77c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_57493649-8132-4119-818a-cdb54ee278e1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic and diluted ordinary shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_cd00227b-f397-4f01-8637-28c030198b64_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_66dfb1d0-742b-4fe7-ada1-f2911afe0e62_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a3f0fbf8-56d3-4860-88e6-28fef4cca96a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a3f1292f-2ea6-4401-9073-4ba1247133ec_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_d4b94042-3e96-48f1-9cc0-5f54f4a2e912_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2233c2da-90a7-4e52-be68-63b52d54620a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes and Income Tax Credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_324fe130-99f3-4360-a8fd-23fa383518fb_negatedTerseLabel_en-US" xlink:label="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets, net</link:label>
    <link:label id="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Net Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Net Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:to="lab_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_GainLossOnDispositionOfLeaseholdImprovements_2e5f93bc-df9a-4a92-8e5d-9f552a508376_terseLabel_en-US" xlink:label="lab_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of leasehold improvements</link:label>
    <link:label id="lab_autl_GainLossOnDispositionOfLeaseholdImprovements_label_en-US" xlink:label="lab_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Leasehold Improvements</link:label>
    <link:label id="lab_autl_GainLossOnDispositionOfLeaseholdImprovements_documentation_en-US" xlink:label="lab_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:href="autl-20210331.xsd#autl_GainLossOnDispositionOfLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:to="lab_autl_GainLossOnDispositionOfLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease_a125b2fb-7bd8-4d71-a01c-47db17cea6f6_terseLabel_en-US" xlink:label="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, expense, decrease</link:label>
    <link:label id="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease_label_en-US" xlink:label="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Increase (Decrease)</link:label>
    <link:label id="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease_documentation_en-US" xlink:label="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:href="autl-20210331.xsd#autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:to="lab_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_bb50a3a8-24cb-45e3-8730-04923b20c3e0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses_d975cc42-2575-48a3-b8f5-d3881fbcbc92_terseLabel_en-US" xlink:label="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Cost Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Cost Included In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:href="autl-20210331.xsd#autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d4a57f47-6754-4c94-aca2-0c268eaf0021_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_00e715b0-742b-462b-88b8-bd424ff2f291_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock par value (usd/gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_173a7d12-1534-4e74-805a-ccb7b0e7c273_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock par value (usd/gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_12ddf2df-deea-42e7-aca9-bb9deace4989_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e2d37045-8d6f-4ab2-90fc-f2f550c7a238_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1eea255b-2912-46ba-a6a2-b644f1e24a08_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7be00d69-2e86-4088-94df-5d8cd65835e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d9742be-cdf1-43b0-bf3f-373b037e36a8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_LicenseAgreementsAbstract_c14c7e0b-ec0c-4b51-b16f-7bb72a954c3d_terseLabel_en-US" xlink:label="lab_autl_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_autl_LicenseAgreementsAbstract_label_en-US" xlink:label="lab_autl_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_autl_LicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_autl_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LicenseAgreementsAbstract" xlink:href="autl-20210331.xsd#autl_LicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_LicenseAgreementsAbstract" xlink:to="lab_autl_LicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_caead10b-40f5-456c-accb-7d471ae3c6cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_0f8043d3-55a0-4936-a303-e8201ebd6345_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9675546e-840c-40f4-bf23-165b68335663_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7f522284-42bd-424c-b056-101cb1110947_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0d603386-fafa-4b10-a4c0-013ad2f6c9ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_559c34a0-5a91-4306-affa-ea6cc8185ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d044e80-55e6-4cbb-9329-e5c08cd06ad8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_90fb3ea7-bf6e-49c9-9f8d-a753a66b4d24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7a82f54f-7ce9-4682-9f39-aad2e9accd4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ad217a4f-3c5b-467e-bc45-75db3ea22a29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f75df35d-6f86-49cb-9227-478031587f96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_81124e33-c795-44f4-8c5c-486da7c7055f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on termination of operating lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_084b9bee-0a43-46bf-aa5b-028204b9ee3d_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on termination of operating lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_94ceb8c5-8208-4e06-a2d7-29d22780dd2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8b68bc2c-b66e-4e79-8387-3d496ab3bee4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_05353b7e-8f30-432a-b202-f8531a63fb5a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2b5057e1-ad4d-44c4-b624-099f8023b013_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_978a34e5-9fa2-4830-a1aa-ada9cb9141aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled of forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3f9a4ca0-daeb-49b3-aba4-a70d43a8e552_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_97a731ab-17f4-457a-910c-2ef44d41f416_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_12488fa8-5006-4d54-a71a-4520da523311_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b79687bc-afea-4a40-bf60-e8466e6d68e7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6bd930e6-d470-46f5-bbed-c8de5f1ab0aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d7fcd470-402d-47f8-a086-624f5bd84def_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7ee31ce3-7539-4913-80d4-25eac14bb920_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6b9bd6a9-a1dc-42ba-92cf-1f88414893e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per ordinary share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_OrdinarySharesMember_59d5f97c-128e-4240-9daa-fcbf863f4422_verboseLabel_en-US" xlink:label="lab_autl_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_autl_OrdinarySharesMember_b6f740f3-da05-449c-9a7c-9a796ba8c720_terseLabel_en-US" xlink:label="lab_autl_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_autl_OrdinarySharesMember_label_en-US" xlink:label="lab_autl_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:label id="lab_autl_OrdinarySharesMember_documentation_en-US" xlink:label="lab_autl_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_OrdinarySharesMember" xlink:to="lab_autl_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6014a997-e498-476e-8d03-fe083e225d6f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb9d5464-fd78-44d3-a678-4253be510549_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_23c2a1f6-97df-4000-b1aa-3a44d601e10a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_281251db-5958-47be-9880-30ea26f3566c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_8793ff73-46da-4a58-868d-3f7a48f78e53_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_062eac86-6b11-4967-bd61-04b2334ad0d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (aggregate intrinsic value)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_21999fbe-f760-425f-8fa7-20e5a9822047_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c225dde9-e6a4-40e5-889f-47d4b92bd19e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share price of issuance (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ac502d2d-b5a3-489d-99d3-524f5b08cc71_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_7c2c86a2-ed0a-4bd9-93b8-6f7e701bee76_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_05ff4783-e44a-4b3e-b05e-d5fb676c2351_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_b731a1d0-e38b-4a1a-bc14-fdaa21fe144b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_992496d7-cc9d-4401-8b3c-645804722436_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent costs</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ConditionalPaymentBasis_1a146370-4271-4631-adf5-6f5fd4082ec9_terseLabel_en-US" xlink:label="lab_autl_ConditionalPaymentBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional payment, regulatory approval (gbp per share)</link:label>
    <link:label id="lab_autl_ConditionalPaymentBasis_label_en-US" xlink:label="lab_autl_ConditionalPaymentBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payment Basis</link:label>
    <link:label id="lab_autl_ConditionalPaymentBasis_documentation_en-US" xlink:label="lab_autl_ConditionalPaymentBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payment Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentBasis" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ConditionalPaymentBasis" xlink:to="lab_autl_ConditionalPaymentBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_304ad869-898a-45e5-a7f3-ee96faa794e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_CommissionPercentageOfGrossSalesPrice_33535f33-a4f5-43fd-b35f-84c663adafc8_terseLabel_en-US" xlink:label="lab_autl_CommissionPercentageOfGrossSalesPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percentage of gross sales price</link:label>
    <link:label id="lab_autl_CommissionPercentageOfGrossSalesPrice_label_en-US" xlink:label="lab_autl_CommissionPercentageOfGrossSalesPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, Percentage Of Gross Sales Price</link:label>
    <link:label id="lab_autl_CommissionPercentageOfGrossSalesPrice_documentation_en-US" xlink:label="lab_autl_CommissionPercentageOfGrossSalesPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, Percentage Of Gross Sales Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CommissionPercentageOfGrossSalesPrice" xlink:href="autl-20210331.xsd#autl_CommissionPercentageOfGrossSalesPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_CommissionPercentageOfGrossSalesPrice" xlink:to="lab_autl_CommissionPercentageOfGrossSalesPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3f23233a-97d3-46f0-8d18-7cf048762610_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_ada0e7e5-9192-4fb1-bff3-53c15d69a266_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_535630f6-0b16-4c71-877a-202c23bb6962_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1767d17e-7d0e-4ec3-9563-2a33e8c17519_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc8299bc-84af-441e-871a-fb51f2e669c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e82df65b-f080-4827-aed3-058929401eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs and Accrued Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22a691c0-17b2-437c-a0ed-08e65da33d83_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting right percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d17be82-66b2-4e0d-b602-9331a6792343_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_141afe01-2228-481e-8f9f-11e49c862d7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_45b59886-d849-4cbc-b389-8aa4b3e20914_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_788d408d-01c1-4150-af12-e24674bdd777_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares - forfeited</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d83e507f-5b4c-4ae4-af5e-4d2c7868fe4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b18244a6-12d7-4761-8b26-5007abd6255e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent_9f9459f0-4a68-4d22-8a9d-d10b7f7069f1_terseLabel_en-US" xlink:label="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development claims receivable</link:label>
    <link:label id="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent_label_en-US" xlink:label="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Claims Receivable, Current</link:label>
    <link:label id="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent_documentation_en-US" xlink:label="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Claims Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:href="autl-20210331.xsd#autl_ResearchAndDevelopmentClaimsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:to="lab_autl_ResearchAndDevelopmentClaimsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_067f9e8a-d6c2-4f30-9533-0268b958a744_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_66b91ee1-fb94-4766-a6bc-729d33732625_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8e77c7f8-81d5-47c6-aa59-cf9eeac1871c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c5a47bda-4f2c-444b-95dd-1ca6f1234409_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_OfficeSpaceInRockvilleMarylandMember_0fea7ca1-db51-4574-9e28-149a4b648b3a_terseLabel_en-US" xlink:label="lab_autl_OfficeSpaceInRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Rockville, Maryland</link:label>
    <link:label id="lab_autl_OfficeSpaceInRockvilleMarylandMember_label_en-US" xlink:label="lab_autl_OfficeSpaceInRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Rockville, Maryland [Member]</link:label>
    <link:label id="lab_autl_OfficeSpaceInRockvilleMarylandMember_documentation_en-US" xlink:label="lab_autl_OfficeSpaceInRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Rockville, Maryland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeSpaceInRockvilleMarylandMember" xlink:href="autl-20210331.xsd#autl_OfficeSpaceInRockvilleMarylandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_OfficeSpaceInRockvilleMarylandMember" xlink:to="lab_autl_OfficeSpaceInRockvilleMarylandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_de540f99-2587-4eb5-ade4-95e97986e011_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_8ede2c5d-1cc9-4b87-a6e8-222d45c27ca6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f03f2b9a-1e3a-475e-9d78-39c0c483dd2c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c4722608-5616-408c-8fca-a7763adb0683_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d28efaec-5a44-4765-8744-326a8199e545_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_cdc415c5-c409-431a-aef0-9d4c3cf78a67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_62d748ec-b470-4665-9e44-66ef961a4837_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_74478faf-8a8f-437d-85ee-88159dfe0118_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0422b768-64d5-4fe8-8d58-e7be699cef9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ec4521a8-133c-4a5f-a979-b0b435a382d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, shares issued in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_104b4f22-2ff3-4c6e-a4ca-7ace2124ee6a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted incentive shares and units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_eb11a2f8-92f9-4ada-a2cb-856681e4cbbf_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfUnitsInRealEstateProperty_498499e6-b1da-4acb-a8b3-e61fa7ac5a1b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfUnitsInRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of units</link:label>
    <link:label id="lab_us-gaap_NumberOfUnitsInRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_NumberOfUnitsInRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units in Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfUnitsInRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfUnitsInRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfUnitsInRealEstateProperty" xlink:to="lab_us-gaap_NumberOfUnitsInRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_1a065c54-572d-407b-94e9-ee855e4b1dee_negatedLabel_en-US" xlink:label="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets, current</link:label>
    <link:label id="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_label_en-US" xlink:label="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets, Current</link:label>
    <link:label id="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_documentation_en-US" xlink:label="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:to="lab_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8468b48b-0073-46c4-910c-5a65542f9343_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_50a767f4-8012-4c1d-a13c-f3a721e1ec6e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation not yet recognized for unvested shares</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94f3eb92-e833-450b-9b1e-b69c5bf1499b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ant-dilutive shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7b7ee6aa-ed1c-4ca5-aaec-70ddc88894cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_0f5764cd-82ca-4f00-a0bd-3162a4e5db4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred cost</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent" xlink:to="lab_us-gaap_DeferredCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14627725-13e0-4423-b2e0-fbed0df892e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_48d087a5-028b-416d-b88f-a4778370d920_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_976e5c1a-bb46-419a-90dc-acb310689f24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ClinicalActivitiesMember_18cb12d4-1e95-470e-85c0-18f1fe8eae5f_terseLabel_en-US" xlink:label="lab_autl_ClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Activities</link:label>
    <link:label id="lab_autl_ClinicalActivitiesMember_label_en-US" xlink:label="lab_autl_ClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Activities [Member]</link:label>
    <link:label id="lab_autl_ClinicalActivitiesMember_documentation_en-US" xlink:label="lab_autl_ClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ClinicalActivitiesMember" xlink:href="autl-20210331.xsd#autl_ClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ClinicalActivitiesMember" xlink:to="lab_autl_ClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3e43bf55-c769-440a-b190-61d3b07b55a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_06ef68f6-508d-433a-b757-43386f004253_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a3d2085e-be2f-43b6-93c2-2cf5bd38fb40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deposits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17f01665-9b0d-41fb-a8b9-2cc7b371959d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b02f5113-0723-4a3a-a399-5a6ac864fae8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ae96cc14-eecf-430d-8f6c-e23686916a10_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f6b72ef6-f1df-48b1-b36f-05a9bd94bfa3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_69d7f28f-8b5b-42dd-b3a8-b53e93a9441a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1f5ae86-8e64-4d51-93cf-89b3963d0851_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_80058dde-0cf0-40c1-a43b-803d9eb30db1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ordinary shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4dd5b86-b9eb-4e17-91b4-861672a7463a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fd6bbe49-b620-44c2-b349-dfaf8bccaa6b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c71576db-d468-4db2-b76c-aaf318347486_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4b17189a-9656-4d46-8efb-d4f4370e8648_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_0245b552-dbbf-4723-ace9-4af090d4eb4b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of leasehold</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Leasehold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_56eb8b2d-8a45-4227-b880-bbf011d37e0c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_af305af3-b73e-438a-a7f4-f3760046c982_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a90d6dc1-2cd4-4893-b786-fd1ff2c5f9f3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_aadb1611-e169-4d1a-8be8-10a409ac2505_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2d229d00-2032-4afd-bca3-605f72a4de9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ImperialForestHouseLimitedMember_f37f7a36-5c05-4869-9c54-30faf1ad4b1e_terseLabel_en-US" xlink:label="lab_autl_ImperialForestHouseLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imperial (Forest House) Limited</link:label>
    <link:label id="lab_autl_ImperialForestHouseLimitedMember_label_en-US" xlink:label="lab_autl_ImperialForestHouseLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imperial (Forest House) Limited [Member]</link:label>
    <link:label id="lab_autl_ImperialForestHouseLimitedMember_documentation_en-US" xlink:label="lab_autl_ImperialForestHouseLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imperial (Forest House) Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ImperialForestHouseLimitedMember" xlink:href="autl-20210331.xsd#autl_ImperialForestHouseLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ImperialForestHouseLimitedMember" xlink:to="lab_autl_ImperialForestHouseLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_9f9727ad-b9cc-4527-865d-e0e5cde8d5ee_terseLabel_en-US" xlink:label="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Space in Enfield, United Kingdom</link:label>
    <link:label id="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_label_en-US" xlink:label="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Space In Enfield, United Kingdom [Member]</link:label>
    <link:label id="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_documentation_en-US" xlink:label="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Space In Enfield, United Kingdom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:href="autl-20210331.xsd#autl_ManufacturingSpaceInEnfieldUnitedKingdomMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:to="lab_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet_763aa05e-b9b5-4c14-ba9e-4d34dd69b1e9_terseLabel_en-US" xlink:label="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets terminated and obtained in exchange for operating lease liabilities, net</link:label>
    <link:label id="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet_label_en-US" xlink:label="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net</link:label>
    <link:label id="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet_documentation_en-US" xlink:label="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:href="autl-20210331.xsd#autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:to="lab_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_8a548522-3342-493d-82fb-c98f85c5824e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets, non-current</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c2210d49-07b6-42bc-ade5-3341e68eadd0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd988333-5207-413e-9b89-17c11bec3b6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fc7051d3-27ac-45e0-b2ad-578e408e786b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_04f65551-fdcd-4056-8d38-b7ae8630eb5e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9255339f-b03c-463e-9839-ac31182fc51e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a3a94ad6-02da-4b7f-81b5-c3d350b978fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ac530b42-4885-48c3-9df8-f31fcdf51824_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba513a8d-98eb-4d2c-a81e-dfb0e505a898_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_LicenseAgreementsTextBlock_8afee33d-815c-4855-a17e-b671050e95e3_terseLabel_en-US" xlink:label="lab_autl_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_autl_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_autl_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_autl_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_autl_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LicenseAgreementsTextBlock" xlink:href="autl-20210331.xsd#autl_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_LicenseAgreementsTextBlock" xlink:to="lab_autl_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_5ccb69b7-a1a5-4cf7-b85b-9f7b1d021a7f_terseLabel_en-US" xlink:label="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum nominal shares authorized for grant</link:label>
    <link:label id="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_label_en-US" xlink:label="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Nominal Amount Of Shares Authorized For Grant</link:label>
    <link:label id="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_documentation_en-US" xlink:label="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Nominal Amount Of Shares Authorized For Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:href="autl-20210331.xsd#autl_MaximumNominalAmountOfSharesAuthorizedForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:to="lab_autl_MaximumNominalAmountOfSharesAuthorizedForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_SaleOfStockAuthorizedAmount_a2069ec6-5500-420c-8d25-3884d4a3a1b6_terseLabel_en-US" xlink:label="lab_autl_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, authorized amount</link:label>
    <link:label id="lab_autl_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_autl_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Amount</link:label>
    <link:label id="lab_autl_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_autl_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SaleOfStockAuthorizedAmount" xlink:href="autl-20210331.xsd#autl_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_SaleOfStockAuthorizedAmount" xlink:to="lab_autl_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_29c6bd51-86dc-4fd1-9017-3e6a3db1a084_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_4d58d730-5e74-4315-9c52-21d4b64ffdfc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Subject to Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_70845ba3-6a95-4e85-811d-af595b032536_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e2a0e715-c0fd-41e2-94f7-7f34923c38b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_cdae3a95-9241-4adb-988d-370ea0f10d45_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1deb4c2f-2c77-46d8-8309-e018e7ee2bf9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c9a4251e-eb87-4f72-8588-333999b64d9b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5dd3738c-a2e4-4c04-958e-7072e17bd202_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_OperatingLeaseRentFreePeriod_91e3d333-1d3f-46de-9e81-8d59f8dd36e6_terseLabel_en-US" xlink:label="lab_autl_OperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease rent free period</link:label>
    <link:label id="lab_autl_OperatingLeaseRentFreePeriod_label_en-US" xlink:label="lab_autl_OperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Rent Free Period</link:label>
    <link:label id="lab_autl_OperatingLeaseRentFreePeriod_documentation_en-US" xlink:label="lab_autl_OperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Rent Free Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OperatingLeaseRentFreePeriod" xlink:href="autl-20210331.xsd#autl_OperatingLeaseRentFreePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_OperatingLeaseRentFreePeriod" xlink:to="lab_autl_OperatingLeaseRentFreePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e69d5e84-118e-457e-ab81-0966d5f07d58_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_b6a51094-ac6a-44a9-9fc1-5fb89206a5df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_4cac8a83-0e67-414b-a038-0c3768f71ee8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions to defined benefit pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2b644b9e-6326-4564-982f-67680e043e9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_c4a1df17-b6e3-4b4e-9400-ca6cc2616196_terseLabel_en-US" xlink:label="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_label_en-US" xlink:label="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities</link:label>
    <link:label id="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_documentation_en-US" xlink:label="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:to="lab_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_AccruedResearchAndDevelopmentCostCurrent_0036824f-943a-4752-8cce-ea76a226be25_terseLabel_en-US" xlink:label="lab_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_autl_AccruedResearchAndDevelopmentCostCurrent_label_en-US" xlink:label="lab_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Cost, Current</link:label>
    <link:label id="lab_autl_AccruedResearchAndDevelopmentCostCurrent_documentation_en-US" xlink:label="lab_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:href="autl-20210331.xsd#autl_AccruedResearchAndDevelopmentCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:to="lab_autl_AccruedResearchAndDevelopmentCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bc0697b4-2589-4f12-a084-7eec6de75c90_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation not yet recognized for unvested shares vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1ab51909-289d-4513-92e5-41bf8ce2a74f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52a6728d-6a74-4b28-89bc-71441382804a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f4f92b24-8cc7-4b28-b438-9052eaa24e98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e777f225-a1c7-42a3-91d3-26aab77f3f68_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9b1f7cd0-306c-4567-9bea-428419ee911e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c5463360-00c3-478c-980d-14841a23aead_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6a89ff9-26fe-41da-af1d-9bc315aebe17_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_DeferredClassBSharesMember_38e1f6c9-9fc6-45f3-8f7e-d8b10591c192_terseLabel_en-US" xlink:label="lab_autl_DeferredClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred B Shares</link:label>
    <link:label id="lab_autl_DeferredClassBSharesMember_label_en-US" xlink:label="lab_autl_DeferredClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class B Shares [Member]</link:label>
    <link:label id="lab_autl_DeferredClassBSharesMember_documentation_en-US" xlink:label="lab_autl_DeferredClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class B Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_DeferredClassBSharesMember" xlink:to="lab_autl_DeferredClassBSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_24fc42f4-b5a1-44d6-94d5-84c4023347b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_DeferredClassCSharesMember_1c830a22-2c9b-48c2-bda9-b1916a2c3e02_terseLabel_en-US" xlink:label="lab_autl_DeferredClassCSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred C Shares</link:label>
    <link:label id="lab_autl_DeferredClassCSharesMember_label_en-US" xlink:label="lab_autl_DeferredClassCSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class C Shares [Member]</link:label>
    <link:label id="lab_autl_DeferredClassCSharesMember_documentation_en-US" xlink:label="lab_autl_DeferredClassCSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class C Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_DeferredClassCSharesMember" xlink:to="lab_autl_DeferredClassCSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_DeferredClassASharesMember_c8df42e7-1fc9-4d9f-8251-bfc7e941c930_verboseLabel_en-US" xlink:label="lab_autl_DeferredClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred shares</link:label>
    <link:label id="lab_autl_DeferredClassASharesMember_a599eff5-90f6-4ca9-a20c-042b76a2ddb3_terseLabel_en-US" xlink:label="lab_autl_DeferredClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_autl_DeferredClassASharesMember_label_en-US" xlink:label="lab_autl_DeferredClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class A Shares [Member]</link:label>
    <link:label id="lab_autl_DeferredClassASharesMember_documentation_en-US" xlink:label="lab_autl_DeferredClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Class A Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_DeferredClassASharesMember" xlink:to="lab_autl_DeferredClassASharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e21a6bc4-a704-4486-bee1-1c5784baa5b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_5c13337b-f370-475f-b024-1a2280488b20_terseLabel_en-US" xlink:label="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Manufacturing Space in Rockville, Maryland</link:label>
    <link:label id="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_label_en-US" xlink:label="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Manufacturing Space in Rockville, Maryland [Member]</link:label>
    <link:label id="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_documentation_en-US" xlink:label="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Manufacturing Space in Rockville, Maryland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:href="autl-20210331.xsd#autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:to="lab_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_8b129a82-3b99-4a27-bfb7-18a3d0407b13_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsLineItems_5cb47db4-b370-4da0-b142-f2969a9474e8_terseLabel_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License Agreements</link:label>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsLineItems_label_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License Agreements [Line Items]</link:label>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of License Agreements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsLineItems" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems" xlink:to="lab_autl_ScheduleOfLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8eee020d-442d-42dc-8142-cbd4c7edbe8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8c939232-bd99-4e90-8e8a-1086fe65835d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of restricted shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8161caf4-3a62-444e-8957-efd9b13c2f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b63199c-84c5-4c9f-a189-17f17fb59095_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_302218ed-a6d4-4f76-9ef9-be23af28d88b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_ca1ad0ae-5d6d-424a-af92-5c6daef3cd91_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under construction</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bbe0ab7e-bdba-4f47-8ad6-9a6d04430863_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4a0d084f-3c67-464d-9672-94b9929b9968_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_881b1996-84b0-45ec-831a-7204cd5e060e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseIncentiveReceivableCurrent_941d3d3c-a2bd-4303-bdfd-1d73e2e59648_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncentiveReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease receivables from terminations</link:label>
    <link:label id="lab_us-gaap_LeaseIncentiveReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LeaseIncentiveReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentiveReceivableCurrent" xlink:to="lab_us-gaap_LeaseIncentiveReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7b4635f9-daa7-4c11-a010-8fee32905ba5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5a0de6b6-0555-4ab6-aa6f-bf5e558b8d12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_LetterofCreditCollateralMember_d45a3b19-13d6-4cbc-bbb8-c4114086ea3b_terseLabel_en-US" xlink:label="lab_autl_LetterofCreditCollateralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_autl_LetterofCreditCollateralMember_label_en-US" xlink:label="lab_autl_LetterofCreditCollateralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Collateral [Member]</link:label>
    <link:label id="lab_autl_LetterofCreditCollateralMember_documentation_en-US" xlink:label="lab_autl_LetterofCreditCollateralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Collateral [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LetterofCreditCollateralMember" xlink:href="autl-20210331.xsd#autl_LetterofCreditCollateralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_LetterofCreditCollateralMember" xlink:to="lab_autl_LetterofCreditCollateralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e73013fb-309b-481a-b5b3-8156657e9048_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ba19f503-4461-4c6c-87f8-e3a5349f68fa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f25eb0e2-6013-43e1-aa83-90799de55431_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (aggregate intrinsic value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aa895e0a-b0fd-4c38-a2eb-cde375726442_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63bc8e2f-606c-4eb3-8a33-bc5daa23e45c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c592cb5-0ee9-451b-9e1b-eb224d6cbbfc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ae9d357-d2d4-40be-9ff5-2b7a580cab06_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a9b25626-84e4-4c69-8db4-1359e23bed8e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_PaymentOfUpfrontFees_3ad692ce-f382-4b1e-99c6-9cf8e997d8cf_terseLabel_en-US" xlink:label="lab_autl_PaymentOfUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of upfront fees (usd/gbp per share)</link:label>
    <link:label id="lab_autl_PaymentOfUpfrontFees_label_en-US" xlink:label="lab_autl_PaymentOfUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Upfront Fees</link:label>
    <link:label id="lab_autl_PaymentOfUpfrontFees_documentation_en-US" xlink:label="lab_autl_PaymentOfUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Upfront Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PaymentOfUpfrontFees" xlink:href="autl-20210331.xsd#autl_PaymentOfUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_PaymentOfUpfrontFees" xlink:to="lab_autl_PaymentOfUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_fd0f620e-668b-4475-8cfa-83cfa8be094d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent_fa0a0993-a4ee-4f9a-a795-2425a8080bfd_terseLabel_en-US" xlink:label="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized implementation costs included in accrued expenses</link:label>
    <link:label id="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent_label_en-US" xlink:label="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent</link:label>
    <link:label id="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:href="autl-20210331.xsd#autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:to="lab_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_81ffd3da-d178-49f9-8660-4b6434d7a125_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1763e785-27a4-46ba-880b-92e88ebc6427_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_36acb2aa-05f8-4936-969a-b6d91e57ceae_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant income receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6f1526c0-babf-4425-9af6-dd07cbbd7e70_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_34209ab6-4657-4c95-9bf2-9702a0ec7e50_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_220a8777-d0d0-4a5b-8d54-73e70b613e92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_a3da4034-3d95-4e90-b1ef-99d5ce07667d_terseLabel_en-US" xlink:label="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="autl-20210331.xsd#autl_NetIncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ff0ecb6-5ba1-48f4-994b-9e073b920abd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a9583eb8-2867-4f47-8473-d62f8d9812ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6e878c5d-209b-48bd-92e2-19a83d31af4b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_d5e4ebcc-06ab-4d90-b99f-a43d55f38bdd_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0f40e716-0cbc-40a9-b6a2-8672941449f0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_17e24c9b-2e4f-4bf9-8d62-75246bb6d58f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (net of amount capitalized)</link:label>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_label_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit and Share-based Payment Arrangement, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16ac9340-5e85-46a1-8ab1-681656e4e74e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ef9cac7-df7a-467c-a930-a1487fc366c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_SecurityDepositMember_960bf0a5-7ceb-4274-8b16-9ed7e0843297_terseLabel_en-US" xlink:label="lab_autl_SecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:label id="lab_autl_SecurityDepositMember_label_en-US" xlink:label="lab_autl_SecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit [Member]</link:label>
    <link:label id="lab_autl_SecurityDepositMember_documentation_en-US" xlink:label="lab_autl_SecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SecurityDepositMember" xlink:href="autl-20210331.xsd#autl_SecurityDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_SecurityDepositMember" xlink:to="lab_autl_SecurityDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_441f2ea3-cedf-4b3c-9759-9318e2588f6b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d250e12c-64b4-424b-8925-7b52140abeb5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d525959d-e421-47ec-be4b-5c2c577a141d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e1d3725f-a704-4faa-aed3-a046b6fbaf00_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8d79556e-f2fc-40a1-a500-4219556947f4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_eb358919-72e6-4f67-a320-4c9cebee29a6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Income</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_05cbd4de-c0c2-43b8-9e62-e835f29f10cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_28a36ba3-e818-4f45-9893-8c8a51933192_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2da6956e-4b3f-4b40-9842-15429388a9d1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_505a2a4c-7017-4f3c-af00-f87b64d6ca2f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a442fdad-3e37-4660-b9f7-d94def8dac64_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6b3188e6-e586-48ad-89df-6154c55486e2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_bc78d106-524a-445b-83e5-53e7e954153e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_05c278a6-521b-4b2d-95c4-2829713d0cfc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_969e58f7-f533-4558-a345-683ef88b2a78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_721ebd1d-a15f-4eea-b81e-5b75264787ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36505fa5-cf92-4c36-bad5-caa5c3b10468_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_441efac6-9174-4ad6-8ec6-23c9b5185a77_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f8610372-1d32-47d4-b359-94be781e7725_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d96b0330-eeb3-494a-a41f-8f8ede7b0bef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2dcedb97-5f3c-4ed2-bbeb-60958feb9d22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_88491c44-5800-4cf4-a0cd-5786048ed428_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cc5cb59b-2d5f-4769-939b-c846dbd18864_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c83cc6a-d31b-453f-9e2b-29794f9170c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets, non-current</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_08d3e6b2-1818-4ae4-88f7-7ca9c13f3d9b_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_85c05830-8415-4870-b615-3aa83fbd0c35_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_642fab40-43fd-44a3-9bcf-9867fdccab76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8202441a-da7c-40bb-ac79-689c2a1b2ce4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6074c605-3a86-43b0-8b51-f0ac01f1f987_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash flow information</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7486b2b7-21bd-49bf-ac51-b11ebb257881_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0635edbc-9947-4580-b72a-eecc48375650_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_fece3142-804e-4133-99e6-b9e26dcc9e03_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b3b8816c-20da-4805-8f3e-62f4de8c1cbf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_f806892c-0906-41b4-a8d0-99c5fb524722_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_52a2e195-01dd-405d-aff8-86bcb8467210_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ConditionalPaymentsAxis_89d43c3d-ae69-4f46-a992-7831e9f76022_terseLabel_en-US" xlink:label="lab_autl_ConditionalPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payments [Axis]</link:label>
    <link:label id="lab_autl_ConditionalPaymentsAxis_label_en-US" xlink:label="lab_autl_ConditionalPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payments [Axis]</link:label>
    <link:label id="lab_autl_ConditionalPaymentsAxis_documentation_en-US" xlink:label="lab_autl_ConditionalPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Payments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsAxis" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ConditionalPaymentsAxis" xlink:to="lab_autl_ConditionalPaymentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a562135-890e-4c35-924f-8690f915ce2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_d6504e6b-9b69-492c-beee-21f7064e4c2e_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of leased Assets, net, operating leases</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Leased Assets, Net, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_acbf1cf2-41d7-4088-8b45-11a4edc0b470_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bc5f9065-be5f-4069-9501-d44daa933946_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6539b016-5f24-4cf1-9112-c653d9b0b2d0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_8f842f25-3358-40ae-a60b-66dbcd18f453_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of geographic regions</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_44d0121b-2293-4597-adf6-eef7268b31b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c42d2e93-33b9-4bd4-951d-31e215adaa2c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsTable_8ee29ff2-1ab5-4ef9-b989-43589b9e448b_terseLabel_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License Agreements [Table]</link:label>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsTable_label_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License Agreements [Table]</link:label>
    <link:label id="lab_autl_ScheduleOfLicenseAgreementsTable_documentation_en-US" xlink:label="lab_autl_ScheduleOfLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License Agreements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsTable" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable" xlink:to="lab_autl_ScheduleOfLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f66202a8-0933-4a21-abd3-6abb45114cc6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_1ca02cd4-6abb-4f42-8f65-1eff12175c10_negatedTerseLabel_en-US" xlink:label="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of share-based compensation expense</link:label>
    <link:label id="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_label_en-US" xlink:label="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Reversal Of Cost Recognition</link:label>
    <link:label id="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_documentation_en-US" xlink:label="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Reversal Of Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:href="autl-20210331.xsd#autl_APICShareBasedPaymentArrangementReversalOfCostRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:to="lab_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_26530f6b-bb33-4034-bfdf-649c7fc251b1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_f520ddca-addc-4ec9-a311-52b5a96c59af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_LeaseTerminationFeeExpense_d9fe9cc7-7da9-4518-801a-8adb883c205b_terseLabel_en-US" xlink:label="lab_autl_LeaseTerminationFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination fee expense</link:label>
    <link:label id="lab_autl_LeaseTerminationFeeExpense_label_en-US" xlink:label="lab_autl_LeaseTerminationFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Fee Expense</link:label>
    <link:label id="lab_autl_LeaseTerminationFeeExpense_documentation_en-US" xlink:label="lab_autl_LeaseTerminationFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LeaseTerminationFeeExpense" xlink:href="autl-20210331.xsd#autl_LeaseTerminationFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_LeaseTerminationFeeExpense" xlink:to="lab_autl_LeaseTerminationFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_CapitalizedSharebasedCompensation_51a34303-f2b5-432b-9b46-7a6e9d8acbba_terseLabel_en-US" xlink:label="lab_autl_CapitalizedSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation</link:label>
    <link:label id="lab_autl_CapitalizedSharebasedCompensation_label_en-US" xlink:label="lab_autl_CapitalizedSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Share-based Compensation</link:label>
    <link:label id="lab_autl_CapitalizedSharebasedCompensation_documentation_en-US" xlink:label="lab_autl_CapitalizedSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CapitalizedSharebasedCompensation" xlink:href="autl-20210331.xsd#autl_CapitalizedSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_CapitalizedSharebasedCompensation" xlink:to="lab_autl_CapitalizedSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ddca0e0d-4929-4dc0-a2d3-279920cc79dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate of income tax (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_903ee960-beb9-4abf-a23a-82c5e88896ee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ea6625d-be0c-4adc-813a-7a6850b0b9be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aac61f07-9379-4ea6-b680-eff4b54e223f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f29b14a-124f-484d-bb13-10cc9f0f304a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc6caaff-2d1b-4f78-878e-c9ccd3a6c245_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_AuthorizedGrantLife_9b8c1f24-c0a5-4129-98f0-6c16313a3af4_terseLabel_en-US" xlink:label="lab_autl_AuthorizedGrantLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized grant, life</link:label>
    <link:label id="lab_autl_AuthorizedGrantLife_label_en-US" xlink:label="lab_autl_AuthorizedGrantLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Grant, Life</link:label>
    <link:label id="lab_autl_AuthorizedGrantLife_documentation_en-US" xlink:label="lab_autl_AuthorizedGrantLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Grant, Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AuthorizedGrantLife" xlink:href="autl-20210331.xsd#autl_AuthorizedGrantLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_AuthorizedGrantLife" xlink:to="lab_autl_AuthorizedGrantLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_066a3bb3-83a9-4ea2-ae6d-ce52f3fe7e67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease contract term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_b809284c-ff11-437d-9fcf-365d5bc6d868_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing_b85c8daa-e102-4dbc-945b-74874d64a397_terseLabel_en-US" xlink:label="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to prepaid facility and manufacturing</link:label>
    <link:label id="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing_label_en-US" xlink:label="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) To Prepaid Facility And Manufacturing</link:label>
    <link:label id="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing_documentation_en-US" xlink:label="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) To Prepaid Facility And Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:to="lab_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb2eac4d-f906-4003-8d13-9026bbfd78e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_UCLBusinessplcMember_32d51ae9-59f4-4aeb-a060-0fa6eca5831b_terseLabel_en-US" xlink:label="lab_autl_UCLBusinessplcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCL Business plc</link:label>
    <link:label id="lab_autl_UCLBusinessplcMember_label_en-US" xlink:label="lab_autl_UCLBusinessplcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCL Business plc [Member]</link:label>
    <link:label id="lab_autl_UCLBusinessplcMember_documentation_en-US" xlink:label="lab_autl_UCLBusinessplcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCL Business plc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_UCLBusinessplcMember" xlink:href="autl-20210331.xsd#autl_UCLBusinessplcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_UCLBusinessplcMember" xlink:to="lab_autl_UCLBusinessplcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e2f13704-71b4-4a1b-bac1-5f75946406dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_RegulatoryApprovalMember_1a031f40-70c6-44b8-8326-fa105f86bd35_terseLabel_en-US" xlink:label="lab_autl_RegulatoryApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval</link:label>
    <link:label id="lab_autl_RegulatoryApprovalMember_label_en-US" xlink:label="lab_autl_RegulatoryApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval [Member]</link:label>
    <link:label id="lab_autl_RegulatoryApprovalMember_documentation_en-US" xlink:label="lab_autl_RegulatoryApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_RegulatoryApprovalMember" xlink:href="autl-20210331.xsd#autl_RegulatoryApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_RegulatoryApprovalMember" xlink:to="lab_autl_RegulatoryApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_LeaseAssetsTerminated_42636d93-0291-48fe-be37-346277df7d9d_terseLabel_en-US" xlink:label="lab_autl_LeaseAssetsTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease assets terminated</link:label>
    <link:label id="lab_autl_LeaseAssetsTerminated_label_en-US" xlink:label="lab_autl_LeaseAssetsTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets Terminated</link:label>
    <link:label id="lab_autl_LeaseAssetsTerminated_documentation_en-US" xlink:label="lab_autl_LeaseAssetsTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LeaseAssetsTerminated" xlink:href="autl-20210331.xsd#autl_LeaseAssetsTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_LeaseAssetsTerminated" xlink:to="lab_autl_LeaseAssetsTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_577e498f-6bfd-46c4-b4f3-148f656ec67f_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_31fbf02e-7097-40ac-8092-099619b604fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e31a80c4-63e5-4173-abb0-3fa5b94e6ade_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_5a0f4c0d-f7fc-48ea-839d-b41d47fb7f25_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_57ca69bd-2377-4d7e-a095-57958826b019_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_49cf3379-18db-4108-875a-0e12be3aee70_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. statutory tax rate (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e786fe3e-81c0-4ca5-bb14-b4ede240394d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_PublicStockOfferingMember_8931f3bc-32a1-4da6-968d-8dcf2e5e9633_terseLabel_en-US" xlink:label="lab_autl_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters public offering</link:label>
    <link:label id="lab_autl_PublicStockOfferingMember_label_en-US" xlink:label="lab_autl_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_autl_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_autl_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PublicStockOfferingMember" xlink:href="autl-20210331.xsd#autl_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_PublicStockOfferingMember" xlink:to="lab_autl_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_autl_PerformanceBasedMember_ac96906d-4ba3-485c-b20b-e6540f02144d_terseLabel_en-US" xlink:label="lab_autl_PerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based</link:label>
    <link:label id="lab_autl_PerformanceBasedMember_label_en-US" xlink:label="lab_autl_PerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based [Member]</link:label>
    <link:label id="lab_autl_PerformanceBasedMember_documentation_en-US" xlink:label="lab_autl_PerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PerformanceBasedMember" xlink:href="autl-20210331.xsd#autl_PerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_autl_PerformanceBasedMember" xlink:to="lab_autl_PerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_bbf7b825-45bf-4fa0-8ef1-b117509fe601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_704700a7-bd45-425c-b6be-2c883f4d5dd8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3e3bfd77-b7a2-493e-a14d-24494be7aecc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment (useful life)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_5c9aefbe-bf66-4c2d-b700-cacd036d4ac1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_61dbcda2-36af-4129-8076-1926b565eb2f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a7a953b3-b3f1-42f6-b64e-9a52fdeca11f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_38e98f25-6b95-4da4-8364-3589fb8503c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>autl-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4bcd3eb4-10e7-4e34-90fc-44982d8f32d4,g:18493315-f48a-42e0-95f1-197175e795ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.autolus.com/role/Cover" xlink:type="simple" xlink:href="autl-20210331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_754ccba4-2efb-4d5f-8bd2-23855610b330" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_EntityRegistrantName_754ccba4-2efb-4d5f-8bd2-23855610b330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e6400e2a-b776-425a-8877-5428fbf0105d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_EntityCentralIndexKey_e6400e2a-b776-425a-8877-5428fbf0105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_54d23140-1272-4ea6-ac20-64307970cb7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_DocumentType_54d23140-1272-4ea6-ac20-64307970cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ce854dad-6dd2-4297-b513-3075b5a17ed3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_DocumentPeriodEndDate_ce854dad-6dd2-4297-b513-3075b5a17ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b17b6efa-ca57-4ed2-9bb4-c3153b152cca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_AmendmentFlag_b17b6efa-ca57-4ed2-9bb4-c3153b152cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_97355f8a-43b1-4a16-beb6-4071c6e68665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_DocumentFiscalYearFocus_97355f8a-43b1-4a16-beb6-4071c6e68665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bb41b409-9e3c-4dc5-8d86-3599124ebf92" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bb41b409-9e3c-4dc5-8d86-3599124ebf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06245f93-9367-4fa6-91c0-a044bba432cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4519b8c0-cd01-4f28-b5b0-0ed171a36597" xlink:to="loc_dei_CurrentFiscalYearEndDate_06245f93-9367-4fa6-91c0-a044bba432cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_375c66ac-d7dc-4c25-a246-206a0021ae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_375c66ac-d7dc-4c25-a246-206a0021ae6e" xlink:to="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aeea5ebe-2030-460c-9a63-dbef19e4c010" xlink:to="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_c06071f4-ec7f-4296-a4ef-a0739b1a4095" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_OrdinarySharesMember_c06071f4-ec7f-4296-a4ef-a0739b1a4095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_c5a9602e-ff10-4968-a8a9-5e7ef6d0d0e0" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassASharesMember_c5a9602e-ff10-4968-a8a9-5e7ef6d0d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_b07ade74-63ac-4170-ad75-9a43abe25c3a" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassBSharesMember_b07ade74-63ac-4170-ad75-9a43abe25c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_ac686163-fb96-455c-b4b4-91635b73eb42" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af706df3-45e7-465d-aa5d-25d5f60a6c46" xlink:to="loc_autl_DeferredClassCSharesMember_ac686163-fb96-455c-b4b4-91635b73eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f6ab89d-867f-4652-9a2a-791552bd7238" xlink:to="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:to="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_5fd52653-cc1c-4300-971c-31b211ee2a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_Cash_5fd52653-cc1c-4300-971c-31b211ee2a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5c80e8fc-37fe-4f8a-b2d9-f3f92231e0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_RestrictedCashCurrent_5c80e8fc-37fe-4f8a-b2d9-f3f92231e0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3dcc59d3-9d01-4918-a9d7-348ab7e0bb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3dcc59d3-9d01-4918-a9d7-348ab7e0bb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0351cbf-4bc5-4099-a148-c15c53d72eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84613e6a-5484-4994-af33-044bfad6f3af" xlink:to="loc_us-gaap_AssetsCurrent_d0351cbf-4bc5-4099-a148-c15c53d72eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7a99a5bc-3ec6-4720-a5fd-66bb75a1b35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7a99a5bc-3ec6-4720-a5fd-66bb75a1b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5a37905-34f0-4727-8275-a244d04cf3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5a37905-34f0-4727-8275-a244d04cf3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_c2555db7-36e1-477b-ac9d-a593a613398f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_c2555db7-36e1-477b-ac9d-a593a613398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_6faa0fd0-a0f2-48c5-8660-dfff7c81b271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_6faa0fd0-a0f2-48c5-8660-dfff7c81b271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f0c54a4e-d555-4090-bd61-0ed83bd3840c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f0c54a4e-d555-4090-bd61-0ed83bd3840c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d269cd10-0b04-4af8-b501-0141f224c282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_94b182e4-943b-4bcc-add3-a91eb8d72d26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d269cd10-0b04-4af8-b501-0141f224c282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_784f3342-1542-4dc1-ab3a-df8bc919f401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5036a84e-6d43-43d6-aeb4-6a49a318bfaf" xlink:to="loc_us-gaap_Assets_784f3342-1542-4dc1-ab3a-df8bc919f401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_959be36b-0072-4a4e-8942-6739d7dba5b1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3a5eb9d4-22ce-498b-93f9-26710942ea82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_AccountsPayableCurrent_3a5eb9d4-22ce-498b-93f9-26710942ea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7148539f-4371-4433-8980-9a8ed226a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7148539f-4371-4433-8980-9a8ed226a8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cced0879-e9a2-450b-8fb5-bc43de148804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cced0879-e9a2-450b-8fb5-bc43de148804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_61f97950-4444-4838-bbb1-b02ee4fb9082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ffc49b9-673a-44c5-85b9-5ca571e03cb5" xlink:to="loc_us-gaap_LiabilitiesCurrent_61f97950-4444-4838-bbb1-b02ee4fb9082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47301d03-8faa-42fc-b13c-53455634f199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5bce89-b0ff-4fe7-af4e-8e82ed148f86" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47301d03-8faa-42fc-b13c-53455634f199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a1ba8d2-3f8f-46c2-a29d-fd0d6e717a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_Liabilities_7a1ba8d2-3f8f-46c2-a29d-fd0d6e717a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_625df893-c84a-4b47-9f85-12a7a4ca18a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_CommonStockValue_625df893-c84a-4b47-9f85-12a7a4ca18a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ab04194d-5be5-46a4-b7f5-fb03be670ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ab04194d-5be5-46a4-b7f5-fb03be670ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c251a69-18c0-4028-ac24-06aa2166084b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c251a69-18c0-4028-ac24-06aa2166084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82d16718-fd72-404e-b44c-c4f7abd06744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82d16718-fd72-404e-b44c-c4f7abd06744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b388df47-93f5-408b-9379-340edc5f9fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_400c33ef-2cc2-4581-ae7a-1873d4187e61" xlink:to="loc_us-gaap_StockholdersEquity_b388df47-93f5-408b-9379-340edc5f9fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e7f08dd-14a0-4ad9-9a08-d05348dc0ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46e5081-7f47-4cf6-a731-671ff91323b4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e7f08dd-14a0-4ad9-9a08-d05348dc0ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParentheticals"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ef6d4467-6f09-42e2-a3c3-db24bb37cafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef6d4467-6f09-42e2-a3c3-db24bb37cafa" xlink:to="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23aead98-3565-4fd1-a8f0-84a24d4d68ca" xlink:to="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_f7b3f526-49ba-4766-9f81-bd94d1a12817" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_OrdinarySharesMember_f7b3f526-49ba-4766-9f81-bd94d1a12817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_a96663b1-4982-4e36-80b6-52fc1b1bf291" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassASharesMember_a96663b1-4982-4e36-80b6-52fc1b1bf291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_82870303-dcaa-449f-bea4-92529f72f0e1" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassBSharesMember_82870303-dcaa-449f-bea4-92529f72f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_4fe691ea-3d51-4e90-a8f3-d0bb1f3bb045" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bec96fd9-617d-4cb2-a6b6-ec4b29656365" xlink:to="loc_autl_DeferredClassCSharesMember_4fe691ea-3d51-4e90-a8f3-d0bb1f3bb045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2e188db-3f39-40d7-a680-6b5c83ed150f" xlink:to="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e5216aa-a8e0-49a6-aead-dcb00643f95a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3a1f9e-7a66-4b42-9845-fc72c6059fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa3a1f9e-7a66-4b42-9845-fc72c6059fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a653e8d2-d428-4cc8-b4b3-45298cb3874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a653e8d2-d428-4cc8-b4b3-45298cb3874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c60d8663-c6f4-430c-b201-fe703c061a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesIssued_c60d8663-c6f4-430c-b201-fe703c061a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b121dea-bbd1-4ed9-b6b1-3531afff0fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2a790d2e-b533-45d0-9de1-c2a09e7ca3d1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b121dea-bbd1-4ed9-b6b1-3531afff0fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1501c59e-2a47-450f-8990-089503a3912f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_Revenues_1501c59e-2a47-450f-8990-089503a3912f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58481a4f-b4f6-478e-b354-adf40484050d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58481a4f-b4f6-478e-b354-adf40484050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0698197a-780f-49ea-ac91-6ce9d7bf9980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0698197a-780f-49ea-ac91-6ce9d7bf9980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_f4de2567-facb-455d-81d0-f6ba9c8e863d" xlink:href="autl-20210331.xsd#autl_GainLossOnDispositionOfLeaseholdImprovements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:to="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_f4de2567-facb-455d-81d0-f6ba9c8e863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_799af570-4f42-4f89-bd72-aa07b029263f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6639056e-1a44-4027-af7f-8663fb4dc753" xlink:to="loc_us-gaap_OperatingIncomeLoss_799af570-4f42-4f89-bd72-aa07b029263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_073141d1-0a61-42a9-82b9-05a92c2079c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_073141d1-0a61-42a9-82b9-05a92c2079c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_a43164de-6891-42f8-a702-6df7284aa82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_073141d1-0a61-42a9-82b9-05a92c2079c4" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_a43164de-6891-42f8-a702-6df7284aa82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_30c932a8-3eee-446d-b12a-9628b58997db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_073141d1-0a61-42a9-82b9-05a92c2079c4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_30c932a8-3eee-446d-b12a-9628b58997db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7f128cd7-4156-40d9-a818-c9b1618b1dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_073141d1-0a61-42a9-82b9-05a92c2079c4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7f128cd7-4156-40d9-a818-c9b1618b1dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e53aedb7-eb35-4642-ae9f-f100ad86a678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e53aedb7-eb35-4642-ae9f-f100ad86a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4e52289d-ecd2-4e64-afe3-f42e1fdc4ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4e52289d-ecd2-4e64-afe3-f42e1fdc4ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f06541ce-48eb-4496-8f4f-8e13d6a68926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_NetIncomeLoss_f06541ce-48eb-4496-8f4f-8e13d6a68926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_afd65e6f-5ddf-47b9-a009-de7372297192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_afd65e6f-5ddf-47b9-a009-de7372297192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_627f6466-cd73-4872-a3fc-bed785c654ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_afd65e6f-5ddf-47b9-a009-de7372297192" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_627f6466-cd73-4872-a3fc-bed785c654ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de1ee9e7-40d7-4bcd-9779-821263d60a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_afd65e6f-5ddf-47b9-a009-de7372297192" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_de1ee9e7-40d7-4bcd-9779-821263d60a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4d7d424e-277d-470d-993d-11d18d39a3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4d7d424e-277d-470d-993d-11d18d39a3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_732e15c9-ebc2-4fb7-a59a-f9010d4ea720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60c74555-41dc-409f-bc1f-ae24369780dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_732e15c9-ebc2-4fb7-a59a-f9010d4ea720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_13d712f1-bad2-49ab-b582-acca959ade56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_13d712f1-bad2-49ab-b582-acca959ade56" xlink:to="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1262c60-c839-4eaf-9533-cbb38e51cdbe" xlink:to="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f967d2ef-bd51-4c2d-9fe6-c88f9e885c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_CommonStockMember_f967d2ef-bd51-4c2d-9fe6-c88f9e885c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fbe6d6e2-8a7c-43f2-8175-4556ac2b12ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fbe6d6e2-8a7c-43f2-8175-4556ac2b12ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_deb8f97f-d8f2-460b-876b-530905310d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_deb8f97f-d8f2-460b-876b-530905310d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ab9092d-810b-40f7-b10a-f1157386b67d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00b7b320-c6ff-4047-b19e-b4709e223d88" xlink:to="loc_us-gaap_RetainedEarningsMember_1ab9092d-810b-40f7-b10a-f1157386b67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349afc34-488f-493f-8e01-03f02cf398b0" xlink:to="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_a4b50016-7a86-4143-bafb-cfb16043b3bb" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_OrdinarySharesMember_a4b50016-7a86-4143-bafb-cfb16043b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_ce12854e-d482-4c3b-91c8-d13f974330d6" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassASharesMember_ce12854e-d482-4c3b-91c8-d13f974330d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_6c39ecc0-14c2-47ec-8dbd-cfb7134740e7" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassBSharesMember_6c39ecc0-14c2-47ec-8dbd-cfb7134740e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_541463c0-a4df-41f2-9797-682de1ff64e7" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_95153def-31fa-402c-91cc-5a4a6dcae8d0" xlink:to="loc_autl_DeferredClassCSharesMember_541463c0-a4df-41f2-9797-682de1ff64e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47d39c4f-f8ed-49e8-bcf8-30b5d4be436a" xlink:to="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ab96173-9445-4187-90b8-47c878665a1e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_218f84dd-28b1-4aa7-bf6d-460736e39642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockholdersEquity_218f84dd-28b1-4aa7-bf6d-460736e39642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1c8a9ad7-6caf-4f51-9118-d55fad4589e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_SharesOutstanding_1c8a9ad7-6caf-4f51-9118-d55fad4589e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7169844f-4a12-49d2-aa01-e21915ac3c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7169844f-4a12-49d2-aa01-e21915ac3c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99a73fdf-3560-4714-827c-d20458a1e45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_99a73fdf-3560-4714-827c-d20458a1e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d52a2ff-a19e-4e6e-92e1-ece99cd4e576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d52a2ff-a19e-4e6e-92e1-ece99cd4e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_2a15e936-2177-4c07-92ab-a11f5dfca191" xlink:href="autl-20210331.xsd#autl_APICShareBasedPaymentArrangementReversalOfCostRecognition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition_2a15e936-2177-4c07-92ab-a11f5dfca191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_998e52f0-bd20-4b1a-b539-2a725e17614f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_998e52f0-bd20-4b1a-b539-2a725e17614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_99248a26-76df-41d1-90ac-66afcfc84d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_99248a26-76df-41d1-90ac-66afcfc84d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9b234083-cd29-46dd-995d-156b60cfdaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9b234083-cd29-46dd-995d-156b60cfdaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0c81aad-bac5-4c5d-ba45-7e4a21a2adb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c0c81aad-bac5-4c5d-ba45-7e4a21a2adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20ec7ade-13b9-4a55-b580-b44e2fea829d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20ec7ade-13b9-4a55-b580-b44e2fea829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9794ed3c-d520-4745-a260-45fbca7992bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_NetIncomeLoss_9794ed3c-d520-4745-a260-45fbca7992bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e97d450-900a-497f-9127-439a3b0fecdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_StockholdersEquity_0e97d450-900a-497f-9127-439a3b0fecdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a39fef5c-9c57-4795-bd47-3e9988f255ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48c0acff-9139-4c61-9111-beb10ef9ef4b" xlink:to="loc_us-gaap_SharesOutstanding_a39fef5c-9c57-4795-bd47-3e9988f255ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="autl-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0dd03c5-75f8-4a53-aa31-78f3580f9855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0dd03c5-75f8-4a53-aa31-78f3580f9855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_889fc6f2-7ff4-470d-9e4a-33edef1aa175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0dd03c5-75f8-4a53-aa31-78f3580f9855" xlink:to="loc_us-gaap_NetIncomeLoss_889fc6f2-7ff4-470d-9e4a-33edef1aa175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0dd03c5-75f8-4a53-aa31-78f3580f9855" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_977bf89e-7848-406a-b350-51b1d04b131d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_977bf89e-7848-406a-b350-51b1d04b131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_b87339e5-8d8f-4e91-89bb-0da53b51995f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_b87339e5-8d8f-4e91-89bb-0da53b51995f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_06eaf72d-6337-44e0-9814-e9afacf0f85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_06eaf72d-6337-44e0-9814-e9afacf0f85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_55584f9a-ff35-44ad-8ad4-1dfc8129825b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_55584f9a-ff35-44ad-8ad4-1dfc8129825b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c74ca929-35c5-4d0c-a726-8944a9ea87fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c74ca929-35c5-4d0c-a726-8944a9ea87fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ac4ae0c-af5b-473f-b9cd-1460e13c1be7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_b61acb21-06b8-4b6c-a35a-464b24cb1366" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent_b61acb21-06b8-4b6c-a35a-464b24cb1366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f83b5c1e-8cdf-4122-b5fe-101f73ae00db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f83b5c1e-8cdf-4122-b5fe-101f73ae00db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ac0494aa-2caf-41eb-b342-8741f1b822bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ac0494aa-2caf-41eb-b342-8741f1b822bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_06bdf1b2-27f2-4679-aead-6b236bdcbf12" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets_06bdf1b2-27f2-4679-aead-6b236bdcbf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb5f0903-5fa0-4352-96df-6d5605efd735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb5f0903-5fa0-4352-96df-6d5605efd735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_934bf0af-6015-4e14-a80f-b72b041d2cdc" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities_934bf0af-6015-4e14-a80f-b72b041d2cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_025e86da-28a6-4850-8fd7-fbda9e92d118" xlink:href="autl-20210331.xsd#autl_NetIncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d08389a1-fbfb-4368-a18b-d0fc36a6e41a" xlink:to="loc_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities_025e86da-28a6-4850-8fd7-fbda9e92d118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0092e7d1-912c-45c4-aede-e41eef0cc4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0dd03c5-75f8-4a53-aa31-78f3580f9855" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0092e7d1-912c-45c4-aede-e41eef0cc4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27cfb292-835e-4542-b2bd-af5d642643ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27cfb292-835e-4542-b2bd-af5d642643ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84ee704b-5f62-4e0d-a067-65df89a3caca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27cfb292-835e-4542-b2bd-af5d642643ec" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84ee704b-5f62-4e0d-a067-65df89a3caca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e52b2857-27e2-435b-bde7-7d5adaf9b239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27cfb292-835e-4542-b2bd-af5d642643ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e52b2857-27e2-435b-bde7-7d5adaf9b239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c3e01f26-ad28-4cdf-a50b-883cae506d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c3e01f26-ad28-4cdf-a50b-883cae506d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe205671-fde0-43be-8e2b-3fdd6eeff3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c3e01f26-ad28-4cdf-a50b-883cae506d04" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe205671-fde0-43be-8e2b-3fdd6eeff3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f71380a-e196-48bb-89ed-020cd83f69ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c3e01f26-ad28-4cdf-a50b-883cae506d04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f71380a-e196-48bb-89ed-020cd83f69ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_548f10b0-95e9-4982-abed-115b582e0f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_548f10b0-95e9-4982-abed-115b582e0f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5aa4c1c2-960c-40a0-bbf9-466d33c97b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5aa4c1c2-960c-40a0-bbf9-466d33c97b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9026cf95-77ee-4c29-a355-7635f76f68af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9026cf95-77ee-4c29-a355-7635f76f68af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c908cc74-5aa3-4efc-b7a8-f744720161e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c908cc74-5aa3-4efc-b7a8-f744720161e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_83347dc0-1593-4452-9756-d2a4863e9e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_83347dc0-1593-4452-9756-d2a4863e9e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet_f3c33f32-ae91-4b56-b869-64c51a054f6a" xlink:href="autl-20210331.xsd#autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet_f3c33f32-ae91-4b56-b869-64c51a054f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent_bd98a995-c851-47f9-8666-14260ec8008e" xlink:href="autl-20210331.xsd#autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent_bd98a995-c851-47f9-8666-14260ec8008e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses_e94ee35a-afc9-4d3c-a127-31c131d7cf66" xlink:href="autl-20210331.xsd#autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses_e94ee35a-afc9-4d3c-a127-31c131d7cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CapitalizedSharebasedCompensation_c78efe4d-b8c4-4975-8531-c4967917a70e" xlink:href="autl-20210331.xsd#autl_CapitalizedSharebasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_autl_CapitalizedSharebasedCompensation_c78efe4d-b8c4-4975-8531-c4967917a70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LeaseAssetsTerminated_850b264b-a763-43ce-a9a1-b8dc0e4b5bde" xlink:href="autl-20210331.xsd#autl_LeaseAssetsTerminated"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_ae7c6e1f-ff24-44e8-97a4-0f4b0c22e24d" xlink:to="loc_autl_LeaseAssetsTerminated_850b264b-a763-43ce-a9a1-b8dc0e4b5bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_eb85f19f-cd2d-4a8b-affb-f310674d8d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7631549-bd70-4813-906b-e8fb1d4085ad" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_eb85f19f-cd2d-4a8b-affb-f310674d8d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_d242ebe3-da11-40d5-ad6c-dc918869959d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_eb85f19f-cd2d-4a8b-affb-f310674d8d75" xlink:to="loc_us-gaap_Cash_d242ebe3-da11-40d5-ad6c-dc918869959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c67b32e8-5b74-47f2-a5d7-b259777ae073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_eb85f19f-cd2d-4a8b-affb-f310674d8d75" xlink:to="loc_us-gaap_RestrictedCashCurrent_c67b32e8-5b74-47f2-a5d7-b259777ae073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ab376cf-e4f3-4e87-b4d6-bcff47638a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_eb85f19f-cd2d-4a8b-affb-f310674d8d75" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ab376cf-e4f3-4e87-b4d6-bcff47638a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/NatureoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3615eb40-e7b4-42b9-85d1-b6fa9eb64f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_f065627d-a294-4282-801b-54d602311e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3615eb40-e7b4-42b9-85d1-b6fa9eb64f1e" xlink:to="loc_us-gaap_NatureOfOperations_f065627d-a294-4282-801b-54d602311e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#NatureoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/NatureoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f99cdff-54b6-49e9-8429-70c188da6111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f99cdff-54b6-49e9-8429-70c188da6111" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5e34fbe-9beb-49b7-9151-75cdcb21e39d" xlink:to="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_0efe7cfb-0638-4947-866f-495437c63cc0" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2b5357ab-520c-4ec6-97a3-2b61a53a37ab" xlink:to="loc_autl_OrdinarySharesMember_0efe7cfb-0638-4947-866f-495437c63cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59954ee1-90d1-4d06-a9e9-67d8ea181918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2fbae489-66ce-486e-881e-9c02faa3b553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_us-gaap_IPOMember_2fbae489-66ce-486e-881e-9c02faa3b553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_99d08d0d-6125-43c3-8929-90d1f2b91d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_99d08d0d-6125-43c3-8929-90d1f2b91d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PublicStockOfferingMember_0ca0f53c-8d03-4c50-af57-ef440e8b54d6" xlink:href="autl-20210331.xsd#autl_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_860bbdca-cbde-4d61-aabf-2aa6dfb9128c" xlink:to="loc_autl_PublicStockOfferingMember_0ca0f53c-8d03-4c50-af57-ef440e8b54d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5c5b51f4-f009-416d-84a3-ac6e5a270f7b" xlink:to="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7bff6ef6-ea49-4a73-b259-80edf3220302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7bff6ef6-ea49-4a73-b259-80edf3220302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7e42bec4-29a7-4b88-a77a-26b6b4948502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7e42bec4-29a7-4b88-a77a-26b6b4948502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1d7c78f0-b6fd-4bf8-bace-5aa5241c5408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1d7c78f0-b6fd-4bf8-bace-5aa5241c5408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_419de4ae-8a08-4cc5-b0b8-192cdae43156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_NetIncomeLoss_419de4ae-8a08-4cc5-b0b8-192cdae43156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5d1f9179-354d-405b-94de-8ad8391d4f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5d1f9179-354d-405b-94de-8ad8391d4f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_978dd8d4-4d15-482b-b492-3fe9b4b94416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5664546b-abbc-4c58-8b6b-235c541f339d" xlink:to="loc_us-gaap_Cash_978dd8d4-4d15-482b-b492-3fe9b4b94416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9d39b02-aa74-48b6-b376-7593f1528c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e490572a-9a19-4467-a6bc-96cc852d54d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9d39b02-aa74-48b6-b376-7593f1528c38" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e490572a-9a19-4467-a6bc-96cc852d54d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81229066-7d3b-4c33-be85-b073537e9b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81229066-7d3b-4c33-be85-b073537e9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_261b4544-c59a-4073-9c02-9733e2d71f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_UseOfEstimates_261b4544-c59a-4073-9c02-9733e2d71f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_aac51a6a-e058-46d4-a3d5-0258000f8762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_aac51a6a-e058-46d4-a3d5-0258000f8762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eb387b61-fd57-40d0-8a13-6b7f4673c769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eb387b61-fd57-40d0-8a13-6b7f4673c769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_43c184cc-52a2-46b4-a9e0-c5f3acb028b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_43c184cc-52a2-46b4-a9e0-c5f3acb028b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a802c4fc-8e47-4441-8022-c77f606f4734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a802c4fc-8e47-4441-8022-c77f606f4734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_beccfcbb-ea01-4816-94fd-abfeafcee0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_beccfcbb-ea01-4816-94fd-abfeafcee0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_fc33a059-d6b1-42c4-82f9-60ecfdafcfd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_fc33a059-d6b1-42c4-82f9-60ecfdafcfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_27990cca-fb36-4d50-b457-14e4d7126cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_27990cca-fb36-4d50-b457-14e4d7126cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_507d44c2-0d03-4bfa-8bb3-5cf99fac83c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_507d44c2-0d03-4bfa-8bb3-5cf99fac83c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_afd5440c-94b1-4abc-b67a-4087b35c9e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_afd5440c-94b1-4abc-b67a-4087b35c9e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f0e34806-d1af-489c-863c-0c266a41d425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f0e34806-d1af-489c-863c-0c266a41d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b74ef1f1-acf8-4a5b-a4f6-e2369a32cca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b74ef1f1-acf8-4a5b-a4f6-e2369a32cca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PatentCostsPolicyTextBlock_c943f38a-f3a2-4e92-8ac7-5ba0719b9c31" xlink:href="autl-20210331.xsd#autl_PatentCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_autl_PatentCostsPolicyTextBlock_c943f38a-f3a2-4e92-8ac7-5ba0719b9c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bcaa7416-84bd-4ccf-b9f8-198d977886ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bcaa7416-84bd-4ccf-b9f8-198d977886ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d9eedb73-6bf8-4cd4-b0ba-19f48a342049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d9eedb73-6bf8-4cd4-b0ba-19f48a342049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0c9653d3-24ea-4cdd-99e6-29481ccc7d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0c9653d3-24ea-4cdd-99e6-29481ccc7d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_94dcd308-d5ce-46f8-bf9c-df97ef8d3d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_94dcd308-d5ce-46f8-bf9c-df97ef8d3d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a90df71e-079b-4f8a-a740-a9783701b52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a90df71e-079b-4f8a-a740-a9783701b52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1dff6783-3f71-404d-9099-641813f4fa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3feaf23a-b8cf-4b32-a00a-988b656fc4a2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1dff6783-3f71-404d-9099-641813f4fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a73e1d29-b559-430b-b441-beb350984284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_578a5829-2fff-42b8-9904-0db0cbfc34e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a73e1d29-b559-430b-b441-beb350984284" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_578a5829-2fff-42b8-9904-0db0cbfc34e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9fd2d15e-dcf1-4027-a9ff-4d96b4223ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9fd2d15e-dcf1-4027-a9ff-4d96b4223ec1" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_c3b23c50-ad35-4756-8447-84ab372aa767" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LetterofCreditCollateralMember_c8a1e739-9c92-4c3f-955a-20a93161c198" xlink:href="autl-20210331.xsd#autl_LetterofCreditCollateralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:to="loc_autl_LetterofCreditCollateralMember_c8a1e739-9c92-4c3f-955a-20a93161c198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SecurityDepositMember_c30cad89-c194-4fff-b531-ed5df43ad3fa" xlink:href="autl-20210331.xsd#autl_SecurityDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66ca7b79-253e-47b5-8a52-122ef2f2f7f7" xlink:to="loc_autl_SecurityDepositMember_c30cad89-c194-4fff-b531-ed5df43ad3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_6cebc8dd-0436-4eb2-9d21-20ea53889213" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2092ccbf-0291-4e9c-a9f9-6a5710a3b5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_70a4561e-0107-4d94-b3cd-ac7670bf1efc" xlink:to="loc_us-gaap_RestrictedCashCurrent_2092ccbf-0291-4e9c-a9f9-6a5710a3b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_72541c2d-becc-4732-bdc0-3d7c36edaad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72541c2d-becc-4732-bdc0-3d7c36edaad5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d55c6cf3-bd94-4baa-830f-e38da1fb94fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_806c4bd1-a761-4500-9829-bc136dbe1031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_OfficeEquipmentMember_806c4bd1-a761-4500-9829-bc136dbe1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2deeec75-dd46-4fa5-b8c9-c75c2dd0924a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_EquipmentMember_2deeec75-dd46-4fa5-b8c9-c75c2dd0924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7bc5ec22-630a-4e0e-bf60-c182ca192492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cfac125-5467-492d-8eba-bf8ac94c55c7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7bc5ec22-630a-4e0e-bf60-c182ca192492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:to="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cdba4101-753e-4c5f-84ea-ca4707c64ba7" xlink:to="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a394d3fa-2997-40e2-aa56-1970b9a3488b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:to="loc_srt_MinimumMember_a394d3fa-2997-40e2-aa56-1970b9a3488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfec9ad5-9356-44a6-a817-173c75d1b5a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7959ec0a-5a36-4a82-a58a-9de8991ef601" xlink:to="loc_srt_MaximumMember_dfec9ad5-9356-44a6-a817-173c75d1b5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_569a1052-2ee8-4127-a290-19b7f4afed20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b090342c-6b13-4571-92fb-b43477d7df48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b090342c-6b13-4571-92fb-b43477d7df48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_cd6996c2-0d2c-42e3-903a-0416557e91e1" xlink:href="autl-20210331.xsd#autl_GainLossOnDispositionOfLeaseholdImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_autl_GainLossOnDispositionOfLeaseholdImprovements_cd6996c2-0d2c-42e3-903a-0416557e91e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1fcbd65a-efa2-4583-8cb7-0bf722207fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1fcbd65a-efa2-4583-8cb7-0bf722207fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52f7e02e-4cba-4dc6-964d-5c92960a1fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8a2e5f49-3a10-4770-9120-c884837fa493" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_52f7e02e-4cba-4dc6-964d-5c92960a1fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a9cf3c5c-de2d-445c-b023-4fab861af785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ba7d2915-dd2d-420d-b09d-f4627fb230dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a9cf3c5c-de2d-445c-b023-4fab861af785" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ba7d2915-dd2d-420d-b09d-f4627fb230dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19c3b6aa-1000-42b1-8987-347fc5770aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c2a38467-01ac-475e-a989-44a9d466f235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19c3b6aa-1000-42b1-8987-347fc5770aec" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c2a38467-01ac-475e-a989-44a9d466f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2fe91d4a-4eb7-453c-b6fb-f7a8c963f58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19c3b6aa-1000-42b1-8987-347fc5770aec" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2fe91d4a-4eb7-453c-b6fb-f7a8c963f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00cd39a9-0ea8-4474-a193-e7b0804e034d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ResearchAndDevelopmentTaxCredits_78bf6577-5981-4d47-8840-ea7232edf1be" xlink:href="autl-20210331.xsd#autl_ResearchAndDevelopmentTaxCredits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00cd39a9-0ea8-4474-a193-e7b0804e034d" xlink:to="loc_autl_ResearchAndDevelopmentTaxCredits_78bf6577-5981-4d47-8840-ea7232edf1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49819c54-3691-4649-ba89-0ccdc07749c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a0fee1ad-0d91-4315-acec-d191a8d9a249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49819c54-3691-4649-ba89-0ccdc07749c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a0fee1ad-0d91-4315-acec-d191a8d9a249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesPatentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b474859a-7542-4d09-8668-9f1694b18472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_f09fac72-6e94-4bd7-a80b-48827fc0f0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b474859a-7542-4d09-8668-9f1694b18472" xlink:to="loc_us-gaap_ProfessionalFees_f09fac72-6e94-4bd7-a80b-48827fc0f0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5cc4065-5c21-4fcf-8a66-60758a29b2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a49c871f-22cd-4384-b912-60976eb78cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5cc4065-5c21-4fcf-8a66-60758a29b2e4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a49c871f-22cd-4384-b912-60976eb78cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ced27492-3a7b-4e01-9749-969803c96a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ced27492-3a7b-4e01-9749-969803c96a02" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9804518a-df4f-4cfb-8c27-3d48dc410672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0447e92e-125b-41e6-a7e8-aff0ccb3c978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0447e92e-125b-41e6-a7e8-aff0ccb3c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a8ea7aa-7b16-446f-b76a-a1f0cf305c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd1e596-bc44-48c9-b638-8523eb32c142" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a8ea7aa-7b16-446f-b76a-a1f0cf305c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66ae71f1-b7ac-4f09-a81c-e9bb55a8e3b4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283a04a0-8430-41d1-82df-84c37ff3faf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_254a89df-aa43-4145-ba50-23fa570b643f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283a04a0-8430-41d1-82df-84c37ff3faf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrent"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d45658fd-8ed6-4aca-bb54-680406370dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_aa459f14-9889-4378-bd07-52185f935159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d45658fd-8ed6-4aca-bb54-680406370dd1" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_aa459f14-9889-4378-bd07-52185f935159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentTables"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_419e7c03-2684-4a10-acd0-c6d5c9c28057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c3ec1887-0904-4f49-b421-03a9552f51f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_419e7c03-2684-4a10-acd0-c6d5c9c28057" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c3ec1887-0904-4f49-b421-03a9552f51f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent_060aa267-8df2-4986-8989-35d2b835e660" xlink:href="autl-20210331.xsd#autl_ResearchAndDevelopmentClaimsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_autl_ResearchAndDevelopmentClaimsReceivableCurrent_060aa267-8df2-4986-8989-35d2b835e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_16d8c7eb-e64b-43d8-a2d1-c3fbe33f10c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_16d8c7eb-e64b-43d8-a2d1-c3fbe33f10c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_5527c71e-2124-4c16-b077-468501e9f629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_5527c71e-2124-4c16-b077-468501e9f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivableCurrent_683e330d-468f-4577-ba91-0cfc99751e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_LeaseIncentiveReceivableCurrent_683e330d-468f-4577-ba91-0cfc99751e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_311b88d2-868d-4378-a39a-1e2fe88a38ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_GrantsReceivableCurrent_311b88d2-868d-4378-a39a-1e2fe88a38ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_a8ea2b7e-9877-4ac8-b51e-8c21f5558bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_a8ea2b7e-9877-4ac8-b51e-8c21f5558bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_b40b58cc-b43c-4b72-a9c2-dc5d3311131d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_DeferredCostsCurrent_b40b58cc-b43c-4b72-a9c2-dc5d3311131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bfaa1caf-1935-41e0-8b43-d98982f76ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7058d389-6d65-41f8-af59-5f143922515e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bfaa1caf-1935-41e0-8b43-d98982f76ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PrepaidExpensesandOtherAssetsCurrentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3bc022c7-3adb-404b-8739-cc7953acc1be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing_a41bd731-6a75-470c-b64e-ef73c0d73c1b" xlink:href="autl-20210331.xsd#autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3bc022c7-3adb-404b-8739-cc7953acc1be" xlink:to="loc_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing_a41bd731-6a75-470c-b64e-ef73c0d73c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6b4bfe18-68a1-4443-81d7-b4164d25e899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f8f5517-b480-40be-a299-441fa7d75a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6b4bfe18-68a1-4443-81d7-b4164d25e899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f8f5517-b480-40be-a299-441fa7d75a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6940a9ea-470d-45b9-a87f-c176d3907511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_63b70f54-8fb5-4497-9b4e-f0ce98a88dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6940a9ea-470d-45b9-a87f-c176d3907511" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_63b70f54-8fb5-4497-9b4e-f0ce98a88dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cef32208-6f00-4473-8f33-1b9e32bb6d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cef32208-6f00-4473-8f33-1b9e32bb6d83" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1111df7c-12f0-4cc8-bb92-f61d4334fa95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_861f2e9e-7c07-4470-8c15-016ccea1a96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_EquipmentMember_861f2e9e-7c07-4470-8c15-016ccea1a96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_88a48ba4-0bd8-49f0-98ff-34329bf105fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_OfficeEquipmentMember_88a48ba4-0bd8-49f0-98ff-34329bf105fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_05968d3f-4ddb-430c-8bd8-11da20b42aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_05968d3f-4ddb-430c-8bd8-11da20b42aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbe11102-62be-41c4-a2bd-a058eb4862fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbe11102-62be-41c4-a2bd-a058eb4862fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_74802b5e-8356-4b13-889b-9c1ce1170604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da091206-e601-480a-9ba5-d1f9c8b8c93f" xlink:to="loc_us-gaap_AssetUnderConstructionMember_74802b5e-8356-4b13-889b-9c1ce1170604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73ac52aa-53f7-4c89-9283-a740ec017c41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8d0496ae-37bf-4c6b-b7f4-829211818b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8d0496ae-37bf-4c6b-b7f4-829211818b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70d6dfd4-02cd-4e0d-bd37-8c2f2182d8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70d6dfd4-02cd-4e0d-bd37-8c2f2182d8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ed69a869-28fb-4950-8527-a9da28614780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a73ebe2a-30eb-47cf-8151-36132c4b1f1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ed69a869-28fb-4950-8527-a9da28614780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#PropertyandEquipmentNetNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_55a5bd96-9be7-4b0d-8e19-ce2ba32958b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bf11712c-339b-4a59-b216-654591549bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_55a5bd96-9be7-4b0d-8e19-ce2ba32958b4" xlink:to="loc_us-gaap_Depreciation_bf11712c-339b-4a59-b216-654591549bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_224ae1b4-ed66-407c-bc69-b841b5b55b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_dbd29ff3-b5ec-4366-8d56-67cab6f72c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_224ae1b4-ed66-407c-bc69-b841b5b55b74" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_dbd29ff3-b5ec-4366-8d56-67cab6f72c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e64b6d3b-2837-4bda-929f-08ed9a7cbda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e21ec96d-fe18-4330-acaa-ed303dbed8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e64b6d3b-2837-4bda-929f-08ed9a7cbda0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e21ec96d-fe18-4330-acaa-ed303dbed8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#AccruedExpensesandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8a588a0f-bc1e-4124-95d6-be5108524d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8a588a0f-bc1e-4124-95d6-be5108524d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedResearchAndDevelopmentCostCurrent_b2cf3c97-3458-490e-8e58-b52337f722fc" xlink:href="autl-20210331.xsd#autl_AccruedResearchAndDevelopmentCostCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_autl_AccruedResearchAndDevelopmentCostCurrent_b2cf3c97-3458-490e-8e58-b52337f722fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedLicenseFeesCurrent_80500cc1-727d-46de-8400-62f2b78640a4" xlink:href="autl-20210331.xsd#autl_AccruedLicenseFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_autl_AccruedLicenseFeesCurrent_80500cc1-727d-46de-8400-62f2b78640a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f14f9679-928f-4547-987c-67c23f5e71e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f14f9679-928f-4547-987c-67c23f5e71e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_1f26f73e-9af9-4fca-b951-146a170bd9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_us-gaap_TaxesPayableCurrent_1f26f73e-9af9-4fca-b951-146a170bd9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_afb5f328-2a4f-4dca-9750-a7ec9f490bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_afb5f328-2a4f-4dca-9750-a7ec9f490bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b9197439-8aaa-465e-84e5-fa30eed1694c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0e7bcde7-ac25-4dbd-b11c-05ee88a3ce7a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b9197439-8aaa-465e-84e5-fa30eed1694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9320330b-dad6-4080-98b4-4bcbd3738aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e116fb8-dbab-414e-9917-565e31af98d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9320330b-dad6-4080-98b4-4bcbd3738aef" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e116fb8-dbab-414e-9917-565e31af98d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOrdinarySharesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_055b13cc-7a77-40be-bde4-02a76e907803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_055b13cc-7a77-40be-bde4-02a76e907803" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb961ec6-258e-49b6-9ce8-67126c8fdc6e" xlink:to="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OrdinarySharesMember_28e96b9f-880e-485b-96a7-46893c4a9765" xlink:href="autl-20210331.xsd#autl_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:to="loc_autl_OrdinarySharesMember_28e96b9f-880e-485b-96a7-46893c4a9765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:href="autl-20210331.xsd#autl_DeferredClassASharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_702d6ee6-e1ce-41a8-885a-21b72f7bb177" xlink:to="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassBSharesMember_d7071dec-204d-4ac0-ac53-034983a5af5c" xlink:href="autl-20210331.xsd#autl_DeferredClassBSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:to="loc_autl_DeferredClassBSharesMember_d7071dec-204d-4ac0-ac53-034983a5af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_DeferredClassCSharesMember_b810808b-0785-4555-aa3a-f33897991b5c" xlink:href="autl-20210331.xsd#autl_DeferredClassCSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_DeferredClassASharesMember_1e860081-ca59-4951-8c2b-8f0fdd1fa773" xlink:to="loc_autl_DeferredClassCSharesMember_b810808b-0785-4555-aa3a-f33897991b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d5a48a6-ea53-4793-b2b9-f4be8ee8d513" xlink:to="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_fe41d74e-8070-48da-9115-26c6c20de130" xlink:href="autl-20210331.xsd#autl_MaximumNominalAmountOfSharesAuthorizedForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_autl_MaximumNominalAmountOfSharesAuthorizedForGrant_fe41d74e-8070-48da-9115-26c6c20de130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AuthorizedGrantLife_a518d580-14ac-4a0d-8e12-524cb684bcf6" xlink:href="autl-20210331.xsd#autl_AuthorizedGrantLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_autl_AuthorizedGrantLife_a518d580-14ac-4a0d-8e12-524cb684bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_33fdbfa9-281f-46a0-9ef4-555a3b0d9947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_us-gaap_CommonStockSharesIssued_33fdbfa9-281f-46a0-9ef4-555a3b0d9947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1f3aeea6-5f83-4a53-9e57-305cc5987154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b18849f2-98f5-4ca1-95e7-f5bff32ac092" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1f3aeea6-5f83-4a53-9e57-305cc5987154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareholdersEquityOpenMarketSalesAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_34ab775d-3fdf-4ed8-8cfd-8d4d662881c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_34ab775d-3fdf-4ed8-8cfd-8d4d662881c4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5f0c019-28a1-4dce-a4fc-3d77dff21bc6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PublicStockOfferingMember_4d43a855-3398-49a8-8716-0062d95f8ab1" xlink:href="autl-20210331.xsd#autl_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8027062-4595-4504-bf18-b3edad02079a" xlink:to="loc_autl_PublicStockOfferingMember_4d43a855-3398-49a8-8716-0062d95f8ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9c472cf-7841-4d25-9882-192343a50045" xlink:to="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_SaleOfStockAuthorizedAmount_87df3484-daed-4758-945a-d73cfa164cbd" xlink:href="autl-20210331.xsd#autl_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_autl_SaleOfStockAuthorizedAmount_87df3484-daed-4758-945a-d73cfa164cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CommissionPercentageOfGrossSalesPrice_4a5210d8-ef77-4ef8-a950-bc2451ef8c42" xlink:href="autl-20210331.xsd#autl_CommissionPercentageOfGrossSalesPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_autl_CommissionPercentageOfGrossSalesPrice_4a5210d8-ef77-4ef8-a950-bc2451ef8c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e201bc66-ba13-47af-b8a4-effbdff540dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e201bc66-ba13-47af-b8a4-effbdff540dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4da56f7-fa2e-4387-9206-365acd248536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_68778f78-e2b6-45ba-8c8a-71dfbec3c4b5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4da56f7-fa2e-4387-9206-365acd248536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0dc3890-f809-488f-ac43-0e09bf791bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0a05a498-0692-4127-99af-4ac59d636b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0dc3890-f809-488f-ac43-0e09bf791bb2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0a05a498-0692-4127-99af-4ac59d636b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70e1fc27-f1bb-4fba-bc10-74cb2b457e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_96a538c3-4bfa-48dc-864e-16b949f7ec14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70e1fc27-f1bb-4fba-bc10-74cb2b457e98" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_96a538c3-4bfa-48dc-864e-16b949f7ec14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab6e8b6d-931d-4d3e-b9f1-3a82fae3608b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70e1fc27-f1bb-4fba-bc10-74cb2b457e98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab6e8b6d-931d-4d3e-b9f1-3a82fae3608b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_f2ff52ce-6dc5-46e5-9a21-c201af73aa39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70e1fc27-f1bb-4fba-bc10-74cb2b457e98" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_f2ff52ce-6dc5-46e5-9a21-c201af73aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_95e316d4-5218-48fe-b67c-1cb6aadd817e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70e1fc27-f1bb-4fba-bc10-74cb2b457e98" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_95e316d4-5218-48fe-b67c-1cb6aadd817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensation2018Planand2017PlanDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b661ebe-f3ef-4985-bb6c-0733607064e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b661ebe-f3ef-4985-bb6c-0733607064e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:to="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_49753946-8281-492c-916d-6544a762524f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PerformanceBasedMember_77888f31-9760-42d6-ac36-e2f4ea2aa4a5" xlink:href="autl-20210331.xsd#autl_PerformanceBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_autl_PerformanceBasedMember_77888f31-9760-42d6-ac36-e2f4ea2aa4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_198f5400-3fbb-4afc-a7ce-bb414e8f11b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_198f5400-3fbb-4afc-a7ce-bb414e8f11b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d8bb18-79cd-48ce-8d0c-f7067a2fdbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac9b0e-885a-49a3-ac2d-72ab189cbe58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8d8bb18-79cd-48ce-8d0c-f7067a2fdbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:to="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_4df166d4-c45f-4b76-9d5e-6d2d3839850e" xlink:to="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_90160653-248e-4c21-ac6e-55c9e7dd6f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_90160653-248e-4c21-ac6e-55c9e7dd6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16f3c476-06cb-41ac-9fd0-ab3125579fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_74b3bf06-8929-4993-a617-6bd565d13205" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16f3c476-06cb-41ac-9fd0-ab3125579fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99fb7c02-c412-48c2-94ee-0807a2916c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ecd966e6-7149-4b18-8bae-52bd6fa4ede8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ecd966e6-7149-4b18-8bae-52bd6fa4ede8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a2662376-dd72-4cc9-8840-b1ccb3755956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a2662376-dd72-4cc9-8840-b1ccb3755956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ccb0ab40-b124-44c8-aaa6-e8c234e32172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed6c675c-c5ca-4652-bcfb-56d6318edc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ccb0ab40-b124-44c8-aaa6-e8c234e32172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_139ed161-f638-4b1f-9a62-393797036841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_139ed161-f638-4b1f-9a62-393797036841" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:to="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4a14d5d7-0ddc-4c66-813e-9005e73999a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4e64aa1-efea-4290-935d-9dcae1a3c7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8153808c-d185-4231-b684-eebba3ab85b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4e64aa1-efea-4290-935d-9dcae1a3c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:to="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_871fb28b-58ee-44c2-9133-b75b0ac329f5" xlink:to="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d84c574-c110-4a30-86f5-f61035ae64bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94f0ad63-f255-4cc2-a422-a22ce34fa910" xlink:to="loc_srt_MaximumMember_1d84c574-c110-4a30-86f5-f61035ae64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9dc5a4dd-7e35-42de-8824-a2d706fae817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8edc68bb-873e-4f41-b680-9fa88228f412" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ffec7386-f784-4856-adc0-51aad966398b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ffec7386-f784-4856-adc0-51aad966398b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_132051ed-a3c0-4090-9f8b-76189d353ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_132051ed-a3c0-4090-9f8b-76189d353ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4c54cf4-9dfd-4d72-8645-e67f285dc697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4c54cf4-9dfd-4d72-8645-e67f285dc697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6247066d-209a-472c-81bc-32c7c64dae83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6247066d-209a-472c-81bc-32c7c64dae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7a8984c1-6466-446a-b963-1bcbbad8d8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7a8984c1-6466-446a-b963-1bcbbad8d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac9fe82e-29a4-426a-a20c-a30bddbf3969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71c993f7-4c3b-46ff-b605-1286e1ebcc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac9fe82e-29a4-426a-a20c-a30bddbf3969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7db10109-dc26-4177-9d5f-d2af1e71ccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7db10109-dc26-4177-9d5f-d2af1e71ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_391187b5-6fbd-42b4-9a76-3e4e005714d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_391187b5-6fbd-42b4-9a76-3e4e005714d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6caec012-b9e9-4678-8584-2a127b1458ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6caec012-b9e9-4678-8584-2a127b1458ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_38c92c62-a60f-43fd-a665-98f1bcad18f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_38c92c62-a60f-43fd-a665-98f1bcad18f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce4662db-5b63-4038-bdd1-a9c07d7c6425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8aac690e-59fa-4d4b-b419-d2f039deb30e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce4662db-5b63-4038-bdd1-a9c07d7c6425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9ac15b06-0346-451d-bd1a-5dae26f64eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9ac15b06-0346-451d-bd1a-5dae26f64eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32a29b82-1f98-4b18-8959-18903ec4979c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32a29b82-1f98-4b18-8959-18903ec4979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e227c7a5-eda7-4fe6-8288-af3578a9f32f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e227c7a5-eda7-4fe6-8288-af3578a9f32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0ce014eb-d5a2-4903-81a2-55acb0d1df02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0ce014eb-d5a2-4903-81a2-55acb0d1df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b57ffa4b-f33e-4c95-b505-0285a3ff9ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b57ffa4b-f33e-4c95-b505-0285a3ff9ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8e348099-3dac-4365-9a0d-fe6ec36bba34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8e348099-3dac-4365-9a0d-fe6ec36bba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b17bc3c6-998f-4bdf-97f3-a743e1ad3e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_08824dcf-7516-4c5b-a5e3-e32a71555a72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b17bc3c6-998f-4bdf-97f3-a743e1ad3e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_31939389-1b8e-43d5-92be-ab3b61309a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_31939389-1b8e-43d5-92be-ab3b61309a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_634888bc-8520-40d8-b4cd-304321fb3f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_634888bc-8520-40d8-b4cd-304321fb3f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f2863ba0-7d15-423b-a6d5-80c610d88340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f2863ba0-7d15-423b-a6d5-80c610d88340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a5ce5627-285e-4e32-87fe-f9496dedbd59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f2863ba0-7d15-423b-a6d5-80c610d88340" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a5ce5627-285e-4e32-87fe-f9496dedbd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b5bcafa3-3af5-459b-bb75-062da6f77f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b5bcafa3-3af5-459b-bb75-062da6f77f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a869f691-5447-47b2-8e49-2de113ba8dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a869f691-5447-47b2-8e49-2de113ba8dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_207c30e4-e96c-4ccd-a730-2b8849d9ce4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_207c30e4-e96c-4ccd-a730-2b8849d9ce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aeeceb0b-d496-475f-8215-38f137581a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_207c30e4-e96c-4ccd-a730-2b8849d9ce4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aeeceb0b-d496-475f-8215-38f137581a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b475687f-118f-48e9-a555-8c083df689d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b475687f-118f-48e9-a555-8c083df689d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6841cf8c-2af3-4497-afd1-c130ecd6f3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b842e537-4391-4fcc-a521-73be66577420" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6841cf8c-2af3-4497-afd1-c130ecd6f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareOptionsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b77a6225-f692-4f83-8f55-5766222a6d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b77a6225-f692-4f83-8f55-5766222a6d54" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:to="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c3057db-a520-4f2e-8f4f-7b0c39029036" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10144bac-894b-46c0-83ae-8aa4481d8b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3db75dbf-1dd6-4e26-bf5a-20107b1a27ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10144bac-894b-46c0-83ae-8aa4481d8b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5f0cb654-a00d-418f-95d9-5c1ec24ca50b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_061ede0a-aab0-4e05-afeb-457047a37a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_061ede0a-aab0-4e05-afeb-457047a37a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4353cbd6-7c9b-4c81-8af5-75d48610e3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4353cbd6-7c9b-4c81-8af5-75d48610e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72f17eeb-aa7e-4d4f-907c-63e075ea5798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72f17eeb-aa7e-4d4f-907c-63e075ea5798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_177100da-cd56-4da5-9bd7-fe36588bc0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f61bbfd8-252d-4586-a91a-a754278f776d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_177100da-cd56-4da5-9bd7-fe36588bc0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa3e46e9-b0ac-4294-9852-a364117ad2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa3e46e9-b0ac-4294-9852-a364117ad2db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:to="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7b7ffa0d-a39b-4a31-aed3-61e4bf565837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_092e2f0f-9c65-4aa8-b168-de27798b01b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884e235a-60b9-4e49-9d9f-26ef06e2e69a" xlink:to="loc_us-gaap_RestrictedStockMember_092e2f0f-9c65-4aa8-b168-de27798b01b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4ac44f4-cacf-4a56-81f2-c48d2a723d85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf6bb572-2092-47d1-ac19-7c6f29fa6e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf6bb572-2092-47d1-ac19-7c6f29fa6e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3b6653d7-0588-4dc3-9427-c4e16686baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3b6653d7-0588-4dc3-9427-c4e16686baf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1035620d-c229-45ab-b5c0-133ba27ba3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1035620d-c229-45ab-b5c0-133ba27ba3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9dcb91fd-d291-46bd-abf5-d9c481c8902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9dcb91fd-d291-46bd-abf5-d9c481c8902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21727a03-75aa-4994-84bc-fe5ee90edc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_780a42a3-fcab-415f-a317-035ed5aef7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21727a03-75aa-4994-84bc-fe5ee90edc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23d6d52f-da35-43bc-bd31-75cc4ca2d24c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34daa6fe-37bd-4cb7-b4a7-735ca5057376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34daa6fe-37bd-4cb7-b4a7-735ca5057376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc911153-03db-44f5-a5f9-175b860fae30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc911153-03db-44f5-a5f9-175b860fae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_17e8f243-4339-4f4e-bf56-2cd99ce81246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_17e8f243-4339-4f4e-bf56-2cd99ce81246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b1c282f5-f0b6-407a-bae0-084e3565da90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b1c282f5-f0b6-407a-bae0-084e3565da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b2cee2b-c253-46cf-9d46-64c06ed0ae44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f9d9c11-c2eb-425d-8837-f90b3963ddb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b2cee2b-c253-46cf-9d46-64c06ed0ae44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a4d2c05-ff67-4c6d-91a1-674ca458258d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a4d2c05-ff67-4c6d-91a1-674ca458258d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:to="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_836bf5bc-ac80-4985-bf67-a54f731d0d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b9811438-482d-44c3-8735-6238d74867bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e67eb-91c5-4c8d-a093-eb17f703c7f3" xlink:to="loc_us-gaap_RestrictedStockMember_b9811438-482d-44c3-8735-6238d74867bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ae52140-058d-4fbd-8e30-455a0b6b6cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1a48dde9-ffe1-42c3-b807-0abbcd77225a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1a48dde9-ffe1-42c3-b807-0abbcd77225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2e011d7-3d39-4f96-bc28-a030f44fc12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90e88c23-8510-4b4e-81b6-7178bb0a44fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c2e011d7-3d39-4f96-bc28-a030f44fc12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f7a99d4-e0d0-4b97-a33f-84c3e52a80e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f7a99d4-e0d0-4b97-a33f-84c3e52a80e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:to="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_986a2617-5718-4859-941d-17af9e47e3aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a7140ba7-05a1-4a3a-9143-d1794e3230f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4eb6570c-d02a-4ad0-9602-18b8eadd0d34" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a7140ba7-05a1-4a3a-9143-d1794e3230f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:to="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_76f74bb6-6d62-4c50-ba52-92473ced59cb" xlink:to="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940fc5cf-4e60-4c6e-a445-e90f427dcfd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940fc5cf-4e60-4c6e-a445-e90f427dcfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c69d51a5-d041-491b-b024-0c900bdcacd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_04e6afa5-b3c4-4bbb-8da0-6c4c9076ebbf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c69d51a5-d041-491b-b024-0c900bdcacd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3fb95d3-50fb-4886-9cd0-0289ca9c5cf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d555774-4d56-40bc-be72-279546b2680c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d555774-4d56-40bc-be72-279546b2680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5887e454-0658-4f25-8210-65c99d7472dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5887e454-0658-4f25-8210-65c99d7472dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2377c8da-5167-47e0-a39f-ecfa552b939e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2377c8da-5167-47e0-a39f-ecfa552b939e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa405e3c-59e5-439a-bdcf-2e00b50fe7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aa405e3c-59e5-439a-bdcf-2e00b50fe7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0636879b-ca01-4ebb-a6ab-49f7692b7301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69e86c6c-1dbb-4379-949c-9617b3de6974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0636879b-ca01-4ebb-a6ab-49f7692b7301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21303da5-22c2-44a7-9d02-56fb226c2911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21303da5-22c2-44a7-9d02-56fb226c2911" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:to="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_303b6ea9-70b5-4e53-bca9-31aa1a20fc53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3fc2187a-bae1-443f-8326-95c47bc94cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2fec511-932c-4372-8570-9f8585482139" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3fc2187a-bae1-443f-8326-95c47bc94cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba736fb8-2847-481b-8cb9-ce751453024a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6c640d6-304c-4506-95c1-c466d05c5b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d6c640d6-304c-4506-95c1-c466d05c5b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7dedf9b3-7266-4eaf-abed-61a9478b814f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7dedf9b3-7266-4eaf-abed-61a9478b814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_561356a9-57a9-44ea-94fb-55bd36d8fb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_561356a9-57a9-44ea-94fb-55bd36d8fb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc631932-239f-4ca0-a3c0-b2c4abdaffb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc631932-239f-4ca0-a3c0-b2c4abdaffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7afcba45-1126-4fb1-9e6a-6d334f035c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83a5f222-a83f-4df2-aebe-2de033a72dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7afcba45-1126-4fb1-9e6a-6d334f035c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df1a4a85-0cf2-4bfa-92ad-2a93188ce0d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1948a696-b958-417d-950b-4c8f31f9b2ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1948a696-b958-417d-950b-4c8f31f9b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5506f568-60d0-4024-ad57-0697e618c954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5506f568-60d0-4024-ad57-0697e618c954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7f374adf-7c65-4a0b-8522-0abc2159a9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7f374adf-7c65-4a0b-8522-0abc2159a9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b79c3bbf-dbf3-44ca-a7d4-e6ac0d1bdcf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b79c3bbf-dbf3-44ca-a7d4-e6ac0d1bdcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19b5b5c0-0163-495f-bf21-dcaa26a125a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5057f919-bafd-4c30-b780-c95ae573bd46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19b5b5c0-0163-495f-bf21-dcaa26a125a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679c8280-261b-4201-8951-f0b88fa1b3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679c8280-261b-4201-8951-f0b88fa1b3c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_371c71ab-d0f4-4f0d-97f6-2851a990bfea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9046137-e755-480e-b0aa-981b2637d2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9046137-e755-480e-b0aa-981b2637d2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_071f59fa-45bc-4a06-a109-822b8e862208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_071f59fa-45bc-4a06-a109-822b8e862208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_CapitalizedFixedAssetsMember_d2538723-1f99-4d72-9946-50d87d1bbfcc" xlink:href="autl-20210331.xsd#autl_CapitalizedFixedAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efaed3d0-a022-4bf1-a910-91aa72d7f25e" xlink:to="loc_autl_CapitalizedFixedAssetsMember_d2538723-1f99-4d72-9946-50d87d1bbfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638e1d04-c625-49f3-83cb-ffff0960c7e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72c6bbd8-4e83-484c-9000-11a6e2694ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a628120-9d69-4dda-abd8-124cf45491fd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72c6bbd8-4e83-484c-9000-11a6e2694ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f71d96e-20cd-4515-bfc9-a94add9aee24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease_9a8a1282-45da-4466-a071-2feb284cede5" xlink:href="autl-20210331.xsd#autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f71d96e-20cd-4515-bfc9-a94add9aee24" xlink:to="loc_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease_9a8a1282-45da-4466-a071-2feb284cede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreements" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_autl_LicenseAgreementsAbstract_2fdd5f6c-6d62-410b-b7b1-ac6ea9d6ae74" xlink:href="autl-20210331.xsd#autl_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LicenseAgreementsTextBlock_9a2ab542-5f57-4fb4-b102-2e73b6120f32" xlink:href="autl-20210331.xsd#autl_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_LicenseAgreementsAbstract_2fdd5f6c-6d62-410b-b7b1-ac6ea9d6ae74" xlink:to="loc_autl_LicenseAgreementsTextBlock_9a2ab542-5f57-4fb4-b102-2e73b6120f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_autl_LicenseAgreementsAbstract_ddec8c4a-05ba-43c6-9761-d1ef286d6759" xlink:href="autl-20210331.xsd#autl_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_LicenseAgreementsAbstract_ddec8c4a-05ba-43c6-9761-d1ef286d6759" xlink:to="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4eb595c0-b36a-4c2e-886c-2cff79923f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_UCLBusinessplcMember_400da149-a276-45a6-be64-8156a9ecb760" xlink:href="autl-20210331.xsd#autl_UCLBusinessplcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48ee3409-573d-4d58-986f-9ef89efb876a" xlink:to="loc_autl_UCLBusinessplcMember_400da149-a276-45a6-be64-8156a9ecb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ConditionalPaymentsAxis_523f24ef-d6dc-415f-ab91-47e07f2fb10f" xlink:to="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ClinicalActivitiesMember_007f3810-b9d7-469e-876d-3ec2df3a94cb" xlink:href="autl-20210331.xsd#autl_ClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_ClinicalActivitiesMember_007f3810-b9d7-469e-876d-3ec2df3a94cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_RegulatoryApprovalMember_58d0a4c3-5aba-4a83-9267-72d289babf6b" xlink:href="autl-20210331.xsd#autl_RegulatoryApprovalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_RegulatoryApprovalMember_58d0a4c3-5aba-4a83-9267-72d289babf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ProductSalesMember_3cb592e0-2550-44d9-b760-bdd2386d15ce" xlink:href="autl-20210331.xsd#autl_ProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_ProductSalesMember_3cb592e0-2550-44d9-b760-bdd2386d15ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_NetSalesLevelsMember_5c027fb9-fc5f-4684-9a84-b82e3ea30d4e" xlink:href="autl-20210331.xsd#autl_NetSalesLevelsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ConditionalPaymentsDomain_9075759d-6e84-4da1-beee-025f33826783" xlink:to="loc_autl_NetSalesLevelsMember_5c027fb9-fc5f-4684-9a84-b82e3ea30d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00a7a9d5-17ef-4feb-8861-5c4e2247d3d7" xlink:to="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5a75396-2b25-4b6c-acb5-84b376f12835" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:to="loc_srt_MinimumMember_e5a75396-2b25-4b6c-acb5-84b376f12835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56c76db1-663d-4302-af6a-58184e09671c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52b6a963-8611-4575-b775-c81a319e4299" xlink:to="loc_srt_MaximumMember_56c76db1-663d-4302-af6a-58184e09671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:href="autl-20210331.xsd#autl_ScheduleOfLicenseAgreementsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsTable_3f43fd93-082b-4ed8-821c-8913a1dfb44e" xlink:to="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_510a3bce-3e78-4824-a5de-1299bef4aa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_510a3bce-3e78-4824-a5de-1299bef4aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_PaymentOfUpfrontFees_fb4fafc1-8792-44fe-b45a-951ce30a8c4a" xlink:href="autl-20210331.xsd#autl_PaymentOfUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_PaymentOfUpfrontFees_fb4fafc1-8792-44fe-b45a-951ce30a8c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AccruedLicenseFeesCurrent_0553066b-9f33-4a9b-b7c1-dee74f9f9b15" xlink:href="autl-20210331.xsd#autl_AccruedLicenseFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_AccruedLicenseFeesCurrent_0553066b-9f33-4a9b-b7c1-dee74f9f9b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ConditionalPaymentBasis_de629d8a-bcce-4b76-8553-600a35278c55" xlink:href="autl-20210331.xsd#autl_ConditionalPaymentBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_autl_ScheduleOfLicenseAgreementsLineItems_63083ba9-0e9c-45c2-9c19-694dd547be4c" xlink:to="loc_autl_ConditionalPaymentBasis_de629d8a-bcce-4b76-8553-600a35278c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxes" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_404e0e0f-d03d-4167-bbaa-e71af161f885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4468aa30-ed63-4c9b-9a35-31ed9c5668ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_404e0e0f-d03d-4167-bbaa-e71af161f885" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4468aa30-ed63-4c9b-9a35-31ed9c5668ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_053a9f49-7d56-4049-bf44-930f151180b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_053a9f49-7d56-4049-bf44-930f151180b7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5b11fdef-1b90-469d-a4d5-01455f596868" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_2d608aa5-73a9-4d1a-82b9-6419b7377852" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9d8472cc-1bd2-48b3-95bf-00d8564e604e" xlink:to="loc_srt_SubsidiariesMember_2d608aa5-73a9-4d1a-82b9-6419b7377852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_ab8361a7-162c-4944-856b-90cd4166fd39" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bcf1b0c1-506d-4bfa-8fb1-586b3cd2591c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bcf1b0c1-506d-4bfa-8fb1-586b3cd2591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4372610-43fd-4202-819a-96d62720c65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4372610-43fd-4202-819a-96d62720c65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18e2a2e0-5f9b-478c-8176-a2cd879442bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18e2a2e0-5f9b-478c-8176-a2cd879442bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2c1dbc9-2b49-4be2-a7c2-f339cd502093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e2d1a915-1fd9-44d5-9776-2b19ae668f5d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2c1dbc9-2b49-4be2-a7c2-f339cd502093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19c8afa9-3483-48ec-836f-8ed67a3a6aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e4c46fde-d215-4cde-9207-56158a1ed3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19c8afa9-3483-48ec-836f-8ed67a3a6aab" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e4c46fde-d215-4cde-9207-56158a1ed3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#CommitmentsandContingenciesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3f7de1d-b80a-4312-b219-daa63d40c3d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3f7de1d-b80a-4312-b219-daa63d40c3d5" xlink:to="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02f7f63b-3e00-414d-abdc-1c60e9537635" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9094a191-1014-4816-b78b-ee17bc1943d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:to="loc_us-gaap_BuildingMember_9094a191-1014-4816-b78b-ee17bc1943d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_AdditionalSpaceMember_84325674-89f7-4629-816d-b2db4eff2292" xlink:href="autl-20210331.xsd#autl_AdditionalSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4959db7-bfb8-4836-8ec2-a9425c09de65" xlink:to="loc_autl_AdditionalSpaceMember_84325674-89f7-4629-816d-b2db4eff2292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9441c14d-23a2-4cfa-8897-28e9c8fd0a27" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ImperialForestHouseLimitedMember_659e77ea-0f8a-4840-929f-9ee6a988cea8" xlink:href="autl-20210331.xsd#autl_ImperialForestHouseLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_ImperialForestHouseLimitedMember_659e77ea-0f8a-4840-929f-9ee6a988cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_c2f0bf67-4b1f-46e9-a37b-98b808b084ee" xlink:href="autl-20210331.xsd#autl_ManufacturingSpaceInEnfieldUnitedKingdomMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_ManufacturingSpaceInEnfieldUnitedKingdomMember_c2f0bf67-4b1f-46e9-a37b-98b808b084ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeSpaceInRockvilleMarylandMember_794c93cb-71f3-4ea9-81a1-a240dfc571e6" xlink:href="autl-20210331.xsd#autl_OfficeSpaceInRockvilleMarylandMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_OfficeSpaceInRockvilleMarylandMember_794c93cb-71f3-4ea9-81a1-a240dfc571e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_18f32e83-6dc1-4209-83b6-f99dda21fbfe" xlink:href="autl-20210331.xsd#autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2bfb8763-f193-4d40-a11c-1e7573342ae9" xlink:to="loc_autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember_18f32e83-6dc1-4209-83b6-f99dda21fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89122ff0-b162-4f21-82a2-644d501c1daa" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_22955f70-a6b0-4bde-bbe2-94634b54469f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd764a24-7e08-4550-85f9-cf1aa9834dd4" xlink:to="loc_us-gaap_SubsequentEventMember_22955f70-a6b0-4bde-bbe2-94634b54469f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ab3625e2-3154-497a-b2f0-cbb1c2bd626e" xlink:to="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5537b067-b140-4705-95e7-5f5532620343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5537b067-b140-4705-95e7-5f5532620343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_a9b2642f-50f7-406c-8592-f7944e1f7c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_a9b2642f-50f7-406c-8592-f7944e1f7c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentiveReceivable_4aef07ac-e842-41a0-91f6-70d5eea306da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_LeaseIncentiveReceivable_4aef07ac-e842-41a0-91f6-70d5eea306da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfUnitsInRealEstateProperty_db7880fe-9d58-4c4d-824e-b981e4b4a753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfUnitsInRealEstateProperty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_NumberOfUnitsInRealEstateProperty_db7880fe-9d58-4c4d-824e-b981e4b4a753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_LeaseTerminationFeeExpense_271abda7-109f-4f2b-a640-3bc37db84229" xlink:href="autl-20210331.xsd#autl_LeaseTerminationFeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_autl_LeaseTerminationFeeExpense_271abda7-109f-4f2b-a640-3bc37db84229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_autl_OperatingLeaseRentFreePeriod_eddf472c-daac-416e-853b-047dbdf6865e" xlink:href="autl-20210331.xsd#autl_OperatingLeaseRentFreePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_autl_OperatingLeaseRentFreePeriod_eddf472c-daac-416e-853b-047dbdf6865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_678ea56d-d7e1-49fb-b9dc-b120067194f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_678ea56d-d7e1-49fb-b9dc-b120067194f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_58f650a8-e9cc-4aed-8c95-252f34df4470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_46f40f1b-24fc-477f-ad1b-7f6873a09ade" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_58f650a8-e9cc-4aed-8c95-252f34df4470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5c189d4-4b2c-4774-9d74-98c080c2f8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8194f1bb-816a-422e-8722-667c1cbc823d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5c189d4-4b2c-4774-9d74-98c080c2f8fd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8194f1bb-816a-422e-8722-667c1cbc823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="autl-20210331.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_580d5968-44bf-4571-92a8-b5a33da99526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_e1d9afed-5132-41f1-a1bb-28933fc8a60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_580d5968-44bf-4571-92a8-b5a33da99526" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_e1d9afed-5132-41f1-a1bb-28933fc8a60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cbfee54f-a6e4-4877-9307-1b6ecb556b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_580d5968-44bf-4571-92a8-b5a33da99526" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cbfee54f-a6e4-4877-9307-1b6ecb556b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_37050750-52fb-43a7-83b0-1d6f1ddbda44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_580d5968-44bf-4571-92a8-b5a33da99526" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_37050750-52fb-43a7-83b0-1d6f1ddbda44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.autolus.com/role/SubsequentEvent" xlink:type="simple" xlink:href="autl-20210331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.autolus.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_616730cb-a047-4551-af5f-a98e5d04355b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5481bdf7-473c-4865-a875-14edc4fd38a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_616730cb-a047-4551-af5f-a98e5d04355b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5481bdf7-473c-4865-a875-14edc4fd38a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>autl-20210331_d2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:autl="http://www.autolus.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="autl-20210331.xsd" xlink:type="simple"/>
    <context id="i66aae6507b744c1d8f4b560d2b970ce2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id858f1b0dc6f47c58cb69a3594277923_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfa8aa73c88c4f96977e727aa35b5250_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ice90221976d446d9a888b6ac5bc8d1a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25cf6d3934504912b31c2783e517e671_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40a6c0216e3a4a178d18533172f5eead_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i56612f0340b24dd9ae96b45ea23779ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cfb1d3e9b454ea1902388d923852617_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f164bd4080b4036848be45a434b1183_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib659d9739ed84217a438b97c75c6edb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e043145ac6040a696157aeace3f9b4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1be88049689e47d9a6b45c2c0165bca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice6c95b827c147d9834cea80ba9c76ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8a397d0ab374ebf9ecf4ba734ae5899_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i973d0bab1a8546f9883c52cfb0e637fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee15fdaf6af94a6fabfb9578aff371ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5635c7ca4780434ab4798595f173a5b3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7fc130c21a1045bb8cb7f0a7e50d23cc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i43bf285d959642828ad34fca6a197946_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8124081013b040f48152051d2fef650f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if0c21a05bfb74f80973b93799c2a14b9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i022edc107d0143858a241d8c91b0faa5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia0691ee4c8ba40abae69ca13311d4688_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8412d6479b1f4abeb4d9efb97ec4a49c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6fd77def720648068ce0e83aceb985cb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d535d1cff574284bf3469db856638c1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i210da8084e084840a2b797ed219d3290_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d4a40b22a3e4903aa2404f3046690ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4384483d59d8411298573965d8975dfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49989be8f3a74255a4d08b2dfaf2f5a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id192f441ae29485b91f10751a6a033c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b837afacb0f45118327f9635557485f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9abac6332284e97991a2832e326a6ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i435a50a0218748dd91c2cfcdbc133e2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50b508b0d25c4c9f8965def0a415d097_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb2969b50377465b89f51740cb4e64f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62cebd19059d4be08369d4361a770ec4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i23fe26c1f0bd4aba944f09803669b655_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:DeferredClassCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ica69ca24ff9c48549c99f04588c27692_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e5ee0501a8f469a8d6aff5456d7a531_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b543afe63da4f298f4f355d5b1fa4ec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="i3c4daa51bf814b1b806ec67107d32d58_D20180622-20180622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="i5a82058bfcb64fce894d3dd5382848b0_I20180622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-22</instant>
        </period>
    </context>
    <context id="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-15</startDate>
            <endDate>2019-04-15</endDate>
        </period>
    </context>
    <context id="i85577d0805ae43f28ac6d00d72e6ffc9_I20190415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-15</instant>
        </period>
    </context>
    <context id="idece61323c9d42bdbbd6d64fe516d660_D20190415-20190415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-15</startDate>
            <endDate>2019-04-15</endDate>
        </period>
    </context>
    <context id="ia9549cc85aa24734a469de8134065606_D20200127-20200127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-01-27</endDate>
        </period>
    </context>
    <context id="i64e0070edc0a4b0c87c8b6d88f9244d0_I20200127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-27</instant>
        </period>
    </context>
    <context id="i0dc3cbb83148416dbc07992923a63cad_D20200127-20200127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-01-27</endDate>
        </period>
    </context>
    <context id="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i932c7033a2c64d83b9e11b73ab217086_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="id8c4c15ff52c42d49a43d574cf188723_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i41d639c705934456ab14641f84359651_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i524bbe2dd39341faac717c3d8d151567_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i25159a1662d546f8b7c7111c26504274_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">autl:LetterofCreditCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb4a12fcb03747dfaa82aec40ecf9ab6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">autl:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if32728553356471ba7bc0e4c651239d0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i444cc5149ffb4ff3aebc41d214a9558c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb6476ec587b401aaa02d1e7fc32b2d9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibe7330eedb514187a0f2f7858509b56d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia59d20ea5e8a4d7cbfe95212fb978221_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b4f427ba0764b8d8cd7204223dfb93f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41fb8cf98b7c46c1b399e564aa4b4ec1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ca9e1c4a7374941a2c5d250cd93db6f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1fac6fac3aa7454b9e09eae49685ed05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i54aa60e569634a13a1858ea934dcb0bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6617f38eb9f4460a622b2d3e9279f54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53347ee136fa448db35974e8e31a9d0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b2f75a31f494e2aa9a5db9ab782201c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i847ce03d632a4b45add274b3cfcf12b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia61a689210f94943a3d41c76d40e1ebd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2651a7e1481c490393262e2898c2333d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic33f618510fd4997a9c685478ea3f3ba_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i493cf0d67e02413cabd32aafc94e263f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52a9ff78fd994500b70e17771c035eaf_I20180626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">autl:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-26</instant>
        </period>
    </context>
    <context id="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2018-06-26</startDate>
            <endDate>2018-06-26</endDate>
        </period>
    </context>
    <context id="i89ef2b2dd83148a89ab674028ea86908_I20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="i2070486d12ea46aa83b02cb4d9488798_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">autl:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied33dc884b13464f896f1ce66590f479_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i152c0f30695a40f9a86760ec0cbcc834_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">autl:PerformanceBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">autl:PerformanceBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c228c3581004647bb72617df8c2b232_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i916d4ef54fa54d7793e6e79e3ce53f4b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i049951a6daee47029d1139d31d05bfa3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a573508e9c143009ce350d6d6b25350_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic01ce88311fc413e92a876264e4e7673_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a527a130d6d456fb3e905c90988f2cb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb6abb4fb36a41389bd1c9e0a53cb994_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id91d5db238bf4cbf8f5dd387c179eec8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6c78c180c11e46c6bbf16e7e78cf9f89_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54c774dce7d34ff78fe33ab4eb91cbee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5403abf0cda041f49722bec6a5bd107b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">autl:CapitalizedFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c5ac4db8415442786609952726649c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">autl:CapitalizedFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65bb2de6245d44fd989ae0fadd180dcf_D20140901-20140930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-01</startDate>
            <endDate>2014-09-30</endDate>
        </period>
    </context>
    <context id="i2dae7352e4564813bd4e58c8bfac3d0c_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i194d9cd7426f43bdb92c35c4b53da10d_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i8cc189fb946a4e56907d007ff790d9d3_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i740603bdf79a4a19ab28501a2828b0da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6f3546488134bd188df42bb75467850_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:RegulatoryApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d5ef338879d45cfa5e65e5c7f749b73_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i836d7bd86d1742f8b994ba61b0ebc03a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">autl:UCLBusinessplcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:NetSalesLevelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ba521a09dfc43cc965da6b20f859156_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i340f4450111245dd99b493da501889f5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="autl:ConditionalPaymentsAxis">autl:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba75fdc622554754b612b6ca2d81e8dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib312439b752b4257b958d24ddae1acc2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie8fc906e9cef419a9335fea6d40a569f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">autl:AdditionalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d9b766ba80440d696ca8311b8127c2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ImperialForestHouseLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ManufacturingSpaceInEnfieldUnitedKingdomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:ManufacturingSpaceInEnfieldUnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9aa970f510b84d03bcdab0bf779d4aaa_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeSpaceInRockvilleMarylandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i1a1eb5a9f0484994b0f3d8ee7aa1718f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeSpaceInRockvilleMarylandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1cd6038d37304152829044a7577d308f_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7eb8d879d3684656b339162dcd9fbfcb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idda9c1c6f5574294ad1bf162a75b78b0_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001730463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">autl:OfficeAndManufacturingSpaceinRockvilleMarylandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="region">
        <measure>autl:region</measure>
    </unit>
    <unit id="segment">
        <measure>autl:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="unit">
        <measure>autl:unit</measure>
    </unit>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i444cc5149ffb4ff3aebc41d214a9558c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yOC9mcmFnOmNlMjNiNzFkMWY2NDQ2ZGU5YTRmZTEwYjY4MjYxMTE3L3RhYmxlOjdiZDMzOWZjOWM3NzRiMzg4ZDkzYjU4Zjg2ODczNzgyL3RhYmxlcmFuZ2U6N2JkMzM5ZmM5Yzc3NGIzODhkOTNiNThmODY4NzM3ODJfMi0xLTEtMS0w_2ff72b78-18eb-4332-bcc3-445d98df0b41"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:EntityRegistrantName
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18wLTEtMS0xLTEyMg_72695144-99f4-4bb3-a007-ced49a3a8d64">Autolus Therapeutics plc</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18xLTEtMS0xLTEyMg_112f6498-621c-4523-8a07-3be80ab3bb5f">0001730463</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18yLTEtMS0xLTEyMg_0bd63f36-1afb-4b16-8627-a729df4cb26a">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y18zLTEtMS0xLTEyMg_1defc65d-0f91-4135-8126-8e4b9edbb3a6">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y180LTEtMS0xLTEyMg_d3849bfe-1b7e-4136-b39d-249538ba339e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y181LTEtMS0xLTEyMg_6f92aa2f-1b39-4e2e-90c7-17a99d553b8f">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y182LTEtMS0xLTEyMg_a41256ce-e0d0-45ce-8201-ec4e373bd528">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlOTcxNWZjNDY1ZTRmZjU4MGNiYzQ5MGY2NTA5NjE4L3NlYzoxZTk3MTVmYzQ2NWU0ZmY1ODBjYmM0OTBmNjUwOTYxOF80L2ZyYWc6MmUxMGJmOTk1Y2RkNDljODg1MjI4ODliYThjMmVhMTQvdGFibGU6NGM4ODI4ZGIzM2JhNDhiZTg3YTJlNzdiNzA4MThlN2MvdGFibGVyYW5nZTo0Yzg4MjhkYjMzYmE0OGJlODdhMmU3N2I3MDgxOGU3Y183LTEtMS0xLTEyNQ_e70f33e0-a833-4f7b-a96f-b975c015d30b">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:Cash
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV80LTEtMS0xLTA_99f7ae98-aa40-47e5-8411-8692218dc0c5"
      unitRef="usd">239012000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV80LTMtMS0xLTA_1697cf66-bcec-4770-bbfb-f945c30a89d1"
      unitRef="usd">153299000</us-gaap:Cash>
    <us-gaap:RestrictedCashCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV81LTEtMS0xLTA_e9b6abcb-0e4e-447d-b5a3-89c04d010cda"
      unitRef="usd">786000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV81LTMtMS0xLTA_f1b7e974-6777-4c7a-9ca6-acfc9d2a1c86"
      unitRef="usd">786000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV82LTEtMS0xLTA_5f9a0295-4954-40c5-90df-f02c2d7cc0c8"
      unitRef="usd">48262000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV82LTMtMS0xLTA_4a881862-1c0d-43d8-99a7-61e887bce381"
      unitRef="usd">42899000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV83LTEtMS0xLTA_6e50a027-2f4b-41af-94c2-1f691edf9160"
      unitRef="usd">288060000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV83LTMtMS0xLTA_ff0d5079-a6d4-4856-bdb5-c79e983ac820"
      unitRef="usd">196984000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV85LTEtMS0xLTA_12d64a1d-5420-4b9c-8756-15029e634dce"
      unitRef="usd">33543000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV85LTMtMS0xLTA_66f3814c-4b9c-46d7-97b1-220cdda8e26b"
      unitRef="usd">38046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMC0xLTEtMS0w_0e9d04fd-4381-4fe0-aacf-28011d43761a"
      unitRef="usd">21199000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMC0zLTEtMS0w_ace863ea-a557-4d5e-a8ca-85378187806e"
      unitRef="usd">51637000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMS0xLTEtMS0w_75c4e83d-671e-40c3-aa5e-af66ad4222b9"
      unitRef="usd">1836000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMS0zLTEtMS0w_dadc0148-9e82-4745-8ae1-d8ca0fdb60bf"
      unitRef="usd">2625000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMi0xLTEtMS0w_95b5be6d-7397-4509-bc04-ad4c19b89e6e"
      unitRef="usd">2939000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMi0zLTEtMS0w_e65044a1-d0b5-4669-944c-9ab9fca63332"
      unitRef="usd">3033000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMy0xLTEtMS0w_15ac3488-c9f4-43e0-a2ac-173c7a58722e"
      unitRef="usd">2034000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xMy0zLTEtMS0w_657507e9-e4d2-47ac-b37b-f10bda04a777"
      unitRef="usd">1754000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNC0xLTEtMS0w_e56d05cb-dabd-42b1-93a3-362ec6ffebaa"
      unitRef="usd">135000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNC0zLTEtMS0w_13552b83-3541-484a-9226-be3ebdd0d0a0"
      unitRef="usd">158000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNS0xLTEtMS0w_dad76068-d64a-4e63-ac4a-aeea5cc5d29d"
      unitRef="usd">349746000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xNS0zLTEtMS0w_704782fa-c3cc-434d-9ab5-13d175baad9a"
      unitRef="usd">294237000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOC0xLTEtMS0w_813961aa-9c54-4371-8b33-73c78def7294"
      unitRef="usd">2259000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOC0zLTEtMS0w_9684184f-7eb5-4ded-b9fe-4a24222c782b"
      unitRef="usd">2263000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOS0xLTEtMS0w_284b3b98-70cb-442b-91ed-b51a7b887faf"
      unitRef="usd">24683000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8xOS0zLTEtMS0w_e72ad1d3-8971-49ff-92b6-82c7dc4d9b74"
      unitRef="usd">27781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMC0xLTEtMS0w_46ec1feb-68a5-40ae-999e-cd6724603bfa"
      unitRef="usd">3657000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMC0zLTEtMS0w_fca41aa0-b23a-4175-a59f-625d86921201"
      unitRef="usd">3590000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMS0xLTEtMS0w_09efac10-b2c7-4d51-b42c-8f46a8a08f48"
      unitRef="usd">30599000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMS0zLTEtMS0w_da720d41-e0f9-4311-b5c0-8d23d5bd4cbf"
      unitRef="usd">33634000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMy0xLTEtMS0w_c0fd2bce-09fb-407e-a871-c78abbb9b776"
      unitRef="usd">19580000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yMy0zLTEtMS0w_45df437c-a9eb-443a-b678-68e98a4a443c"
      unitRef="usd">50571000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNC0xLTEtMS0w_1b502878-33b3-4623-90ad-40cfbd66c6ae"
      unitRef="usd">50179000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNC0zLTEtMS0w_1e2c327c-0112-4a99-b734-a048e6e30414"
      unitRef="usd">84205000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMjI_9876af70-0c55-4433-ab9a-78ad8ba2f89d"
      unitRef="usdPerShare">0.000042</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMjI_c109a7c5-6ad3-4f47-8c79-72b067c2bbac"
      unitRef="usdPerShare">0.000042</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMzY_d9dc114e-9d06-4488-a104-be8a01719be1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfMzY_e73be7dd-8b65-4fd1-bac2-7bde5535f602"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfODk_2ef92cbb-f7a4-4f10-9ef4-66225eb217aa"
      unitRef="shares">70515354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfODk_4db1cefe-cddf-4b51-9282-76842e5eb743"
      unitRef="shares">70515354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfOTY_1a387c04-5bdb-4734-b067-1073a90d930b"
      unitRef="shares">52346231</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0wLTEtMS0wL3RleHRyZWdpb246Mzc5ODQ4YjkyM2M1NDYxYWI1ZTE1ODBmMmYwZjYyZDFfOTY_d1f88395-7cfd-44dd-8154-40392415c0fd"
      unitRef="shares">52346231</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0xLTEtMS0w_2918f491-7f8a-4831-9196-f39c367fbd36"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ice90221976d446d9a888b6ac5bc8d1a6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yNy0zLTEtMS0w_a63e4520-c7f1-4a39-946f-82a94c1dcca3"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMjI_5f490979-b6ad-4113-96c8-bf54a9bb8c66"
      unitRef="gbpPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i25cf6d3934504912b31c2783e517e671_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMjI_e20cdac2-e1b1-4b21-939c-526f2658a046"
      unitRef="gbpPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i25cf6d3934504912b31c2783e517e671_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_95102ad8-586d-409f-a770-52d75bbef36e"
      unitRef="shares">34425</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_9f4c0fcf-0f9f-4047-bb80-8051faca737c"
      unitRef="shares">34425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i25cf6d3934504912b31c2783e517e671_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_a6720add-1ae1-4b7c-8528-18cb4dde39ef"
      unitRef="shares">34425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i25cf6d3934504912b31c2783e517e671_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_b806e9da-a9e9-4617-ab2d-760cf2034224"
      unitRef="shares">34425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_ce730b8f-ed2d-4022-a490-3b99de83a713"
      unitRef="shares">34425</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0wLTEtMS0wL3RleHRyZWdpb246MDY5YTY2NjUyNTUxNDU4MWExZmI2MTc2MzQ2YTRkZWRfMzY_e8886ebc-e612-4a74-8c90-b1731d589c41"
      unitRef="shares">34425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0xLTEtMS0w_323c3c0e-a3c3-41aa-a151-68e89b761c4f"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i25cf6d3934504912b31c2783e517e671_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOC0zLTEtMS0w_86ea5c5d-9a04-4bdf-98c7-06933e851acc"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMjQ_0e8ab42d-e691-4be6-8828-94f51dc6a1d1"
      unitRef="gbpPerShare">0.00099</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMjQ_a89d1dc3-11b5-4295-ae1f-40ab6056db7c"
      unitRef="gbpPerShare">0.00099</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_55636322-dde9-4c00-b3f8-f041b1284d41"
      unitRef="shares">88893548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_73c72b96-876e-4340-bb60-f07b0001e220"
      unitRef="shares">88893548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_c6a603f1-240a-4e4e-acd8-7ac743d67a36"
      unitRef="shares">88893548</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_d036ec7e-c51f-4a3e-975e-d736fec3d9dc"
      unitRef="shares">88893548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_eab78b24-4cff-4937-adcf-21da1dde8a7d"
      unitRef="shares">88893548</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0wLTEtMS0wL3RleHRyZWdpb246YmQ1MGVhYjk5NThiNDEyMmE2ODI5ZmFiODFiZmY1MDVfMzg_f431558f-2e99-4158-8e7d-a002402beab0"
      unitRef="shares">88893548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0xLTEtMS0w_3d26b86f-1c15-48a0-aff7-abc83a6a71c2"
      unitRef="usd">118000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i56612f0340b24dd9ae96b45ea23779ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8yOS0zLTEtMS0w_74e838fd-717f-48cb-998c-c91007735939"
      unitRef="usd">118000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMjQ_3564a666-5259-4faa-9feb-bbcd3dd9c4d5"
      unitRef="gbpPerShare">0.000008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6f164bd4080b4036848be45a434b1183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMjQ_3f4b3f0e-bc67-474b-aabf-c62d8404723d"
      unitRef="gbpPerShare">0.000008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_7cd96333-b462-4f64-accd-b7990879d3c7"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_9eadb403-5084-45f9-9eb0-f10b42c7fb79"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6f164bd4080b4036848be45a434b1183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_a1ecb67e-9a89-4b31-be61-afdcebeac4a6"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f164bd4080b4036848be45a434b1183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_c47c4053-16b2-4d82-9c07-3ac8bff5a079"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6f164bd4080b4036848be45a434b1183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_e519cb49-262d-47a4-9b9e-6dd94ce886c0"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0wLTEtMS0wL3RleHRyZWdpb246MjY2NTIwYTljMmNjNGZiMzhiMjA3MDIxMjVmZDZjZjlfMzg_e908cbe7-b3f6-4ee9-8f7f-41c0d571c98b"
      unitRef="shares">1</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockValue
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0xLTEtMS0w_94ebfcc1-a112-457a-8d2a-1479a1bca033"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6f164bd4080b4036848be45a434b1183_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMC0zLTEtMS0w_adcda38a-cf4d-4b3f-b707-e550eae92ad4"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMS0xLTEtMS0w_8ce395a2-3d76-40bb-ade0-a4d9b19b7461"
      unitRef="usd">716544000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMS0zLTEtMS0w_bd556359-787a-4dab-80f0-f686a99206b3"
      unitRef="usd">595016000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMi0xLTEtMS0w_c91d0f28-d603-4a0e-93db-c8653df103da"
      unitRef="usd">-4588000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMi0zLTEtMS0w_ee4fb888-2bad-48c5-ba94-ff4cb1b0deca"
      unitRef="usd">-5861000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMy0xLTEtMS0w_d1fdf613-edee-49d3-a4e4-cdfdc4c24fec"
      unitRef="usd">-412510000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zMy0zLTEtMS0w_24e1ef05-08ed-4aef-bfa0-294b44749040"
      unitRef="usd">-379244000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNC0xLTEtMS0w_8b741c12-0e7f-498a-b926-62885d7025da"
      unitRef="usd">299567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNC0zLTEtMS0w_e5093cae-e809-49c5-bcc6-5a0f3877da07"
      unitRef="usd">210032000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNS0xLTEtMS0w_946ae501-8c54-485f-9319-d3a42672ec00"
      unitRef="usd">349746000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF83L2ZyYWc6ZGUyNzNlY2JhMGYzNDZmN2I1N2VmZWIxZDZmNTJhYmUvdGFibGU6NmQ5ZmEwOGU1YmRhNDAwM2E5YjNlNDk2MTY0Y2YyYzkvdGFibGVyYW5nZTo2ZDlmYTA4ZTViZGE0MDAzYTliM2U0OTYxNjRjZjJjOV8zNS0zLTEtMS0w_1232941f-2111-49eb-a571-27e02d541837"
      unitRef="usd">294237000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMi0xLTEtMS0w_0e6d4746-577a-41bf-9c66-9a963a75a2ae"
      unitRef="usd">269000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMi0zLTEtMS0w_1953e57a-1895-4923-a60d-b10b5b6392f8"
      unitRef="usd">338000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNS0xLTEtMS0w_c65e5467-6cff-4fb8-b024-c215d79ce9dc"
      unitRef="usd">30731000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNS0zLTEtMS0w_c154992a-8070-4321-b5ae-403fd222d949"
      unitRef="usd">31287000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNi0xLTEtMS0w_ae43df72-1d67-4334-afce-55dbab1e0010"
      unitRef="usd">8738000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNi0zLTEtMS0w_9633c970-9410-4439-a846-9b26ff64ef86"
      unitRef="usd">7614000</us-gaap:GeneralAndAdministrativeExpense>
    <autl:GainLossOnDispositionOfLeaseholdImprovements
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0xLTEtMS01MTM_4d41eb0a-7da4-4a35-b4a3-fb1f761f2d84"
      unitRef="usd">-672000</autl:GainLossOnDispositionOfLeaseholdImprovements>
    <autl:GainLossOnDispositionOfLeaseholdImprovements
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0zLTEtMS01MTM_fedbdd3d-6ea9-4e0b-ac88-e1c3763b7732"
      unitRef="usd">0</autl:GainLossOnDispositionOfLeaseholdImprovements>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0xLTEtMS0w_3c591f49-13fb-4239-860f-20014cbe7f0d"
      unitRef="usd">-39872000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfNy0zLTEtMS0w_8b608ae4-7237-4d31-9480-2113874f93b7"
      unitRef="usd">-38563000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfOS0xLTEtMS0w_5533ff2e-007f-4df9-abfa-094d33115fc6"
      unitRef="usd">44000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfOS0zLTEtMS0w_9eb7147c-dd24-4f5a-88f8-8d30a66b85fe"
      unitRef="usd">510000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTAtMS0xLTEtMA_9f2fc6a5-9830-46c7-8bbf-f7d8a52014e0"
      unitRef="usd">838000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTAtMy0xLTEtMA_15774857-33d5-4ac1-830a-85965d64db19"
      unitRef="usd">4484000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTEtMS0xLTEtMA_57188941-a48d-478a-a54f-5ac7a40aaf67"
      unitRef="usd">882000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTEtMy0xLTEtMA_3246538c-9899-4169-8fb8-b9f37c5a00b6"
      unitRef="usd">4994000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTItMS0xLTEtMA_a073e640-eca8-4297-86f8-9a5793b77f51"
      unitRef="usd">-38990000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTItMy0xLTEtMA_14214454-21ae-44fb-aa75-a9ee8b256f96"
      unitRef="usd">-33569000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTMtMS0xLTEtMA_2dc9ceb5-9312-4830-8642-3917dc5b4f49"
      unitRef="usd">-5724000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTMtMy0xLTEtMA_c4d3df85-6774-431b-b80c-b37542af028e"
      unitRef="usd">-3696000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTQtMS0xLTEtMA_1cb67fb1-089b-4c42-8a93-a03f22a31e1e"
      unitRef="usd">-33266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTQtMy0xLTEtMA_221d2b01-88dd-4e87-8e81-8460e8cb8c2e"
      unitRef="usd">-29873000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTYtMS0xLTEtMA_6a1b9cdd-0590-4bd1-888f-74237fb93a71"
      unitRef="usd">1273000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTYtMy0xLTEtMA_bcf30158-8aaf-4e8e-867b-49e11f906ac9"
      unitRef="usd">-17701000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTctMS0xLTEtMA_18f1d1d0-b039-4b99-a9cd-d61f089ea5c3"
      unitRef="usd">-31993000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTctMy0xLTEtMA_36400336-796e-43c7-9d4b-a04f4e71bcd1"
      unitRef="usd">-47574000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTktMS0xLTEtMA_6693b4db-5796-4d73-aa8a-51e4c84a0699"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMTktMy0xLTEtMA_60d6d5d6-85f0-403a-9a09-48cb1cdc1cae"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMjAtMS0xLTEtMA_5433869e-29ef-4b7a-b0f9-b75d336deb0a"
      unitRef="shares">62447606</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMC9mcmFnOjYzYThjYzFjY2I4YTQyM2U5NjljMGJhNGViMDYzMDMwL3RhYmxlOjVhYmU2MTY3Njc3ZjQ5MTliOWIwNWU0MGUwOTBmODA3L3RhYmxlcmFuZ2U6NWFiZTYxNjc2NzdmNDkxOWI5YjA1ZTQwZTA5MGY4MDdfMjAtMy0xLTEtMA_0d4de522-d004-4114-8589-4bacaf915465"
      unitRef="shares">49859739</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="ib659d9739ed84217a438b97c75c6edb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xLTEtMS0xNTcx_6c3e7402-c71c-4705-b20b-bf7f9ab4fc27"
      unitRef="shares">44983006</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib659d9739ed84217a438b97c75c6edb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0zLTEtMS0xNTcx_71c10fa3-e03d-4af6-a1f3-6f7925bf7032"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy01LTEtMS0xNTcx_367ce8a2-5ed5-4529-a628-07f67f5c1d1c"
      unitRef="shares">34425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1711957ddc874dde9df98c5e7ae0bb8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy03LTEtMS0xNTcx_3452f5fa-a512-4b95-91df-51e90f2a9cfc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i1e043145ac6040a696157aeace3f9b4b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy05LTEtMS0xNTcx_d9d67685-f647-44aa-942b-cd7ab24e1053"
      unitRef="shares">88893548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1e043145ac6040a696157aeace3f9b4b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMS0xLTEtMTU3MQ_5034f3ba-9995-4eeb-94a7-cd8f0533961c"
      unitRef="usd">118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i1be88049689e47d9a6b45c2c0165bca2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMy0xLTEtMTU3MQ_3a8b6170-fc0d-4aff-8e17-cd3cb35572c1"
      unitRef="shares">1</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1be88049689e47d9a6b45c2c0165bca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNS0xLTEtMTU3MQ_c1eb495a-cd30-49e2-9d89-7e738b3bda9f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice6c95b827c147d9834cea80ba9c76ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNy0xLTEtMTU3MQ_8f72ef9f-b8b9-492e-84e0-42245fbda3f1"
      unitRef="usd">500560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8a397d0ab374ebf9ecf4ba734ae5899_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xOS0xLTEtMTU3MQ_e0df04ff-8750-4ccd-b9ab-8e7ed64090af"
      unitRef="usd">-8691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i973d0bab1a8546f9883c52cfb0e637fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMS0xLTEtMTU3MQ_c09c7830-69b9-4d75-b500-feecddb8d1e3"
      unitRef="usd">-237150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee15fdaf6af94a6fabfb9578aff371ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMy0xLTEtMTU3MQ_9e1c2bf2-d59c-4a06-b12f-b0c10030d431"
      unitRef="usd">254839000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xLTEtMS0xNTcx_b7eace6b-2676-4f2c-9c62-a53e2ba9994e"
      unitRef="shares">7250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0zLTEtMS0xNTcx_891bfd4a-dfa5-4844-9230-d3a2e959a9a3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xNy0xLTEtMTU3MQ_745023ed-c110-4ed1-bf8f-b0edc95ad92c"
      unitRef="usd">73952000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0yMy0xLTEtMTU3MQ_aaa9be15-1f46-4ed2-a5ac-f27a80ac3efe"
      unitRef="usd">73953000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNS0xNy0xLTEtMTU3MQ_5a47eafa-e2cc-4849-b403-dfe215d718a2"
      unitRef="usd">6235000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNS0yMy0xLTEtMTU3MQ_90e9c36d-aa60-4311-af46-e8c68828520e"
      unitRef="usd">6235000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0xLTEtMS0xNTcx_a7dd7066-80d4-48b0-9a62-6da8f8b1b6f8"
      unitRef="shares">50</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib2af07f077af4f43bcbb4ef5452596a8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS0xNTcx_36d6df8f-6f5e-4829-bb00-656350397231"
      unitRef="shares">14976</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i28b09fa5bb574be89f6f4c4f93515120_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xNy0xLTEtMTU3MQ_793088e7-520c-493f-a2e3-28bb5a2fc981"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0yMy0xLTEtMTU3MQ_846fe5bc-b9b1-4680-b5fb-1f76a5fe739e"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5635c7ca4780434ab4798595f173a5b3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0xOS0xLTEtMTU3MQ_e41eb002-60fe-4887-82bb-15010cb5da4c"
      unitRef="usd">-17701000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0yMy0xLTEtMTU3MQ_4baf2f4c-e68e-41ed-bd16-9834539546c1"
      unitRef="usd">-17701000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i7fc130c21a1045bb8cb7f0a7e50d23cc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMS0xLTEtMTU3MQ_63ed0be7-6a37-4efd-8a49-152f9d54b62c"
      unitRef="usd">-29873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMy0xLTEtMTU3MQ_d8e28100-44bd-4e58-8974-ac561de43e4e"
      unitRef="usd">-29873000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i43bf285d959642828ad34fca6a197946_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMS0xLTEtMTU3MQ_2490bc8d-4931-4488-bfc0-9a5af3c0cb29"
      unitRef="shares">52247932</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i43bf285d959642828ad34fca6a197946_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMy0xLTEtMTU3MQ_6ba470cb-9ee8-448c-9f1e-7d2694b54965"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8124081013b040f48152051d2fef650f_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNS0xLTEtMTU3MQ_801bd5ac-a422-41a8-8187-a492923dc239"
      unitRef="shares">34425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8124081013b040f48152051d2fef650f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNy0xLTEtMTU3MQ_c0869079-11b5-431f-aace-41a23205496f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if0c21a05bfb74f80973b93799c2a14b9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtOS0xLTEtMTU3MQ_4670c6bb-7d86-48e0-89e6-8453b106a36a"
      unitRef="shares">88893548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if0c21a05bfb74f80973b93799c2a14b9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTEtMS0xLTE1NzE_c0230d0b-6a6e-4013-bb52-887708d8b1dd"
      unitRef="usd">118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i022edc107d0143858a241d8c91b0faa5_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTMtMS0xLTE1NzE_a2402e89-be44-4747-845d-f635abfd38ed"
      unitRef="shares">1</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i022edc107d0143858a241d8c91b0faa5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTUtMS0xLTE1NzE_6d0e2a3a-198b-473e-8ebb-40c7a88f4a00"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0691ee4c8ba40abae69ca13311d4688_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTctMS0xLTE1NzE_c736f58d-be94-41af-9165-33992dfc08c3"
      unitRef="usd">580772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8412d6479b1f4abeb4d9efb97ec4a49c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTktMS0xLTE1NzE_ca597388-8c60-4a86-bee4-6814c795053a"
      unitRef="usd">-26392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6fd77def720648068ce0e83aceb985cb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjEtMS0xLTE1NzE_9e808179-8a70-4ac9-bdac-e149bd66b788"
      unitRef="usd">-267023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d535d1cff574284bf3469db856638c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjMtMS0xLTE1NzE_d3c51e11-2821-4143-9417-59c6ae8e1ee4"
      unitRef="usd">287478000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xLTEtMS0w_32e30bdb-df71-468c-972f-67716e1a1fe9"
      unitRef="shares">52346231</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5cb7da1a2d6d4c51942f73399ad8cb5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0zLTEtMS0w_9fd7759e-9750-433c-a68d-e93e089a91c2"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i210da8084e084840a2b797ed219d3290_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy01LTEtMS0w_9d0b5b8f-74dd-424f-99ec-aa2cf65acd9b"
      unitRef="shares">34425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i210da8084e084840a2b797ed219d3290_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy03LTEtMS0w_19417d6b-f74c-4017-b6d0-309b520cc085"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy05LTEtMS0w_ce82a33a-ae04-4076-9d02-2de4c2658d24"
      unitRef="shares">88893548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icfbe19a2a2b9465b8e6576f5eb15700e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMS0xLTEtMA_cff94f94-6013-457d-bfe8-100dafb416dc"
      unitRef="usd">118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0d4a40b22a3e4903aa2404f3046690ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xMy0xLTEtMA_98ea6a5c-df4c-4e5f-a1da-1b930720c5f2"
      unitRef="shares">1</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0d4a40b22a3e4903aa2404f3046690ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNS0xLTEtMA_cd7b35ba-07a7-4166-9c6a-bbaae04406a0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4384483d59d8411298573965d8975dfb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xNy0xLTEtMA_7dd17076-1e15-439a-8afb-db107705acdb"
      unitRef="usd">595016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49989be8f3a74255a4d08b2dfaf2f5a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0xOS0xLTEtMA_72779ec3-8798-43c7-b216-53ba35d0e804"
      unitRef="usd">-5861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id192f441ae29485b91f10751a6a033c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMS0xLTEtMA_b0606912-9927-4f73-acf4-3003bab1550b"
      unitRef="usd">-379244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMy0yMy0xLTEtMA_8d72f6fd-a8f9-4275-a554-6c5b8c0d5f3c"
      unitRef="usd">210032000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xLTEtMS0w_9c727132-4241-45d3-8c4f-03f78d4a69ee"
      unitRef="shares">18147078</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0xNy0xLTEtMA_065857bd-ad5a-4f90-a627-b9b803f9fd7f"
      unitRef="usd">122198000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNC0yMy0xLTEtMA_7d0aad2b-f479-4f85-b1ee-c421305a962b"
      unitRef="usd">122198000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <autl:APICShareBasedPaymentArrangementReversalOfCostRecognition
      contextRef="i10c1964393e944e5aac5a6c9452f11b3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0xNy0xLTEtNTI3_1586bd38-0552-4d8a-b034-7e6d782629bc"
      unitRef="usd">670000</autl:APICShareBasedPaymentArrangementReversalOfCostRecognition>
    <autl:APICShareBasedPaymentArrangementReversalOfCostRecognition
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNi0yMy0xLTEtNTI3_7cb121d3-d607-4d0b-b2b1-a459c0687928"
      unitRef="usd">670000</autl:APICShareBasedPaymentArrangementReversalOfCostRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i8b837afacb0f45118327f9635557485f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS01Mjc_a7ee6f7a-ad15-4659-9646-6454f526d0dd"
      unitRef="shares">21500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib8ba7b64ef9640f289004c73f3fd4ce4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfNy0xLTEtMS0w_f895d897-b826-4933-b36e-48540502cd11"
      unitRef="shares">545</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib9abac6332284e97991a2832e326a6ee_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0xOS0xLTEtMA_aeb9e025-19f2-42db-a9a3-388dcd23101c"
      unitRef="usd">1273000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOC0yMy0xLTEtMA_13e229f2-41ed-4e16-8162-1ac93b60cef6"
      unitRef="usd">1273000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i435a50a0218748dd91c2cfcdbc133e2d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMS0xLTEtMA_be0102ed-085a-4571-9813-25acef2fbe69"
      unitRef="usd">-33266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfOS0yMy0xLTEtMA_50952211-0d1d-422e-b68d-6df61887ef20"
      unitRef="usd">-33266000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i50b508b0d25c4c9f8965def0a415d097_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMS0xLTEtNTc_67c48f7c-2be4-4adb-924b-1a79026f7a11"
      unitRef="shares">70515354</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i50b508b0d25c4c9f8965def0a415d097_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMy0xLTEtNTc_7ef7b8d7-822b-4a9b-9d1a-76b119c95bfb"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idb2969b50377465b89f51740cb4e64f0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNS0xLTEtNTc_2716b536-ada1-4378-94ad-1f4ec7196092"
      unitRef="shares">34425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idb2969b50377465b89f51740cb4e64f0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtNy0xLTEtNTc_def6975d-901e-4edb-97c0-08c9182b0e23"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i62cebd19059d4be08369d4361a770ec4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtOS0xLTEtNTc_fd80fe46-7838-4d9f-a8e6-01cff60e7326"
      unitRef="shares">88893548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i62cebd19059d4be08369d4361a770ec4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTEtMS0xLTU3_e50c1bbb-8043-42ab-9299-a096b828e178"
      unitRef="usd">118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i23fe26c1f0bd4aba944f09803669b655_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTMtMS0xLTU3_af820320-a6b2-41e2-89d6-2e306db857bb"
      unitRef="shares">1</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i23fe26c1f0bd4aba944f09803669b655_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTUtMS0xLTU3_8bbf0307-a38e-481d-b617-96864e8b4e06"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica69ca24ff9c48549c99f04588c27692_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTctMS0xLTU3_0f7df668-e8f2-4f15-a774-73a1ce387d3d"
      unitRef="usd">716544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e5ee0501a8f469a8d6aff5456d7a531_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMTktMS0xLTU3_622f201c-a501-41d6-a8a1-208833478a1e"
      unitRef="usd">-4588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b543afe63da4f298f4f355d5b1fa4ec_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjEtMS0xLTU3_15d0f98d-723a-430e-98f7-acce28560a0b"
      unitRef="usd">-412510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xMy9mcmFnOmMxMDJlZTE4YjVjYTQ2NGRiZTAwZDQ2MGNhNzYyNzI1L3RhYmxlOmQzOThjYzIzOTc5NzQ5ZDliOTIzMDlmYzc2Y2M3NDg1L3RhYmxlcmFuZ2U6ZDM5OGNjMjM5Nzk3NDlkOWI5MjMwOWZjNzZjYzc0ODVfMTAtMjMtMS0xLTU3_c7aa8043-6b16-4185-aa22-6dec3f285e25"
      unitRef="usd">299567000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMy0xLTEtMS0w_a1e892df-c645-49bc-b768-d86a34783534"
      unitRef="usd">-33266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMy0zLTEtMS0w_19bbd8a0-edee-4793-b090-9ca818d71198"
      unitRef="usd">-29873000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNS0xLTEtMS0w_e2f5ca49-d51a-4d34-8959-a2d4e895c1ed"
      unitRef="usd">1662000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNS0zLTEtMS0w_39d54603-2ff3-4a79-a281-ffa4fd09ce67"
      unitRef="usd">1261000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNi0xLTEtMS0w_227d206b-86d2-4e01-9c53-0b2c3b316779"
      unitRef="usd">-670000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfNi0zLTEtMS0w_e1457d2c-3f8b-46e8-8ad3-df268e66f10a"
      unitRef="usd">6189000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOC0xLTEtMS0w_93ef03e9-cbb5-421e-befc-153868f62494"
      unitRef="usd">-11000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOC0zLTEtMS0w_c90f4485-45ff-4d0b-9817-1b347347c97b"
      unitRef="usd">160000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOS0xLTEtMS0w_72a418ab-7080-49f2-82d3-9a1b2332fb89"
      unitRef="usd">-672000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfOS0zLTEtMS0w_1d8f0ef7-c40e-4471-b439-13e8ca9f7bad"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTAtMS0xLTEtMTQ2MA_01b38746-edd3-4a90-b465-2322b5e9352f"
      unitRef="usd">280000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTAtMy0xLTEtMTQ2MA_a4dee05f-2274-44f3-9b21-03090442a57e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTEtMS0xLTEtMA_49a7e743-f6da-481e-be9e-1c88472416cd"
      unitRef="usd">5050000</autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent>
    <autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTEtMy0xLTEtMA_e670d3d2-88ec-4162-a0e5-3b9efe3c40ae"
      unitRef="usd">1186000</autl:IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTItMS0xLTEtMA_7599b8dc-c06a-4379-9b5b-cff4b3162e83"
      unitRef="usd">-163000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTItMy0xLTEtMA_1475570d-dd3e-4bb0-a092-dc8f8687ee5d"
      unitRef="usd">233000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTMtMS0xLTEtMA_27cc51b3-9324-4362-96a5-77001ada1cf1"
      unitRef="usd">-811000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTMtMy0xLTEtMA_b78f8f3b-584c-4374-bcb0-e529cf3f1e73"
      unitRef="usd">18000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTQtMS0xLTEtMA_3cfc44b7-8c23-4256-b29a-4aead84d2c41"
      unitRef="usd">-1085000</autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets>
    <autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTQtMy0xLTEtMA_8733cb42-18c9-4255-bf40-3a7622cf322a"
      unitRef="usd">-769000</autl:IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTUtMS0xLTEtMA_b36f5ccb-2d75-4504-9e69-514b2aa8ba5a"
      unitRef="usd">-902000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTUtMy0xLTEtMA_050f2a16-f264-4dab-856a-e18f1b0b93f9"
      unitRef="usd">-124000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTYtMS0xLTEtMA_6ff28310-abf3-4d0d-8d88-bc3968d563c2"
      unitRef="usd">-1649000</autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities>
    <autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTYtMy0xLTEtMA_b11df567-29f9-4131-bf47-40e5a04e8e4a"
      unitRef="usd">-361000</autl:IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities>
    <autl:NetIncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTctMS0xLTEtMA_1cd6e936-dfcf-4230-8ceb-bb5066b1e718"
      unitRef="usd">70000</autl:NetIncreaseDecreaseInOperatingLeaseLiabilities>
    <autl:NetIncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTctMy0xLTEtMA_0ed0dc12-f368-431b-9fbd-69d8f7b414b3"
      unitRef="usd">-297000</autl:NetIncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTgtMS0xLTEtMA_de372599-7047-49fb-b9c4-721c1b28de1e"
      unitRef="usd">-37343000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMTgtMy0xLTEtMA_53726674-a8b8-468f-ad20-2e2cde5f53ec"
      unitRef="usd">-24033000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjAtMS0xLTEtMA_1554d247-fa86-4748-bac9-f83f80f55c3d"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjAtMy0xLTEtMA_def8e665-59c8-4081-86a3-dd476eb461a5"
      unitRef="usd">2637000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjEtMS0xLTEtMA_f84d95c0-fab9-4514-b930-31679266638e"
      unitRef="usd">-1900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjEtMy0xLTEtMA_5fcceccb-ae39-448a-b042-082825d8f56a"
      unitRef="usd">-2637000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjMtMS0xLTEtMA_5ca34c13-44ec-4f6f-9922-38c28e878b08"
      unitRef="usd">123324000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjMtMy0xLTEtMA_0f24aaac-cfa4-488b-acc2-eeb6f3a3642e"
      unitRef="usd">74310000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjQtMS0xLTEtMA_ea1366aa-9796-4fc4-abf8-9921bb1ed587"
      unitRef="usd">123324000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjQtMy0xLTEtMA_c1f965a6-8e8e-4c62-82da-ef08c40bd294"
      unitRef="usd">74310000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjUtMS0xLTEtMA_e357667e-9591-4011-9043-ebe3ae3c9509"
      unitRef="usd">1632000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjUtMy0xLTEtMA_2c520fc6-f437-44a6-b75c-cdcbadfddcdd"
      unitRef="usd">-14972000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjYtMS0xLTEtMA_da84137a-c374-41cf-820c-1532d51cac9a"
      unitRef="usd">85713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjYtMy0xLTEtMA_91b1e487-618a-413d-aaae-977861d56415"
      unitRef="usd">32668000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjctMS0xLTEtMA_f612fcb6-d97b-4672-bf69-d4974ebe2521"
      unitRef="usd">154085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iee15fdaf6af94a6fabfb9578aff371ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjctMy0xLTEtMA_643273c0-93ff-4eab-ba55-c6bb5f97badd"
      unitRef="usd">211430000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjgtMS0xLTEtMA_3c0758b4-89a1-4382-8167-d0866a362c8e"
      unitRef="usd">239798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d535d1cff574284bf3469db856638c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMjgtMy0xLTEtMA_c5a11027-345e-4e3f-bb59-fa948d9b6e47"
      unitRef="usd">244098000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzEtMS0xLTEtMA_87f0316e-8d06-497d-aed0-cccfc5c3720f"
      unitRef="usd">569000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzEtMy0xLTEtMA_598ea9be-84f1-487b-9f04-3c1dac440e50"
      unitRef="usd">4624000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzItMS0xLTEtMA_4e1465a1-1f42-4433-bce4-9b8875387860"
      unitRef="usd">0</autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet>
    <autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzItMy0xLTEtMA_d95cef0a-23a4-4582-ad06-7c49142f3a91"
      unitRef="usd">2487000</autl:RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet>
    <autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzMtMS0xLTEtMA_acefd3c4-c5be-46e4-8cc8-17ea2609af13"
      unitRef="usd">190000</autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent>
    <autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzMtMy0xLTEtMA_d0183572-e7ab-4529-b5bc-1ec30df29bb3"
      unitRef="usd">607000</autl:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent>
    <autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMS0xLTEtNTM5_f74b3a43-c978-4305-9d05-96ae04f5b239"
      unitRef="usd">1124000</autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses>
    <autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMy0xLTEtNTM5_43cbec74-73a4-4ba3-8f85-a1b785718490"
      unitRef="usd">334000</autl:IssuanceCostIncludedInAccountsPayableAndAccruedExpenses>
    <autl:CapitalizedSharebasedCompensation
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMS0xLTEtMA_79e6d8fc-bc74-49a5-8c68-6be6e7467e5c"
      unitRef="usd">0</autl:CapitalizedSharebasedCompensation>
    <autl:CapitalizedSharebasedCompensation
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzQtMy0xLTEtMA_75091513-fc63-4701-82a7-ce5668fe604e"
      unitRef="usd">46000</autl:CapitalizedSharebasedCompensation>
    <autl:LeaseAssetsTerminated
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMS0xLTEtMjAyMA_e8d1b123-f6ed-478b-aea4-29472928c45e"
      unitRef="usd">28517000</autl:LeaseAssetsTerminated>
    <autl:LeaseAssetsTerminated
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMy0xLTEtMjA1OQ_f1773a77-8139-4f13-8503-d1af0583fdb0"
      unitRef="usd">0</autl:LeaseAssetsTerminated>
    <us-gaap:Cash
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMS0xLTEtMA_af7ce17c-3126-484a-b9cb-e4e87993d9a1"
      unitRef="usd">239012000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i6d535d1cff574284bf3469db856638c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzctMy0xLTEtMA_67eac220-2a0a-4f8c-ad06-01c6d7c9f210"
      unitRef="usd">243312000</us-gaap:Cash>
    <us-gaap:RestrictedCashCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzgtMS0xLTEtMA_4a40803e-d959-4f0a-b70f-993417dd6aa9"
      unitRef="usd">786000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6d535d1cff574284bf3469db856638c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzgtMy0xLTEtMA_fb25f723-5d7b-4445-b87b-cafb5439211b"
      unitRef="usd">786000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzktMS0xLTEtMA_40128a9f-bd55-4781-9c7c-4c19a7e5a7a5"
      unitRef="usd">239798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d535d1cff574284bf3469db856638c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8xNi9mcmFnOmM2NGQwZThjOTMyMDRmNWFiOGJlNzY1ZWM2MWIyMGIwL3RhYmxlOjYxMWU1YmNlYTQ1OTRlMGI4M2Y2Y2YzZWNmOGQwYjdjL3RhYmxlcmFuZ2U6NjExZTViY2VhNDU5NGUwYjgzZjZjZjNlY2Y4ZDBiN2NfMzktMy0xLTEtMA_214c0a7e-0063-4094-9b9d-5bde5e480f15"
      unitRef="usd">244098000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfNjQ4MA_76a69095-fb0c-48df-9c5d-0f6513156755">Nature of the Business&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autolus Therapeutics plc (the &#x201c;Company&#x201d;) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a public limited company incorporated in England and Wales. On June 22, 2018, the Company completed its initial public offering ("IPO") of American Depositary Shares (&#x201c;ADSs&#x201d;). In the IPO, the Company sold an aggregate of 10,147,059 ADSs representing the same number of ordinary shares, including 1,323,529 ADSs pursuant to the underwriters&#x2019; option to purchase additional ADSs, at a public offering price of $17.00 per ADS. Net proceeds were $156.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2019, the Company completed an underwritten public offering of 4,830,000 ADSs representing 4,830,000 ordinary shares, at a public offering price of&#160;$24.00&#160;per ADS, which includes an additional 630,000 ADSs issued upon the exercise in full of the underwriters&#x2019; option to purchase additional ADSs.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$108.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2020, the Company completed an underwritten public offering of&#160;7,250,000&#160;ADSs representing&#160;7,250,000&#160;ordinary shares, at a public offering price of&#160;$11.00&#160;per ADS.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company sold an aggregate of 1,718,506 ADSs under its Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC as sales agent. Aggregate net proceeds to the Company, after commission fees and offering expenses, were $15.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, the Company completed an underwritten public offering of 14,285,715 ADSs, which includes the full exercise by the underwriters to purchase an additional 2,142,857 ADSs, at a public offering price of $7.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were $106.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception, including net losses of $33.3 million and $29.9 million for the three months ended March 31, 2021 and 2020, respectively.  In addition, the Company had an accumulated deficit of $412.5 million and $379.2 million as of March 31, 2021 and December 31, 2020, respectively. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or that additional funding will be available on terms acceptable to the Company, or at all. The Company believes the cash on hand at March 31, 2021 of $239.0 million will be sufficient to fund the Company&#x2019;s operations for at least twelve months from the issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Impact of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In response to the ongoing coronavirus 2019, or COVID-19, pandemic, the Company established a cross-functional task force and have implemented business continuity plans designed to address and mitigate its impact on the Company's employees and business.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;While the Company has not experienced any significant financial impact to date, the overall disruption caused by the COVID-19 pandemic on global healthcare systems, and the other risks and uncertainties associated with the pandemic, could cause its business, financial condition, results of operations and growth prospects to be materially adversely affected. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, our global workforce transitioned to working remotely with the exception of research and clinical trial related activities that required laboratory-based activity or manufacturing. We implemented protocols and procedures to ensure the safety of our employees working on site, including requirement to wear personal protective equipment, temperature checks at entry and offered COVID-19 testing for any employee with symptoms or at suspected risk of exposure to virus. In June 2020, we began the implementation of our workplace re-entry plan, based on a phased approach that is principles-based and local in design, with a focus on continuity of patient treatment and working to bring its workforce back on-site safely. We have also implemented policies to control and limit office and lab access in line with social distancing guidelines and for contact tracing if needed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to track COVID-19 developments in Europe and the United States closely for their potential impact on our clinical trial sites, logistics and supply chain to ensure we can continue to maintain clinical trial conduct and data integrity. As the patients in our clinical trials are severely immune suppressed as a consequence of their underlying disease and the treatment they receive in the trials, we are also monitoring other transmissible infectious diseases, including influenza.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not aware of any specific event or circumstance that has impacted on its operations in a manner which would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities during the three months ended March 31, 2021. However, these estimates may change, as new events occur and additional information is obtained, relating to the COVID-19 pandemic or otherwise. Changes in estimates would be recognized in the consolidated financial statements as soon as they become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfOTUw_171bcb98-ce05-4d99-94fa-1d51487495a5"
      unitRef="shares">10147059</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3c4daa51bf814b1b806ec67107d32d58_D20180622-20180622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTAxNw_fa73b5ad-75ce-4980-8b2e-63fdf9154a50"
      unitRef="shares">1323529</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5a82058bfcb64fce894d3dd5382848b0_I20180622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTEyMQ_8e5bd9a3-2993-4009-97f0-f436d287b568"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i47b94fd995dd4027b19995e1ab8876dd_D20180622-20180622"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTE1MQ_d247d0fa-0066-47a5-a1ca-916567deace2"
      unitRef="usd">156500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTMyOQ_21b64f0e-9025-4dee-9eb2-a16cc2f0ca1e"
      unitRef="shares">4830000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTM1MA_21b64f0e-9025-4dee-9eb2-a16cc2f0ca1e"
      unitRef="shares">4830000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i85577d0805ae43f28ac6d00d72e6ffc9_I20190415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTQwMA_8fdea881-6120-49c9-87b2-b2375efe1ff2"
      unitRef="usdPerShare">24.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idece61323c9d42bdbbd6d64fe516d660_D20190415-20190415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTQ0MQ_5d23f8be-d73d-4112-b576-738a273caaf0"
      unitRef="shares">630000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i43192cf6a4864277901b94cf4e81044c_D20190415-20190415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTYzNg_5836282a-ca75-4299-896e-1ef1aa0c8e32"
      unitRef="usd">108800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia9549cc85aa24734a469de8134065606_D20200127-20200127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTcxOQ_4bc9841e-e65a-45e0-8880-2f5e9db3b3e0"
      unitRef="shares">7250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia9549cc85aa24734a469de8134065606_D20200127-20200127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTc0MA_c4e72a27-38d1-4da5-b884-4fbb1fafbfbe"
      unitRef="shares">7250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i64e0070edc0a4b0c87c8b6d88f9244d0_I20200127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTc5MA_2868b956-a580-4802-a904-65c51c3a7451"
      unitRef="usdPerShare">11.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0dc3cbb83148416dbc07992923a63cad_D20200127-20200127"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjE5OTAyMzI3MDgzOA_c9ef9d63-5dc5-4317-a03d-d3cdd1936df1"
      unitRef="usd">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0Mjg0Mg_aafa6d7f-8483-460f-bf9f-1f9280598056"
      unitRef="shares">1718506</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0MzA1Ng_e47b2913-8a7b-4e75-8085-1ee24f5a950c"
      unitRef="usd">15300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i932c7033a2c64d83b9e11b73ab217086_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDQ5OQ_7858eae3-e9b1-4fa0-b98f-46b5e8064a8d"
      unitRef="shares">14285715</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id8c4c15ff52c42d49a43d574cf188723_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDU4OA_29b4dff6-7b7f-464f-a766-0782d483053d"
      unitRef="shares">2142857</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i41d639c705934456ab14641f84359651_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTYzNDYyOA_4d9e1186-1414-42b3-8a64-1bf0390a29e7"
      unitRef="usdPerShare">7.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i524bbe2dd39341faac717c3d8d151567_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMTA5OTUxMTY0MzAzNQ_9441f5d5-8504-49ad-8ea4-6dc4efa12b87"
      unitRef="usd">106900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjk3Ng_b8edda7a-1096-40f7-88df-1f5fc9275a60"
      unitRef="usd">-33300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMjk4Mw_0e38074d-2500-4203-a16e-dc340851eaed"
      unitRef="usd">-29900000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzEyOQ_8c188b27-5ef0-41d0-aac5-3771e9d9a0b4"
      unitRef="usd">-412500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzEzNg_65b8fb2f-cdf8-4f78-87b1-b675b84684f2"
      unitRef="usd">-379200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yMi9mcmFnOjlhNGIzYjdjMTFjMDRiZTE5NWY0MmUyYjliNTU0NDgwL3RleHRyZWdpb246OWE0YjNiN2MxMWMwNGJlMTk1ZjQyZTJiOWI1NTQ0ODBfMzc3Nw_094a2f47-e336-4abb-a5d0-1d7470020c21"
      unitRef="usd">239000000.0</us-gaap:Cash>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1Nzc_fbec7e60-e83a-4dae-8aec-45e9a2d69a00">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include those of the Company, its wholly-owned subsidiary, Autolus Limited, and its U.S. subsidiary, Autolus Inc., and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers cash and cash equivalents in the condensed consolidated financial statements to include cash at banks with a maturity of less than three months, which is subject to an insignificant risk of changes in value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a lease that requires a letter of credit supported by $0.6 million&#160;deposit held by the Company's bank for the duration of the lease and a credit card arrangement that requires a security deposit of $0.2 million. The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the Company's condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash and restricted cash. The Company places cash and restricted cash in established financial institutions. The Company has no significant&#160;off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of March 31, 2021 and December&#160;31, 2020, the Company&#x2019;s property and equipment consisted of office equipment, lab equipment, furniture and fixtures, and leasehold improvements. The office equipment has an estimated useful life of three years, lab equipment has an estimated useful life of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09"&gt;five&lt;/span&gt;&#160;or&#160;ten years, and furniture and fixtures have an estimated useful life of&#160;five years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Assets under construction primarily consist of costs incurred with leasehold improvements, and, once placed into service, will be depreciated over the shorter of the lease term or the estimated useful life of the asset.  Upon retirement or sale, the cost of assets are disposed of, and the related accumulated depreciation, is removed from the accounts and any resulting gain or loss is included in the statement of operations and other comprehensive loss. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized a disposal loss of $0.7 million in the three months ended March 31, 2021 in leasehold improvements which are no longer being utilized in the facility in White City,  and did not recognize a disposal loss in the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates an asset for potential impairment when events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Recoverability is measured by comparing the book value of the asset to the expected future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the asset exceeds the fair value. The Company did not recognize an impairment in the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received, initial direct costs, or prepayments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company accounts for the lease and non-lease components of leases for classes of all underlying assets and allocates all of the contract consideration to the lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets are related to acquired software licenses with finite lives and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators of impairment are present, the Company tests for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company evaluates the useful lives for these intangible assets each reporting period to determine whether events and circumstances warrant a revision in their remaining useful lives.&#160;The Company did not recognize an impairment loss in the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and its chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment, which is the business of developing and commercializing gene therapies; however, the Company operates in two geographic regions: the United Kingdom and the United States. Substantially all of the Company&#x2019;s assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, depreciation expense, third-party license fees, external costs of outside vendors engaged to conduct clinical development activities, clinical trials, costs to manufacture clinical trial materials and certain tax credits associated with research and development activities. The Company recorded the U.K. research and development expenditure credit (&#x201c;RDEC&#x201d;) in the amount of $30,000 and $28,000 for the three months ended March 31, 2021 and 2020, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, as reductions of research and development expenses within the Company&#x2019;s statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing its condensed consolidated financial statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company&#x2019;s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes judgments and estimates in determining the accrued balance in any accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for equity awards based on the grant date fair value of the award. The Company recognizes share-based compensation expense for awards granted to employees that have a graded vesting schedule based on a service condition only on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards (the &#x201c;graded-vesting attribution method&#x201d;), based on the estimated grant date fair value for each separately vesting tranche. For equity awards with a graded vesting schedule and a combination of service and performance conditions, the Company recognizes share-based compensation expense using a graded-vesting attribution method over the requisite service period when the achievement of a performance-based milestone is probable, based on the relative satisfaction of the performance condition as of the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For share-based awards granted to consultants and&#160;non-employees,&#160;compensation expense is recognized using the graded-vesting attribution method over the period during which services are rendered by such consultants and&#160;non-employees&#160;until completed. The measurement date for employee awards is the date of grant, and share-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on an accelerated basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 7 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility.&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lacks company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, it uses a combination of the historical volatility of the ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as the Company has adequate historical data regarding the volatility of its own traded security price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;&#160;The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair market value of the Company&#x2019;s ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select Market on the date the grant is approved by the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement and Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its condensed consolidated financial statements in its functional currency, which is the pound sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates.&#160;Non-monetary&#160;assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. The Company recorded a  foreign exchange loss of $1.2 million and foreign exchange gain of  $4.3 million for the three months ended March 31, 2021 and 2020, respectively. Foreign exchange gains are included in other income in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, the condensed consolidated financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#x2019; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining the Company's net loss but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses patent prosecution and related legal costs as they are incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company recorded patent expenses of $0.5 million and $0.6 million for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received research grants under which it is reimbursed for specific research and development activities. Payments received are recognized as income in the statements of operations and comprehensive loss over the period in which the Company recognizes the related costs. At the time the Company recognizes grant income, it has complied with the conditions attached to it and the receipt of the reimbursement is reasonably assured. The Company has received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance. For grants with refund provisions, the Company reviews the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. The Company has determined that the likelihood of any repayment events included in its current grants is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:232%"&gt;License Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASC Topic 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company  fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License Fees and Multiple Element Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contingent Research Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company&#x2019;s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. The Company considers all relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For three months ended March 31, 2021, the Company has not recognized any variable consideration with regards to the development milestones which are included in the license agreement that was executed in the period. This is due to the fact that those development milestones have not yet been met and the recognition of the related revenue is not yet probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision (benefit) for income taxes represents income taxes paid or payable (or a reduction of such amounts) for the current year plus deferred taxes. Deferred taxes result from differences between the condensed consolidated financial statements and tax bases of the Company&#x2019;s assets and liabilities, and are adjusted for changes in tax rates and tax law when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in the United Kingdom and the United States. The calculation of the Company&#x2019;s tax provision involves the application of United Kingdom and United States tax law and requires judgment and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the realizability of its deferred tax assets at each reporting date, and establishes a valuation allowance when it is more likely than not that all or a portion of its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. The Company considers all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that the Company&#x2019;s deferred tax assets are not more likely than not realizable, the Company establishes a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a&#160;two-step&#160;approach for recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that the Company believes is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in the Company&#x2019;s income tax returns and the amount of tax benefits recognized in the its condensed consolidated financial statements represent the Company&#x2019;s unrecognized income tax benefits, which it either records as a liability or reduction of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company benefits from the U.K. research and development tax credit regime under both the small and medium sized enterprise, or SME, scheme and by claiming an RDEC in respect of grant funded projects. Under the SME regime, a portion of the Company&#x2019;s losses can be surrendered for a cash rebate of up to 33.35% of eligible expenditures. SME credits are accounted for within the tax provision in the year in which the expenditures were incurred. RDEC credits are accounted for within other income in the condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 220,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive loss is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company recorded a gain of $1.3 million and a loss of $17.7 million related to foreign currency translation adjustments during the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per ordinary share is determined by dividing net loss by the weighted average number of ordinary shares outstanding during the period. For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted incentive shares and units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,914,949&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,241,779&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,636,977&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JOBS Act and Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These exemptions provided by the JOBS Act will apply until December 31, 2023 or such earlier time that the Company no longer meets the requirements of being an emerging growth company. The Company would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, has more than $700 million in market value of its securities held by non-affiliates as of the last day of its second fiscal quarter, or it issues more than $1 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also currently relies on other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging growth company, the Company is not required to, among other things, (i)&#160;provide an auditor&#x2019;s attestation report on the Company&#x2019;s system of internal controls over financial reporting pursuant to Section&#160;404(b), (ii)&#160;provide all of the compensation disclosure that may be required of&#160;non-emerging&#160;growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv)&#160;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#x2019;s compensation to median employee compensation. These exemptions will also apply until the Company is no longer an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company's financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1NzI_e49c51d9-48f8-47a9-adca-9d4ed1e5496e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include those of the Company, its wholly-owned subsidiary, Autolus Limited, and its U.S. subsidiary, Autolus Inc., and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTQ_5818996d-45ad-46df-b366-57f13505447d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which &lt;/span&gt;&lt;/div&gt;they become known. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1NzM_ca461ba1-a803-4ebc-8ed7-fc75e7509ddc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers cash and cash equivalents in the condensed consolidated financial statements to include cash at banks with a maturity of less than three months, which is subject to an insignificant risk of changes in value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="i25159a1662d546f8b7c7111c26504274_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTcwNQ_8f196ecd-e8a2-49dc-94e4-3843784c3487"
      unitRef="usd">600000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="idb4a12fcb03747dfaa82aec40ecf9ab6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTgzOQ_cfe92b2c-7353-4b6b-a995-54760a966d4e"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTc_65bc0eb5-3877-4ca5-8a9b-0b41f9e36a1a">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the Company's condensed consolidated statements of cash flows.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTg_1a0fe020-31a8-4c77-a832-0f6c72c53ff8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1Nzk_46619496-59c0-4f13-b49a-7fc9b76f99b9">Concentration of Credit RiskFinancial instruments that subject the Company to credit risk consist primarily of cash and restricted cash. The Company places cash and restricted cash in established financial institutions. The Company has no significant&#160;off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTM_25478c91-3a51-4d4a-b2ed-0065bbfd0722">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of March 31, 2021 and December&#160;31, 2020, the Company&#x2019;s property and equipment consisted of office equipment, lab equipment, furniture and fixtures, and leasehold improvements. The office equipment has an estimated useful life of three years, lab equipment has an estimated useful life of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09"&gt;five&lt;/span&gt;&#160;or&#160;ten years, and furniture and fixtures have an estimated useful life of&#160;five years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Assets under construction primarily consist of costs incurred with leasehold improvements, and, once placed into service, will be depreciated over the shorter of the lease term or the estimated useful life of the asset.  Upon retirement or sale, the cost of assets are disposed of, and the related accumulated depreciation, is removed from the accounts and any resulting gain or loss is included in the statement of operations and other comprehensive loss. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized a disposal loss of $0.7 million in the three months ended March 31, 2021 in leasehold improvements which are no longer being utilized in the facility in White City,  and did not recognize a disposal loss in the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;The Company evaluates an asset for potential impairment when events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Recoverability is measured by comparing the book value of the asset to the expected future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the asset exceeds the fair value.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if32728553356471ba7bc0e4c651239d0_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzE1OA_607a8340-f852-4fcd-bd1d-88f3ade147a6">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idb6476ec587b401aaa02d1e7fc32b2d9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIxNA_e60e6f6f-c5a3-43d2-8663-7fc9b14e4573">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibe7330eedb514187a0f2f7858509b56d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzI3OA_d085c8a0-2f90-4edc-91f5-49a53c3ad334">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <autl:GainLossOnDispositionOfLeaseholdImprovements
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTgxMg_5113d2fd-7cdc-4149-a3fc-b6c4f3694a1c"
      unitRef="usd">-700000</autl:GainLossOnDispositionOfLeaseholdImprovements>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjE5OTAyMzI4OTYwMw_f1b3d8ff-614d-497c-a08b-cbd76d99268b"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMyNg_9c5851e1-ff8c-4e16-8ca5-b661a18665cd"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMyNg_c5e91b69-9d9d-40d0-b2ae-c2bc230c90cb"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODA_59061fc7-e0da-43eb-9ead-d9bd402c0407">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received, initial direct costs, or prepayments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company accounts for the lease and non-lease components of leases for classes of all underlying assets and allocates all of the contract consideration to the lease component.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODE_c65958eb-cd3f-4cb3-b573-3b5359dbd35b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets are related to acquired software licenses with finite lives and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators of impairment are present, the Company tests for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company evaluates the useful lives for these intangible assets each reporting period to determine whether events and circumstances warrant a revision in their remaining useful lives.&#160;The Company did not recognize an impairment loss in the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMzNw_9c5851e1-ff8c-4e16-8ca5-b661a18665cd"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTMzNw_c5e91b69-9d9d-40d0-b2ae-c2bc230c90cb"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDE_ad3f25f3-66e0-4401-9a62-e958a0653566">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and its chief operating decision maker, the Company&#x2019;s Chief Executive Officer, view the Company&#x2019;s operations and manage its business as a single operating segment, which is the business of developing and commercializing gene therapies; however, the Company operates in two geographic regions: the United Kingdom and the United States. Substantially all of the Company&#x2019;s assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfNzk3OQ_0836ef41-b0ef-41fc-a4e8-007231988538"
      unitRef="region">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDg_40cb3316-63aa-4b0c-97bf-68b92505a7a6">Research and Development CostsResearch and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, depreciation expense, third-party license fees, external costs of outside vendors engaged to conduct clinical development activities, clinical trials, costs to manufacture clinical trial materials and certain tax credits associated with research and development activities.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing its condensed consolidated financial statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company&#x2019;s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes judgments and estimates in determining the accrued balance in any accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <autl:ResearchAndDevelopmentTaxCredits
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfODc1MA_f2d72510-093e-468b-aaaa-95c736f6b2b3"
      unitRef="usd">30000</autl:ResearchAndDevelopmentTaxCredits>
    <autl:ResearchAndDevelopmentTaxCredits
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfODc1Nw_ebb6c020-e4c5-455f-8047-e029852e646f"
      unitRef="usd">28000</autl:ResearchAndDevelopmentTaxCredits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTE_17bc1cb3-397f-4955-b60c-d4e04bf4c3c1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for equity awards based on the grant date fair value of the award. The Company recognizes share-based compensation expense for awards granted to employees that have a graded vesting schedule based on a service condition only on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards (the &#x201c;graded-vesting attribution method&#x201d;), based on the estimated grant date fair value for each separately vesting tranche. For equity awards with a graded vesting schedule and a combination of service and performance conditions, the Company recognizes share-based compensation expense using a graded-vesting attribution method over the requisite service period when the achievement of a performance-based milestone is probable, based on the relative satisfaction of the performance condition as of the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For share-based awards granted to consultants and&#160;non-employees,&#160;compensation expense is recognized using the graded-vesting attribution method over the period during which services are rendered by such consultants and&#160;non-employees&#160;until completed. The measurement date for employee awards is the date of grant, and share-based compensation costs are recognized as expense over the employees&#x2019; requisite service period, which is the vesting period, on an accelerated basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 7 for the Company&#x2019;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility.&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lacks company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, it uses a combination of the historical volatility of the ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as the Company has adequate historical data regarding the volatility of its own traded security price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;&#160;The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend.&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of ordinary shares.&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair market value of the Company&#x2019;s ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select Market on the date the grant is approved by the Board.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDM_b223a483-0a70-43c5-885c-e01279f76461">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement and Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its condensed consolidated financial statements in its functional currency, which is the pound sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates.&#160;Non-monetary&#160;assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. The Company recorded a  foreign exchange loss of $1.2 million and foreign exchange gain of  $4.3 million for the three months ended March 31, 2021 and 2020, respectively. Foreign exchange gains are included in other income in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, the condensed consolidated financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#x2019; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining the Company's net loss but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MTM0OA_38fb8a72-37bb-4dff-92a8-5ec08411d23e"
      unitRef="usd">-1200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTM3MDg_1efcb543-7e34-4cd3-8e04-22342086f0d9"
      unitRef="usd">4300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <autl:PatentCostsPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTI_4e7aea17-6a15-4ede-a936-310825a5aa27">Patent CostsThe Company expenses patent prosecution and related legal costs as they are incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</autl:PatentCostsPolicyTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTQ4NjA_e3657fef-7eef-4a3d-a65a-27c84639775a"
      unitRef="usd">500000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMTA5OTUxMTY2MjQ4Mw_17670df9-5f28-427f-b334-81064ead0cb2"
      unitRef="usd">600000</us-gaap:ProfessionalFees>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTA_88e5758d-93e3-47ee-9d05-1240ab78b648">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received research grants under which it is reimbursed for specific research and development activities. Payments received are recognized as income in the statements of operations and comprehensive loss over the period in which the Company recognizes the related costs. At the time the Company recognizes grant income, it has complied with the conditions attached to it and the receipt of the reimbursement is reasonably assured. The Company has received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance. For grants with refund provisions, the Company reviews the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. The Company has determined that the likelihood of any repayment events included in its current grants is remote.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1OTU_85511d77-2baa-4323-97ca-ebd63e6b3948">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:232%"&gt;License Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASC Topic 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company  fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License Fees and Multiple Element Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contingent Research Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company&#x2019;s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. The Company considers all relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For three months ended March 31, 2021, the Company has not recognized any variable consideration with regards to the development milestones which are included in the license agreement that was executed in the period. This is due to the fact that those development milestones have not yet been met and the recognition of the related revenue is not yet probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTE_a823b08f-ef35-4b95-ac35-f03786f5b19d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision (benefit) for income taxes represents income taxes paid or payable (or a reduction of such amounts) for the current year plus deferred taxes. Deferred taxes result from differences between the condensed consolidated financial statements and tax bases of the Company&#x2019;s assets and liabilities, and are adjusted for changes in tax rates and tax law when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in the United Kingdom and the United States. The calculation of the Company&#x2019;s tax provision involves the application of United Kingdom and United States tax law and requires judgment and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the realizability of its deferred tax assets at each reporting date, and establishes a valuation allowance when it is more likely than not that all or a portion of its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. The Company considers all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that the Company&#x2019;s deferred tax assets are not more likely than not realizable, the Company establishes a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a&#160;two-step&#160;approach for recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that the Company believes is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in the Company&#x2019;s income tax returns and the amount of tax benefits recognized in the its condensed consolidated financial statements represent the Company&#x2019;s unrecognized income tax benefits, which it either records as a liability or reduction of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Credit&lt;/span&gt;&lt;/div&gt;The Company benefits from the U.K. research and development tax credit regime under both the small and medium sized enterprise, or SME, scheme and by claiming an RDEC in respect of grant funded projects. Under the SME regime, a portion of the Company&#x2019;s losses can be surrendered for a cash rebate of up to 33.35% of eligible expenditures. SME credits are accounted for within the tax provision in the year in which the expenditures were incurred. RDEC credits are accounted for within other income in the condensed consolidated statements of operations and comprehensive loss.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTI_9846371f-0406-4f2e-8fc8-040098a009f1">Comprehensive Loss&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 220,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive loss is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjUzOTg_db7fc2ff-7504-4469-b776-edce411d2c26"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMjU0MjM_1eda1123-633d-4503-a6ca-282c4365e5bd"
      unitRef="usd">-17700000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA1ODQ_bad07445-f48e-471f-9c7d-b038e388f9d7">Net Loss Per ShareBasic and diluted net loss per ordinary share is determined by dividing net loss by the weighted average number of ordinary shares outstanding during the period. For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MTc_b21750f4-f0f5-4617-9f59-70d968fa010d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted incentive shares and units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,914,949&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,241,779&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,636,977&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia59d20ea5e8a4d7cbfe95212fb978221_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMi0xLTEtMS0w_874ba1b6-eb02-45d1-8410-3592d0d2abf4"
      unitRef="shares">1360159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2b4f427ba0764b8d8cd7204223dfb93f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMi0zLTEtMS0w_63f1dfda-38a7-47db-adae-a0090eea19be"
      unitRef="shares">722028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41fb8cf98b7c46c1b399e564aa4b4ec1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMy0xLTEtMS0w_4ce7eeda-0486-4a92-b0c1-ec96f49c9d90"
      unitRef="shares">6881620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ca9e1c4a7374941a2c5d250cd93db6f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfMy0zLTEtMS0w_769253d1-fbb5-4d7c-80a3-ffc97c4a88aa"
      unitRef="shares">5914949</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfNC0xLTEtMS0w_97da7562-0a30-461d-8d6a-61f09e1a30ac"
      unitRef="shares">8241779</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RhYmxlOmFmNGUyY2NjNDhmOTQ3NGU5YzFkMTM5MzY2ZjU3ZjQzL3RhYmxlcmFuZ2U6YWY0ZTJjY2M0OGY5NDc0ZTljMWQxMzkzNjZmNTdmNDNfNC0zLTEtMS0w_9e991973-a358-4d67-bf59-682f4e955ac5"
      unitRef="shares">6636977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzA2MDY_d9c671a9-bdb9-47ec-9405-7a04dd2c35b0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company's financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTQ2_fbc1df91-cfe9-40e9-9837-5e1feac30803">Prepaid Expenses and Other Assets, Current&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets, current consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development claims receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease receivables from terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in prepayments of $2.7 million as at March 31, 2021 when compared to December 31, 2020 is primarily related to decreases in prepayments for clinical trials and lower payments of directors' and officers liability insurance due to the timing of payments in the period when compared to the same period in the prior year. &lt;/span&gt;&lt;/div&gt;The increase in research and development claims receivable is due to an increase in the effective tax rate when compared to the same period last year. More information on the movement in the tax position between periods can be found in Note 9.</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTQ4_523b3b51-d28e-4eaa-a904-db0c8855f230">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets, current consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development claims receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease receivables from terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <autl:ResearchAndDevelopmentClaimsReceivableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMS0xLTEtMS0w_486842c2-8748-46cc-b74c-2240b7af3d15"
      unitRef="usd">30791000</autl:ResearchAndDevelopmentClaimsReceivableCurrent>
    <autl:ResearchAndDevelopmentClaimsReceivableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMS0zLTEtMS0w_89a0e00a-c59d-4f3a-96de-45d008a5861f"
      unitRef="usd">24711000</autl:ResearchAndDevelopmentClaimsReceivableCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMi0xLTEtMS0w_2b43a35e-4079-4795-8e92-8da29c5b4f85"
      unitRef="usd">7477000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMi0zLTEtMS0w_aa226961-3375-447b-a3e1-b8e6ef8ddc52"
      unitRef="usd">10206000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMy0xLTEtMS0w_2f5ed664-f444-4b36-838b-d25eb5c51eb9"
      unitRef="usd">3292000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfMy0zLTEtMS0w_e642ef92-0683-4f34-9a67-2a0143ff821e"
      unitRef="usd">3124000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:LeaseIncentiveReceivableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNC0xLTEtMS0w_572881fa-dad9-443f-8dc9-794913c38cb5"
      unitRef="usd">4480000</us-gaap:LeaseIncentiveReceivableCurrent>
    <us-gaap:LeaseIncentiveReceivableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNC0zLTEtMS0w_e32985eb-1c9e-4ba2-b685-7c2a3a9692e7"
      unitRef="usd">1237000</us-gaap:LeaseIncentiveReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNi0xLTEtMS0w_a64da9fd-433c-491f-8f6c-df63c8c98489"
      unitRef="usd">411000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNi0zLTEtMS0w_11c1107b-85a2-4d9e-94fc-2814c1d1a239"
      unitRef="usd">414000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNy0xLTEtMS0w_56a181cc-b400-4bf0-a4a6-16fb845b2301"
      unitRef="usd">257000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfNy0zLTEtMS0w_e5784a11-7a65-49e8-b6d1-375f58d6be6b"
      unitRef="usd">199000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0xLTEtMS0yNDc_5c0836a9-da1b-4d48-a091-4930586e7b01"
      unitRef="usd">1554000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0zLTEtMS0yNDM_e2c04a7a-2443-4c6d-a135-96dcf53f5d9f"
      unitRef="usd">3008000</us-gaap:DeferredCostsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0xLTEtMS0w_20cdce4f-f1c9-49cf-a002-1734c31cfc44"
      unitRef="usd">48262000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RhYmxlOmQ3YTM2NjljYTM0YzRmYzRiYjBjZDcyN2FkYjJlMjc3L3RhYmxlcmFuZ2U6ZDdhMzY2OWNhMzRjNGZjNGJiMGNkNzI3YWRiMmUyNzdfOC0zLTEtMS0w_b467ddff-cdcb-4173-88bc-816f5f7a7044"
      unitRef="usd">42899000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <autl:IncreaseDecreaseToPrepaidFacilityAndManufacturing
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zMS9mcmFnOjA3MmY0MTk0NjRlNDQ4ZDg5YTUxMGFiNmM0MjA1YjIxL3RleHRyZWdpb246MDcyZjQxOTQ2NGU0NDhkODlhNTEwYWI2YzQyMDViMjFfMTA5OTUxMTYyODc5Nw_933c804d-0ece-4427-9cbc-81982371b7ab"
      unitRef="usd">-2700000</autl:IncreaseDecreaseToPrepaidFacilityAndManufacturing>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMjU2_cd110598-7fa8-4a81-a07a-3d4fe21d25ea">Property and Equipment, Net&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets under construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for the three months ended March 31, 2021 and 2020 was $1.8 million and $1.3 million, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMjU0_42178805-a4a1-4aef-acff-12fb522e90c8">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets under construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1fac6fac3aa7454b9e09eae49685ed05_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMS0xLTEtMS0w_cea6c002-c9ca-4019-886f-b7884f3556a8"
      unitRef="usd">23774000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i54aa60e569634a13a1858ea934dcb0bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMS0zLTEtMS0w_4c8a64fd-55fa-4b95-945f-7169e95b4c83"
      unitRef="usd">23491000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic6617f38eb9f4460a622b2d3e9279f54_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMi0xLTEtMS0w_5e049d8b-1535-4d7e-a1a8-f18be8aa8c75"
      unitRef="usd">3122000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53347ee136fa448db35974e8e31a9d0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMi0zLTEtMS0w_00d1e3c0-5a5b-476f-b0ad-bcd74e1d4f42"
      unitRef="usd">2928000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0b2f75a31f494e2aa9a5db9ab782201c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMy0xLTEtMS0w_3e85e099-2faa-46dd-934f-0dc50c378436"
      unitRef="usd">1350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i847ce03d632a4b45add274b3cfcf12b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfMy0zLTEtMS0w_a42a2ed3-9a33-48b1-8433-a7f891918187"
      unitRef="usd">1340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia61a689210f94943a3d41c76d40e1ebd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNC0xLTEtMS0w_cf9a79a2-27e6-4b7b-ae97-aba31ebd433b"
      unitRef="usd">10374000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2651a7e1481c490393262e2898c2333d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNC0zLTEtMS0w_5ad9d366-386a-484c-8d70-a6575939ba9d"
      unitRef="usd">10629000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic33f618510fd4997a9c685478ea3f3ba_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNS0xLTEtMS0w_3d598a10-6154-4c3f-935d-553a3e4d811a"
      unitRef="usd">11332000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i493cf0d67e02413cabd32aafc94e263f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNS0zLTEtMS0w_a50616fb-0918-48f7-8843-34f9ed823680"
      unitRef="usd">14321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNi0xLTEtMS0w_2a52648a-16f3-42e2-a058-73dc7acb12ae"
      unitRef="usd">16409000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNi0zLTEtMS0w_b13282ce-f112-41e0-840e-d93d2cb4cebf"
      unitRef="usd">14663000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNy0xLTEtMS0w_49612f5a-aed6-45ac-b46d-1d9e4ee784e0"
      unitRef="usd">33543000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RhYmxlOjRlZGZkMDNkZWZmZDRjNTlhYTZmNjVjYjgzYTkwNzU4L3RhYmxlcmFuZ2U6NGVkZmQwM2RlZmZkNGM1OWFhNmY2NWNiODNhOTA3NThfNy0zLTEtMS0w_9aebdf85-1b37-496e-bf24-0b2eecf3e5bc"
      unitRef="usd">38046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMTYy_a84cdeec-acc4-4679-9bea-6e60c7e36618"
      unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNC9mcmFnOjQ0Mzg3ZmY3YjFmZTRjN2FiMTY2YjM1NjcyNDBlZTg4L3RleHRyZWdpb246NDQzODdmZjdiMWZlNGM3YWIxNjZiMzU2NzI0MGVlODhfMTY5_c7f6b6cc-e1e9-41c8-a1dc-a97e8cb099d9"
      unitRef="usd">1300000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RleHRyZWdpb246N2QxY2IyM2YxMTY4NDE0Y2FlZTgzMzIzNDE5MmFmODFfMTM3_40f16188-a3f9-4ef3-bd19-7be047be5833">Accrued Expenses and Other Liabilities&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCLB milestone and option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate income and local taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RleHRyZWdpb246N2QxY2IyM2YxMTY4NDE0Y2FlZTgzMzIzNDE5MmFmODFfMTM4_6e89fd5e-25c2-48b8-9c43-32f38b0903f5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCLB milestone and option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate income and local taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMS0xLTEtMS0w_c574d2ea-987e-46bf-b3ec-8e0bf39837c6"
      unitRef="usd">8695000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMS0zLTEtMS0w_0149144b-da3d-44ad-8236-b9cecceca360"
      unitRef="usd">8732000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <autl:AccruedResearchAndDevelopmentCostCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMi0xLTEtMS0w_dc49e6d8-844a-4660-8b44-e11328a9a7ae"
      unitRef="usd">11468000</autl:AccruedResearchAndDevelopmentCostCurrent>
    <autl:AccruedResearchAndDevelopmentCostCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMi0zLTEtMS0w_0f6300cc-34f3-4edf-8315-bd409e99c286"
      unitRef="usd">15343000</autl:AccruedResearchAndDevelopmentCostCurrent>
    <autl:AccruedLicenseFeesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMy0xLTEtMS0w_c18026b1-21c7-4a9b-883b-bc15e62f8866"
      unitRef="usd">206000</autl:AccruedLicenseFeesCurrent>
    <autl:AccruedLicenseFeesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfMy0zLTEtMS0w_52088972-8176-45d6-bab9-67e6a47c1b57"
      unitRef="usd">205000</autl:AccruedLicenseFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNC0xLTEtMS0w_07eadf4b-357b-4106-9d0f-8cfb0b204fea"
      unitRef="usd">3311000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNC0zLTEtMS0w_1759521a-4632-4eff-ab41-f6f723f6a6b6"
      unitRef="usd">3005000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNS0xLTEtMS0w_b5257cad-2c7a-459c-b795-2592d171ec65"
      unitRef="usd">429000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNS0zLTEtMS0w_aafd7016-cd57-45b5-a45e-08f07b6bf561"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNi0xLTEtMS0w_cb9d8410-af37-4830-8ba2-bf0302f09707"
      unitRef="usd">574000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNi0zLTEtMS0w_db4c79eb-feed-476c-ad2e-af509d51d6c5"
      unitRef="usd">496000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNy0xLTEtMS0w_49ec0813-bf70-4a64-8af4-83a7aeb8738c"
      unitRef="usd">24683000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8zNy9mcmFnOjdkMWNiMjNmMTE2ODQxNGNhZWU4MzMyMzQxOTJhZjgxL3RhYmxlOjdkZjY5M2QwMDZkNzQzZmNhNmNjNjQzNjE0ODk3NWM1L3RhYmxlcmFuZ2U6N2RmNjkzZDAwNmQ3NDNmY2E2Y2M2NDM2MTQ4OTc1YzVfNy0zLTEtMS0w_2ad85656-3c2a-4e27-962f-a03c838d78b3"
      unitRef="usd">27781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5Mw_37010284-75a6-4e98-aafe-181f0311f8c1">Shareholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of March 31, 2021, the Company has not declared any dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective from June 26, 2018, the board of directors has the authority to allot new ordinary shares or to grant rights to subscribe for or to convert any security into ordinary shares in the Company up to a maximum aggregate nominal amount of&#160;$8,400. This authority runs for five years and will expire on June 26, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective from June 26, 2018, the board also has the authority to allot ordinary shares for cash or to grant rights to subscribe for or to convert any security into ordinary shares in the Company without first offering them to existing shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of&#160;$8,400. This authority runs for five years and will expire on June 26, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 the Company&#x2019;s issued capital share consisted of&#160;70,515,354&#160;ordinary shares, with a nominal value of&#160; $0.000042&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share, (ii)&#160;34,425&#160;deferred shares, with a nominal value of&#160;&#xa3;0.00001&#160;per share, (iii)&#160;88,893,548&#160;B deferred shares, with a nominal value of&#160;&#xa3;0.00099&#160;per share and (iv)&#160;1&#160;C deferred share, with a nominal value of&#160;&#xa3;0.000008. Each issued share has been fully paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 18, 2020, the Company entered into an Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC, under which the Company may, at its option, offer and sell ADSs having an aggregate offering price of up to $100&#160;million from time to time through Jefferies, acting as sales agent. Any such sales made through our sales agent can be made by any method that is deemed an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act, or in other transactions pursuant to an effective shelf registration statement on Form F-3.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company agreed to pay Jefferies a commission of 3.0% of the gross proceeds of any sales of ADSs sold pursuant to the Sales Agreement. During &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;three months ended March 31, 2021,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; the Company issued an aggregate of 1.7&#160;million ADSs under the Sales Agreement for net proceeds, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;after underwriting discounts and offering expenses of $15.3&#160;million&lt;/span&gt;.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <autl:MaximumNominalAmountOfSharesAuthorizedForGrant
      contextRef="i52a9ff78fd994500b70e17771c035eaf_I20180626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfNTU1_2a5a5359-e35b-4ae2-a51f-939f9ead5d6d"
      unitRef="usd">8400</autl:MaximumNominalAmountOfSharesAuthorizedForGrant>
    <autl:AuthorizedGrantLife
      contextRef="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfNTgz_8afbea30-f495-4576-91c2-b8617a38db97">P5Y</autl:AuthorizedGrantLife>
    <autl:MaximumNominalAmountOfSharesAuthorizedForGrant
      contextRef="i52a9ff78fd994500b70e17771c035eaf_I20180626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfOTU1_e9812bfd-d4e8-4706-8bd2-5189a019e4fe"
      unitRef="usd">8400</autl:MaximumNominalAmountOfSharesAuthorizedForGrant>
    <autl:AuthorizedGrantLife
      contextRef="i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfOTgz_1d686b76-bcdf-4497-9301-753d598fb365">P5Y</autl:AuthorizedGrantLife>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTA4MA_1b2fa88b-acbf-4ddb-8985-6ed58c720f4b"
      unitRef="shares">70515354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibfa8aa73c88c4f96977e727aa35b5250_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTEyNQ_0aeabc4e-b86e-4eec-9c2b-93c41f319864"
      unitRef="usdPerShare">0.000042</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTE0NA_400c0f13-0618-4a4f-bb2e-e360d598e209"
      unitRef="shares">34425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib6f8d96d62384b18b833f68e6f8ef67b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTE4OA_c1b9d2e0-2bae-4b93-9804-1ed11a5975c0"
      unitRef="gbpPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTIwOA_14e35812-2c98-4ee7-8ea3-4e73969a1b7c"
      unitRef="shares">88893548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i40a6c0216e3a4a178d18533172f5eead_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTI1NA_51746136-3c0b-45d1-9057-1b5e7d2f44cf"
      unitRef="gbpPerShare">0.00099</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTI3Ng_5bd37fe3-bd81-458a-ba92-f2d8460e6ce6"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5cfb1d3e9b454ea1902388d923852617_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTMyMQ_bbb52178-55fb-49fd-9b76-39082a427470"
      unitRef="gbpPerShare">0.000008</us-gaap:CommonStockParOrStatedValuePerShare>
    <autl:SaleOfStockAuthorizedAmount
      contextRef="i89ef2b2dd83148a89ab674028ea86908_I20200918"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTYxOA_a07ea4e4-f5cf-461d-8b6f-6996a1fba112"
      unitRef="usd">100000000</autl:SaleOfStockAuthorizedAmount>
    <autl:CommissionPercentageOfGrossSalesPrice
      contextRef="i89ef2b2dd83148a89ab674028ea86908_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMTk5OQ_8b191cda-c6e7-4452-9058-6471a3c139d0"
      unitRef="number">0.030</autl:CommissionPercentageOfGrossSalesPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2070486d12ea46aa83b02cb4d9488798_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5OTAyMzI1ODAzNA_31f0e2b9-2452-46a5-876f-8b138bc3f80d"
      unitRef="shares">1700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80MC9mcmFnOmRlNDMxMGFlNGIwMDQzYzk4ZDc3MGE3YjgxZWRjNzM2L3RleHRyZWdpb246ZGU0MzEwYWU0YjAwNDNjOThkNzcwYTdiODFlZGM3MzZfMjE5OTAyMzI1ODAxOQ_2a2f1bcf-1db2-4156-a007-bb3609bf4c9a"
      unitRef="usd">15300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMQ_f65eda25-7c55-40c3-a8be-7960d38cb312">Share-Based Compensation&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the Company's 2018 Equity Incentive Plan (the "2018 Plan") and 2017 Stock Option Plan (the "2017 Plan"), as well as restricted shares granted as employee incentives, typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining three years, unless the award contains specific performance vesting provisions. For equity awards issued that have both a performance vesting condition and a services condition, once the performance criteria is achieved, the awards are then subject to a four-year service vesting with 25% of the award vesting on the first anniversary of the performance condition being achieved and the balance vesting monthly over the remaining three years. Options granted in January 2021 contained performance conditions related to specified clinical milestones. Options granted under the 2018 Plan and 2017 Plan generally expire 10 years from the date of grant. For certain senior members of management and directors, the board of directors has approved an alternative vesting schedule. Restricted stock units awarded in December 2019 vest over a&#160;3-year service period with&#160;50%&#160;of the award vesting one and a half years, or 18 months, from commencement date and the remaining&#160;50%&#160;of the award vesting at the end of the third year.  Restricted stock units awarded in January 2021 contained a performance condition related to specified clinical milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Option Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted by the Company during the three months ended March 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.032%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;6.08 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62% to 0.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.33% to 81.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,954,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#x2019;s ADSs for those share options that had exercise prices lower than the fair value of the Company&#x2019;s ADSs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of share options granted was $5.96 per share for the three months ended March 31, 2021, of which none were vested at the date of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the total unrecognized compensation expense related to unvested options was $9.4 million, which the Company expects to recognize over a weighted average vesting period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, the Company granted 1,602,500 options with performance conditions related to specified clinical milestones.  As of March 31, 2021, the performance conditions were not determined to be probable and no expense was recorded for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s restricted ordinary shares during the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;restricted   &lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, there was no unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A restricted stock unit (&#x201c;RSU&#x201d;) represents the right to receive one of the Company&#x2019;s ADSs upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#x2019;s ADSs on the date of grant. The Company historically granted RSUs with service conditions that vest over&#160;3-year service period with&#160;50%&#160;of the award vesting one-and-half years from grant date and the remaining&#160;50%&#160;of the award vesting at the end of the third year. In January 2021, the Company awarded restricted stock units that contained a performance condition based on a condition related to a specified clinical milestone. In March 2021, the Company awarded restricted stock units with service conditions that vest over a four year period with 25%  on the first anniversary of the grant date, and the balance vesting quarterly over the remaining three years.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the 2018 Plan for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;restricted   &lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, there was&#160;$2.0 million&#160;of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average vesting period of&#160;2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, the Company awarded 920,000 RSUs with a performance condition related to a specified clinical milestone.  As of March 31, 2021, the performance condition was not determined to be probable and accordingly, no expense was recorded for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development expenses, general and administrative expenses, and capitalized to property and equipment is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized to property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The decrease in share-based compensation expense of $6.9 million in the three months ended March 31, 2021 relates to forfeitures of share-based payment awards as a result of the reduction in workforce that began to take place during the period.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5Ng_fcd68f2d-0dc8-4c87-a648-2c9610aca19e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjc2_55bf2c50-403d-46c3-a6b8-a1a69bdb6998"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied33dc884b13464f896f1ce66590f479_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfNDAx_b0a7ce5b-0025-42af-b06e-90dacd9e667f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5OQ_a055a95a-1fbc-4d4a-9577-8cd6e42c77e8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i152c0f30695a40f9a86760ec0cbcc834_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfNjc1_c9de6f00-5a2d-4ec7-8d57-6abf58024b40"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfODE5_8a200fb5-f51f-42d7-b33b-1d94e1c00f72">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfODkw_e211c186-abe7-4773-bea2-be1915cd0dda">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTEwMg_f5a8d774-0877-4242-8ec9-4adac1da8eaa">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTEzMA_7f0f769b-aad7-4745-85af-780479bd96f0"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTE3OQ_aca0399e-7d42-463a-8ab3-782e57e06ac9">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i830c670237164f47bf2b9d0130f56fab_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTE3OQ_d285f589-b8b4-4084-a3b0-42910c622893">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTIzMQ_d430edd9-660b-4c50-bef4-8dcbf6e7f6a6"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzM5Mw_39a7eadb-7703-414d-9b3c-dfab2ecb332d">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted by the Company during the three months ended March 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.032%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;6.08 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62% to 0.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.33% to 81.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i916d4ef54fa54d7793e6e79e3ce53f4b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMi0xLTEtMS0wL3RleHRyZWdpb246YWI1ZjVkNjJjNWFhNDcxYzgyNWM3ZGVlYWU5ODg3MmZfMTA_7c11fee7-6bd0-4aea-b67f-0d33005c6eba">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMy0xLTEtMS0wL3RleHRyZWdpb246Y2RjMmNjZjRjMTZmNDY0ZDlkMDc2Y2RmZDM4ZmI0YTBfNA_788ab23a-c852-41ea-a08b-7a8591df2729"
      unitRef="number">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfMy0xLTEtMS0wL3RleHRyZWdpb246Y2RjMmNjZjRjMTZmNDY0ZDlkMDc2Y2RmZDM4ZmI0YTBfMTA_131a9961-29c1-4cea-b825-4cb61ae0c780"
      unitRef="number">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNC0xLTEtMS0wL3RleHRyZWdpb246ODMwNzJiYjkwZTIyNDc5NThlYWM2Y2RmZmNhYjVmMjRfNA_0858b9b7-b6c7-4bb3-82cd-0880e629fbf6"
      unitRef="number">0.8133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNC0xLTEtMS0wL3RleHRyZWdpb246ODMwNzJiYjkwZTIyNDc5NThlYWM2Y2RmZmNhYjVmMjRfMTA_b2e2ae9a-7070-40e9-92a1-b42dfaf9ed65"
      unitRef="number">0.8134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjFlZDgxNmUyYTdmMTQ4ZjRhZjZjYTljMmYzODA4ZjcxL3RhYmxlcmFuZ2U6MWVkODE2ZTJhN2YxNDhmNGFmNmNhOWMyZjM4MDhmNzFfNS0xLTEtMS0w_348e9b34-aa33-47e9-ba84-b5f003f60bd6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMg_2dd8a1b2-6710-4230-9b24-506143a40266">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes activity for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,954,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,881,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS0xLTEtMS0w_f672e071-272d-468b-aa3b-a2a9a2c0a946"
      unitRef="shares">5611429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS0zLTEtMS0w_f3d80b98-3702-4789-b781-9722ee0d9cab"
      unitRef="usdPerShare">17.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i049951a6daee47029d1139d31d05bfa3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS01LTEtMS0w_aaa4530a-3f37-4d98-ac11-23cba5cfa74a">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id858f1b0dc6f47c58cb69a3594277923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMS03LTEtMS0w_011688a6-82ca-4904-a959-ea486412d4bf"
      unitRef="usd">4262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMi0xLTEtMS0w_d54c9ad1-137d-4ac3-92cc-11ad02701cc2"
      unitRef="shares">1828200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMi0zLTEtMS0w_a8df24f7-9ef6-4b21-8f66-10cf190d1a90"
      unitRef="usdPerShare">8.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMy0xLTEtMS0w_4167ea30-46c6-41ef-bafd-f02ce66f0047"
      unitRef="shares">545</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfMy0zLTEtMS0w_b4d8d750-08b2-4772-90c6-e6ffbf812bee"
      unitRef="usdPerShare">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNC0xLTEtMS0w_929bd46f-5e4c-4ece-a0ae-c18933b2373d"
      unitRef="shares">557464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNC0zLTEtMS0w_3b091fb9-6323-45ea-acc6-971d47c1e60e"
      unitRef="usdPerShare">16.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS0xLTEtMS0w_c4211b0c-359b-4cf9-9490-b746b2f97677"
      unitRef="shares">6881620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS0zLTEtMS0w_f22daeea-d114-403f-b96e-77bac4183be4"
      unitRef="usdPerShare">14.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS01LTEtMS0w_b2e7b57f-2d8d-4568-bb6a-049d5db5de74">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNS03LTEtMS0w_3fe64876-9684-4763-b8b1-44a81f6cb12e"
      unitRef="usd">2194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi0xLTEtMS0w_e9a61e66-af22-4fbd-ab28-50587c75a8a6"
      unitRef="shares">2954620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi0zLTEtMS0w_64f9de6b-cf76-4ade-8458-13727874cbd1"
      unitRef="usdPerShare">17.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi01LTEtMS0w_a496427e-26d5-4485-901f-25141ab81dd3">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNi03LTEtMS0w_6baf1374-3cfc-49b3-a312-2d1509d03fbd"
      unitRef="usd">2055000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy0xLTEtMS0w_d2002b70-504e-4033-8933-1dce18d2df3b"
      unitRef="shares">6881620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy0zLTEtMS0w_08be0740-cdf3-45b5-bb55-efeff4f86490"
      unitRef="usdPerShare">14.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy01LTEtMS0w_d6ae29e2-114c-4c16-bb46-031e23e46e63">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjcyY2QyYzcyY2Q2MTRlOTM5NzZlZmNkMjBjNjkxMmQ2L3RhYmxlcmFuZ2U6NzJjZDJjNzJjZDYxNGU5Mzk3NmVmY2QyMGM2OTEyZDZfNy03LTEtMS0w_6414f2de-5474-448c-afcf-f4e6fb8582cb"
      unitRef="usd">2194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTg4NQ_c962f604-5659-4224-b37c-8649711c9dc4"
      unitRef="usdPerShare">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjAyNQ_c43256c1-c0b1-4f89-ab8b-e1a7fea83080"
      unitRef="usd">9400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjExMA_d45c0366-ff09-428d-ae68-dbd54cca8e54">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ib89704d2fb2942e1aac143125d76070f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzEyMQ_286b4021-3b34-4a79-8ef8-5b270f4abd1c"
      unitRef="shares">1602500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMA_b8811f18-9b82-40d1-95ce-1b400b702bd7">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the Company&#x2019;s restricted ordinary shares during the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;restricted   &lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the 2018 Plan for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of &lt;br/&gt;restricted   &lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309,900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0a573508e9c143009ce350d6d6b25350_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMS0xLTEtMS0w_d51741ca-1a63-48bf-8ed6-6ae488698120"
      unitRef="shares">90383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0a573508e9c143009ce350d6d6b25350_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMS0zLTEtMS0w_8e31f0ad-0846-4e16-b63f-2c0ab87ffa5f"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMi0xLTEtMS0w_b4f9ff76-6696-4ce6-a200-8f3f96796955"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMi0zLTEtMS0w_9f563f78-8662-499b-9f39-808c9178e829"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMy0xLTEtMS0w_df2bdf0e-81c5-48d5-8ffa-af7fd9ef519f"
      unitRef="shares">40124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfMy0zLTEtMS0w_559d831e-265d-4081-9cec-bae0228313f4"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNC0xLTEtMS0w_54688498-7e50-4bad-835d-da6e2b805ea5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i80937deba2fd433a8e2090b5cb9f9123_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNC0zLTEtMS0w_74252d81-a5d4-46fe-a909-ba7693d3f05a"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNS0xLTEtMS0w_3b5349a6-7151-434c-89a0-e94c2773b55f"
      unitRef="shares">50259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjllZjQxYWUzNGNkZjQxODE5ZDZlNzkyYWFhNTdhN2FjL3RhYmxlcmFuZ2U6OWVmNDFhZTM0Y2RmNDE4MTlkNmU3OTJhYWE1N2E3YWNfNS0zLTEtMS0w_c69dc343-d944-4858-aa6b-3c6008eaaeb0"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMTk2Ng_e38dfe8f-3ea6-4666-bb1a-f3ee3677ccf1"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjY5MA_77049c7a-1339-46e7-b80d-337f3c0f2a12">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjcxOA_d75bbdcf-d29a-4f82-88c6-6bdaa67c9b97"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8a87e415876f4c6095819254f6e7bfb4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjc5NQ_4c9c071e-6e41-45a2-bbf5-da14995a23c8"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjE5OTAyMzI2MjIwMw_64571aae-f970-4c1b-9389-04bc793f1e96">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMjE5OTAyMzI2MjIwNQ_591e9d0c-4c3a-4883-9fe7-e5aa167e8677"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i10245c9aec3142079b7a1b719d1c89b1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzNDM3Mg_8a200fb5-f51f-42d7-b33b-1d94e1c00f72">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic01ce88311fc413e92a876264e4e7673_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMS0xLTEtMS0w_d6ed4ab1-acbe-478f-8426-ab283c8f3535"
      unitRef="shares">415000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic01ce88311fc413e92a876264e4e7673_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMS0zLTEtMS0w_d8c53a7a-4853-4c05-991f-7a476fa2bba1"
      unitRef="usdPerShare">12.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMi0xLTEtMS0w_e4489b08-6188-4ac3-9fa2-1d03a2b428d3"
      unitRef="shares">1035650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMi0zLTEtMS0w_529cca18-ec29-4afc-b4c7-41b8443ae6ea"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMy0xLTEtMS0w_184fea5c-565f-46c9-a063-5c278f58b331"
      unitRef="shares">21500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfMy0zLTEtMS0w_f3156d51-6ef3-4c3f-a8ea-96cc6013ea90"
      unitRef="usdPerShare">8.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNC0xLTEtMS0w_693119eb-edd7-4de1-9a78-b2d99d0c928f"
      unitRef="shares">119250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNC0zLTEtMS0w_d4f4262d-8518-4fcc-b22e-b3ca6e2f3cd1"
      unitRef="usdPerShare">11.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNS0xLTEtMS0w_e091492d-314d-4d11-885f-9f544d41f926"
      unitRef="shares">1309900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOjg5ZTEyNzYzOGU3ZTQ2MjM5NjExNGY0NmVhYjgyMTA1L3RhYmxlcmFuZ2U6ODllMTI3NjM4ZTdlNDYyMzk2MTE0ZjQ2ZWFiODIxMDVfNS0zLTEtMS0w_690e4743-a7d7-4225-9637-71e5de1ed97e"
      unitRef="usdPerShare">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i7a527a130d6d456fb3e905c90988f2cb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzAyMA_15abd93a-9549-4f42-b23a-8f15f4141850"
      unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzE2NA_556b4d8b-eb44-4327-b024-b93b744daee0">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i9c228c3581004647bb72617df8c2b232_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzMyOA_0cad9a8e-072c-47ac-b623-86563e95131e"
      unitRef="shares">920000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMzQwMw_fb1de7fe-6568-4ec7-a842-a92edaa8ee8c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development expenses, general and administrative expenses, and capitalized to property and equipment is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized to property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb6abb4fb36a41389bd1c9e0a53cb994_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMi0xLTEtMS0w_72b44415-840b-487f-89e6-82c6d43edbb6"
      unitRef="usd">-1654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id91d5db238bf4cbf8f5dd387c179eec8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMi0zLTEtMS0w_d1da2dd3-f4e6-49ee-8c3d-5011213e30d9"
      unitRef="usd">4562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c78c180c11e46c6bbf16e7e78cf9f89_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMy0xLTEtMS0w_fd4df79a-c707-4fbc-99e4-51b6ffbe50ef"
      unitRef="usd">984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54c774dce7d34ff78fe33ab4eb91cbee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfMy0zLTEtMS0w_2baa69b1-c713-422b-b5b3-0f764ce94e9b"
      unitRef="usd">1627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5403abf0cda041f49722bec6a5bd107b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNC0xLTEtMS0w_48b778b7-6f1e-4eed-9786-081ef5526f17"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c5ac4db8415442786609952726649c3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNC0zLTEtMS0w_6832183c-9946-43b5-b6b5-13a819fd7129"
      unitRef="usd">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNS0xLTEtMS0w_eacc96c0-fda4-4281-ab7f-0aa1815ed333"
      unitRef="usd">-670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RhYmxlOmJlZGI3ODU3OWUyYzQ3NDk5NzlkZDM2ZjE3ODY3ZDE0L3RhYmxlcmFuZ2U6YmVkYjc4NTc5ZTJjNDc0OTk3OWRkMzZmMTc4NjdkMTRfNS0zLTEtMS0w_a549dffd-2012-4ccd-aa8a-6cf818ce9c7c"
      unitRef="usd">6235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <autl:ShareBasedPaymentArrangementExpenseIncreaseDecrease
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80My9mcmFnOjg2ZGE2ZmFmMzUyYjQyNDBiYmFhMWNjMzZhMjkwNGI0L3RleHRyZWdpb246ODZkYTZmYWYzNTJiNDI0MGJiYWExY2MzNmEyOTA0YjRfMTA5OTUxMTYzMzY1MA_7e549b55-6ab0-4b3d-a9ea-83aaa01d7912"
      unitRef="usd">-6900000</autl:ShareBasedPaymentArrangementExpenseIncreaseDecrease>
    <autl:LicenseAgreementsTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfNDYzNA_95e39a84-a1ec-49ae-9606-11dfbda79de2">License AgreementsUCL Business plc License&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2014, the Company entered into an exclusive license agreement (the &#x201c;License&#x201d;) with UCL Business Ltd. (&#x201c;UCLB&#x201d;), the technology transfer company of University College London (&#x201c;UCL&#x201d;), to obtain licenses to certain technology rights in the field of cancer therapy and diagnosis. In March 2016, the License was amended to include additional rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consideration for the License in September 2014, the Company issued 1,497,643&#160;ordinary shares to UCLB. The Company paid upfront fees of $0.3 million and issued an additional 313,971 ordinary shares to UCLB when the License was amended in March 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the License was further amended and restated to include a license to the Company's product candidate, AUTO1, for which UCL is conducting Phase&#160;1 clinical trials of AUTO1 in pediatric and adult ALL patients. The Company paid an upfront fee of &#xa3;1.5 million for consideration for the amended and restated License and paid the additional &#xa3;0.35&#160;million in connection with UCLB's transfer of clinical data to the Company in December 2020. No equity was issued as part of the upfront fee consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company may be obligated to make payments to UCLB under the amended and restated License upon the initiation of certain clinical activities in an aggregate amount of &#xa3;0.18&#160;million, the receipt of specified regulatory approvals in an aggregate amount of &#xa3;37.5&#160;million, the start of commercialization in an aggregate amount of &#xa3;18 million, and the achievement of net sales levels in an aggregate amount of &#xa3;51 million, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technologies. On a per-product basis, these milestone payments range from &#xa3;1 million to &#xa3;18.5 million, depending on which T cell programming modules are used in the product achieving the milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of any of the Company&#x2019;s products that use the&#160;in-licensed&#160;patent rights, the Company will be obligated to pay UCLB a flat royalty for each licensed product ranging from the&#160;low-&#160;to&#160;mid-single&#160;digits, depending on which technologies are deployed in the licensed product, based on worldwide annual net sales of each licensed product, subject to certain reductions, including for the market entry of competing products and for loss of patent coverage of licensed products. The Company may deduct from the royalties payable to UCLB one-half of any payments made to a third party to obtain a license to such third party&#x2019;s intellectual property that is necessary to exploit any licensed products. Once net sales of a licensed product have reached a certain specified threshold, the Company may exercise an option to buy out UCLB&#x2019;s rights to the remaining milestone payments, royalty payments, and sublicensing revenue payments for such licensed product, on terms to be negotiated at the time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License expires on a product-by-product and country-by-country basis upon the expiration of the royalty term with respect to each product in each country. The Company may unilaterally terminate the license agreement for any reason upon advance notice to UCLB. Either party may terminate the License for the uncured material breach by the other party or for the insolvency of the other party. If UCLB terminates the License following the Company&#x2019;s insolvency or the Company&#x2019;s material breach of the License, or if the Company terminates the License unilaterally, all rights and licenses granted to the Company will terminate, and all patent rights and&#160;know-how&#160;transferred to the Company pursuant to the License will revert back to UCLB, unless and to the extent the Company has exercised its option to acquire ownership of the licensed patent rights. In addition, UCLB has the right to negotiate with the Company for the grant of an exclusive license to the Company&#x2019;s improvements to the T cell programming modules the Company has licensed on terms to be agreed upon at the time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noile-Immune Biotech Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. ("Noile") under which the Company will have the right to develop CAR T cell therapies incorporating Noile&#x2019;s PRIME (proliferation-inducing and migration-enhancing) technology. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient&#x2019;s own T cells.&lt;/span&gt;&lt;/div&gt;The Company paid an upfront fee and may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology.</autl:LicenseAgreementsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i65bb2de6245d44fd989ae0fadd180dcf_D20140901-20140930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjYzNA_fb63075c-76f4-4673-a3a3-622ec9cdb55e"
      unitRef="shares">1497643</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <autl:PaymentOfUpfrontFees
      contextRef="i2dae7352e4564813bd4e58c8bfac3d0c_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjY5Ng_985d751a-f851-409f-aa89-508846859b4b"
      unitRef="usd">300000</autl:PaymentOfUpfrontFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNjcyNQ_24a39264-09ab-4ed6-8663-f14c6bcb66b2"
      unitRef="shares">313971</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <autl:PaymentOfUpfrontFees
      contextRef="i194d9cd7426f43bdb92c35c4b53da10d_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzA1NQ_c9dd087e-351b-40d7-94a1-39800b54a210"
      unitRef="gbp">1500000</autl:PaymentOfUpfrontFees>
    <autl:AccruedLicenseFeesCurrent
      contextRef="i8cc189fb946a4e56907d007ff790d9d3_I20180331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzEzOA_708297de-7e9e-4bc2-bbfb-0824538b51fb"
      unitRef="gbp">350000</autl:AccruedLicenseFeesCurrent>
    <autl:ConditionalPaymentBasis
      contextRef="i740603bdf79a4a19ab28501a2828b0da_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzQ3NQ_45c047d9-8144-420a-8683-d9286e8a1d35"
      unitRef="gbp">180000</autl:ConditionalPaymentBasis>
    <autl:ConditionalPaymentBasis
      contextRef="ia6f3546488134bd188df42bb75467850_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzU1Mg_2a9b2505-5b83-4e59-8a9e-aa29a06365a0"
      unitRef="gbp">37500000</autl:ConditionalPaymentBasis>
    <autl:ConditionalPaymentBasis
      contextRef="i6d5ef338879d45cfa5e65e5c7f749b73_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzYxNA_9a7f8417-bece-4d79-9925-291c44b664e0"
      unitRef="gbp">18000000</autl:ConditionalPaymentBasis>
    <autl:ConditionalPaymentBasis
      contextRef="i836d7bd86d1742f8b994ba61b0ebc03a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzY4NQ_43e05189-d229-4d41-9f1f-ea75c2a65516"
      unitRef="gbp">51000000</autl:ConditionalPaymentBasis>
    <autl:ConditionalPaymentBasis
      contextRef="i6ba521a09dfc43cc965da6b20f859156_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzg3MA_0b5b87b8-3449-4716-8def-51c150f528e7"
      unitRef="gbp">1000000</autl:ConditionalPaymentBasis>
    <autl:ConditionalPaymentBasis
      contextRef="i340f4450111245dd99b493da501889f5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80Ni9mcmFnOmViNjBhMTM0M2UyNTQzZDM4NWVhMTBlYzg3YjQ0OTdhL3RleHRyZWdpb246ZWI2MGExMzQzZTI1NDNkMzg1ZWExMGVjODdiNDQ5N2FfMTA5OTUxMTYzNzg3Nw_d9527168-95d0-41cb-a5ab-a94285d24378"
      unitRef="gbp">18500000</autl:ConditionalPaymentBasis>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTQ5NA_3d7f14c0-9a15-4b52-83ae-426d43d1a040">Income Taxes&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is based upon the estimated annual effective tax rates for the year applied to the current period loss before tax plus the tax effect of any significant unusual items, discrete events or changes in tax law. Fluctuations in the distribution of pre-tax income among the Company&#x2019;s operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the three months ended March 31, 2021 and 2020, the actual effective tax rates were 14.4% and 11.0%, respectively. The increase in the effective tax rate for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020 was due an increase in the forecast proportion of qualifying research and development expenditure for the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actual effective tax rates are lower than the 19% statutory rate of U.K. tax primarily due to the manner in which the UK research and development credit operates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit for the three months ended March 31, 2021 increased to $5.7 million from $3.7 million for three months ended March 31, 2020 due to an increase in pre-tax losses and the increased effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries a&#160;$2.0 million&#160;deferred tax asset balance related to its U.S. subsidiary.  The Company has recorded a valuation allowance against the net deferred tax asset where the recoverability due to future taxable profits is unknown.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTA5OTUxMTYyOTUyOA_321e3847-5bb1-42b3-b5be-4b6b2d47d91e"
      unitRef="number">0.144</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfNTI0_62625404-883a-4bac-a320-1046dffefdd4"
      unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfODUw_b13c53f3-877a-4ee9-a461-c1e2364c0ce5"
      unitRef="number">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTAwNw_c1dd690f-032a-4a4f-a153-6d82515e1d57"
      unitRef="usd">-5700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTAxNQ_1fb8a4fd-5a69-45d6-ad3c-bc6ec2d631bb"
      unitRef="usd">-3700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iba75fdc622554754b612b6ca2d81e8dc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF80OS9mcmFnOjUyNGRhMGNjZDhlOTQzNGQ5NDRlYTk3MWRjZDY1YmMxL3RleHRyZWdpb246NTI0ZGEwY2NkOGU5NDM0ZDk0NGVhOTcxZGNkNjViYzFfMTI3NA_418ffbf6-6f20-45e1-8f03-835ee087d2dd"
      unitRef="usd">2000000.0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUwMg_cdf2ebf5-af30-499e-992d-2cd76f93369b">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an exclusive license agreement with UCLB which has subsequently been amended and restated (see Note 8). In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments upon the achievement of specified milestones. The Company has estimated the probability of the Company achieving each potential milestone in accordance with ASC 450,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company concluded that, as of March 31, 2021, there were no milestones for which the likelihood of achievement was probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of March 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s corporate headquarters are located in London, United Kingdom. The Company leases space at this location from Imperial (Forest House) Limited under a ten-year lease, the term of which commenced in September 2015. The lease included an option for the Company to lease additional space within a 15-month period, which the Company exercised in October 2016. The exercise of the option resulted in a separate new lease agreement with a concurrent term through September 2025. The landlord exercised its option to give notice in September 2020 to terminate the Forest House lease and pay the Company a break-lease payment fee in September 2021. The Company recorded a $1.3&#160;million gain upon the notice of lease termination in the third quarter of 2020 and has a lease incentive receivable of $1.5&#160;million as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company signed a binding letter of intent to enter into a lease for manufacturing space in Enfield, United Kingdom. The letter of intent required the Company to enter into a 15-year lease provided that the landlord completed the required leasehold improvements described in the agreement. The Company executed lease agreements for three manufacturing space units, each for 15-year lease terms. The leases commenced in February 2019 with option to terminate the lease in February 2029.  In March 2021, the Company surrendered one of the units. Upon the surrender, the Company recognized a $0.1&#160;million gain in other income after a after recognizing a termination fee of $0.2&#160;million. The Company has no further obligations for the surrendered unit and the right of use asset and lease liability which were recorded for this unit have been written off in the period. The Company is actively seeking to sub-lease or assign the remaining lease arrangements to a third party. The Company completed an asset impairment analysis of the right of use asset concluding the undiscounted cash flows exceeded the carrying value as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company executed an agreement to sublease office space in Rockville, Maryland for a term through October 2021.  The Company then terminated the sublease in February 2020 and immediately entered into a five-year lease for the same space with the landlord. As a result of the sublease termination, the Company recognized a $0.2 million gain in other income (expense) in the three months ending March 31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he lease related to this facility is classified as an operating lease. The Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. These costs are considered to be variable lease payments and are not included in the determination of the lease&#x2019;s right-of-use asset or lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2019, the Company executed a lease agreement to lease additional office and manufacturing space in Rockville, Maryland. The lease agreement required the Company to enter into a lease provided that the landlord completes the required leasehold improvements described in the agreement. The lease commenced in August 2020 for a term through June 2036. In March 2021, the Company announced plans to move the site of its global launch of manufacturing capacity to the United Kingdom from the United States. As a part of this strategy, the Company entered into a termination agreement with the landlord of its Rockville, Maryland property to terminate the lease for office and manufacturing space. As a result, the Company recognized a $2.0&#160;million termination fee gain from the landlord, a $2.3&#160;million gain from the removal of the leased right of use asset and corresponding lease liability, and expensed $2.4&#160;million of leasehold improvements for the three months ended March 31, 2021. The $2.0 million termination fee receivable from the landlord in included in Prepaid and other current assets in the Balance Sheet at March 31, 2021. The payment form the landlord  was received in April 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib312439b752b4257b958d24ddae1acc2_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUxMA_c548ad81-852e-48a6-b9ae-795939a545af">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie8fc906e9cef419a9335fea6d40a569f_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMTkxMg_4be6190c-4763-48e6-821e-b2460b54cfef">P15M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i6d9b766ba80440d696ca8311b8127c2b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjI4Mg_d03a93b3-31c5-4445-a8e4-f41a91741ceb"
      unitRef="usd">1300000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:LeaseIncentiveReceivable
      contextRef="i66aae6507b744c1d8f4b560d2b970ce2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjM2MQ_c9466824-5f01-4e80-b771-5a4d7d37ac45"
      unitRef="usd">1500000</us-gaap:LeaseIncentiveReceivable>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDM4NA_e5c41bbb-4d65-4ddd-bd29-fa5cd2b4f937">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:NumberOfUnitsInRealEstateProperty
      contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDU0MQ_7d9e2194-3568-420b-9036-3a1be9769322"
      unitRef="unit">3</us-gaap:NumberOfUnitsInRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6deadfa8fe6145ebb7dd9cc96589cf50_I20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNDU4MA_e5c41bbb-4d65-4ddd-bd29-fa5cd2b4f937">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2ODM4MQ_170a004d-53f7-42f3-9d47-9501f94e95e4"
      unitRef="usd">100000</us-gaap:GainLossOnTerminationOfLease>
    <autl:LeaseTerminationFeeExpense
      contextRef="i63d715b252ad4ce9a1032f7bc25fb5ac_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2OTA2Ng_a7eb66d8-41e9-4a36-af11-2886d14acb6b"
      unitRef="usd">200000</autl:LeaseTerminationFeeExpense>
    <autl:OperatingLeaseRentFreePeriod
      contextRef="i9aa970f510b84d03bcdab0bf779d4aaa_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNzUxMQ_2a2cf439-7707-4d89-af63-6c816f8bc260">P5Y</autl:OperatingLeaseRentFreePeriod>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i1a1eb5a9f0484994b0f3d8ee7aa1718f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfNTkyNg_8b689a1b-d4b7-4c4b-bc26-60d4fa251525"
      unitRef="usd">200000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i1cd6038d37304152829044a7577d308f_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTk1NA_d391d0a6-da6c-4301-b1a0-a752bfa93beb"
      unitRef="usd">2000000.0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="i1cd6038d37304152829044a7577d308f_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTkyNg_16afddf1-7b49-4866-8aab-d8e61c4c9a10"
      unitRef="usd">2300000</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="i7eb8d879d3684656b339162dcd9fbfcb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2NTk0MA_f95aa388-1743-4997-8024-d90318d5b242"
      unitRef="usd">2400000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="idda9c1c6f5574294ad1bf162a75b78b0_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81Mi9mcmFnOjJkZTg4NTJjZGMwNDRlYjk4NmJlOTU4ODRjMzk4ZDY0L3RleHRyZWdpb246MmRlODg1MmNkYzA0NGViOTg2YmU5NTg4NGMzOThkNjRfMjE5OTAyMzI2ODM5Nw_f7f8a268-6c3c-4efa-a78e-5328c02c0089"
      unitRef="usd">2000000.0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfOTc0_f239404e-8394-485a-a40f-4fa9ce56009e">Employee Benefit Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United Kingdom, the Company makes contributions to private defined benefit pension schemes on behalf of its employees. The Company expensed $0.4 million and $0.3 million in contributions for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, the Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code in October 2018. The plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches employee contributions up to four percent of the employee&#x2019;s annual salary. The &lt;/span&gt;&lt;/div&gt;Company expensed $0.1 million and $0.1 million for the three months ended March 31, 2021 and 2020, respectively. The Company pays all administrative fees related to the 401(k) plan.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfMTg1_2faf1350-6410-4ee8-a5ef-4ba929d66103"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfMTky_86c44fb5-af1d-4d2a-bcb7-0843e4f099e0"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzI0_63826f09-fd9f-4cb1-b293-67562dce63d5"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzg5_62105e13-2cd3-4298-a3a7-67e0b8720940"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i82dfc5242fe743bf9382fe7084c8fd48_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81NS9mcmFnOjFmMTRlNGQ5NjNmMjQzNzJhM2NmMjM4MjRkMTRjYTNmL3RleHRyZWdpb246MWYxNGU0ZDk2M2YyNDM3MmEzY2YyMzgyNGQxNGNhM2ZfNzk2_dc977670-bab7-4032-928d-ab75a3e28227"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF81OC9mcmFnOmE0YWQ4NjdhYmRmMDQzMDk5ZTY4NTQ1ZDljNzI5N2M5L3RleHRyZWdpb246YTRhZDg2N2FiZGYwNDMwOTllNjg1NDVkOWM3Mjk3YzlfNTU0_0c1db052-79ef-4691-b086-8f6ac9f3364c">Subsequent EventsThe Company evaluated subsequent events through May 6, 2021, the date on which these financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761657679080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Autolus Therapeutics plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001730463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641755992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 239,012<span></span>
</td>
<td class="nump">$ 153,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets, current</a></td>
<td class="nump">48,262<span></span>
</td>
<td class="nump">42,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">288,060<span></span>
</td>
<td class="nump">196,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,543<span></span>
</td>
<td class="nump">38,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">21,199<span></span>
</td>
<td class="nump">51,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long-term deposits</a></td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Prepaid expenses and other assets, non-current</a></td>
<td class="nump">2,939<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">349,746<span></span>
</td>
<td class="nump">294,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">24,683<span></span>
</td>
<td class="nump">27,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">3,657<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,599<span></span>
</td>
<td class="nump">33,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">19,580<span></span>
</td>
<td class="nump">50,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,179<span></span>
</td>
<td class="nump">84,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">716,544<span></span>
</td>
<td class="nump">595,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,588)<span></span>
</td>
<td class="num">(5,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(412,510)<span></span>
</td>
<td class="num">(379,244)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">299,567<span></span>
</td>
<td class="nump">210,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">349,746<span></span>
</td>
<td class="nump">294,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share value</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember', window );">Deferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember', window );">Deferred B Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share value</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember', window );">Deferred C Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641754728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | $ / shares</a></td>
<td class="nump">$ 0.000042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember', window );">Deferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember', window );">Deferred B Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember', window );">Deferred C Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761645777080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(30,731)<span></span>
</td>
<td class="num">(31,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(8,738)<span></span>
</td>
<td class="num">(7,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_GainLossOnDispositionOfLeaseholdImprovements', window );">Loss on disposal of leasehold improvements</a></td>
<td class="num">(672)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating expenses, net</a></td>
<td class="num">(39,872)<span></span>
</td>
<td class="num">(38,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(38,990)<span></span>
</td>
<td class="num">(33,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">5,724<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">(33,266)<span></span>
</td>
<td class="num">(29,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency exchange translation adjustment</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (31,993)<span></span>
</td>
<td class="num">$ (47,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per ordinary share (usd per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average basic and diluted ordinary shares</a></td>
<td class="nump">62,447,606<span></span>
</td>
<td class="nump">49,859,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_GainLossOnDispositionOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_GainLossOnDispositionOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761644010552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common shares</div></th>
<th class="th">
<div>Common shares </div>
<div>Ordinary Shares</div>
</th>
<th class="th">
<div>Common shares </div>
<div>Deferred Shares</div>
</th>
<th class="th">
<div>Common shares </div>
<div>Deferred B Shares</div>
</th>
<th class="th">
<div>Common shares </div>
<div>Deferred C Shares</div>
</th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 254,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,560<span></span>
</td>
<td class="num">$ (8,691)<span></span>
</td>
<td class="num">$ (237,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,983,006<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">73,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">6,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted shares - forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on foreign currency translation</a></td>
<td class="num">(17,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,873)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">287,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">580,772<span></span>
</td>
<td class="num">(26,392)<span></span>
</td>
<td class="num">(267,023)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,247,932<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">210,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">595,016<span></span>
</td>
<td class="num">(5,861)<span></span>
</td>
<td class="num">(379,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">122,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,147,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition', window );">Reversal of share-based compensation expense</a></td>
<td class="num">$ (670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on foreign currency translation</a></td>
<td class="nump">$ 1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 299,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 716,544<span></span>
</td>
<td class="num">$ (4,588)<span></span>
</td>
<td class="num">$ (412,510)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_APICShareBasedPaymentArrangementReversalOfCostRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>APIC, Share-Based Payment Arrangement, Reversal Of Cost Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_APICShareBasedPaymentArrangementReversalOfCostRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642420664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,266,000)<span></span>
</td>
<td class="num">$ (29,873,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,662,000<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Share-based compensation (net of amount capitalized)</a></td>
<td class="num">(670,000)<span></span>
</td>
<td class="nump">6,189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Loss (gain) on termination of operating lease</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="num">(160,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">672,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax</a></td>
<td class="num">(280,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent', window );">Prepaid expenses and other assets, current</a></td>
<td class="num">(5,050,000)<span></span>
</td>
<td class="num">(1,186,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets, non-current</a></td>
<td class="nump">163,000<span></span>
</td>
<td class="num">(233,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Long-term deposits</a></td>
<td class="nump">811,000<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets', window );">Right of use assets, net</a></td>
<td class="nump">1,085,000<span></span>
</td>
<td class="nump">769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(902,000)<span></span>
</td>
<td class="num">(124,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,649,000)<span></span>
</td>
<td class="num">(361,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="num">(297,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,343,000)<span></span>
</td>
<td class="num">(24,033,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="num">(2,637,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="num">(2,637,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">123,324,000<span></span>
</td>
<td class="nump">74,310,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">123,324,000<span></span>
</td>
<td class="nump">74,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and restricted cash</a></td>
<td class="nump">1,632,000<span></span>
</td>
<td class="num">(14,972,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and restricted cash</a></td>
<td class="nump">85,713,000<span></span>
</td>
<td class="nump">32,668,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of period</a></td>
<td class="nump">154,085,000<span></span>
</td>
<td class="nump">211,430,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of period</a></td>
<td class="nump">239,798,000<span></span>
</td>
<td class="nump">244,098,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Supplemental non-cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">569,000<span></span>
</td>
<td class="nump">4,624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet', window );">Right of use assets terminated and obtained in exchange for operating lease liabilities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,487,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent', window );">Capitalized implementation costs included in accrued expenses</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">607,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses', window );">Issuance costs included in accounts payable and accrued expenses</a></td>
<td class="nump">1,124,000<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_CapitalizedSharebasedCompensation', window );">Capitalized share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_LeaseAssetsTerminated', window );">Lease assets terminated</a></td>
<td class="nump">28,517,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash</a></td>
<td class="nump">$ 239,798,000<span></span>
</td>
<td class="nump">$ 244,098,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_CapitalizedSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_CapitalizedSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Other Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Cost Included In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_LeaseAssetsTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Assets Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_LeaseAssetsTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_NetIncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase Decrease In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_NetIncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639870776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text">Nature of the Business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc (the &#8220;Company&#8221;) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a public limited company incorporated in England and Wales. On June 22, 2018, the Company completed its initial public offering ("IPO") of American Depositary Shares (&#8220;ADSs&#8221;). In the IPO, the Company sold an aggregate of 10,147,059 ADSs representing the same number of ordinary shares, including 1,323,529 ADSs pursuant to the underwriters&#8217; option to purchase additional ADSs, at a public offering price of $17.00 per ADS. Net proceeds were $156.5 million, after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2019, the Company completed an underwritten public offering of 4,830,000 ADSs representing 4,830,000 ordinary shares, at a public offering price of&#160;$24.00&#160;per ADS, which includes an additional 630,000 ADSs issued upon the exercise in full of the underwriters&#8217; option to purchase additional ADSs.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$108.8 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2020, the Company completed an underwritten public offering of&#160;7,250,000&#160;ADSs representing&#160;7,250,000&#160;ordinary shares, at a public offering price of&#160;$11.00&#160;per ADS.&#160; Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were&#160;$75.0&#160;million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company sold an aggregate of 1,718,506 ADSs under its Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC as sales agent. Aggregate net proceeds to the Company, after commission fees and offering expenses, were $15.3&#160;million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company completed an underwritten public offering of 14,285,715 ADSs, which includes the full exercise by the underwriters to purchase an additional 2,142,857 ADSs, at a public offering price of $7.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were $106.9&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception, including net losses of $33.3 million and $29.9 million for the three months ended March 31, 2021 and 2020, respectively.  In addition, the Company had an accumulated deficit of $412.5 million and $379.2 million as of March 31, 2021 and December 31, 2020, respectively. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or that additional funding will be available on terms acceptable to the Company, or at all. The Company believes the cash on hand at March 31, 2021 of $239.0 million will be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance of these financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Impact of COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the ongoing coronavirus 2019, or COVID-19, pandemic, the Company established a cross-functional task force and have implemented business continuity plans designed to address and mitigate its impact on the Company's employees and business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Company has not experienced any significant financial impact to date, the overall disruption caused by the COVID-19 pandemic on global healthcare systems, and the other risks and uncertainties associated with the pandemic, could cause its business, financial condition, results of operations and growth prospects to be materially adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, our global workforce transitioned to working remotely with the exception of research and clinical trial related activities that required laboratory-based activity or manufacturing. We implemented protocols and procedures to ensure the safety of our employees working on site, including requirement to wear personal protective equipment, temperature checks at entry and offered COVID-19 testing for any employee with symptoms or at suspected risk of exposure to virus. In June 2020, we began the implementation of our workplace re-entry plan, based on a phased approach that is principles-based and local in design, with a focus on continuity of patient treatment and working to bring its workforce back on-site safely. We have also implemented policies to control and limit office and lab access in line with social distancing guidelines and for contact tracing if needed. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to track COVID-19 developments in Europe and the United States closely for their potential impact on our clinical trial sites, logistics and supply chain to ensure we can continue to maintain clinical trial conduct and data integrity. As the patients in our clinical trials are severely immune suppressed as a consequence of their underlying disease and the treatment they receive in the trials, we are also monitoring other transmissible infectious diseases, including influenza.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not aware of any specific event or circumstance that has impacted on its operations in a manner which would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities during the three months ended March 31, 2021. However, these estimates may change, as new events occur and additional information is obtained, relating to the COVID-19 pandemic or otherwise. Changes in estimates would be recognized in the consolidated financial statements as soon as they become known.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639957224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include those of the Company, its wholly-owned subsidiary, Autolus Limited, and its U.S. subsidiary, Autolus Inc., and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). All intercompany accounts and transactions have been eliminated upon consolidation.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they become known. Actual results could differ materially from those estimates.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash and cash equivalents in the condensed consolidated financial statements to include cash at banks with a maturity of less than three months, which is subject to an insignificant risk of changes in value.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a lease that requires a letter of credit supported by $0.6 million&#160;deposit held by the Company's bank for the duration of the lease and a credit card arrangement that requires a security deposit of $0.2 million. The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the Company's condensed consolidated statements of cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and restricted cash. The Company places cash and restricted cash in established financial institutions. The Company has no significant&#160;off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of March 31, 2021 and December&#160;31, 2020, the Company&#8217;s property and equipment consisted of office equipment, lab equipment, furniture and fixtures, and leasehold improvements. The office equipment has an estimated useful life of three years, lab equipment has an estimated useful life of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09">five</span>&#160;or&#160;ten years, and furniture and fixtures have an estimated useful life of&#160;five years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Assets under construction primarily consist of costs incurred with leasehold improvements, and, once placed into service, will be depreciated over the shorter of the lease term or the estimated useful life of the asset.  Upon retirement or sale, the cost of assets are disposed of, and the related accumulated depreciation, is removed from the accounts and any resulting gain or loss is included in the statement of operations and other comprehensive loss. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a disposal loss of $0.7 million in the three months ended March 31, 2021 in leasehold improvements which are no longer being utilized in the facility in White City,  and did not recognize a disposal loss in the three months ended March 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates an asset for potential impairment when events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Recoverability is measured by comparing the book value of the asset to the expected future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the asset exceeds the fair value. The Company did not recognize an impairment in the three months ended March 31, 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received, initial direct costs, or prepayments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company accounts for the lease and non-lease components of leases for classes of all underlying assets and allocates all of the contract consideration to the lease component.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets Subject to Amortization</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets are related to acquired software licenses with finite lives and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators of impairment are present, the Company tests for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company evaluates the useful lives for these intangible assets each reporting period to determine whether events and circumstances warrant a revision in their remaining useful lives.&#160;The Company did not recognize an impairment loss in the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and its chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is the business of developing and commercializing gene therapies; however, the Company operates in two geographic regions: the United Kingdom and the United States. Substantially all of the Company&#8217;s assets are held in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, depreciation expense, third-party license fees, external costs of outside vendors engaged to conduct clinical development activities, clinical trials, costs to manufacture clinical trial materials and certain tax credits associated with research and development activities. The Company recorded the U.K. research and development expenditure credit (&#8220;RDEC&#8221;) in the amount of $30,000 and $28,000 for the three months ended March 31, 2021 and 2020, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, as reductions of research and development expenses within the Company&#8217;s statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing its condensed consolidated financial statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company&#8217;s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes judgments and estimates in determining the accrued balance in any accounting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for equity awards based on the grant date fair value of the award. The Company recognizes share-based compensation expense for awards granted to employees that have a graded vesting schedule based on a service condition only on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards (the &#8220;graded-vesting attribution method&#8221;), based on the estimated grant date fair value for each separately vesting tranche. For equity awards with a graded vesting schedule and a combination of service and performance conditions, the Company recognizes share-based compensation expense using a graded-vesting attribution method over the requisite service period when the achievement of a performance-based milestone is probable, based on the relative satisfaction of the performance condition as of the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For share-based awards granted to consultants and&#160;non-employees,&#160;compensation expense is recognized using the graded-vesting attribution method over the period during which services are rendered by such consultants and&#160;non-employees&#160;until completed. The measurement date for employee awards is the date of grant, and share-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 7 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lacks company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, it uses a combination of the historical volatility of the ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as the Company has adequate historical data regarding the volatility of its own traded security price.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of the Company&#8217;s ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select Market on the date the grant is approved by the Board.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement and Translation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is the pound sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates.&#160;Non-monetary&#160;assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. The Company recorded a  foreign exchange loss of $1.2 million and foreign exchange gain of  $4.3 million for the three months ended March 31, 2021 and 2020, respectively. Foreign exchange gains are included in other income in the statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, the condensed consolidated financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#8217; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining the Company's net loss but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent prosecution and related legal costs as they are incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company recorded patent expenses of $0.5 million and $0.6 million for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received research grants under which it is reimbursed for specific research and development activities. Payments received are recognized as income in the statements of operations and comprehensive loss over the period in which the Company recognizes the related costs. At the time the Company recognizes grant income, it has complied with the conditions attached to it and the receipt of the reimbursement is reasonably assured. The Company has received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance. For grants with refund provisions, the Company reviews the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. The Company has determined that the likelihood of any repayment events included in its current grants is remote.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:232%">License Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASC Topic 606&#8221;).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company  fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contingent Research Milestone Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company&#8217;s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. The Company considers all relevant factors.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For three months ended March 31, 2021, the Company has not recognized any variable consideration with regards to the development milestones which are included in the license agreement that was executed in the period. This is due to the fact that those development milestones have not yet been met and the recognition of the related revenue is not yet probable.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision (benefit) for income taxes represents income taxes paid or payable (or a reduction of such amounts) for the current year plus deferred taxes. Deferred taxes result from differences between the condensed consolidated financial statements and tax bases of the Company&#8217;s assets and liabilities, and are adjusted for changes in tax rates and tax law when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of United Kingdom and United States tax law and requires judgment and estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the realizability of its deferred tax assets at each reporting date, and establishes a valuation allowance when it is more likely than not that all or a portion of its deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. The Company considers all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that the Company&#8217;s deferred tax assets are not more likely than not realizable, the Company establishes a valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a&#160;two-step&#160;approach for recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that the Company believes is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in the Company&#8217;s income tax returns and the amount of tax benefits recognized in the its condensed consolidated financial statements represent the Company&#8217;s unrecognized income tax benefits, which it either records as a liability or reduction of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Credit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company benefits from the U.K. research and development tax credit regime under both the small and medium sized enterprise, or SME, scheme and by claiming an RDEC in respect of grant funded projects. Under the SME regime, a portion of the Company&#8217;s losses can be surrendered for a cash rebate of up to 33.35% of eligible expenditures. SME credits are accounted for within the tax provision in the year in which the expenditures were incurred. RDEC credits are accounted for within other income in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 220,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive loss is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company recorded a gain of $1.3 million and a loss of $17.7 million related to foreign currency translation adjustments during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per ordinary share is determined by dividing net loss by the weighted average number of ordinary shares outstanding during the period. For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:61.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted incentive shares and units</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360,159</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,914,949</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,241,779</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,636,977</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act and Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exemptions provided by the JOBS Act will apply until December 31, 2023 or such earlier time that the Company no longer meets the requirements of being an emerging growth company. The Company would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, has more than $700 million in market value of its securities held by non-affiliates as of the last day of its second fiscal quarter, or it issues more than $1 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also currently relies on other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging growth company, the Company is not required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on the Company&#8217;s system of internal controls over financial reporting pursuant to Section&#160;404(b), (ii)&#160;provide all of the compensation disclosure that may be required of&#160;non-emerging&#160;growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv)&#160;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. These exemptions will also apply until the Company is no longer an emerging growth company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company's financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639866840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets, Current<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Assets, Current</a></td>
<td class="text">Prepaid Expenses and Other Assets, Current<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets, current consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.871%"><tr><td style="width:1.0%"/><td style="width:64.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development claims receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivables from terminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in prepayments of $2.7 million as at March 31, 2021 when compared to December 31, 2020 is primarily related to decreases in prepayments for clinical trials and lower payments of directors' and officers liability insurance due to the timing of payments in the period when compared to the same period in the prior year. </span></div>The increase in research and development claims receivable is due to an increase in the effective tax rate when compared to the same period last year. More information on the movement in the tax position between periods can be found in Note 9.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639935752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.512%"><tr><td style="width:1.0%"/><td style="width:64.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.510%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for the three months ended March 31, 2021 and 2020 was $1.8 million and $1.3 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642292344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">Accrued Expenses and Other Liabilities<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"/><td style="width:66.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCLB milestone and option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate income and local taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639957224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ordinary Shares</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of March 31, 2021, the Company has not declared any dividends.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective from June 26, 2018, the board of directors has the authority to allot new ordinary shares or to grant rights to subscribe for or to convert any security into ordinary shares in the Company up to a maximum aggregate nominal amount of&#160;$8,400. This authority runs for five years and will expire on June 26, 2023. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective from June 26, 2018, the board also has the authority to allot ordinary shares for cash or to grant rights to subscribe for or to convert any security into ordinary shares in the Company without first offering them to existing shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of&#160;$8,400. This authority runs for five years and will expire on June 26, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 the Company&#8217;s issued capital share consisted of&#160;70,515,354&#160;ordinary shares, with a nominal value of&#160; $0.000042</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share, (ii)&#160;34,425&#160;deferred shares, with a nominal value of&#160;&#163;0.00001&#160;per share, (iii)&#160;88,893,548&#160;B deferred shares, with a nominal value of&#160;&#163;0.00099&#160;per share and (iv)&#160;1&#160;C deferred share, with a nominal value of&#160;&#163;0.000008. Each issued share has been fully paid.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Open Market Sale Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 18, 2020, the Company entered into an Open Market Sale Agreement ("Sales Agreement") with Jefferies LLC, under which the Company may, at its option, offer and sell ADSs having an aggregate offering price of up to $100&#160;million from time to time through Jefferies, acting as sales agent. Any such sales made through our sales agent can be made by any method that is deemed an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act, or in other transactions pursuant to an effective shelf registration statement on Form F-3.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company agreed to pay Jefferies a commission of 3.0% of the gross proceeds of any sales of ADSs sold pursuant to the Sales Agreement. During </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three months ended March 31, 2021,</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the Company issued an aggregate of 1.7&#160;million ADSs under the Sales Agreement for net proceeds, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after underwriting discounts and offering expenses of $15.3&#160;million</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641386776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Company's 2018 Equity Incentive Plan (the "2018 Plan") and 2017 Stock Option Plan (the "2017 Plan"), as well as restricted shares granted as employee incentives, typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining three years, unless the award contains specific performance vesting provisions. For equity awards issued that have both a performance vesting condition and a services condition, once the performance criteria is achieved, the awards are then subject to a four-year service vesting with 25% of the award vesting on the first anniversary of the performance condition being achieved and the balance vesting monthly over the remaining three years. Options granted in January 2021 contained performance conditions related to specified clinical milestones. Options granted under the 2018 Plan and 2017 Plan generally expire 10 years from the date of grant. For certain senior members of management and directors, the board of directors has approved an alternative vesting schedule. Restricted stock units awarded in December 2019 vest over a&#160;3-year service period with&#160;50%&#160;of the award vesting one and a half years, or 18 months, from commencement date and the remaining&#160;50%&#160;of the award vesting at the end of the third year.  Restricted stock units awarded in January 2021 contained a performance condition related to specified clinical milestone.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Option Valuation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted by the Company during the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.032%"><tr><td style="width:1.0%"/><td style="width:66.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6.08 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62% to 0.99%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.33% to 81.34%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Options</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ADSs for those share options that had exercise prices lower than the fair value of the Company&#8217;s ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of share options granted was $5.96 per share for the three months ended March 31, 2021, of which none were vested at the date of this report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the total unrecognized compensation expense related to unvested options was $9.4 million, which the Company expects to recognize over a weighted average vesting period of 2.5 years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company granted 1,602,500 options with performance conditions related to specified clinical milestones.  As of March 31, 2021, the performance conditions were not determined to be probable and no expense was recorded for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Ordinary Shares</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s restricted ordinary shares during the three months ended March 31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"/><td style="width:64.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was no unrecognized compensation expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one of the Company&#8217;s ADSs upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#8217;s ADSs on the date of grant. The Company historically granted RSUs with service conditions that vest over&#160;3-year service period with&#160;50%&#160;of the award vesting one-and-half years from grant date and the remaining&#160;50%&#160;of the award vesting at the end of the third year. In January 2021, the Company awarded restricted stock units that contained a performance condition based on a condition related to a specified clinical milestone. In March 2021, the Company awarded restricted stock units with service conditions that vest over a four year period with 25%  on the first anniversary of the grant date, and the balance vesting quarterly over the remaining three years.&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2018 Plan for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:66.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was&#160;$2.0 million&#160;of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average vesting period of&#160;2.5 years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company awarded 920,000 RSUs with a performance condition related to a specified clinical milestone.  As of March 31, 2021, the performance condition was not determined to be probable and accordingly, no expense was recorded for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development expenses, general and administrative expenses, and capitalized to property and equipment is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.474%"><tr><td style="width:1.0%"/><td style="width:64.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.146%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized to property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation expense</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div>The decrease in share-based compensation expense of $6.9 million in the three months ended March 31, 2021 relates to forfeitures of share-based payment awards as a result of the reduction in workforce that began to take place during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761657815848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text">License AgreementsUCL Business plc License<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, the Company entered into an exclusive license agreement (the &#8220;License&#8221;) with UCL Business Ltd. (&#8220;UCLB&#8221;), the technology transfer company of University College London (&#8220;UCL&#8221;), to obtain licenses to certain technology rights in the field of cancer therapy and diagnosis. In March 2016, the License was amended to include additional rights.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the License in September 2014, the Company issued 1,497,643&#160;ordinary shares to UCLB. The Company paid upfront fees of $0.3 million and issued an additional 313,971 ordinary shares to UCLB when the License was amended in March 2016.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the License was further amended and restated to include a license to the Company's product candidate, AUTO1, for which UCL is conducting Phase&#160;1 clinical trials of AUTO1 in pediatric and adult ALL patients. The Company paid an upfront fee of &#163;1.5 million for consideration for the amended and restated License and paid the additional &#163;0.35&#160;million in connection with UCLB's transfer of clinical data to the Company in December 2020. No equity was issued as part of the upfront fee consideration.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may be obligated to make payments to UCLB under the amended and restated License upon the initiation of certain clinical activities in an aggregate amount of &#163;0.18&#160;million, the receipt of specified regulatory approvals in an aggregate amount of &#163;37.5&#160;million, the start of commercialization in an aggregate amount of &#163;18 million, and the achievement of net sales levels in an aggregate amount of &#163;51 million, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technologies. On a per-product basis, these milestone payments range from &#163;1 million to &#163;18.5 million, depending on which T cell programming modules are used in the product achieving the milestone.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of any of the Company&#8217;s products that use the&#160;in-licensed&#160;patent rights, the Company will be obligated to pay UCLB a flat royalty for each licensed product ranging from the&#160;low-&#160;to&#160;mid-single&#160;digits, depending on which technologies are deployed in the licensed product, based on worldwide annual net sales of each licensed product, subject to certain reductions, including for the market entry of competing products and for loss of patent coverage of licensed products. The Company may deduct from the royalties payable to UCLB one-half of any payments made to a third party to obtain a license to such third party&#8217;s intellectual property that is necessary to exploit any licensed products. Once net sales of a licensed product have reached a certain specified threshold, the Company may exercise an option to buy out UCLB&#8217;s rights to the remaining milestone payments, royalty payments, and sublicensing revenue payments for such licensed product, on terms to be negotiated at the time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License expires on a product-by-product and country-by-country basis upon the expiration of the royalty term with respect to each product in each country. The Company may unilaterally terminate the license agreement for any reason upon advance notice to UCLB. Either party may terminate the License for the uncured material breach by the other party or for the insolvency of the other party. If UCLB terminates the License following the Company&#8217;s insolvency or the Company&#8217;s material breach of the License, or if the Company terminates the License unilaterally, all rights and licenses granted to the Company will terminate, and all patent rights and&#160;know-how&#160;transferred to the Company pursuant to the License will revert back to UCLB, unless and to the extent the Company has exercised its option to acquire ownership of the licensed patent rights. In addition, UCLB has the right to negotiate with the Company for the grant of an exclusive license to the Company&#8217;s improvements to the T cell programming modules the Company has licensed on terms to be agreed upon at the time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noile-Immune Biotech Inc.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. ("Noile") under which the Company will have the right to develop CAR T cell therapies incorporating Noile&#8217;s PRIME (proliferation-inducing and migration-enhancing) technology. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient&#8217;s own T cells.</span></div>The Company paid an upfront fee and may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639848296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is based upon the estimated annual effective tax rates for the year applied to the current period loss before tax plus the tax effect of any significant unusual items, discrete events or changes in tax law. Fluctuations in the distribution of pre-tax income among the Company&#8217;s operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the three months ended March 31, 2021 and 2020, the actual effective tax rates were 14.4% and 11.0%, respectively. The increase in the effective tax rate for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020 was due an increase in the forecast proportion of qualifying research and development expenditure for the year.</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual effective tax rates are lower than the 19% statutory rate of U.K. tax primarily due to the manner in which the UK research and development credit operates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit for the three months ended March 31, 2021 increased to $5.7 million from $3.7 million for three months ended March 31, 2020 due to an increase in pre-tax losses and the increased effective tax rate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries a&#160;$2.0 million&#160;deferred tax asset balance related to its U.S. subsidiary.  The Company has recorded a valuation allowance against the net deferred tax asset where the recoverability due to future taxable profits is unknown.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639870216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an exclusive license agreement with UCLB which has subsequently been amended and restated (see Note 8). In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments upon the achievement of specified milestones. The Company has estimated the probability of the Company achieving each potential milestone in accordance with ASC 450,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that, as of March 31, 2021, there were no milestones for which the likelihood of achievement was probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters are located in London, United Kingdom. The Company leases space at this location from Imperial (Forest House) Limited under a ten-year lease, the term of which commenced in September 2015. The lease included an option for the Company to lease additional space within a 15-month period, which the Company exercised in October 2016. The exercise of the option resulted in a separate new lease agreement with a concurrent term through September 2025. The landlord exercised its option to give notice in September 2020 to terminate the Forest House lease and pay the Company a break-lease payment fee in September 2021. The Company recorded a $1.3&#160;million gain upon the notice of lease termination in the third quarter of 2020 and has a lease incentive receivable of $1.5&#160;million as of March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company signed a binding letter of intent to enter into a lease for manufacturing space in Enfield, United Kingdom. The letter of intent required the Company to enter into a 15-year lease provided that the landlord completed the required leasehold improvements described in the agreement. The Company executed lease agreements for three manufacturing space units, each for 15-year lease terms. The leases commenced in February 2019 with option to terminate the lease in February 2029.  In March 2021, the Company surrendered one of the units. Upon the surrender, the Company recognized a $0.1&#160;million gain in other income after a after recognizing a termination fee of $0.2&#160;million. The Company has no further obligations for the surrendered unit and the right of use asset and lease liability which were recorded for this unit have been written off in the period. The Company is actively seeking to sub-lease or assign the remaining lease arrangements to a third party. The Company completed an asset impairment analysis of the right of use asset concluding the undiscounted cash flows exceeded the carrying value as of March 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company executed an agreement to sublease office space in Rockville, Maryland for a term through October 2021.  The Company then terminated the sublease in February 2020 and immediately entered into a five-year lease for the same space with the landlord. As a result of the sublease termination, the Company recognized a $0.2 million gain in other income (expense) in the three months ending March 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he lease related to this facility is classified as an operating lease. The Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. These costs are considered to be variable lease payments and are not included in the determination of the lease&#8217;s right-of-use asset or lease liability.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2019, the Company executed a lease agreement to lease additional office and manufacturing space in Rockville, Maryland. The lease agreement required the Company to enter into a lease provided that the landlord completes the required leasehold improvements described in the agreement. The lease commenced in August 2020 for a term through June 2036. In March 2021, the Company announced plans to move the site of its global launch of manufacturing capacity to the United Kingdom from the United States. As a part of this strategy, the Company entered into a termination agreement with the landlord of its Rockville, Maryland property to terminate the lease for office and manufacturing space. As a result, the Company recognized a $2.0&#160;million termination fee gain from the landlord, a $2.3&#160;million gain from the removal of the leased right of use asset and corresponding lease liability, and expensed $2.4&#160;million of leasehold improvements for the three months ended March 31, 2021. The $2.0 million termination fee receivable from the landlord in included in Prepaid and other current assets in the Balance Sheet at March 31, 2021. The payment form the landlord  was received in April 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639864600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United Kingdom, the Company makes contributions to private defined benefit pension schemes on behalf of its employees. The Company expensed $0.4 million and $0.3 million in contributions for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code in October 2018. The plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches employee contributions up to four percent of the employee&#8217;s annual salary. The </span></div>Company expensed $0.1 million and $0.1 million for the three months ended March 31, 2021 and 2020, respectively. The Company pays all administrative fees related to the 401(k) plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642174824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluated subsequent events through May 6, 2021, the date on which these financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649472360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include those of the Company, its wholly-owned subsidiary, Autolus Limited, and its U.S. subsidiary, Autolus Inc., and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). All intercompany accounts and transactions have been eliminated upon consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which </span></div>they become known. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash and cash equivalents in the condensed consolidated financial statements to include cash at banks with a maturity of less than three months, which is subject to an insignificant risk of changes in value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the Company's condensed consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit RiskFinancial instruments that subject the Company to credit risk consist primarily of cash and restricted cash. The Company places cash and restricted cash in established financial institutions. The Company has no significant&#160;off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. As of March 31, 2021 and December&#160;31, 2020, the Company&#8217;s property and equipment consisted of office equipment, lab equipment, furniture and fixtures, and leasehold improvements. The office equipment has an estimated useful life of three years, lab equipment has an estimated useful life of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjZWIyYmI1OTcyMTQ3NTM4MDQ1YzI2MDg2YjFkZjRkL3NlYzo4Y2ViMmJiNTk3MjE0NzUzODA0NWMyNjA4NmIxZGY0ZF8yNS9mcmFnOjkyNDgwYzlhMzgzNTRhZjQ5ZDQ2OTRlNGE5NGU4NmY1L3RleHRyZWdpb246OTI0ODBjOWEzODM1NGFmNDlkNDY5NGU0YTk0ZTg2ZjVfMzIwOA_d20c0bf9-7fb8-41ea-919b-1d7ccf132a09">five</span>&#160;or&#160;ten years, and furniture and fixtures have an estimated useful life of&#160;five years. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the asset. Assets under construction primarily consist of costs incurred with leasehold improvements, and, once placed into service, will be depreciated over the shorter of the lease term or the estimated useful life of the asset.  Upon retirement or sale, the cost of assets are disposed of, and the related accumulated depreciation, is removed from the accounts and any resulting gain or loss is included in the statement of operations and other comprehensive loss. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a disposal loss of $0.7 million in the three months ended March 31, 2021 in leasehold improvements which are no longer being utilized in the facility in White City,  and did not recognize a disposal loss in the three months ended March 31, 2020.</span></div>The Company evaluates an asset for potential impairment when events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Recoverability is measured by comparing the book value of the asset to the expected future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the asset exceeds the fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received, initial direct costs, or prepayments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company accounts for the lease and non-lease components of leases for classes of all underlying assets and allocates all of the contract consideration to the lease component.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets Subject to Amortization</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets Subject to Amortization</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets are related to acquired software licenses with finite lives and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators of impairment are present, the Company tests for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company evaluates the useful lives for these intangible assets each reporting period to determine whether events and circumstances warrant a revision in their remaining useful lives.&#160;The Company did not recognize an impairment loss in the three months ended March 31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company and its chief operating decision maker, the Company&#8217;s Chief Executive Officer, view the Company&#8217;s operations and manage its business as a single operating segment, which is the business of developing and commercializing gene therapies; however, the Company operates in two geographic regions: the United Kingdom and the United States. Substantially all of the Company&#8217;s assets are held in the United Kingdom.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Accrued Research and Development Expenses</a></td>
<td class="text">Research and Development CostsResearch and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, depreciation expense, third-party license fees, external costs of outside vendors engaged to conduct clinical development activities, clinical trials, costs to manufacture clinical trial materials and certain tax credits associated with research and development activities.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing its condensed consolidated financial statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company&#8217;s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external clinical research organizations and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes judgments and estimates in determining the accrued balance in any accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for equity awards based on the grant date fair value of the award. The Company recognizes share-based compensation expense for awards granted to employees that have a graded vesting schedule based on a service condition only on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards (the &#8220;graded-vesting attribution method&#8221;), based on the estimated grant date fair value for each separately vesting tranche. For equity awards with a graded vesting schedule and a combination of service and performance conditions, the Company recognizes share-based compensation expense using a graded-vesting attribution method over the requisite service period when the achievement of a performance-based milestone is probable, based on the relative satisfaction of the performance condition as of the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For share-based awards granted to consultants and&#160;non-employees,&#160;compensation expense is recognized using the graded-vesting attribution method over the period during which services are rendered by such consultants and&#160;non-employees&#160;until completed. The measurement date for employee awards is the date of grant, and share-based compensation costs are recognized as expense over the employees&#8217; requisite service period, which is the vesting period, on an accelerated basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each share option grant is estimated on the date of grant using the Black-Scholes option pricing model. See Note 7 for the Company&#8217;s assumptions used in connection with option grants made during the periods covered by these condensed consolidated financial statements. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lacks company-specific historical and implied volatility information for our ADSs for expected terms greater than 2.5 years. Therefore, it uses a combination of the historical volatility of the ADSs and also the expected share volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as the Company has adequate historical data regarding the volatility of its own traded security price.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of ordinary shares.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of the Company&#8217;s ADSs underlying the option is equal to the closing price of the ADSs on the Nasdaq Global Select Market on the date the grant is approved by the Board.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement and Translation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement and Translation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its condensed consolidated financial statements in its functional currency, which is the pound sterling. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates.&#160;Non-monetary&#160;assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. The Company recorded a  foreign exchange loss of $1.2 million and foreign exchange gain of  $4.3 million for the three months ended March 31, 2021 and 2020, respectively. Foreign exchange gains are included in other income in the statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, the condensed consolidated financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#8217; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining the Company's net loss but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">Patent CostsThe Company expenses patent prosecution and related legal costs as they are incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received research grants under which it is reimbursed for specific research and development activities. Payments received are recognized as income in the statements of operations and comprehensive loss over the period in which the Company recognizes the related costs. At the time the Company recognizes grant income, it has complied with the conditions attached to it and the receipt of the reimbursement is reasonably assured. The Company has received grants from the U.K. government, which are repayable under certain circumstances, including breach or noncompliance. For grants with refund provisions, the Company reviews the grant to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, then the grant is recognized as grant income. The Company has determined that the likelihood of any repayment events included in its current grants is remote.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:232%">License Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASC Topic 606&#8221;).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from a license agreement with an investee company of one our affiliates. The terms of the agreement included a non-refundable license fee, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. There is no revenue for the three months ended March 31, 2021 and 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company  fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contingent Research Milestone Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC Topic 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company&#8217;s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinate. The Company considers all relevant factors.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For three months ended March 31, 2021, the Company has not recognized any variable consideration with regards to the development milestones which are included in the license agreement that was executed in the period. This is due to the fact that those development milestones have not yet been met and the recognition of the related revenue is not yet probable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes and Income Tax Credit</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision (benefit) for income taxes represents income taxes paid or payable (or a reduction of such amounts) for the current year plus deferred taxes. Deferred taxes result from differences between the condensed consolidated financial statements and tax bases of the Company&#8217;s assets and liabilities, and are adjusted for changes in tax rates and tax law when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of United Kingdom and United States tax law and requires judgment and estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the realizability of its deferred tax assets at each reporting date, and establishes a valuation allowance when it is more likely than not that all or a portion of its deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income of the same character and in the same jurisdiction. The Company considers all available positive and negative evidence in making this assessment, including, but not limited to, the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. In circumstances where there is sufficient negative evidence indicating that the Company&#8217;s deferred tax assets are not more likely than not realizable, the Company establishes a valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a&#160;two-step&#160;approach for recognizing and measuring uncertain tax positions. The first step is to evaluate tax positions taken or expected to be taken in a tax return by assessing whether they are more likely than not sustainable, based solely on their technical merits, upon examination, and including resolution of any related appeals or litigation process. The second step is to measure the associated tax benefit of each position as the largest amount that the Company believes is more likely than not realizable. Differences between the amount of tax benefits taken or expected to be taken in the Company&#8217;s income tax returns and the amount of tax benefits recognized in the its condensed consolidated financial statements represent the Company&#8217;s unrecognized income tax benefits, which it either records as a liability or reduction of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Credit</span></div>The Company benefits from the U.K. research and development tax credit regime under both the small and medium sized enterprise, or SME, scheme and by claiming an RDEC in respect of grant funded projects. Under the SME regime, a portion of the Company&#8217;s losses can be surrendered for a cash rebate of up to 33.35% of eligible expenditures. SME credits are accounted for within the tax provision in the year in which the expenditures were incurred. RDEC credits are accounted for within other income in the condensed consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive Loss<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 220,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span>, which establishes standards for the reporting and display of comprehensive income and its components. Comprehensive loss is defined to include all changes in equity during a period except those resulting from investments by owners and distributions to owners.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted net loss per ordinary share is determined by dividing net loss by the weighted average number of ordinary shares outstanding during the period. For all periods presented, outstanding but unvested restricted shares and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per share are the same for all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company's financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761645836232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.192%"><tr><td style="width:1.0%"/><td style="width:61.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.936%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted incentive shares and units</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360,159</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,914,949</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,241,779</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,636,977</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639860008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets, current consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.871%"><tr><td style="width:1.0%"/><td style="width:64.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development claims receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivables from terminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639860008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.512%"><tr><td style="width:1.0%"/><td style="width:64.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.510%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641986904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.756%"><tr><td style="width:1.0%"/><td style="width:66.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCLB milestone and option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate income and local taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:20.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642341784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted by the Company during the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.032%"><tr><td style="width:1.0%"/><td style="width:66.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6.08 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62% to 0.99%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.33% to 81.34%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Rollforward</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes activity for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,881,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in the Company&#8217;s restricted ordinary shares during the three months ended March 31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"/><td style="width:64.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2018 Plan for the three months ended March 31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:66.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of <br/>restricted   <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development expenses, general and administrative expenses, and capitalized to property and equipment is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.474%"><tr><td style="width:1.0%"/><td style="width:64.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.146%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:2.25pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized to property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:27pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation expense</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761638491848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jan. 27, 2020</div></th>
<th class="th"><div>Apr. 15, 2019</div></th>
<th class="th"><div>Jun. 22, 2018</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,266)<span></span>
</td>
<td class="num">$ (29,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,012<span></span>
</td>
<td class="nump">$ 243,312<span></span>
</td>
<td class="nump">$ 153,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember', window );">Underwriters public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">14,285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Per share price of issuance (usd per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary Shares | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,147,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Per share price of issuance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary Shares | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="nump">1,323,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary Shares | Underwriters public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">4,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Per share price of issuance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of issuance of ordinary shares, net of issuance costs</a></td>
<td class="nump">$ 106,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649481160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_LetterofCreditCollateralMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_SecurityDepositMember', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_LetterofCreditCollateralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_LetterofCreditCollateralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_SecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=autl_SecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641586264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_GainLossOnDispositionOfLeaseholdImprovements', window );">Loss on disposal of leasehold improvements</a></td>
<td class="num">$ (672,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">672,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment (useful life)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment (useful life)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment (useful life)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment (useful life)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_GainLossOnDispositionOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_GainLossOnDispositionOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641333240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641178936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>segment </div>
<div>region</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of geographic regions | region</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639871336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Research and Development (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ResearchAndDevelopmentTaxCredits', window );">Research and development tax credits</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641986904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639871336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Patent Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Patent costs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761657685816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency exchange translation adjustment</a></td>
<td class="nump">$ 1,273<span></span>
</td>
<td class="num">$ (17,701)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649222168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Ant-dilutive shares</a></td>
<td class="nump">8,241,779<span></span>
</td>
<td class="nump">6,636,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted incentive shares and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Ant-dilutive shares</a></td>
<td class="nump">1,360,159<span></span>
</td>
<td class="nump">722,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Ant-dilutive shares</a></td>
<td class="nump">6,881,620<span></span>
</td>
<td class="nump">5,914,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761645661864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ResearchAndDevelopmentClaimsReceivableCurrent', window );">Research and development claims receivable</a></td>
<td class="nump">$ 30,791<span></span>
</td>
<td class="nump">$ 24,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">7,477<span></span>
</td>
<td class="nump">10,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">3,292<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentiveReceivableCurrent', window );">Lease receivables from terminations</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant income receivable</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred cost</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 48,262<span></span>
</td>
<td class="nump">$ 42,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ResearchAndDevelopmentClaimsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Claims Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ResearchAndDevelopmentClaimsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentiveReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.  The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentiveReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641973496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets, Current - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing', window );">Decrease to prepaid facility and manufacturing</a></td>
<td class="num">$ (2.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) To Prepaid Facility And Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642494648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (16,409)<span></span>
</td>
<td class="num">$ (14,663)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">33,543<span></span>
</td>
<td class="nump">38,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">23,774<span></span>
</td>
<td class="nump">23,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,122<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10,374<span></span>
</td>
<td class="nump">10,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 11,332<span></span>
</td>
<td class="nump">$ 14,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641952888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narratives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642571400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Details)<br> &#163; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 8,695<span></span>
</td>
<td class="nump">$ 8,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_AccruedResearchAndDevelopmentCostCurrent', window );">Research and development costs</a></td>
<td class="nump">11,468<span></span>
</td>
<td class="nump">15,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_AccruedLicenseFeesCurrent', window );">UCLB milestone and option</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">&#163; 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">U.S. corporate income and local taxes</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 24,683<span></span>
</td>
<td class="nump">$ 27,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_AccruedLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_AccruedLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_AccruedResearchAndDevelopmentCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Cost, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_AccruedResearchAndDevelopmentCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641599128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Ordinary Shares (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 26, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_AuthorizedGrantLife', window );">Authorized grant, life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_MaximumNominalAmountOfSharesAuthorizedForGrant', window );">Maximum nominal shares authorized for grant | $</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">70,515,354<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
<td class="nump">52,346,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember', window );">Deferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
<td class="nump">34,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember', window );">Deferred B Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
<td class="nump">88,893,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember', window );">Deferred C Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Stock par value (usd/gbp per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_AuthorizedGrantLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Authorized Grant, Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_AuthorizedGrantLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_MaximumNominalAmountOfSharesAuthorizedForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Nominal Amount Of Shares Authorized For Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_MaximumNominalAmountOfSharesAuthorizedForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=autl_DeferredClassCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761645642856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Open Market Sales Agreement (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_CommissionPercentageOfGrossSalesPrice', window );">Commission, percentage of gross sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">1,718,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember', window );">Underwriters public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_CommissionPercentageOfGrossSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission, Percentage Of Gross Sales Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_CommissionPercentageOfGrossSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=autl_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761644127016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2018 Plan and 2017 Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=autl_PerformanceBasedMember', window );">Performance Based | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=autl_PerformanceBasedMember', window );">Performance Based | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=autl_PerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=autl_PerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642166344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Options Valuation Assumptions (Details) - Share options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">0.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percent)</a></td>
<td class="nump">81.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percent)</a></td>
<td class="nump">81.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761644121464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Options Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">5,611,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,828,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(557,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">6,881,620<span></span>
</td>
<td class="nump">5,611,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,954,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">6,881,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 17.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted weighted average exercise price (usd per share)</a></td>
<td class="nump">8.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised weighted average exercise price (usd per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled or forfeited weighted average exercise price (usd per share)</a></td>
<td class="nump">16.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance weighted average exercise price (usd per share)</a></td>
<td class="nump">14.97<span></span>
</td>
<td class="nump">$ 17.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable weighted average exercise price (usd per share)</a></td>
<td class="nump">17.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest weighted average exercise price (usd per share)</a></td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term outstanding (years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term exercisable (years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term vested and expected to vest (years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding (aggregate intrinsic value)</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="nump">$ 4,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable (aggregate intrinsic value)</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest (aggregate intrinsic value)</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649248360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Options Narratives (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share based compensation not yet recognized for unvested shares | $</a></td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation not yet recognized for unvested shares vesting period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period | shares</a></td>
<td class="nump">1,602,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642376408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of restricted shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">90,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(40,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled of forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding ending balance (in shares) | shares</a></td>
<td class="nump">50,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding beginning balance weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled or forfeited weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding ending balance weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642275864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation not yet recognized for unvested shares vesting period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share based compensation not yet recognized for unvested shares other than options</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761641658936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units Narratives (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation not yet recognized for unvested shares vesting period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share based compensation not yet recognized for unvested shares other than options | $</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation not yet recognized for unvested shares vesting period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period | shares</a></td>
<td class="nump">920,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting right percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761645838104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">415,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,035,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(21,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled of forfeited (in shares) | shares</a></td>
<td class="num">(119,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested and outstanding ending balance (in shares) | shares</a></td>
<td class="nump">1,309,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding beginning balance weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">$ 12.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">8.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">8.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled or forfeited weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">11.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested and outstanding ending balance weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="nump">$ 9.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761642353080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Based Compensation Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="num">$ (670)<span></span>
</td>
<td class="nump">$ 6,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="num">(1,654)<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=autl_CapitalizedFixedAssetsMember', window );">Capitalized to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=autl_CapitalizedFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=autl_CapitalizedFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761639630328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease', window );">Share-based payment arrangement, expense, decrease</a></td>
<td class="num">$ (6.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Expense, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761566132024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br> &#163; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_AccruedLicenseFeesCurrent', window );">Accrued license fees payable</a></td>
<td class="nump">&#163; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentsAxis=autl_ProductSalesMember', window );">Product Sales | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentsAxis=autl_ProductSalesMember', window );">Product Sales | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember', window );">UCL Business plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_PaymentOfUpfrontFees', window );">Payment of upfront fees (usd/gbp per share)</a></td>
<td class="nump">&#163; 1,500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember', window );">UCL Business plc | Clinical Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember', window );">UCL Business plc | Regulatory Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember', window );">UCL Business plc | Product Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember', window );">UCL Business plc | Net Sales Levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ScheduleOfLicenseAgreementsLineItems', window );"><strong>Schedule Of License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_ConditionalPaymentBasis', window );">Conditional payment, regulatory approval (gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_AccruedLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_AccruedLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ConditionalPaymentBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conditional Payment Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ConditionalPaymentBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ScheduleOfLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of License Agreements [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ScheduleOfLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ConditionalPaymentsAxis=autl_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ConditionalPaymentsAxis=autl_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=autl_UCLBusinessplcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=autl_UCLBusinessplcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ConditionalPaymentsAxis=autl_ClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ConditionalPaymentsAxis=autl_ClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ConditionalPaymentsAxis=autl_RegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ConditionalPaymentsAxis=autl_RegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_ConditionalPaymentsAxis=autl_NetSalesLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_ConditionalPaymentsAxis=autl_NetSalesLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649293048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate of income tax (percentage)</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.K. statutory tax rate (percentage)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 5,724<span></span>
</td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761637529976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narratives (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>unit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentiveReceivable', window );">Lease incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ImperialForestHouseLimitedMember', window );">Imperial (Forest House) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ManufacturingSpaceInEnfieldUnitedKingdomMember', window );">Manufacturing Space in Enfield, United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_LeaseTerminationFeeExpense', window );">Lease termination fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember', window );">Office and Manufacturing Space in Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases', window );">Gain on sale of leased Assets, net, operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember', window );">Office and Manufacturing Space in Rockville, Maryland | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Imperial (Forest House) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Manufacturing Space in Enfield, United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfUnitsInRealEstateProperty', window );">Number of units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Office Space In Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_autl_OperatingLeaseRentFreePeriod', window );">Operating lease rent free period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=autl_AdditionalSpaceMember', window );">Additional Space | Imperial (Forest House) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_LeaseTerminationFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Termination Fee Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_LeaseTerminationFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_autl_OperatingLeaseRentFreePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Rent Free Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">autl_OperatingLeaseRentFreePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>autl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 40<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566025&amp;loc=d3e44908-112734<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40019-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfUnitsInRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units in a real estate property owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfUnitsInRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ImperialForestHouseLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ImperialForestHouseLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ManufacturingSpaceInEnfieldUnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_ManufacturingSpaceInEnfieldUnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeSpaceInRockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=autl_OfficeSpaceInRockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=autl_AdditionalSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=autl_AdditionalSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139761649223928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions to defined benefit pension</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution percent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,(DH;+0T.!_I2T#4=:ON*%[:6K'F2E<>V\QUK0=A)NCW&\[5OF,6:/\]3/\
M4$L#!!0    ( )N IE*B5]P(C 4  -\8   8    >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULK5EK;]LV%/TKA%%@+=#4(BGJ$3@&\L"P NT6).WVF9'HF*@D
MNB25Q[\?)3FB+5&4A_5++-GG7AU>7IY#,:MG(7^H+6,:O)1%I2X66ZUWY\NE
MRK:LI.J3V+'*_+(1LJ3:W,K'I=I)1O,VJ"R6* BB94EYM5BOVN]NY7HE:EWP
MBMU*H.JRI/+UBA7B^6(!%V]?W/''K6Z^6*Y7._K([IG^OKN5YF[99\EYR2K%
M104DVUPL+N'Y=1@T 2WB;\Z>U<$U:(;R(,2/YN9S?K$(&D:L8)EN4E#S\<2N
M65$TF0R/G_NDB_Z93>#A]5OVW]O!F\$\4,6N1?$/S_7V8I$L0,XVM"[TG7C^
M@^T'1)I\F2A4^Q<\=]B8+$!6*RW*?;!A4/*J^Z0O^T(<!,!P(@#M ]"I 7@?
M@-N!=LS:8=U03=<K*9Z!;- F6W/1UJ:--J/A53.-]UJ:7[F)T^MK4>5F4E@.
MS)42!<^I-C=7M*!5QL!]DUB!]]\K6N?<_/(!G('O]S?@_;L/X!W@%?BV%;6B
M5:Y62VWX-%F7V?[95]VST<2SOU+Y"6#X$:  04?XM3_\AF5]>' <OC15Z$N!
M^E*@-A^>*D4M):LTH$J9,9][,N(^(VXSAE,9J=JZRM)%D3:J66=/:X33 *+5
M\NEP^&,8)!BE:0\[(A7VI$(OJ3NFM.19,\O9!+\N073PX#B)!N3\F"-FI&=&
MO,QN)=M1G@/VLFM:4@'35D#H+9/[.?EH5D0[1R[29$0H3% TK*D#A9*IDD8]
M\<A+_)O0M'CCMN?JHAB-'HZ2)(B" <<Q#*91FH1NDG%/,O:V]Y^B.LM.;O&D
MSYK,S)EQ%*E?V[EB/VN^,QJO/X**.2<I&0T-8Q+B00$<J"0()[HK[9FF_KYO
M!!V(#:@5Z_MI@F8ZGB@(#[JDHSE&$1CAV$T3!E:1 R_1+Z)Z/--,EL:.=D)Q
M=R_MDQQU28*'J]2!,FN"3% \, WX?U=J9=O-21^.B:5X6&$'"@<83]"W0@^1
ME_X-VS##+ >:OG2$G131F&* PR'%,0K&9&*M0NL<T&\=GRM-JT?^4,SVZC[1
M$0%,ABP=()),D+1. OU6TNG>M-[!L4G@,(W#49>.<2@-T>12LH8"R4F67G#Z
MP NN.?.*'K2"#_V*?YEEHJ[,SFA'7ZF9).?H'7*/R*C%7:AHJL6MV,-XCJ"L
MF7.%'A3#23L>$PJC9*C1+E@<)W""N/43Z#>4+\QLRF<Y.APB(O&0H@-%TF""
MH?41Z#>28[>?8SHV"1R0D96X8#C"$S*"K)>@X&33/W$1(.L"R.\")TT5&DLX
M3$DRW/,X8"0@\40[H8,]O5_JN\F:XSC6<!+ >#A)#E@2HF#"39'5>H2]DW2_
MI9)M19$SJ7YK-U'ZU3M#5J"17Z O<_/29MZ630D:OSXS[VL9W7%3$F<9''MZ
M&)%P:'D.'$E-P28V:,C*-?*_ !C1JLNZ:-] .ZW*1+DSM6F.#9Y,JPGEGK_Q
MKOXL)$DRY.V D22:ZC%K!FC6#'K:.=OPC#N-&HV5_BR$B,#16G  <9RB<$H.
MK"L@ORMTJT$Y^LU)V"'Q:4JBH<ZZ<# (,)J@:[T ^;U@M'A;%SN9OD/^7;L/
M!\ZW^T#6*)#?*/Z2.:^H?.T8*]^!@A5T[!?T_ZH5V*HY]JMYFQD\T:)V[F:P
M8RL^/*_P08Y96?W&)V[5YVMX<"KS:_466[W%?KV=J^%8.(=KWPLY9F5E%?ME
MM:_A%;B?K:)5/1S]VBI:E<)^E9JKXEAN(!QJ_0SHF)D5).P7I+Z2UR=4TNH$
M3G]I)4.K%J'_*&&FDOMHXNE'+Z1CM3PX?6Z._K]2^<@K!0JV,3'!I^:L7':G
MZ=V-%KOV0/I!:"W*]G++J!E] S"_;X30;S?-&7?_/XWUOU!+ P04    " ";
M@*920J?#K"($  ##%0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U8
M6X^C-AC]*Q:MMC-2&["YA$R32)U M7U8=;31ML^>X 0T@+.VF>Q6^^-K+L,E
M)-BK31X2".<[_HZ!<\#+$V4O/"9$@"]9FO.5$0MQ?#!-OHM)AOF,'DDNC^PI
MR["0N^Q@\B,C.*J*LM1$EN69&4YR8[VL_GMBZR4M1)KDY(D!7F099E\?24I/
M*P,:;W]\3 ZQ*/\PU\LC/I M$9^.3TSNF2U+E&0DYPG- 2/[E?$'? B16Q94
MB'\2<N*];5!*>:;TI=SY*UH95MD12<E.E!18_KR2#4G3DDGV\;DA-=HQR\+^
M]AO[GY5X*>89<[*AZ;])).*5X1L@(GM<I.(C/;TGC:"JP1U->?4-3C76FQM@
M5W!!LZ98=I E>?V+OS03T2NPK2L%J"E N@5V4V#K%CA-@:-;X#8%E72SUEY-
M7( %7B\9/0%6HB5;N5'-?E4MYRO)RPME*Y@\FL@ZL=[0/)*GG41 ;G&:)A$6
M<N<1ISC?$; MB3FX^Y3C(DKDD7MP]X09R45,1++#*;]?FD+V4;*9NV;,QWI,
M=&7,#YC-@ U_!<A"\&=@ AY+2EY_7Z#;? ?=NY^@9_^NY@RF.0.R:SDMC1;#
M[Z#3:-&49[$]E:@]E:@:Q+DRR-\L2G)YLP,EH]TRVA6C?85Q6Q+%-(T(X[\
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M6#,9P8O%^<RK@4,M771!K>Q2V,DX0'S?7\A$\L\O.%UDH(T,=9!#]5U^P>D
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MDCPIG%Z.;'!0)71;PKM*TQVWEH>*W*2*;),^1J&@BKA3YG9(RJ&0T'#!,$G
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MT:%>IB(4.HXU41" CVQ!=KADHA-<(-+<R[=X'.$=W5I6,N7AX+;APIY\01Y
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M(OP@36R11;V+'^[JL57E(JU!NNET.ZT[2F/0K,.7E$BX>;Q0A+HX$G0 1SJ
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M!P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+55VV[C-A#]E8&P0%M
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M(A<0"LRM4V#T>L0+%,()41B_.LV@=^F(Q^N#^D>?.^6R9@8OE/C."UO-@VD
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M)UUR!-GP)V *CJR$R9"9\M_!CS\3UC>3P/%@9844#X'6L5%AH+.\A-<E5G_
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MVJ^[JHU8$ /,4G&31M6A-#@3%4:[A&G8E;2H8..<Z 4')*R<;9:K00AF;0A
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M?4I^_^!4)+.BH8G:IM*M*TK_/GW0R?NRW8>P"(BI-PP\;P?>3_/1B5H&&>Z
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MP\"[MX N_-4;?QRAMWT-LGK+48&H\*.FI(#(/D0"].,[\G1\<$F@?*]+?=C
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M#^EJHYO'4O-AU<(]4,;*TG/'#6?TOD3- K0^4<IN/GB#[L5Z\0]02P,$%
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M!CJ4!6.O>O(8CQQ/,T($15)#0/58H2DB1",I'F\5J%/OJ1W;XRWZ@PE>!;.
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M@\@) @DY.@9.OP,L0$I'1#)^]9S!$-(!3]=']L\^=\IERRTLM/PN"JRGP<>
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MVAG0?:64W6^<@V&.YK\!4$L#!!0    ( )N IE)F=M=]J@(  .D'   9
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M)? I0YV:+@44E,7DXQ-N# F2T#PF/U0"@LRD!"5[9+X5 G)%SA>@*$OE!?E
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MQB<<DLXA";S;0('E2K#(4FOV8+VU0_.'D&KP=N2D]DVY9^MNI?/C;&VQ%K*
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M.DWSC:#?FN)7\ARG>0HRIMYSDE29 E+W4FTD93_!?^#F7#?+ %X10.\I3]/
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MN++_9%>OG8P<$E=*B[P!HX*<%?65/C=&'  "KP,0-(#@+6#2 0@;0/@6X'<
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M1L#U '5_Q9C<-_0$]=>0Z6]02P,$%     @ FX"F4MTBKMS2 @  " D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULS9;;;N(P$(9?Q8JT4BNU.4$I
M5( $/6CW BVBVNZUP0.QZL19VQ3R]CMV0DJUK8MZM3=@CSU_OIF)9C+<2?6L
M,P!#]KDH]"C(C"EOHDBO,LBI#F4)!9ZLI<JIP:W:1+I40)ESRD64QG$ORBDO
M@O'0V>9J/)1;(W@!<T7T-L^IJJ8@Y&X4),'!L.";S%A#-!Z6= ./8'Z5<X6[
MJ%5A/(="<UD0!>M1,$ENIHES<#>>..STT9K84)92/MO-#S8*8DL$ E;&2E#\
M>X%;$,(J(<>?1C1HGVD=C]<']0<7/ :SI!INI?C-F<E&03\@#-9T*\Q"[KY#
M$]"5U5M)H=TOV35WXX"LMMK(O'%&@IP7]3_=-XDX<DAZ'SBDC4/JN.L'.<H[
M:NAXJ.2.*'L;U>S"A>J\$8X7MBJ/1N$I1S\S?LRH@LLIQL7(K<RQV)JZ=%V2
MGZ5=:/)$Q;:V3306K[&>W8&A7.ASO.E$B*Q/AI%!+JL>K1J&:<V0?L#0(3-9
MF$R3^X(!>^L?83QM4.DAJ&GJ%9Q1%9).<D'2.$T\>ITV21VGU_$F:?EODB9*
MT6(#^)8:LJS(\;TYK9QYLJ.*79 'RI7+)+S)(BT8F8')))-";BH/:[=E[3K6
M[@>L"ZZ?+]<*@/#"@ )MB*(&+NS+P_-M3LY*4"LD.W^O4'[M..REWSR,5RWC
MU1<9Z?YS1K]V' X&/L9>R]CSZMSO2VP<6,@7*;#8@IOJQ!SZ=?M)V.GX *];
MP.LO )Z20+^N!>SZ /LM8/\T0,9?. -\TRL.@OG9_))Q&,<^M$&+-O#JS.HT
M>922^+6!QO]]<TB.VGUR6E'J;DT$7P,YJX J_6X]/I'K$>=*T@%AM-+O(49'
MPRD'M7$C6).5W!:FGE.MM1WSDWJXO5ZOOQ&PKV\X)D; &EWC\!I;@:K';KTQ
MLG2C;BD-#DZWS/!3!92]@.=K*<UA8Q_0?OR,_P)02P,$%     @ FX"F4J^B
M8/6L!   0Q,  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULK5A=<^(V
M%/TK&KK3(3,;; E_L27,)&3;[L.VF6233!\5^P*>M2TJ"4C^?25_$VQ!IKR
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M_K@"&@'7 ]3[!6.R:FB ^MYL]A]02P,$%     @ FX"F4CO;9];P @  $ @
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MDTV55<#SK93F*-@ ]9^ V4]02P,$%     @ FX"F4@1 7VTF P  00L  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULM9;K;]HP$,#_%2N;IDY:R9-7
M!TB%[O6A6P5J^]DD!UA-;&8;TDG[XW=V0J KL+0:7Q*_[NYW9Y]]O5S(![4
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ML>*RS076N"#- IR?":$W'6.@JIH'?P!02P,$%     @ FX"F4M0AY:Y\ @
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MS]#H8L%Q33OR6H-TX\?,3A,/+;\L^2^!QCGP^5YK.ADN0/_?27\!4$L#!!0
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MT0EP4F7'6PZ,+%R7.9,&>E;WF#*:,&47P/Q<2K,9V WJ_SN,_P!02P,$%
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MTAC@_DH(?9B8 ZI6<?074$L#!!0    ( )N IE)9I./C-@(  +D$   9
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M4&;T6M*,+4U_F34&,/809R=ER5<?.9N)G-K)[RTX&I!UG#<O)'O0:E J4SU
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MYCVX\SX*UN^I8/.[\.@/4$L#!!0    ( )N IE*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ FX"F4IJ^QPA+!
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M*^JM!'HKZJT$>NOH89M ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
M;T6]E4!O0[V-0&]#O8U ;T.]C4!O&[TL(=#;4&\CT-M0;R/0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-M'+[L)]';4VPGT=M3;
M"?1VU-L)]';4VPGT=M3;"?2.J'<DT#NBWI% [XAZ1P*](^H="?2.J'<DT#N.
M/E;^I]ZYG'8I7WN^UWC]_Z2ZG,]-U\M?EM\[1S?4!>< /S<\?@%02P,$%
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MK779'/)9]Y7"Y!-02P$"% ,4    " ";@*92!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )N IE+;
M[6Y%[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( )N IE*97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ FX"F4GM'2KNB @
M20@  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( )N IE*B5]P(C 4  -\8   8              " @>8*
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " ";@*920J?#
MK"($  ##%0  &               @(&H$   >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ FX"F4D%I:+:M!   !A   !@
M ("! !4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )N
MIE)OAEMK)P8  "@<   8              " @>,9  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " ";@*922=@N-]8&   !'0  &
M        @(% (   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ FX"F4K)XL*T0#0  \B   !@              ("!3"<  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )N IE)QJ/H9$R0  %1T   8
M              " @9(T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " ";@*92VJC=HX0#  #9!P  &               @(';6   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ FX"F4F_3I$3! @
M"@8  !D              ("!E5P  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " ";@*92SDJ-8-<"   ^!@  &0              @(&-
M7P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )N IE*6
M@-4#@04  *X-   9              " @9MB  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ FX"F4BJ>CP]5"0  IQP  !D
M     ("!4V@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M" ";@*92#)7KR80(   Y%@  &0              @('?<0  >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )N IE+:5G)(- 0  -L)   9
M              " @9IZ  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M A0#%     @ FX"F4MPK$0:!"0  5QD  !D              ("!!7\  'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ";@*92V4@+FU #
M   T!P  &0              @(&]B   >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;%!+ 0(4 Q0    ( )N IE)606X00P(  !\%   9              "
M@42,  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ FX"F
M4F 'J:]V'P  +VH  !D              ("!OHX  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " ";@*92E=6Y];("  "C!0  &0
M        @(%KK@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( )N IE*)RR1T! ,  '<&   9              " @52Q  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ FX"F4HK^*.K) @  ]P4
M !D              ("!C[0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " ";@*92TQ>*>>4"   L!@  &0              @(&/MP
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )N IE*UK)$8
MD@4  +T.   9              " @:NZ  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ FX"F4E]B=N:.!   R!0  !D
M ("!=,   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ";
M@*92&^VEJ6("  !"!P  &0              @($YQ0  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )N IE)>'0BW-0,  $ ,   9
M          " @=+'  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#
M%     @ FX"F4MK@9X%7 @  3@4  !D              ("!/LL  'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ";@*92:N@OU3T"   6
M!0  &0              @(',S0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+ 0(4 Q0    ( )N IE+8Z[HN2P(  $<%   9              " @4#0
M  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ FX"F4LRT
M0AY= @  904  !D              ("!PM(  'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"% ,4    " ";@*92W:WMK3P"   F!0  &0
M    @(%6U0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M )N IE*]_/'E80(  %,%   9              " @<G7  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ FX"F4F9VUWVJ @  Z0<  !D
M             ("!8=H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " ";@*928,M"RB(#  ! "0  &0              @(%"W0  >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )N IE*/:S0%4 (
M ,0$   9              " @9O@  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ FX"F4IP%#_XX P  , P  !D              ("!
M(N,  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ";@*92
M(VT-A$$"   G!0  &0              @(&1Y@  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( )N IE+2TY9/'@,  "T)   9
M      " @0GI  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ FX"F4G[,,!#  P  \@\  !D              ("!7NP  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " ";@*92.]J%^AX#  #$"
M&0              @(%5\   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( )N IE*!$B&K5@,  !D1   9              " @:KS  !X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ FX"F4MTBKMS2
M @  " D  !D              ("!-_<  'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " ";@*92KZ)@]:P$  !#$P  &0
M@(% ^@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )N
MIE([VV?6\ (  ! (   9              " @2/_  !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ FX"F4@1 7VTF P  00L  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( )N IE)9I./C-@(  +D$   9
M  " @<X2 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
MFX"F4I[6TW0V!   6Q(  !D              ("!.Q4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " ";@*929S>90N("  #""   &0
M            @(&H&0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( )N IE)3<=SNZ@0  +P6   9              " @<$< 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ FX"F4H<,R!AQ @
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M2P$"% ,4    " ";@*92O '6P> !  #L(   &@              @ %T+0$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ";@*92%-1Q
MY- !  "M(   $P              @ &,+P$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     /P _ # 1  "-,0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>301</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Shareholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2115103 - Disclosure - Prepaid Expenses and Other Assets, Current</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent</Role>
      <ShortName>Prepaid Expenses and Other Assets, Current</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2119104 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2123105 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/AccruedExpensesandOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2141108 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.autolus.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.autolus.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Prepaid Expenses and Other Assets, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables</Role>
      <ShortName>Prepaid Expenses and Other Assets, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.autolus.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.autolus.com/role/AccruedExpensesandOtherLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.autolus.com/role/ShareBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/NatureoftheBusinessDetails</Role>
      <ShortName>Nature of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/NatureoftheBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Patent Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Patent Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of Significant Accounting Policies - Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414410 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Prepaid Expenses and Other Assets, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Prepaid Expenses and Other Assets, Current - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets, Current - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Property and Equipment, Net - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails</Role>
      <ShortName>Property and Equipment, Net - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Shareholders??? Equity - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails</Role>
      <ShortName>Shareholders??? Equity - Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Shareholders??? Equity - Open Market Sales Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails</Role>
      <ShortName>Shareholders??? Equity - Open Market Sales Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Share-Based Compensation - 2018 Plan and 2017 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails</Role>
      <ShortName>Share-Based Compensation - 2018 Plan and 2017 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Share-Based Compensation - Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Share-Based Compensation - Share Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails</Role>
      <ShortName>Share-Based Compensation - Share Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Share-Based Compensation - Share Options Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails</Role>
      <ShortName>Share-Based Compensation - Share Options Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2436423 - Disclosure - Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails</Role>
      <ShortName>Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437424 - Disclosure - Share-Based Compensation - Restricted Stock Units Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438425 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439426 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails</Role>
      <ShortName>Share-Based Compensation - Share Based Compensation Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440427 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails</Role>
      <ShortName>Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442428 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/LicenseAgreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2444429 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/IncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446430 - Disclosure - Commitments and Contingencies - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails</Role>
      <ShortName>Commitments and Contingencies - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="autl-20210331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.autolus.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.autolus.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="autl-20210331_d2.htm">autl-20210331_d2.htm</File>
    <File doctype="6-K" original="autl-20210331.htm">autl-20210331.htm</File>
    <File>autl-20210331.xsd</File>
    <File>autl-20210331_cal.xml</File>
    <File>autl-20210331_def.xml</File>
    <File>autl-20210331_lab.xml</File>
    <File>autl-20210331_pre.xml</File>
    <File>exhibit992-operatingresult.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "autl-20210331_d2.htm autl-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 14,
   "contextCount": 132,
   "dts": {
    "calculationLink": {
     "local": [
      "autl-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "us-gaap-eedm-def-2020-01-31.xml",
      "srt-eedm1-def-2020-01-31.xml",
      "autl-20210331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "autl-20210331_d2.htm",
      "autl-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "autl-20210331_lab.xml",
      "us-gaap-doc-2020-01-31.xml",
      "dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "autl-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "local": [
      "dei-ref-2020-01-31.xml",
      "us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "autl-20210331.xsd",
      "srt-2020-01-31.xsd",
      "xbrl-instance-2003-12-31.xsd",
      "xbrl-linkbase-2003-12-31.xsd",
      "xl-2003-12-31.xsd",
      "xlink-2003-12-31.xsd",
      "numeric-2009-12-16.xsd",
      "nonNumeric-2009-12-16.xsd",
      "xbrldt-2005.xsd",
      "ref-2006-02-27.xsd",
      "srt-types-2020-01-31.xsd",
      "us-gaap-2020-01-31.xsd",
      "us-roles-2020-01-31.xsd",
      "srt-roles-2020-01-31.xsd",
      "country-2020-01-31.xsd",
      "us-types-2020-01-31.xsd",
      "dei-2020-01-31.xsd",
      "negated-2009-12-16.xsd",
      "net-2009-12-16.xsd",
      "reference-2009-12-16.xsd",
      "us-parts-codification-2020-01-31.xsd",
      "deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 345,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 8,
    "total": 10
   },
   "keyCustom": 27,
   "keyStandard": 274,
   "memberCustom": 19,
   "memberStandard": 23,
   "nsprefix": "autl",
   "nsuri": "http://www.autolus.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": null,
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.autolus.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119104 - Disclosure - Property and Equipment, Net",
     "role": "http://www.autolus.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123105 - Disclosure - Accrued Expenses and Other Liabilities",
     "role": "http://www.autolus.com/role/AccruedExpensesandOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Shareholders\u2019 Equity",
     "role": "http://www.autolus.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Share-Based Compensation",
     "role": "http://www.autolus.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "autl:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141108 - Disclosure - License Agreements",
     "role": "http://www.autolus.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "autl:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Income Taxes",
     "role": "http://www.autolus.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.autolus.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Employee Benefit Plans",
     "role": "http://www.autolus.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Subsequent Event",
     "role": "http://www.autolus.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Prepaid Expenses and Other Assets, Current (Tables)",
     "role": "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables",
     "shortName": "Prepaid Expenses and Other Assets, Current (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.autolus.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "role": "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of the Business (Details)",
     "role": "http://www.autolus.com/role/NatureoftheBusinessDetails",
     "shortName": "Nature of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ic6944aac8c6a4cf4a831485fd0f729c8_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i25159a1662d546f8b7c7111c26504274_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "autl:GainLossOnDispositionOfLeaseholdImprovements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Property Plant and Equipment (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "if32728553356471ba7bc0e4c651239d0_D20210101-20210331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets Subject to Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "region",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "region",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ibfa8aa73c88c4f96977e727aa35b5250_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "role": "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "autl:ResearchAndDevelopmentTaxCredits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "autl:ResearchAndDevelopmentTaxCredits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails",
     "shortName": "Summary of Significant Accounting Policies - Foreign Currency Remeasurement and Translation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Patent Costs (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails",
     "shortName": "Summary of Significant Accounting Policies - Patent Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of Significant Accounting Policies - Comprehensive Loss (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414410 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details)",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "autl:ResearchAndDevelopmentClaimsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Prepaid Expenses and Other Assets, Current (Details)",
     "role": "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails",
     "shortName": "Prepaid Expenses and Other Assets, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "autl:ResearchAndDevelopmentClaimsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "autl:IncreaseDecreaseToPrepaidFacilityAndManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Prepaid Expenses and Other Assets, Current - Narrative (Details)",
     "role": "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails",
     "shortName": "Prepaid Expenses and Other Assets, Current - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "autl:IncreaseDecreaseToPrepaidFacilityAndManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Property and Equipment, Net - Narratives (Details)",
     "role": "http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails",
     "shortName": "Property and Equipment, Net - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Accrued Expenses and Other Liabilities (Details)",
     "role": "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "autl:AuthorizedGrantLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Shareholders\u2019 Equity - Ordinary Shares (Details)",
     "role": "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails",
     "shortName": "Shareholders\u2019 Equity - Ordinary Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i090aa7e7ca87423ca882b5b5d6e7da48_D20180626-20180626",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "autl:AuthorizedGrantLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i89ef2b2dd83148a89ab674028ea86908_I20200918",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "autl:SaleOfStockAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Shareholders\u2019 Equity - Open Market Sales Agreement (Details)",
     "role": "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails",
     "shortName": "Shareholders\u2019 Equity - Open Market Sales Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i89ef2b2dd83148a89ab674028ea86908_I20200918",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "autl:SaleOfStockAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i565ff69f23244cb981adb7c2449fd9a6_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Share-Based Compensation - 2018 Plan and 2017 Plan (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
     "shortName": "Share-Based Compensation - 2018 Plan and 2017 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i152c0f30695a40f9a86760ec0cbcc834_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ib89704d2fb2942e1aac143125d76070f_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Share-Based Compensation - Options Valuation Assumptions (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
     "shortName": "Share-Based Compensation - Options Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ib89704d2fb2942e1aac143125d76070f_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "id858f1b0dc6f47c58cb69a3594277923_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Share-Based Compensation - Share Options Rollforward (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails",
     "shortName": "Share-Based Compensation - Share Options Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Share-Based Compensation - Share Options Narratives (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails",
     "shortName": "Share-Based Compensation - Share Options Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i66aae6507b744c1d8f4b560d2b970ce2_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i0a573508e9c143009ce350d6d6b25350_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
     "shortName": "Share-Based Compensation - Restricted Ordinary Shares Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i0a573508e9c143009ce350d6d6b25350_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436423 - Disclosure - Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
     "shortName": "Share-Based Compensation - Restricted and Ordinary Shares Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i9cc9d8b13a764a0bab69da3a15cb9f71_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437424 - Disclosure - Share-Based Compensation - Restricted Stock Units Narratives (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
     "shortName": "Share-Based Compensation - Restricted Stock Units Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i7a527a130d6d456fb3e905c90988f2cb_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ic01ce88311fc413e92a876264e4e7673_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438425 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Share-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "ic01ce88311fc413e92a876264e4e7673_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "iee15fdaf6af94a6fabfb9578aff371ce_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)",
     "role": "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "iee15fdaf6af94a6fabfb9578aff371ce_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439426 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails",
     "shortName": "Share-Based Compensation - Share Based Compensation Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "autl:ShareBasedPaymentArrangementExpenseIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440427 - Disclosure - Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)",
     "role": "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails",
     "shortName": "Share-Based Compensation - Share Based Compensation Allocation Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "autl:ShareBasedPaymentArrangementExpenseIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442428 - Disclosure - License Agreements (Details)",
     "role": "http://www.autolus.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i2918e15483dd46ecae3732bc7350b3ec_D20160301-20160331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444429 - Disclosure - Income Taxes (Details)",
     "role": "http://www.autolus.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnTerminationOfLease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446430 - Disclosure - Commitments and Contingencies - Narratives (Details)",
     "role": "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails",
     "shortName": "Commitments and Contingencies - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i6d9b766ba80440d696ca8311b8127c2b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnTerminationOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://www.autolus.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of the Business",
     "role": "http://www.autolus.com/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115103 - Disclosure - Prepaid Expenses and Other Assets, Current",
     "role": "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent",
     "shortName": "Prepaid Expenses and Other Assets, Current",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "autl-20210331.htm",
      "contextRef": "i4b20ef6ec49446deb712bcd57ba9bbc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "autl_APICShareBasedPaymentArrangementReversalOfCostRecognition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APIC, Share-Based Payment Arrangement, Reversal Of Cost Recognition",
        "label": "APIC, Share-Based Payment Arrangement, Reversal Of Cost Recognition",
        "negatedTerseLabel": "Reversal of share-based compensation expense"
       }
      }
     },
     "localname": "APICShareBasedPaymentArrangementReversalOfCostRecognition",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_AccruedLicenseFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued License Fees, Current",
        "label": "Accrued License Fees, Current",
        "terseLabel": "UCLB milestone and option",
        "verboseLabel": "Accrued license fees payable"
       }
      }
     },
     "localname": "AccruedLicenseFeesCurrent",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails",
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_AccruedResearchAndDevelopmentCostCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Cost, Current",
        "label": "Accrued Research And Development Cost, Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostCurrent",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_AdditionalSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Space [Member]",
        "label": "Additional Space [Member]",
        "terseLabel": "Additional Space"
       }
      }
     },
     "localname": "AdditionalSpaceMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_AuthorizedGrantLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized Grant, Life",
        "label": "Authorized Grant, Life",
        "terseLabel": "Authorized grant, life"
       }
      }
     },
     "localname": "AuthorizedGrantLife",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "autl_CapitalizedFixedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Fixed Assets [Member]",
        "label": "Capitalized Fixed Assets [Member]",
        "terseLabel": "Capitalized to property and equipment"
       }
      }
     },
     "localname": "CapitalizedFixedAssetsMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_CapitalizedSharebasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Share-based Compensation",
        "label": "Capitalized Share-based Compensation",
        "terseLabel": "Capitalized share-based compensation"
       }
      }
     },
     "localname": "CapitalizedSharebasedCompensation",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_ClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Activities",
        "label": "Clinical Activities [Member]",
        "terseLabel": "Clinical Activities"
       }
      }
     },
     "localname": "ClinicalActivitiesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_CommissionPercentageOfGrossSalesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission, Percentage Of Gross Sales Price",
        "label": "Commission, Percentage Of Gross Sales Price",
        "terseLabel": "Commission, percentage of gross sales price"
       }
      }
     },
     "localname": "CommissionPercentageOfGrossSalesPrice",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "autl_ConditionalPaymentBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Payment Basis",
        "label": "Conditional Payment Basis",
        "terseLabel": "Conditional payment, regulatory approval (gbp per share)"
       }
      }
     },
     "localname": "ConditionalPaymentBasis",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_ConditionalPaymentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Payments [Axis]",
        "label": "Conditional Payments [Axis]",
        "terseLabel": "Conditional Payments [Axis]"
       }
      }
     },
     "localname": "ConditionalPaymentsAxis",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "autl_ConditionalPaymentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Conditional Payments [Axis]",
        "label": "Conditional Payments [Domain]",
        "terseLabel": "Conditional Payments [Domain]"
       }
      }
     },
     "localname": "ConditionalPaymentsDomain",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_DeferredClassASharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Class A Shares [Member]",
        "label": "Deferred Class A Shares [Member]",
        "terseLabel": "Deferred Shares",
        "verboseLabel": "Deferred shares"
       }
      }
     },
     "localname": "DeferredClassASharesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_DeferredClassBSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Class B Shares [Member]",
        "label": "Deferred Class B Shares [Member]",
        "terseLabel": "Deferred B Shares"
       }
      }
     },
     "localname": "DeferredClassBSharesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_DeferredClassCSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Class C Shares [Member]",
        "label": "Deferred Class C Shares [Member]",
        "terseLabel": "Deferred C Shares"
       }
      }
     },
     "localname": "DeferredClassCSharesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_GainLossOnDispositionOfLeaseholdImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Disposition of Leasehold Improvements",
        "label": "Gain (Loss) on Disposition of Leasehold Improvements",
        "terseLabel": "Loss on disposal of leasehold improvements"
       }
      }
     },
     "localname": "GainLossOnDispositionOfLeaseholdImprovements",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent",
        "label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent",
        "terseLabel": "Capitalized implementation costs included in accrued expenses"
       }
      }
     },
     "localname": "HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_ImperialForestHouseLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imperial (Forest House) Limited [Member]",
        "label": "Imperial (Forest House) Limited [Member]",
        "terseLabel": "Imperial (Forest House) Limited"
       }
      }
     },
     "localname": "ImperialForestHouseLimitedMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Net Operating Lease Right-Of-Use Assets",
        "label": "Increase (Decrease) In Net Operating Lease Right-Of-Use Assets",
        "negatedTerseLabel": "Right of use assets, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_IncreaseDecreaseToPrepaidFacilityAndManufacturing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) To Prepaid Facility And Manufacturing",
        "label": "Increase (Decrease) To Prepaid Facility And Manufacturing",
        "terseLabel": "Decrease to prepaid facility and manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseToPrepaidFacilityAndManufacturing",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Other Assets, Current",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets, Current",
        "negatedLabel": "Prepaid expenses and other assets, current"
       }
      }
     },
     "localname": "IncreaseDecreaseinPrepaidExpenseandOtherAssetsCurrent",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_IssuanceCostIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Cost Included In Accounts Payable And Accrued Expenses",
        "label": "Issuance Cost Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Issuance costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IssuanceCostIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_LeaseAssetsTerminated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Assets Terminated",
        "label": "Lease Assets Terminated",
        "terseLabel": "Lease assets terminated"
       }
      }
     },
     "localname": "LeaseAssetsTerminated",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_LeaseTerminationFeeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Termination Fee Expense",
        "label": "Lease Termination Fee Expense",
        "terseLabel": "Lease termination fee expense"
       }
      }
     },
     "localname": "LeaseTerminationFeeExpense",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_LetterofCreditCollateralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of Credit Collateral [Member]",
        "label": "Letter of Credit Collateral [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterofCreditCollateralMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreements [Abstract]",
        "label": "License Agreements [Abstract]",
        "terseLabel": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.autolus.com/20210331",
     "xbrltype": "stringItemType"
    },
    "autl_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreements [Text Block]",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "autl_ManufacturingSpaceInEnfieldUnitedKingdomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Space In Enfield, United Kingdom [Member]",
        "label": "Manufacturing Space In Enfield, United Kingdom [Member]",
        "terseLabel": "Manufacturing Space in Enfield, United Kingdom"
       }
      }
     },
     "localname": "ManufacturingSpaceInEnfieldUnitedKingdomMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_MaximumNominalAmountOfSharesAuthorizedForGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Nominal Amount Of Shares Authorized For Grant",
        "label": "Maximum Nominal Amount Of Shares Authorized For Grant",
        "terseLabel": "Maximum nominal shares authorized for grant"
       }
      }
     },
     "localname": "MaximumNominalAmountOfSharesAuthorizedForGrant",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_NetIncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase Decrease In Operating Lease Liabilities",
        "label": "Net Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NetIncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_NetSalesLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Levels [Member]",
        "label": "Net Sales Levels [Member]",
        "terseLabel": "Net Sales Levels"
       }
      }
     },
     "localname": "NetSalesLevelsMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_OfficeAndManufacturingSpaceinRockvilleMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And Manufacturing Space in Rockville, Maryland [Member]",
        "label": "Office And Manufacturing Space in Rockville, Maryland [Member]",
        "terseLabel": "Office and Manufacturing Space in Rockville, Maryland"
       }
      }
     },
     "localname": "OfficeAndManufacturingSpaceinRockvilleMarylandMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_OfficeSpaceInRockvilleMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space In Rockville, Maryland [Member]",
        "label": "Office Space In Rockville, Maryland [Member]",
        "terseLabel": "Office Space In Rockville, Maryland"
       }
      }
     },
     "localname": "OfficeSpaceInRockvilleMarylandMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_OperatingLeaseRentFreePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Rent Free Period",
        "label": "Operating Lease, Rent Free Period",
        "terseLabel": "Operating lease rent free period"
       }
      }
     },
     "localname": "OperatingLeaseRentFreePeriod",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "autl_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares [Member]",
        "label": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary Shares",
        "verboseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs [Policy Text Block]",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "autl_PaymentOfUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Upfront Fees",
        "label": "Payment Of Upfront Fees",
        "terseLabel": "Payment of upfront fees (usd/gbp per share)"
       }
      }
     },
     "localname": "PaymentOfUpfrontFees",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_PerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based [Member]",
        "label": "Performance Based [Member]",
        "terseLabel": "Performance Based"
       }
      }
     },
     "localname": "PerformanceBasedMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_ProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales [Member]",
        "label": "Product Sales [Member]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "ProductSalesMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering [Member]",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Underwriters public offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_RegulatoryApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Approval [Member]",
        "label": "Regulatory Approval [Member]",
        "terseLabel": "Regulatory Approval"
       }
      }
     },
     "localname": "RegulatoryApprovalMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_ResearchAndDevelopmentClaimsReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Claims Receivable, Current",
        "label": "Research And Development Claims Receivable, Current",
        "terseLabel": "Research and development claims receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentClaimsReceivableCurrent",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_ResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Tax Credits",
        "label": "Research And Development Tax Credits",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCredits",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net",
        "label": "Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net",
        "terseLabel": "Right of use assets terminated and obtained in exchange for operating lease liabilities, net"
       }
      }
     },
     "localname": "RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_SaleOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Authorized Amount",
        "label": "Sale of Stock, Authorized Amount",
        "terseLabel": "Sale of stock, authorized amount"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmount",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_ScheduleOfLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of License Agreements [Table]",
        "label": "Schedule Of License Agreements [Line Items]",
        "terseLabel": "Schedule Of License Agreements"
       }
      }
     },
     "localname": "ScheduleOfLicenseAgreementsLineItems",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "autl_ScheduleOfLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of License Agreements [Table]",
        "label": "Schedule Of License Agreements [Table]",
        "terseLabel": "Schedule Of License Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfLicenseAgreementsTable",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "autl_SecurityDepositMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security Deposit [Member]",
        "label": "Security Deposit [Member]",
        "terseLabel": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDepositMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "autl_ShareBasedPaymentArrangementExpenseIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Expense, Increase (Decrease)",
        "label": "Share-based Payment Arrangement, Expense, Increase (Decrease)",
        "terseLabel": "Share-based payment arrangement, expense, decrease"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementExpenseIncreaseDecrease",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "autl_UCLBusinessplcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCL Business plc [Member]",
        "label": "UCL Business plc [Member]",
        "terseLabel": "UCL Business plc"
       }
      }
     },
     "localname": "UCLBusinessplcMember",
     "nsuri": "http://www.autolus.com/20210331",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r285",
      "r286",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r281",
      "r282",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r191",
      "r209",
      "r210",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r191",
      "r209",
      "r210",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r197",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Subsidiaries"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Total accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r151"
     ],
     "calculation": {
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r40",
      "r41",
      "r42",
      "r339",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r43",
      "r81",
      "r82",
      "r83",
      "r284",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r247"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r212",
      "r214",
      "r250",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r214",
      "r241",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Ant-dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Asset under Construction [Member]",
        "terseLabel": "Assets under construction"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r121",
      "r130",
      "r136",
      "r142",
      "r281",
      "r285",
      "r287",
      "r329",
      "r337"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r37",
      "r77",
      "r142",
      "r281",
      "r285",
      "r287"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.",
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "terseLabel": "Prepaid expenses and other assets, non-current"
       }
      }
     },
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r215",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r23",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r67",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r67",
      "r72",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and restricted cash, end of period",
        "periodStartLabel": "Cash and restricted cash, beginning of period",
        "totalLabel": "Total cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r292"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r77",
      "r93",
      "r94",
      "r95",
      "r97",
      "r99",
      "r103",
      "r104",
      "r105",
      "r142",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Stock par value (usd/gbp per share)",
        "verboseLabel": "Stock par value (usd/gbp per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Share value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r53",
      "r333",
      "r344"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred cost"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r190",
      "r192",
      "r194",
      "r203",
      "r204",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions to defined benefit pension"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Long-term deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r64",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r64",
      "r119"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per ordinary share (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective rate of income tax (percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r259",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.K. statutory tax rate (percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.",
        "label": "Employee Benefit and Share-based Payment Arrangement, Noncash",
        "terseLabel": "Share-based compensation (net of amount capitalized)"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share based compensation not yet recognized for unvested shares vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share based compensation not yet recognized for unvested shares other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share based compensation not yet recognized for unvested shares"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r102",
      "r143",
      "r172",
      "r179",
      "r244",
      "r245",
      "r246",
      "r269",
      "r270",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r147",
      "r326"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyRemeasurementandTranslationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement and Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.",
        "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases",
        "terseLabel": "Gain on sale of leased Assets, net, operating leases"
       }
      }
     },
     "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedTerseLabel": "Loss (gain) on termination of operating lease",
        "verboseLabel": "Gain on termination of operating lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant income receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "auth_ref": [
      "r64",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.",
        "label": "Impairment of Leasehold",
        "terseLabel": "Impairment of leasehold"
       }
      }
     },
     "localname": "ImpairmentOfLeasehold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r64",
      "r148",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsSubjecttoAmortizationDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r121",
      "r129",
      "r132",
      "r135",
      "r137",
      "r327",
      "r331",
      "r335",
      "r345"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r261",
      "r262",
      "r264",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r263",
      "r266",
      "r271",
      "r274",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r91",
      "r92",
      "r120",
      "r258",
      "r272",
      "r275",
      "r346"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.autolus.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r72",
      "r254",
      "r255",
      "r263",
      "r264",
      "r265",
      "r267",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes and Income Tax Credit"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Long-term deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r72",
      "r146",
      "r322",
      "r323",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets Subject to Amortization"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentiveReceivable": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.",
        "label": "Lease Incentive Receivable",
        "terseLabel": "Lease incentive receivable"
       }
      }
     },
     "localname": "LeaseIncentiveReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentiveReceivableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.  The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Lease Incentive Receivable, Current",
        "terseLabel": "Lease receivables from terminations"
       }
      }
     },
     "localname": "LeaseIncentiveReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease contract term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r77",
      "r131",
      "r142",
      "r282",
      "r285",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r77",
      "r142",
      "r287",
      "r330",
      "r341"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r77",
      "r142",
      "r282",
      "r285",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r52",
      "r65",
      "r77",
      "r84",
      "r86",
      "r87",
      "r88",
      "r89",
      "r91",
      "r92",
      "r96",
      "r121",
      "r129",
      "r132",
      "r135",
      "r137",
      "r142",
      "r287",
      "r332",
      "r343"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to ordinary shareholders",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "terseLabel": "Supplemental non-cash flow information"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of geographic regions"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfUnitsInRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of units in a real estate property owned as of the balance sheet date.",
        "label": "Number of Units in Real Estate Property",
        "terseLabel": "Number of units"
       }
      }
     },
     "localname": "NumberOfUnitsInRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r121",
      "r129",
      "r132",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Total operating expenses, net"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r279",
      "r280",
      "r283"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency exchange translation adjustment",
        "verboseLabel": "Unrealized gain on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets, Current"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r32"
     ],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r193",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r207",
      "r208",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets, current",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds of issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Patent costs"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPatentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r150"
     ],
     "calculation": {
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r152",
      "r342"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r72",
      "r152",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment (useful life)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r253",
      "r372"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedTerseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs and Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r9",
      "r71"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted incentive shares and units",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r179",
      "r247",
      "r340",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r143",
      "r244",
      "r245",
      "r246",
      "r269",
      "r270",
      "r349",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r77",
      "r117",
      "r118",
      "r128",
      "r133",
      "r134",
      "r138",
      "r139",
      "r140",
      "r142",
      "r287",
      "r335"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Per share price of issuance (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r214",
      "r240",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Share Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PropertyandEquipmentNetDetails",
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r9",
      "r71",
      "r328",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r215",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r220",
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Rollforward"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r75",
      "r103",
      "r104",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled of forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled or forfeited weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested and outstanding ending balance (in shares)",
        "periodStartLabel": "Unvested and outstanding beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of restricted shares",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested and outstanding ending balance weighted average grant date fair value (usd per share)",
        "periodStartLabel": "Unvested and outstanding beginning balance weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled or forfeited weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding (aggregate intrinsic value)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r222",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance weighted average exercise price (usd per share)",
        "periodStartLabel": "Beginning balance weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest (aggregate intrinsic value)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, shares issued in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r213",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedOrdinarySharesRollforwardDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedandOrdinarySharesNarrativesDetails",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r72",
      "r215",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Stock option vesting right percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r237",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable (aggregate intrinsic value)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term exercisable (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term vested and expected to vest (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r75",
      "r77",
      "r93",
      "r94",
      "r95",
      "r97",
      "r99",
      "r103",
      "r104",
      "r105",
      "r142",
      "r172",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOrdinarySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r102",
      "r143",
      "r172",
      "r179",
      "r244",
      "r245",
      "r246",
      "r269",
      "r270",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r102",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r172",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r13",
      "r14",
      "r172",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted shares - forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r172",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r172",
      "r179",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r172",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r172",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r77",
      "r141",
      "r142",
      "r287"
     ],
     "calculation": {
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.autolus.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r299",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r299",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r299",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/NatureoftheBusinessDetails",
      "http://www.autolus.com/role/ShareholdersEquityOpenMarketSalesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "U.S. corporate income and local taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/PrepaidExpensesandOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/ShareBasedCompensation2018Planand2017PlanDetails",
      "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average basic and diluted ordinary shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.autolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40010-112707"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40019-112707"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121566025&loc=d3e44908-112734"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r373": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001730463-21-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001730463-21-000008-xbrl.zip
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MC6!N3#[",M@8.4QDX),09@(C 0N7++N2=?L<"T?W';=[I:5>6KMYS+A9H9C
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MO(#GLB]5>J4]T=@3$KGTTKE$P%V.*F]63;I,B[AW$O";V,W%J$"^&Z'3ZK8
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MU*'$E0&VI 5R)$;D.24,"VLD=94MW56RS3:WN%Z_["4! SD[CJ&T?X_#L2V
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MUT?OP?ZW,JB$--<,<8D3<LDD1.#$U%@8^+_,T61%]*[ %ZMP6P]! >:2+',
MZ-M[;9N/@.99)@#P32P9M[V_[>1?C!>_V?E[Z4[7^Y]8P!O^].NO+WIVW!N7
M]]DC>,^SS4Z(132IEV+\YM&P4;SRAKI<3X6[U>6O>V3_Z'WDRE&3&W7:7$L>
ME4 ::X%(C)0G 38&]CEV^8Q=<2KTGO*Q<##L_1)=4\X%4M+CSI\-=QB:-(QZ
MA1FSU$L>-',F$N(4LXX2A;7L]ADE%,U>U#/COO;9U_V??Q,'O[U76NAH(T/1
M.+ )D\7(&9W@]' B:BP!'0/L,[Y+M8"#8TVB0)L[="[^D%6LN)/G_N4NZ+_L
M5U[U)-\D8J$]]T2D)*CG-'!C.0M" ;@3K15E5=-^K*:]X\#SJ7$\I"21<BKK
M%T_(*BD15AI$IAD6##2-[A).=[6XV+7]SI+4. 'KPP!4"<,X%](Z G='DN9,
M&"E(UXY@G=)41\,&6O#G&6@!#_D4T!(13CCBU.437G)$7,+,8$M-5&#M?3M?
M[8X=#1NQ24&Y<Y&&P'(3J@2\4A'E6="!B%SO<P7V5#9YUVSRZ_YO[X'PDR2"
MR&W?RRRO@'0>%R&#YS%90IU6.<HDGUW,L;VFD^'A)*N=*[T83]V'Z$OR<-,?
M?VQWQC37MDQL?SC)IERVQ-K ;[3-X R-)V#/=24:^>]=3W+7'\W+BW+E1H#G
M;LZ6TM9W>VXZR673\S*/R6AW5BI5[$K7,M(XZ4]&0!  T8?PT(NBI5QBU1\.
M1Y_:(L/\8=BYL*(9_H>]C_$LH\1X-!S&P6Y&!OCHK+_Z<I74XCYW6PK<+VW3
MBPE[E(MVAN5V &6F@_:KRK+DI[2N/^A/SO)JC&.ISUGB+;X=AI7_F*898>;U
MD,]Z;YI1SJ',A4.A%+..<WE/;CHV..NL[N6E^)SKFIKXO],^?$4NH.JG7)8R
M6?ZZ'*>Q0*#*S2U_&*SP43-9*1G(!5V@#&4)2[+F[ >XD8*-;4NG\L"C7$AV
M"@OVR99E[.>RM%'1@TSG\K2O\E2EU@K(6_=UZV_WI 7<4N]45@>0.< ;,W[/
MA56^O3],C06=@54JZSK,H]K!%AGG^K*%F%#;$#_?,URQE4<_5P*]_ 1V2S\M
MGP)=[D*I_2JKOV:52I':>.I]'(^!M,*B3?+&F.\!(+=QN)LO#)]M5NVG3DIE
M_AG\&VY@"LRW&9W,"L[*EQ8GR&/##J#M1<F[TJJ%JF>%@4>";V\WU/R +NO2
M%KH,"EW+G\LJ ]NI[*5.CN>_!90X;Y2LGOE%%OQ@-,[YQ.-^WK9M99>/)3]E
M6><S/>C>>14YO.7Q4'"LYTT KS8XW_=CGLT\.HF_PCT_W?/[PT>V?_3>Z1B"
M5181;"3B."FD<STU'.3)&ZJ$E65X\AH/T"PQI"#()E*_Z82?*O6;2)V__OP>
M1Z:QX@%1@3'8!YCEO-B(@F<<:T&BC=E*-&N(VESJ\R+JXR;&'C"7R7&N;<Y
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MQ2EBBA$C5H.&@YI;S2C"27I%O6 IZ0=JL&71]XKL>TO"?Y2!DWE&VVS'SX,
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MZQC@+L?Y^E]+3G1LZ6AC3_MQ_,_E.?.+Q6B_K[5#+CVWFW@$/]_*;.8-3VQ
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MET_98$1N +@96XY6B_A]^3-'!GJ]UL_>KD:=G2.'38H3! $4Q +JY3N0_G]
M)#HES#&%%=EZ0V#;B\9E RC0SFV._9X1J^;8'^38N^='5BFF VZAI3H!-$D<
MX)"&(C0L>((MH\QMO<%\];&7N>.;1YS:*X:R-)7$ZTT%T502-Y7$-QG"<FU%
M[X+UF"K"DM0Q0E-.50@KIHQ8#IUW=EG*U97QQ"=U%:_DCUF13/\BCH3V8GU:
MC#/TILBU@ZZB8=4;KG2WKVIW7]'H?H,R[>M-]DW9]%OZYSL%9.E:5Z[PI7^)
M^N" UCJN$O5GXY$N0HGYW+TXX'ZR%A9ZU;2.^6AB1&THJBN\%"D!)<H);MG-
M1KB%<&TOJY;7&_X8]?/ZT!!E+<.=O;";?G/S6&D$P"@;O&LC3'-_KNQA]+Y5
MW(%07SM:S3K*GLB^*]:6Y\K+>H=Z1C_4$!8WW6Z%>L1B=/O\?H1(<FT@_0J?
M,Z3DPPZ%^7>A%N$BE"7X!_87CG6P10%=7F<V<P%+?ZS:R]'X6 Z+*I^"S\O/
M9*&:)=YV,0XN^Q>7166!W^SC<4$,2S[AS,OMA^/**<;?*A[:<#SJ]_-(=;'P
M625O(7#RNKE(3K&0M^C7S3, Q>9*$^I:]455,5'P9;TD^BKJF7^V?.-/IZ9,
M:@0\C>H88BYA_FS+V]4@V6NUAK,:BFO;R1XY\QAB"W^%T,+;6F1A[ZR8[OZQ
M+*8.S?ZO&;C_W1%*E4:APH^(U($PV@PH!C4PU$*J'-5$HZ7P7VJ,0)P20Q45
MABF;.BJA]_-PXK2Z$K/R!:F\2$0@4E&K3D:_@(9;B263S8?A"C63IR&]L@IP
M.^=R;++Y(N;C6/P4A?.*>J[PA>VE^%1QN[41P/JMBWO&VQ3J<G#6'UU86S3\
MY[AEX0/!*_T1Q%=0=?K$VXG]6@N.+#51U-N]O/%G&&",XWMS()RU_H*\4-L_
M?]0/Y26*2K&X-[*6UO67*U<0BQYF,V[B<\0@;/WO<QGU1JLJ/6^W!@&KZ:QO
MRR?_+7RZ",OE#PG*6\B)5STJPB,7N*%ES*X]?T@SR*K5QW75<X0!XGXSMUOO
MEPBAZ$Y:M_7%0)_10(5)X\5>E#L8WJSEGF>'LF KW89><DS5<D%7;-,-CO:\
M;!&0(0'^HW(39'W5Q6(\A_I;A;ZEW!Y3>>/40K%_4>$?UIRY(H)6FIBK-B(0
M2P7S6I8HFHA@\0N(H$!-]0-=YO/8\]$/>=-HF.1%DZ%UH1( [?RUE;00;>RJ
M+6Z&MGL+VB@HH9C_7-9O%"9T7BT]S%%#O-4<&[6N7W+^4K"5^I&&^][ *B3D
M8#9[HV#0P'#%%\O]*>H;RMG7<;OR5IBUW#'+!=5AP[)JIV:];;-%1BM_+7,L
M%%M4$J]X,^9P@DUH^T6E<I2GV[\ U:YML/'_.9M#W86]G821L"/MO9=?Y:GG
ME7NN+ +%%:CXA6+I935=4TB^.5JM<>)??:F_@R_Z9-0//M]9"?VHPP<&(V/[
MVZTOGO)#M*V55J'H%343U9CU:9;G)ST?#FTN8:..JJ\Q#+<WMC[5O9CEWHKE
M[16.S^U&M$<XRZ5UA*NO>K!J<F<L@_>.86R,_./&I'(6_.CA,>A;EQ/&9MC1
MJZGG7=F_\&,45&!HDB@JX.L_RV=_9JY^Y&7<<NM:S[DK@3USG\#O"PA1V#!I
MHW72\Z;.. 8^8GPI]!+/'>Y<16/@VM%TW-K9_9(+REDW2^SWGFMJQ]M)CE ;
M%>+8AJ$:WCP.0B/.?%PP)0/SU%936T'Q9KQIWJB8+<")Y;*K]I4Y8VWM5<^F
MRI^<MXXGN<U[9@M,5#DLF]'S6Q0&3/2:8_1JU/)+R/5^-!6\D+2%IIAKH,\#
M/).Y-7BQ$[I+CKT%4 79YI85HI%A<EVQJFHV9A ZBW-Z?SFQ$@CI.?ED3ICM
MUXDL1PU>7>I75YY9//D8B:T:CTS125\>>.$!9I'?G.>XPM4KK=::KQS=XM#]
M[H\KD%CQU;.^](?]PU-JOR_+;Q<+^$5I)$R# BZDKN< $#:*6L:KUQA,J1HQ
MJ. )._]V<!&+IL&OVU^\H!Q'M^&B==$+%:.>\7_$L*QU+HBAHC<R2IO*!IL+
M242[*KQ=FD&1?&(SYVS^G)=X<W@**TD\C_;\FI1421O_0"&E8K8WQ7A96EE!
M"?Y0+NUX%.AH3K>%T,.L:79NGE;LO8T3#6/#:'G!F 0:!=TC/9U%P54"==NL
MZ"8M==Z9O(@9@84+E'#!HY"7L'E[0P3TO*:8N:D>N?KP$6S*1YKRD9N4CUQ;
M#K*0Y.$R211CQ$!M*4-&*4JMDH8398C0UZ1U;BC;5Y=)7Y=>VA2=\'XN)+(@
M(#=&/U3!&W]&W^UD/D&S:)5&CZD&]E(+8(303MT$T/U1#.5$'V/.XRH435=F
M1OY?ZT-_I (I1V2P4#48%E$/#<VR2+UBYNV/&9CR7Z,YFV))'3S):.Q\MN/;
M4(HPU!?[?JU9'K_/=H8F_ID7'S1 AW[-G2.%,9&4$P!E"@$E.@&<)QI8B$*K
M0\J\//E%<L0%:;1*VFA]MO4P?C"2:O3QBX2"9]4CO0+O\);54,$<#%]QTV%D
MHU"J4VS@0FKA;#0-J0VOJ_U2C@,VXM!.@I"MH5#52U_\"D8!HZZ8Z%U<-=8Q
M34[*,%.T1)=O7:1(*CCW NQLS6<G!6)="(:7LV+/QC9T[^9YI15PAR:V ^8J
MH3L:@D'Q-/DK-WND<M!L[=%NN>[<?RN6G#_$\L++H'UT'F<";[OUKOSF<3SY
M8IA07$4OZH.(2K.PRHOZ-?(%+XX>JN %R^A> +&)H =EX+\&EU:XJLN5!?G\
MS=;R&-_-F(USO48IQY+\%8.?^_)G,QTGQ]F >SM'A#OE[58,2*H4H,8Y(+#D
M(!1 <XJ0P<2K$K2-UT_'B2/O%HDC'XOE6D_:X9(T1'$7HNB0T+6*K/<$$DI
M:@D%5!L"N(44>,N#8LB9@T9LO:';9#TEW*6UI5Z,'@MBENEH6;KEFL>_,AK8
MI4%KV5U*SU^DY1 */F;&0 UT:SH.D^^R<C3>S:V(>1^F5LX\*4RN4AG&0*D)
M$++CK)H[N*AG5WY]M;I<K]RC^=(/NNJ'#9F?,B$TS H]O7QM&3#5CI?N4:M0
M6H GJXH]PN N.ZZJ-<K:K$$Q_6_^;E4,L)976GRL:DM+[1_3_'/JOV;-SF$;
MEW/]ZH2_6#Q<'-3_9#/='NJY%_EE23S/[A-\SW5S"-MY@C!'88F59FOWJ$%0
MN+D3')LL_Y%AG%3LUG_U+JY_CH]'U*;22I0")E$21JY:( 5A@"#(<2(3*7&Z
M&%%CB<8.2@F)UU2"2\$T35&"$LZ14W0)-2'?]%>&D7#M)LU//RM%ZUF^5V?C
M418QAPI+KX0S[=OC"A&@K,XJQ$[>7Y)W@G@/+*16L[*8K_AXCKB9ESM($P1:
MJ!:.CDBU@+)'7A?U$K$0]M9*_F:=_<7#5O=^>K=F:3"SLUD6/<WWUK[F@9Z?
MJ%_#D8VA=NN\=1J AB0Q0+)$ IQJ3AD1:9K(,,4SN=I/>59OI#G457[HZ2?:
M.3]"*4NA<0(D#G- <>J (MX/X0BR .P"M<+A?-DC>A]+S:B/BIX4K=G/>?EP
M>)!7;P5@3Q9'G-LD3;@!@E@"J.=V( Q, ,(42I5RQ9:U^@NU+C_$!,W'Z,3^
M L;'_LE\Z4/5B5GU31:UPOET^B(F/<F["GH#-1UG!7QY51=Y$^R>UC_E!))9
MZ^=27?Z](@5+W0O^,K,QI"N::JK>E++OU#O(M9JA-=\J\G5QI;%"\Z3 P(RU
MH-6HD5E33VBTD*$Q*+APO4EMQ+W?A[/)K-&EV-QRJE*H;AJ%F3,QY#\=VX5V
MLKG#*\ZLPD6/\$?'84>&=8S(?,O/Y$6L0\E/N$1GFL/VKK?TAO*)V$ <IF?D
M3YIC9H:X1G'C L/)A9Q%2&-&G,RE?J;0G9W5LIY+N.C]WG?;[YV,1B9'."C&
MUA0 [VO?+_>PRJ76RL?*N;6#T22B9]GA_$?G*;!^NLO;7;]L648TOZ3\.<ME
M%<CI=1<_YHMBG'-2[EU<1%C>LT(6%YKNO:>@MT4_]C=_J&^]]/)[,7[U:L\_
MQ]<CGB0(F30%6 7(0(()$*F6P"K#B&6*"+J$9><M8N?OIXRR_B?"7&!_,)8;
M0:'A.GGQ:A(3'&;D%5AT!1V]K%DA*+FJPZD7M59\K"P$;;-I(;P*7(1"V@7^
MWYG! 7SQDM3$JN2W(Q/T9#%#J:A)WODR@YG;'YUYCF:0M1^[[>'F=3YQ2XK#
MS/5**18*:5]*ANR92GSB NO;.=O&<F/7)P_6D-Q+G'.S1+NQH'44"#/ !=4*
MB^)TJPH#.@!2YF'Z&/\/(>S9@)5"7\\.O_:]XL+Q^T4B>C*:Q,Q&_H42LJ0J
M[9]=]VSLE6'O+*(!Q^O*"L12'GM_,!^&$YNKPS"1T%]I;=F)4XY(#%TUTKE>
MOY>##,<5E#,48RRJNE2E>F4<_95;*-'XJ6%GMF?C\?)<P?0LQ"'FNY]7 V7&
M2-OQM!\&Z/CUQ9E*8=!)WI@Z'EW(?HDEL[QM8YL/F)GM]*U=X\6&Z%M5$=^<
MG*_ABZ8<^0U"33ER4XY\DW+D:\N+%^Q'3+%.)4,)A)0ZBB07"6<P21.KF11Z
M73[A6KMS\U5;.<MS"8LI:#2O2B)R6(7-6U,_:C&R4/=#6V[:]\JCGQ?OC91_
MZ"*PD#O$$9ZXU" +/FP!5Y'-MR_'>5_9'ZW?>K^7J&.EN3=#4AOT GT=CT*C
M48B>E' *1;2C!,'ZTU_%7V:I**P^?_F*J\6I;35,C=KCU7WZVM7R?)#I!20#
M/:DO)TPR6QAM&5?GEU<O]5RNE<LKH^OW*ZX1L6:&L0CZA_3G%Q3QW+#,</T?
MOY>#.VH;N'3UROY>_;"SK/^L*S^S_7Y5MYW]&97H;_YNXUETMTY'$0?EM]!<
MF/T^1P0YCDE0ZS$PLGH%#VU[UES!S6T8B[9HZ0F&W$G<XTZ)Z_.NGU/,SFQ^
M^(U0$U<_\ 8(J/B\'UW-BBVH<L7,24]\WCB<Y@9T/J5W5:2J8L0JEI>7?:RC
M\U+>S.I)UTYSKT4Q*W<VWF7>-&Y[^]>_[,_)V7S ;3'"MQQD6QKLD^5^[O*]
M4,0<.-;9$L2P]JZM8J#5"Z'_(0@#_\%I0+FO(>'');;K'\\CC]5,SJIK4_D'
MZ)=!V&+7<DF9K9G47>+_Q6%!^52@\#DO=0,R?"7[0N^]-6N/8.74Q!M],ZRZ
ME"8E_$[L5QV'W96MLU%OF(ODN,?%B/KJ<^TE;5@"^;A"0N?BKD!N#.Y%67.6
M"[J<'O)A!C5G[RIZN&KZ9*$5<KS0XJ:K!TV6CS*T <%3C@/ ;:QU6KY0;>OJ
MA0WE@FO"^_6X^SM+1YZM.?,2;F4TG9Q-)]6'\[G?M5<B1NE5=E:MV7[Y-O/L
M56KT168JH9266G!++HURHA ;5;-5$6;:;GTK8_?5Z- P[BMWKN42Y:^0?^?>
MZ O/%$ LPA**B5K7\LP56GXE]X;-7;Q7<9-BMHA?6GACY)?@J4.NE^[Y.54?
MF\O1O%X+(W>ZCH/@KE"9.Q4279EI?/F6Q5Q0<V8_YWPU<WQ6F])+?2;+)G1\
MPQ.G[465Y35].ZJ>$L&Q74STN_96V4F<@ZR6FUN6;IKKCS77*6ZTXG(1K[*"
M8(A58''I>6:Z1!XL;('8?!)]L.$D*HIQ)OO+PUP\*TT+:,(%;7)I"PX.4=$(
M9C9#19P.BXSIY&)IBLUD_:/UL@AU:?]OFC-_&$G8_U$F=7/CHW2G2AOBVMVN
M2")L>-;R(N(X %;(' -EDC_;:%CL2XC'3LY'+9N;X<4@MX4$9C%W/ )I%)Y3
MN[+7!C*HV@*^:VQ';KOU[]K'#7LWM\#"%1Z%T^L5\>)X,M>>17&UVK&V"T@E
M&8 $7X_B_UBYXW.,'@O <P^]9)F &E713T[S*[1A!<"^P!F+UZ\JTF.(NE31
MN9VW)A21$_8"?P<T*G]\8647)4$L^DJ!.B:%IU@: 8NTI6<:H&BHCER:@\3D
ME0J@_DH@[!QV(T_*SUNQ,X.E=MVJJF6&<5JE"?RR7!AFF >,8K&*]C[=>@E9
M%F#,6'<6ELA!RY>LV9FI7EA+_F#M63TF4AUY;A?G,B3*RN-1K:$Q *.4'0V+
MAOCKX9RY[&Z^4UDE:*\\]FQ!X/9RY-,UPCFW+%=*Z%R*3G-95I^SL%))]K(:
M*P\7-$01!51Y$T]A8\;QFIX!1X/*=YW1;DEANEQ9+GVM6:/9QK'_N-R@R%)%
MU\Y\7BR2U1P,<*G99FIC/D8;17ZUC)I,?SW$^&%GYY^\<B"<;L E"N/Y"N3?
M7EYW9\LSK\=K;V,1;+=V9O-6RWNL(N7\H(:CXD/UL%3$7%XM*@.U>6?<_@A&
M5G'Y:T[P(7*-FWNH[V/V]IK,[;P.SE/UD[EDA7]YS2D717;'.=3=J&@>GV6C
M:Q)K5NZW:) OI]NC[#B/L,BA@V3VT4)%%++($\6TBF_6H;2\CEJWC*JR($PM
MB:4 W@^N5T#6X^[U>LQ26A6&7_AZ:>-?.V#C11!+,RON=NEUW*37F_3Z3=+K
MUZ;+%]+K FOH%*3*<!4&E2E"G+ H30UDB<+FT0=TYYT%^_+GJR^QQ9W]=T>2
M8Z(@=\ ZDH" UP:D]K\Y2%+.7**0,$N(;0ESS"'HCUM13CD7&O/$)LBR5"7:
M7%5BNQ%ASB7^R9W]O!W"D\8O,5QN?7UM_IR3\)PUESJB LV!%5R48?2B*Z5T
MCU88$\:6J4?Y<QUD4EEN5T&Z%A&".*?:"ZH8J],%TE%>RC^;NQ.MF47C:C&4
M<2L8_:_%DY=8<-ZQ:L\]1P5X5'3#ENM?M^P95.UH,8B9QP&"N5E@)H0(R>I=
M*F^93P@8Y3"IN5-0U3ZW?BN2M;\O'^@XC#'/RD:(V>L1;35>+N]&B946LQF7
M,6$4TLO%"G^O'K=LGPAXZ:VS_C1;V*3MUN[\IOG;3_M%0MWT7($E'&I3)^?6
M5O4N-T;?B/:KW^Q08K*(Q5$?SK!B-W-7*T(,QW1G694;@VMY+9"_< %*4=RF
M+\_S@RL_%8?;#^/ O/P<<L3CN)2"%FH7G&UZN%(,T177+X KO/_6"S6YX7*_
MF)C)@^ZG!4+O'/D5'/MU&$R-UO_/.]DFE",7KDGQ<K1+RDBF[.MI?ZXH:?',
MPQ[/>*(:2UFD4ONUFK 5MYV[977P>6@O3LRLE2O,32O\U0YMOJ; 6_/]WF4I
M_PO$_Y72?;(8XC15[L+OE9<QO>RD"(OWIV4\NC\ZCTG7R&!Y,FDP&A=9D1A7
M&Q:1KUF 3=8GG*U;3I4^4N4S_#KL%>JY8M:@.)RKE&X,)IW9N.Z\L#ZVW^4=
M <7W9@HL:H*"3PLFR[RU'.19G! Z+C/BU3NGTW$O,[T2I&=MJ$H&F+]X^=P?
M_I'GZ8?VN,"SB(#=>5)T(+_G)1"]K!9WK=4SMJMQK/W>H)>KV':1!\A'P)FY
M[-;<QLRI R\N3A>-C]HFM"LM<-:7PV%>:QK$]W&OF"L[5Q(0R'A<).=RX>><
ME^UAZU<]J(D2*3[I?$5&)=%6,EJA-U;R2<FN?3L?Z;J6 W\5WJAJS&+F)L>W
MG)R/0"@1+M N"^.N2/S,:K#"4<]*4*IH?'[\11"G4$:N-\XFL>PXEMJ-*J$Y
M_V'_UW<;$.SG;$%EB]=CXC :'-;3WC @#R^'G*L2X97GG?D3\&NLC_WSUI/-
MATOZK_;\!:P^R5MG@@,=*JJC& BYVZ*^N5UP=5DM'#,(TU(ZY*6+!7+8V9D-
M8Z)C_=^D+,(I!D'G6Y/98,O5]Z:L)BN<BC)C'TVXHL:P3&24.U?5,X:,NM_I
M(H.Q5+FD;#\D0[*U>F/&#]XL76-[SM(CM27=X.Q6%YI6UEY^J-F*+,S<;>II
M]OR:M\6TK2S\E2N:#N?N4"VO7$![AC%0U*'D#DX$()(UWR]R2\T[6"&;[B-$
M-L'M+QH>2K>_]=8_7F_R@)AMFR(IU[3&7!?'F9.P%07/HQZL1:.(_G'<T)!$
M"85Z>:Q!C8K*G6P0#84HA4UO.FAED69C"/7,6QDV5D=]Z;QK1S5?5/IYH:G[
MTIL!48*W/N^^>YN/98^0-;/1,Z&<-G9 1H5?\_=MN&2QI/:\<;F*GPK0X5!%
M$=*GT1G.,])Q$%(^?V1L50%D.#T+8H.0;9+\=Q1SGAQZP<"((%HF']RX'9>0
M;TZNX(L 37'5D'DJ"[H6?)SX8G3%Y_ VZE=OG=L:XMAVOD77WFP5>.@:J?0
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MVU$VR=[*LYB$N+2FV,*=H8G[EF_;;N7[OF(2ID>)/R>B$@0,#I@45DH@!:3
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MWYX%?0K<Z;((V$Q+P,G6M37-K7,;&FT#-&"_/SK/_KA.(A2 9F'H5OT4TC4
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M&LW> *V\!.%\:<<C([.'*Z^Y2A;N%@<=)&$C F\E K_,1. 1H=P*12B0DA!
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M%,S: CXL0)XVLZQOI>C+I>B(MD^.F=&6R4P2:4%V !" /!FP2<8PC4UZ<VD
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M/'5/>R@QX(-GU9[J/\_>__-&=#[ZT_?]MWVX_U5[_TQ^.'PO.H=OZ(?]WD=
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MM#L]&\+5>R<3R#\_P^\-23$I%9?]_>7RB\^_=QO],)X/YU*^Q=>+KY=.MD8
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M8GA$]7$VCG^<C(>HY6F9@)A]&V3CC&>83S#),2*S+! /"(WR&*(.+&OC&X?
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M1#J5B=?XF]9&<FHI4VUV_SR(;*/93OKGFE&H:ZY68?O]\M.W"PU?C<LW+VD
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MA#R K?]1FWL=O)ND;N0GW_H?J=FPZ29JVD"*%KH[@]$__.0/F)5+.*;'GR<
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MZ\&X5C3\:8XWY]178,NOSG[W?U!+ P04    " ";@*92.<3$(?A)  !Y4 ,
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MO6$B0RF<U-0;!^C0 [&<BTDLL<PZP;CY':<-YD"R&WI-WB'KQSMD!68Q9:O
M2(R@N&6 R6K:?I2DIP@=)?:'],<SA71[V0T8(+Y/UO,[9&$TSG Z/4J@?4-I
M'2&HH,#3]W2PM1^HZ _I\S.%='O9;0S2_ML/:V(A+_&?[;OVO<9:OO N+\81
M+^9WJ1R\A]_:R_;:T>\Q1M?Z^P66> RLD$/E%<:,6=,F7 SMO"5@2GWZ^ZV]
M=O!N?RIKP0TBG0NYGA!8K]]@@D0,,*-D\;I)%ZWAN_T]$A(3:#U+= P&+>O*
M30Q\RARB0.:SC2C3V5<T[(A]C]J%/M)NT!'P5F:=%L^KV9+QM$RRO\ZSY<8[
M0I3(B\]@T9B:;!?@G=)0HA71,-TJN="!MJ/*-O2"<G.%PR XM(@6?"%Q=2 _
MNUJ\F\[&_YW3"(V6N=9G)24<J!A=/92K$(1W,4AG59/.,X_0=(ZJL9/<&Q1
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M-%00D0!0J&NGRE)'V+LDT J97).!WU_CW;2=(GX'0?PX[Z;98$M!5L>*U>X
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MFU6"60NN6+T6E(B1D,!E2=+7&EDPP41L4]W_%4:E=]'OPR!^G%%I)TTH.D3
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MWR J>=<+NWX(.,___B__/U!+ P04    " ";@*92*REEME*@  !$^08 %0
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M<H$XA4#E0AC[+U& (06!2#B24@N&!/991[J'F]QB4.\;BUK$Z)5JA/3D_ L
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MA.2/CM%&I8W+6A^RA<,=+^-,^'6YTJJHGLS;=[NP'HYBU=1J>[?X6!>"."A
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MNVV\^;=B43P\/<PR+FD*508DRB% F<: <R6!(%)A;?9;D/G'GHPB^M28<A.
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MPL#<Z:B_5Q&GD[I>4;II_WFC%6PZJ<9NF:;3%XS<OJ:-?/J[L>V4-#;=NIO
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MHYAI9:8B21("$+$' 9IJ$,<*44&R1.9>]:?/C#,U@ON\6S??NTS,223=V"H
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MHGLO@= 9P'OVYO%B="_)OQ>&>_'B:RI\;ES1[RWB-B?9NBY2A5*N,08BSRA
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M7V0WW]E&LOLBO\]5JF+6/N'7HA1L_A^*K=XNY!M6J1ECDL=9' ,5VX(U,F:
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M.K5XW.^OOZ26*M4FD2I*K;G C-VN+HGG/)0>GD.>Q8.K ^$V$C'WQL^/@QU
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M.<IIW%&IR0>)4T;RNK9'3.=Q&Y7/ULI;*U7:>#.:J%3:(N2)3+7UP!2@BB2
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M"RA!S8[6 <>U.UQT/S,\G"[J&Y-0%O][OQ2K)U6UH_E%;6>$)-P\-Q@0Q&.
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MQK7Y(N*<B1\VNJWJ7+Q\_*"8>=WGC!>Y2+9#1W$<OIU!*93D- >9#;=%2D+
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M/-#YPAX.=)%)9GS)I_FRL)I_4JIJ%SR35"LJ1 YRR2A 64( B1,&").<D%3
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MW9'K(^>T-N)N0-I[_^V6L?JD:.^V7U=K&QA4E"W^,-=J1CD1B:T<+&*6 91
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MN/8:+S4G]8/YZ=__3_V)^<,>^?_[__E_4$L#!!0    ( )N IE*=R(0Y^VP
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M.EU.,&?4.=1C<<F($1:)$2,AA5RXSRHR?L_9Z(#@N4U1)SC:0\T/(>8@F7<
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MJ* HX#=2!UL38,3N<'BY,QP&OW-I#H?]Y=B!@WGI1;V9SO)K^KB<>.U#EB8
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M\G)U@YG:H1F5Y(;L*QCG*Q_% 5HFP*1BA5.(3C0ZW+B?H'$]\H'U/F^@A [
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M:.3>1*UVGD$4T .2KLC_%4_IXX<%SI;DY-5Y;9N5Y@P+(46$&%(FC@P'Q%!
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M%P1MA>P]U=D!/*^:0OZVFL>__3Z;KI;O?_O]O)22*66S%QFXT+1S\FP ;7:
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M+KZM?W+(V?.VCVYC@[9@HXUA8EH'+F,$B[61<FT^%5*N&9)H3?;,.M:DH<?
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M,2KG=FFF0W+RK"><CGG6=1@F>@A #A3 7]93-3<;ZR9K=EZ_===@2('"!R>
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M.C"=[@^L9^2\:9MJ5F5-XB@B$PE5 1OH)YX)SV03]^#>+F;VD.=!PFHJMG2
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M9&Z,,P%+N[K?/1SP0#,KCDD@=T#<45^.5W6?MV^$Q"4C6((H!'FZFC@8=&3
MI0PHB',2VW5,V\,!#S3YXI@D<0?$'<$\]Q?)LYFT<8="/L7@>4F01"T+-R$!
MAJ(A>?+<>72>B;XB)^//>*!9'L<DEKOA[EN0S(<VO>!66&22G']$4-XK<"I$
M*%GG[%E.D1V8U;J-']G? )=CDLI=,'?HXUN&$^?%:H:[C.:E=OKBG R.6LX@
M= +GI(7B69#>R)1"7SW;VM#A0'W2@PG%-L/D4;NCP\EW(E5"-"6#M&29J!@L
M!(46K-2U'%%;:0_U^CW62K@>I*=#33 *RM]<=/AE\J7H.>=:DJV6B/^*?!34
MQ0.W.CC#"F;9USR;J2EPH'?Y-Z4.6H+ZJ$V"^_'"EPG';79%*$DFH?2@BLJU
MZ88!$9/W,3LNU('9!2,I</0Q[B/0!BU!?=3:X,X@ZI>I%G@43I#F+"P84,PB
M!,PDO$YEJ8U.Z _,,!AS_*,/JA^!'F@&YZ-6 B-<*Q9$S%D$8CO94LK$ CXI
M T9%9G)BF-711ON./GY_! J@$90GC?WOMX8;EP^JF1OVWAZUZC[JN,<>OH]*
M;H4JB<CH8BK&@HHF@>?(P5@546DGM&O2G^]8*KD]9BVX8C4;+9%U'T@UD7L/
M2FNDJSZ8B&TR/+Y7<H]$;[M*[C$8Z,"XNU_6Z:0A=S1$P.AHR]YI<D^)F*A5
ML9(GEGP3*^LH*[E'(>'92NXQ;.D 4TUJ-W/6V5BR^#R/NK9<2X#,2\B!VV*9
MC+;,D]%ZX)7<H["UCTKN,8SN .R/UP4'[SA7TH%RM5N4BA*<E1J,D"Y9Y8P-
M32R!;Z62>Q1(!E5RC^%8![";(/'&L^Q<%'1.S4GR@\K@>#!@N74A,%2JY%DT
MZC=3R;V+A;!G '0 ^7:M76^^=/4?/8SMG'!4+J7LR;/(')0@W1 <L\ PA)BL
M%4*WG;&P[Q-W?F-,#.V]M1">$F?'+)"/-X&-(C/.DP69UF^GWD"(PM'%+UDA
MAD8NFMQ7';85[B\'J'/1VQU1!]I)=6WB_DD'WD_X_;GE]A%W'WS</@+NY*N@
M]TE!9JG*2IVY*F4!1^X'F8;H6&X2U#B6@'N6)7B=)&A6 GENSH"/1$DFG(_H
MHXZES:OP]X#[2/2V"[B/P4 '1M/]Z)MW!H7A%K3E-?2@/7C%$W"+Q6=EL\0F
MGL51!MQ'(>'9@/L8MG2 J28A-I6#T99%2$P@*"1">L,$<!=<QI18DO-DW!QX
MP'T4MO81<!_#Z [ _IBQ]_[W/S=A7+1<L8"U(0SRVI@6P7,E(7'K59:"#/M]
MM%"]OZO.PRG-0?-\ 'X'#FX-Q\_Y+*PF F3- 5\L/USU13;%JD#>KDE&@(J:
M04 MP ME9<Q)^]AD%L*=/1Q+<'R7VWQ;EG2@WC9;WX@94]E@00U!1D4F=@C@
M$C(P447/K,DA-!E4=V\7\ZJOK7GY.":V(&P'J'A"F-;20@)%0O=NF3<*U"M6
MJG0 '9'5/*@,J)2&[%E1PJ98TCX+IQ[;8Q>(V@8)P^RQG=ER$(C[X]^KS=&B
M\4ES(F%BBJYLSP,$)A0P(B +*6),30;^C=CCO+?B/A&W'5OZ1=R8MP?CLS/1
M1.")B*JDK;Z5CV2:<AMDRL;;OJI$QJ4TM"OV[,)JVS, #AGRZU\V6N7J;8N?
MF*2UMI8TRGHN(*N-=')M56R]5B8(XUA?_04?.43GGO+$ )P*_[NBH1=)""^?
M/3QW]O>U].J<*! K:C[D$^V<S4K3E6>T U6$!B<XW;0Z>I^LLB*U$XFI3W/P
MF0$[R\:L^.A 2.;+3!+2VDA&*FA>:VML9G7R5X$<R8[5(GCI#ROW9I(,N/Z:
M;TPC;(>!LV,6R,?SE1 5TUE&T#[75HD>@=RX B*3/T<&=VY45=!A!EQ__2XZ
M%[W=$=6!O&W-G*LB[ >#U)F1QED?(")A7F5B%IK:--@7:[P(5C+>E</TV"D.
MM#G$S![3SG@X^'30O22!SI/ZV7'"I^"2R80:A(@"5&T.ZA,3H$T)0I@H/&^B
M<HXEX3.@E40J!\(IL@\=#^!B\!"SU5QIR81J,U[Q>\+G2/2V2_@<@X$.;);[
MV5]$P& R>K!D7]$=HR6$2+^5')&CJ$^$33*^CS+A<Q02GDWX',.6#C#5)*6K
MB)*CYAR\%+$:8@*<M@Q\<=IIY4CZYYFG>> )GZ.PM8^$SS&,[@#LSZ<+RA(%
M=U<M%,EH5[7^0 H#7D=%SJM7,36)3'YK"9^C0#,JX7,,![M(^)S Z4V%HT*G
M@<5"EE0H"%Y@ H%><N=B9JFOV<7C$A4.(+UT%]MASP#H0 =O?>+MAG@YB;H(
M(0 =:0.5B$280P:1,I,2K4C)=B4>6QVS\UMB8A#OOQ7KMH@Z[$MF]"RZ9*)1
M+!F03-'-KMGZZN40E3&)Z:B#/51A&S'_L#\YVP/09YM_. 9SW]RDI!.;<BH^
M2+#"&/(8L0#M)H'AZ)5UP7'5I.IC7P<\T$RF8Q+('1!WU.;H@ZGFVG"I#7K0
MEGY11!CPJ@30.B1IDBO!BL.2Q/L'/- TIV.2Q!T0]RU,Z_YZGGF,1G(O!8B:
M&:8BUARQR""(J# D+"4<YC2@D6+97PK4,8GE;KC[%B3SH4UOL<2 2@/GPM1N
MIAQ\-@@F2:D*DSJ:;\"/["_5ZIBD<A?,33I+IVN!'#5/J<XE+IY["%CJT&))
M&LTZ!M%KS-K*D YMSN96=#A0G_1@@K'-,'G4[NB(L6+<*X>FMC#UM9:)VP1>
MLU";XQ?)R;D7L:]V[ON>D'?($=YVTM.A)A@%Y6\N.OPR^;1FIFCCP*S[<M:6
M#YBT!6:\S88[PD%?71"FIL"!WN7?E#IH">JC-@G&CARW15J%J8"-1H-"TJ-.
MDU_',$3!M4<_T^"L?5'@Z&/<1Z -6H+ZJ+7!N,'CUD<90H$4BJPSKA#0UO[=
M!B-+O%9^]I5U..GQCSZH?@1ZH!F<CUH)C'*M@@XZ5BDU1#.O"X0B.*2(* QR
MH?' 5,#$48)#CM\?@0)H!.5)8__[*-E^@L*G:S5#_S9Y^?;0!=N5<F]UY#[*
MN@W=1$Z0\ C# RA!^L]YS:&PX%Q!'F3\/L?GF6(,(UWFB2F(1NC:;T&"DS%
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M8-((W^"Z>'/]WOX^[NJ[?F]X?'),,RT]&9SL'R((SG501%<Z7O2\Y5V/5$Q
MDT^U1DBES;?L8QG]O^VFCH[:-S4\.AKZC5T!PP,N85;A,BJ@@LBL<,=1")""
M* NHE<,M&_**E%LE"\!/)) S!.:\VIL/W^) U6;33'[B<06-.[8(_P/OX_ I
MT7!M6 WMG ][^2V\F1LIY\.437Y+@.;DO,_K"&XM @X8$.@(6L&9XOJ=5S(@
MFU&&5*D3Y<_*(HW+W#=(CP/)(V#J<SA:^TA^OM;-7X#4-G\J<_,#+"Z/X(2
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M6"*3D>'-A/AUH8-I L<TB9 57O-&= )L0<-9D%"O ^"70!-@.% :=>@3-\U
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MQ,SPEXS,@VB.S"2$C%F1CTC+T@'+WFQ@)ULCVO70Y(=X2Y)KXIC?K-D0!,J
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M(T%I>:H1$0H77$<JN;3^ EA$(II L$!!!.0-[F<Z 4J8>\_C- =:^7T/;HP
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MCFBC0\.IP$]E%3/ Y^$;BM:N2U&<#";8DPPR2C_3#_U75D8AJ3"F##ASHJH
M[ )9QY [.S$-S4.1&YW_J4-CG,T%Y^&*--G5 )OT>*P#\L%DPH+[^W]]'#?U
M'X!S[9V%"/6?U&>2\_]S]LE'D!QEJ9)@'Q PR("GR#_.P(NNI#CB<+U)FH8L
M-Q@OG3=:X$![>$<YY[X:VPH*2ZP32( "'2O)8X8(PI #)EL(!8B, "1 (4+-
M)D2FUSB!-R\S4%))/.2W>2VH0YNER$I#W)2BK6*Z;6S"#:/D*HU,X$%42^O]
MY_N/YSWO D@N"%GH>J 9542' 3/#T9"94@: CZN4<:  R%YI*((Z&FP9:J+P
M'\^BD0I/U/C@>-0?]@_ZX>CT1 VU'@U&H_'A*?SW?_K[SVX&M=OD/MY] 0Z3
MW$_A3'!I'ZQW96G-J_:S+>998D^@T;#L_8G4MO>LMKU993U?MMFL;5K;!LJ!
MG+F*SY3 SG*&3HS_DC$MLR%KJ,S;.]Y P;4G]9S8!<A3\$O^_1H9P0T[E*S.
MV+:HB@O%!\]S_=+\XU48Y?-8+5Y&">V6/FK6:P&LJ>Q O7VV!4G10AE?'O?H
M4:.T##\['/:&)\>=C_=[_<YGJX;M'_3Z@X-;#;OZV='^[;Y<N=AA[^A@^% 6
M.^B='*QWLC=4L;RQNLOITJLM=:08L+>JH-(JNM>LL_3MZ@)]Q>'QV+D*T):?
M/)+*;W/"#^D(]K_=$7RC(N.]6GH"EY7M=YSV/9WK.451/ZC6'O?9MZ>][N)/
M9!YG[^P3*SKXI4W?'VS1P?:-#XXVK7[^0(IP[@#Y:0'R<'C+]CL[0-X!\C9M
M_/G1Z=96@>T"9F.F2-)$KP;[A_SF]G8'VCX)4PRH)N(BU]^J[^-NC*_1P_0)
MZT)=)7V?9!_#Y]RBXUZ:K^VZXZUW0]2U87=#6WM#AX=']]=B<B>C;& %ZTQL
M?9(="Y^? .D_N9<^:[LV>&M=T+%_U+^?1GB["UKK@OI^?_ T.A7>Q_'^G.94
M\ =U\S3G+&U*RIRF<>A%,RJ]1AD+G8ZWQREQ/#\Z'NP$PJV]'HP-[0]>[?J.
M;_<UW1L6[63V]2^)^\RF2]9%'\/?OUQL[S2D/TB 'I[Z)YO ]$:'\(!$R2]S
MC6WCQ9[XAT?#KW>QC_%N'^3%]OWA_@;NOSM!V)TS80.W5VM)G2]U?:TKE^W&
MV&IAZGB[8/6=J>BT,A#PD9ML#@XV5,MV1K6[=J?T]W=7M-U7]/S@:(/.U0_8
MZOEPB7V[8/(D8QQ.;ALINC/%W1E7]@].-F7,NTNZ<RN$?W2P =W?64SOTV+J
MT/]O;2M]H,:7DY/![03-)V56>Z"7>^"?GMY2U=M=[_9?[_,#O]__BIZ.1V [
MK6?V]KOY4KWYV.F]5>_X11=4LLL;::P1[A0/_G(UY='!^_ $"-K^]B4*W8/H
M_/CN=N@?;F,2V.YNO_QN#_V#P>;I%=O'IYZP0O5NJ:[^D_2<'/K'@YWS9,LO
M:>@?G6Z:C;*[I#N^I(&_/]C4)/TXG"@/5T=I%G,%!ATE*EMP+T4,2-=9WLX7
MOJW,LW51^T^WD /(\8--'*,/3([?P?$3@>,!AA%O$&VZ@^,='&\C' _]X>D6
M@C')7R](DOAAURSKA^,'T2SK+MK0;75#.QIQ@U;M5''R74N@Z6,\G-7=W)WB
MFUZFL0&T#KU9FF.3IW&,_1T*[[O]WM#V(5F[//GM&RD>?:6#W:8FI:N;R>5Z
MN;9_]RZW_W!6PEQ7D:.J+WFH3<MTT&:_&^[WCC<'/^XI\1U@U^:PN]_SSK$G
M%S4*\[WK:03/]&?JW N+FV?8X9J[WV"YCAFV%I,F1M1@'AMKYZQ][XVD]?L,
M]T;O^$Y+^.7]T:H'A[TC\Q,W^7&;=W?VRPKLHJF!T&&OSY8<,[AT4Z9N+DX[
MY>?1]\W^X.YZ:1JG&YWI%22G@ZU^,/D]O=;4D!"68SO=UYJ(FY9.N&U^+:S:
MS*;)),4<RO,/_WGW>J]_ZH$D'>I9%%#?DN^&O</Z5N13:E4Z<GLFU_?!RX;+
MGFH5!MQ *J6&)W!G-+$*K[![$>VLN\4Z'HGI E?KG$@M7;"1$76V5PMN4MAH
MIY1I'$\:\5ZGV24 8B"->49Z FO&%['CV#Q6\"#DKG+XZ9^ER@KL6/8\:MP2
MM8CJ#2SDP-!C%=0;_37687J=P9IA(Q%W7J]WLG-;N>/F8%J8=VGB?:<SE3-)
M@* ?I]C2)@HLYD2YZ=0U6EC<IC,U+6*PGQ[U_HIMZZ.JTPU,=E2UP4I"TZ&P
MHA>-%?6ZV[W>$>L9G-Z34X@-@VFRYY""!C4]\F'VC>GHX2UH\#Z3+C,_]0ZR
M=,>!FBY":2ZX:IJ^BOA5V=<,==6V >J^.W(PI4&78#MC+=TEJ;F\-%7G=0%&
M<%\69\&&JL XU/J*Y^C&=#P'V/RU<A&A0:EJ;(4!^O#+ ;H.B-L-TYM*\4[%
MK+-:Q:S;R%3?ZM3NM9=W=U&QBG;699&3+Q"UCATR_?4E+4,+.@0L\[A&/^I[
MJZU/B-IIMY0UZ3Z\AIS5=P[-H1(-GHE25HUO+C/L#B[O\C_X* :)(?;&6CJR
MJ1)[R.*?MI&,"VN=[KJ[ D(1(98W5<GE\+>%1^< X?;GRFV+-=)PO2BED-@W
MTYEI#CW1IF4]2BUMQW!7NT6)Z6IIMTL7O[9\;07=.K>PXJQ_9R+H[?7YKV8J
MV6*QJM_KWYIP]K^.;&7<P&L*50TI""=E'6ZLHHQ[2E*O]R(-+ATA*$@G"1Q:
MZ$((Z Q1&NZDE!:@,77B7CMUXGZV=>+>M=6)>\2'MQ*_UB^I)PRDE>L2'+=_
M534$'VD$76X^K6T/9N'&"_S[]VE4:.\<_O*]G],D3%>T'GY$%[0A=-NR#5]F
M3']()W1#8V<Y#[&HUW501Z,3.G\3?Q#FSW0Y,H-3.V!I)0[L:*ICZK<+XC(Z
MV'9PNGPOG'&^ U+G,%HA='A[]<]-ZB3Z?+ $[6M(-21+[?=.:FI9ILETHBII
MAZW;U5HKLY)C4K[6(,XF8N6T7>U#;&>;H8Y)S?L\Z;O./FSSZ1SU)0_[<I.5
MU!%UUNC*F[,NDE7\Z,9M^XY=:**BA/@@<3&/&WJ+$L0VWWVS;VM\9PF?>:#1
MI.Z.#JPR==R%^KDQTR(8_:0^>S^VQ<ROL[W5I_+DXB1.'GB<Q%U;"9;3-AJV
MJMN8VZW+\S;JI"&<U3*ZO8Q V:(B[WEG^8TO>9,,3@S#"$"Z1GK*]+8 VDNN
MMJ0SS]*'ET"IC<66YDWA^.!S309W(M5P>#A8S^MT*)M%D!E_5'!P RUFICY'
MLW+&JP$".ASVAH=_-0[ /TN F_$":?X:[@9\4C2,A_@W[HU70.RKXE'->.V&
M;0=7H %N(WQ\X_S=9%Z2F2A8S';-W8"81>$_GD4C%9ZH\<'QJ#_L'_3#T>F)
M&FH]&HQ&X\-3^.__](?/G(]6#7CG/7I9JXS^+*,0M3H\P7,U1SZ!( /''+2X
M"+Z&>'?0.[X_VG*!#BP"(OS'G",.KK4W58 T25J(81M%!94LK+,[ ]A*@ ;@
M*=&K\'69H1!3%3A&3!6K<Z(GCBU\#!I*+G(@3%PYD7O>[^QK" JA+O XAX.+
MQE&@W)@/''1I)D.^D#;D6A/"C$MTU;$?P'CON]SV0/;2<C)%2[)UW^-$;;Y\
M8TG5EW 6DQ*8=9H!T,S1@""?S<LL+[5C>S91'Q1X8%ZF\(KF4FH'@4977'$G
M<N/?J_P/9("\!AK?"-I($LU&WNNHF/*AQ"I)'&KN=\<QS-,"'9\J;MF@0II+
MC@HB^\9P2(!%ZT@TPE,8DN""0PBBP:6/49:N@X57PD2QEY>P]P* 7VX3CLM"
M9PU*#' 2A)G#S57\)5)N#4D?,+X#7(4I(3;A:X*1>X3 ;1"95_B=H,^@00RZ
MS]D#3"05[SK*-0$S#8)WJY=N%RX=@=YA>02/,&  8"*$8@+KRA*"O@E&(?+2
M9#+FPQI(-Q#N7,/.!/C>&AICB1M"_F"_?V"1O2X45;0/:(".\"S4!*22"2Z0
M6#02,+LTU+".AB=NT!C.>-.RSNAAZ\PAST"JV_"T4MZ6(?=>F.>&RA-Y:]\B
MN;\]Y]R&P-=/Q%5BV AI]L19\G*&X/I?O.DRJW$V@'ZM@JG1M=GA@3(=D%70
MN\*6JLHWJ&DRI5']**X_0-O$/-<OS3]>F=:O44);H(^:$?P@X(F:='+<.STA
M34E2*&5X4:)Z]*B1:\#/CN N#D\['^_W^IW/5@W;/^[U^P>W&G;UL^-^]Z1?
MM-CCM8:](4WUQMSATZ57,5ECT*OD=!=:ULI<^282-*O=#D+?L01/\UNJ6LN6
M^=(K<)*TUDVJ^:+[N:O30L[3V7)JPTVO?WABNUH>ZM$=[OY7A<+3S:'PSDN;
M+-_)/9W^<S*LI"6,$>9M]8*WN 3SUE6.^<6(OF7.'O!*^:Z4O=L5#7@">:@/
M*M7TV!\>;)YK^H"RHG< MTU[>SXX\/>']P-PN]IA7\ !HN1*YVMQ@$=>!.EY
MWS_=WZ"@Y:Y*U9V3&/]H>+QK\_%0* P:H:.0@XS&4:*2X*M1F8?;LZ _&/K#
MC<L6;I]T]LBOZ?C 'V[<]FDGTMS+7;VAZ!#.)W+C^_C?%%5'] @]34XZ.O[V
M) 6=/K#16S::V D[=R>-'OBGMVB=O)-V[E[:J85C;$1I;CK17>6WQU'Y[>30
M/^X/;R=.[*H8[F!YFS8^!#7\Z)8-#.^YE.&C*>^V8?P.,BF*X?E-C'X?K-OG
MK$,=?XRGMC(VZ/4&Z3Y^J]^,3:K?#8_K10Z0^_L2.HD?V(!9&P9/M:Z&U5>^
M!-NZEMK&]T:WD<AQ9SEYKB6J+H[4R!2:X-RIPVJ&N<HPZI-J@4D2$J-T(@GO
M_!?,DTVTJ7CA%%OZY6NN;OUDAXYB9@HSSTZ=6@N50$;U)**P$7-,>6L2.LFG
MC=LV?],J_5K6%<["A4H::<=.JA;6XY" 0PY:QK.(872 X-!N<I[A>6!H>N&]
MUR%%Y9Z3A]U[G457VG=SWLA #S 69*5NW4/SDOM5V1 &H_I@,!(6D,BQ9 2M
MD9.J:Q51HMRYV4;YHMI@F%=-^S=9J"9'^Z2YA%JE!'<((NGX54G%"0@ZZ-CJ
M]?407N@39[N4!_<%5;^>8,G4KT4 ]U<2P,%!'6W6(X"#TPH*OQ$!['\A 70(
M^ST1P/T5!!#(<[U:XE>B@JU$I$Z.&J7XW,366O[[5\7\6X4B/[DDS=-=DN;7
M%I[?68_Y3GB^A?!,.,U,Y%H+R^@[PAL^!LG+$6. N,XY_S->^(:C=,4N ,&*
MXTI:J^@E_&0JCQ+%JN0PK,3U9QE14M06%+S:5OC_U?'GOK7^W!T.W$J!3-;U
MDI,$_EU_4-,/!:KQS9H8(/J%DW#%.4R4PZBX#C(*)&>?WGMO3>$C)9EZ;_4H
M*[&#%*>54Y[,'HEP8XU;LX4GHAP'"R0E<>M$\"V^^/U-[_WXH./:21YU!>WE
MK#8K9_]+)>9>]UONE2FN6YH12&N9D+S8O.JJ, OFILXHY[.Q&5M]VRTB![(B
MYI:VIJ[?G &W*6QL#>U\6R9HTO0^(G_)-B[Y]N!1HTI_IA1*HR\X)2>\O!SE
MA4I$%^M(:#:%XETV3PI<4,8JP^H*M<1P)H-.]G>%5;5$\(*+CW=6@.]Y']QE
MUW.O:<JU4P"_D/[5O* 'I[U&AD;;Z/?8I/!O?SD9#([LN=S]$NI>XT,^YJXL
M?U:_W;((M6("JL"4]4#G^;A$$,4Z3[$N='=] 08K (W3;M"H-YX<KG.AISM8
MN3-8 ;5"C>((??DL0OD>2%F7NC#\,L3"#%C/A?GE.%/P=QE0E0HTD0!!"Z*Y
M+13A%E<0]MT!< B+K+H 09NIA=2P<:=WJU-@?<"$VS X4V!K#2:<UPDF\?\!
MU+.(%SN0?, @.8VP (I3;$/(#4"F>!&:!45 O<V1F<:[>W_ ]P[BA]'0&G0&
M?W:*R6-1J0"I0$IU./"#2<:E#JQ,CJ6A"1KPXQU$/$R(P(9MR!-\3V!#^N,4
M1M!&IA#'\%<)5,':N;#[$6A_4=IMX_J&%[^E:@I5T_E TC_:419HD,S9QLBU
MC%2FV0=R;749T@-,6R5$NY'VEXO[-TMS.D68I/$%;%]G2,H[2T+!?JZB +^-
MU2C-1&YU!L>F5C&I0]P@HG+K.()NO6I=HZP4?7&E,VPN8+1\/ ^IN#46#39S
M-%@^@!'UU[JB^JN:O>!N2QPIM48UHJ0XO33@<C>X0O4"W;%1VRA)K2)H.D<Y
MIA.D?%%!"_2YR!1H:'C7?)U<DP]DH4FIL/*0KIH&8:5 OEJI.R@!Y26ZUTTA
M.3PCJ?#WN8!I83T+N#08A,_;5C=D=U4*TN-$*B-1B2.^J,S:H-WU/@&C\THR
M^R/5GA21U?@?6TN6866SG!P'(PW'>:7%L"!6L?:B2Q1I4?=!& C.R_$8!'7-
MIE%;M,SUB9IB:I43M^9$-72"?@RIHU0=64BY+ @LB@J ^@,Q$U9EM;AM [P!
MP(%NC1GI ]2Z*B]GTHN!]%%4"ZC$%Q,?[SI+T3PK5"I(RS@T=>YI.^I*13&%
M>YC55OB9IVEBP->2N)[W;HQ_2?6LUMIXN"]2,0C\ES'8=RAF:Q7 Y8)S[?U@
M>.!:QSK_9J7,QZ 4S<0+34ELN,2LD#3-]9+"1-> YPJ:>VHNL*.V'5<$9&=[
ME.S%0*%QU?P#WG8 7[.CF(U+'2?TY-%>!ZKDPMZ$%R5<1UK"[4?Y)2-7F00@
MNJ"X0[:[/$^Q,Q2&):%EL"IOV*QJV%JL<3Y5V4P%NJ3PT2Z(1690)J9*J\%#
M6J#^#/#G]"A$Z,>N.DQY#&)5J+\F(V4X]41L8.RMS*,5PK"9TVW?,D,; B)%
MBGR(&^;!'#NCY,.1Y1&N\@!XBX\ .8&[18FB+*@B,L.#=!PCOM2P7+OB7E=5
M46O[WED!'CB<B-H %(E8(#'G.1,\E+]S8U5<-A6:T"J400/%):8KCEX6TS2[
M7Q!Y<G%9_?WZ66Q%8-8.4;\BHE*762E;[;@M+9>NE]IUK+AC[,7FRK9^HUWS
MLJAK'%C=O:QK;@4CUB\3BAV/>."@)\6< <Z(%_A5 60.3'8Z:"H._W< !@TG
M4Y(_5P/3#GX>+?PPZ2*1@L0,A()I1&0G@8FK)MB.08\DT]1TF4>?0S'= <*C
M  2*D\6&O,2&QE%L^ ^@.Y9"YQ!$59"FP=(EF3V09;&3PGR@$VP^2Q#5Z:&@
MG(!<5)BQ&&]:7]VS_7)C%<WRG4OK$4 <ND/8#FL$E::)K6YAJ]OG6M@4)M7H
M8)K MB;1*G/;TW-[$2C\5N_'03(#]H?PV<K<[,W1;!I3MYVK8$KV>'AK'!6<
MJ[-HV(#96:.K0OL)!:J:'@[28L'$I6*X:>JYD"&KRE24M]MF92 RJHAXPX/Z
M]%MZ#5O)I]&\:JM)58/$>T#=D[&#++QD/01AA/ID:"WBS;G1KE=MP?B"HBS<
MPP#%A;'[H8,P%B<>.X4FF=;&6X7..#V) LQ=B/"(T*%',$_D,\LPG4RZX&:K
M(I'<5WT3043>A0*MV@ #:)J>4J=GM@,PR96X<!==?*.]V/LN0!&=Y7YE:R*+
ME9K1HMKQCYI\>,9"CC9.ME18-P:V,!EA%]XK.!DQNI:Y.>VZ,?:&LQ?PL1[!
M'(W^B3@@[6&,K'N&W LA\)$%'O8L*GQNF*Z9<'!:;[W+4,UU:4V[+8Z,,3"[
MPCF!ZIAE"+HZOLBJ34O[,1JPOR;)W/9C0<8\1F!K'1-6G>OXJI7JK=GCZ^A9
M"SUS^XN=M)+)6Y+%NR\OSJU-T/"%:O<99T8C5OV:QDC76!"Y<#Q6_RK#"6,A
M/GEC?'1/*:+[ \OZ(>)S2 D)6,.#1#%!/%0M"_A!#BK3(D%R\AQ&*&4A<0'R
MX5![UI_.SG[EUO;\JG79I)O.YH1& %T,XC0'!,T-QF.&,N++3%VZ+E;\Z@][
MM81N$@+ &C4J.=A!:,:I\VAEE=S86E)JI3HMMPFL%L/1H 1H59;M4D*P) YO
ML'=R8(XH]  ]XJ[_> H<(LT(RG%E&;#L +C]98+1H4#4D8C2LJ_L(5Z!Q(^N
M..9GXF*RE,CXWA5Q!Y6G3**Q+13'2 11%I0SC.LG5B81(67,I\?B'5#(&3V!
M14=LH()[0?RK[@+X9<FW$ !GH]Z,R+FT<PE+1\?WEW';.UA=2-T7YPB!<-Y.
MVV+Q@'.3-F*(1?/P*%[&\;Z3C\X&H=#"V<FG6#TQFT1&$T8HQ_"$3:<^GQ2_
M(5!0S<'7SN[CI^XB_GT:Q7PI;N2 JFCUW-+J#/M:YP&(0DQI9BG] CHH)FUX
MOZ2%Z \#(^UL1%GF<TU:,([UYO,T&D6%=WK:Z[/W&@#XHV9C2.*]1<@^VOMW
M+4Z%P+*H-:#JVD8QQ0B%&9 3+S#L2:J-_%'C0 Y 26YR\<4T]'X@;FLRMBY0
M!]CC@*1S)Z3O*?%XH(>8]X=R,*@N&!1)FE'.*4^@%F%-F'D5VR;DU';&,\E^
M7 0'PX0( JEP%_X$RE>Z-#:\<_;Z@N; +G\).OZL7E*9'5GCR30QI*:"2*JL
M\[7*;%]>XC: #32;6;UHA68K\("D=1W6$F9-E1_KA1_L]X\] A3O V<W_AHK
MK'K!S(\>VU]N&NG$>\-ZRSNS[J713NB7GDR6VT56_-9.*<GU\HGOWIB<L_D8
M?K%1X=61P8DLYDAP@&=>D7Z,88\*CJ_,]C#>T82D2C<\%N(&W$495Z*N519Z
M)BT_E<./LAS]U E,D>5XZ?(V:4XP.2E4%+5N!*:1BDE(-"-1L%SLA&%F>B;6
M14ZZE6#,,HEUGE=+R4G8P@0:K"& # 17CM!0&YX26'-N7OLVM=T>90C"AI!)
M.(?J <C#J;2-9'FW%$XQ(;S5 P8+YU.>!7ZVN8O.0^0 &.H*BS VEM!?>DL6
MRMP#E-Z\'/TA1I>VRS.+;=[>TI!KWV1MR?8(1IKYG%DVS7?[Z^6[D9 P;Z9G
M([34(%;K)"+Y,5%L_*C3"3ZO48H;FJJ\:I"*"!-3$#8AGEE-'DQU6 KQ(OKB
M@@-K*NFFR&AZ^\84D(W62Z!9+)'0YJRDR(@ NZ*AG[P$2.[J%(2__^IZD+UH
M6=RGLX:O(Q-/C*?)!A@Z4W2LLP)1(U=M*$^X3A30#F9QV45E,C62S,#OM:XP
MRJL]F*&*3.$N]W#'H@(YP,\!I+I!;3L7:F@<T:4:$E-W:QYC%WQC@V_Z6QA\
M<P\FL?;3J;1/7X)%!/MNA'-0.D#F6]P,R&R9)01DWF"206H\5::"+0(>I@GA
M$1#N$<F5-1PWP.KA@G(T5XCRT\V:J*ZA8^!!NH]$XJG3VXNN2ZX3,>2B#H%+
M1)Q;7Z%>AT:O1P^%$!I&O%IE:"/L2V0]-Z6I!$0#'4N_])D&Y9R3A$"+#ZC-
M1!LFD+?%@)4TCB9#DW1M5R%>?#=&$4\3[9Y*AXXUI9:(28H-!_26^\Q@%6!@
M ,K8$P;E_2&+#N8.ZYR?TE;J^J??2&(CWXHF@9SU-C3?2KVEP Y"&JO \"\J
M#]6?WD\Q$*C8N] 8LH!I1^2-298%.Y\]-S)IRRJ=#@*LM8KX^71OU0B$YE9_
MC%5PN7<13%,L<B65AO""6*4(=;R4PU$_XIHU0&K?\E][]6&L P''B))Y2=S*
M6,E%VZ)TRLJ2Z\9Z5G8&C+_H'[_*JXS#.!I7>B^#UU6*_"QF;SC+F&Q=63SU
MV_^T=(<:1(C:10HW@:NL*&@; @(8F:M9 Y"([L[G\4+*N%I[O3&]+M4M<A:#
M'H$0IJ\JA0E/@*^ R=F\V7PC'MKSSEK648%:8P<,C;INA+Z77"'^KMMW?)=F
MX'8P>V.0L\+$'NOJ]<8']T0 $5Q)8%#)8L\:MAP_'Y6&F6'&L;L%+""!DK 5
M,2P/(WG#ID"3B7("FD]A,D,'O4-C@J$2</"^MD*2PJ6,3!%T(5C.8NK4S,Y)
M&(79EFS!E<D9DYU/:H)BYZCS<@0W"[H'Z-68;S[76-J83LAX\JLX)#=W'P0R
M6$)9#X62>F)DZX/A_B37H#,WX"3FX4U49JG[\B;9NTJK,=2;R?N:@6@W8<GC
M1#@$OOO$KAJ:?W(ADRK=X]TV+'\@Z&-$%,<.8(XQCH8J$E!V-;$J+^(%@A8I
M(,TQFB4(1NCT+-"!3@ VB:[$MIQ'H1;?'KS6-%CFMIAGS>?/I1<Q3A=MG6+
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MX3)U,Z+$=-*DQKW%\EKXS9Z]\H(77/>S(&DW+<=Y^4WQJ>5\?!.B8XT-8D[
MMVWCL"MR[\@#<1B9_))\JG7A*$=(D-FD,9.Z)>[*L"TQ]QJ5PD=7%-YE A_0
MS,2@S*81:8-<NU'KN7 4Z2I(GW.>C?L+E.7.LJV%G0SC#*@Z"UO^*,0?O[]X
M_X;--DCG33"(O,RQIC/<NXG+K<I1FX_-N"@E4AP&5GNAU'@NJN28&C^^?G,N
M[[>!E93(^(.,.S:-CLIS[&PU4E=<M&-3R\0-0:'C7@<4W"NI;M!ZK5@V'TE5
M[6LS+^!5,H&O'-^[\O*9Z/=8=K*<T8Y" T4][Y_I-5<"NM:F)&"]X87=R(T
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M+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( )N IE*6*D5G>A<  -/U   5
M          "  <XS 0!A=71L+3(P,C$P,S,Q7V-A;"YX;6Q02P$"% ,4
M" ";@*927@!>_G4-   @7P  %               @ %[2P$ 875T;"TR,#(Q
M,#,S,5]D,BYH=&U02P$"% ,4    " ";@*92.<3$(?A)  !Y4 , %0
M        @ $B60$ 875T;"TR,#(Q,#,S,5]D968N>&UL4$L! A0#%     @
MFX"F4BLI9;92H   1/D& !4              ( !3:,! &%U=&PM,C R,3 S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( )N IE*=R(0Y^VP  #8U!0 5
M      "  =)# @!A=71L+3(P,C$P,S,Q7W!R92YX;6Q02P$"% ,4    " ";
M@*92L7KP'I-6   870( '@              @ $ L0( 97AH:6)I=#DY,BUO
H<&5R871I;F=R97-U;'0N:'1M4$L%!@     (  @ & (  ,\' P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
